Role of Pax8 and thyroid hormones in metabolic homeostasis by López Noriega, Livia
                                                                       
                               
 




Department of Regeneration and Cell therapy. 
Thesis presented by Livia López Noriega for the degree of Doctor of 
Philosophy.  
     
Seville, 11 May 2018 
 
Directors:         Tutor:  







Two independent studies indicated that PAX8 could play a role in glucose 
homeostasis and pancreatic islet physiology. Pax8 expression was reported in murine 
islets during gestation while a genome-wide study associated a polymorphism nearby 
PAX8 with type 2 diabetes. In addition, Pax8 is necessary for the synthesis of thyroid 
hormones, which are known to exert profound effects in whole body metabolism. 
Herein, we show that PAX8 protects pancreatic islets from apoptosis and have 
identified a detrimental polymorphism that may be associated with gestational diabetes 
as well as gestational thyroid dysfunction. However, Pax8 +/- female mice did not 
develop glucose intolerance during pregnancy and displayed normal circulating T4 
levels at 5 months old. In contrast to females, Pax8 +/- male mice showed decreased T4 
levels in blood. However, these mice were 8 months old; suggesting that the reduction 
in circulating T4 levels in Pax8 +/- animals may be developed with advancing age. 
Interestingly, untreated Pax8 +/- male mice showed glucose intolerance and insulin 
resistance, while T4 supplementation rescued the phenotype. Therefore, our results 
indicate that the alterations observed in glucose homeostasis are due to reduced T4 
levels in circulation. Noteworthy, insulin signaling was preferentially impaired in the 
liver of Pax8 +/- male mice, where ROS production was found significantly increased. 
We next sought to investigate whether T4 supplementation could enhance glucose 
homeostasis in healthy wild type animals. Remarkably, T4 treatment was found to 
enhance glucose clearance and increase insulin expression in pancreatic islets. Basal 
circulating insulin concentration was also higher in T4-treated mice, which could be 
explained by an upregulation of glucokinase expression in pancreatic islets from these 
animals. Importantly, T4 supplementation also increased circulating insulin levels and 
insulin content in pancreatic islets in a model of experimental autoimmune diabetes. In 
addition, T4 supplementation improved the survival rate of mice treated with 
streptozotocin. Therefore, our results indicate that reduced circulating T4 levels are 
associated with impaired glucose homeostasis whereas T4 supplementation enhances 
glucose clearance and blunts the onset of experimental autoimmune diabetes.   
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1.1. Pancreatic regulation of glucose homeostasis 
Glycaemic control is exquisitely regulated by hormones secreted by the pancreas, 
which exert effects on multiple target tissues. The pancreas has two principal functions: 
1) to facilitate the digestion (exocrine pancreas) and 2) to control glucose homeostasis 
(endocrine pancreas) (Röder et al., 2016). The exocrine function is mediated by acinar 
cells that secrete digestive enzymes such as amylase, pancreatic lipase and trypsinogen, 
through the pancreatic duct into the upper small intestine. The endocrine function is 
achieved through the secretion of different hormones by the islet of Langerhans. These 
micro-organs are clusters of endocrine cells (50-3000 cells) that are found scattered 
throughout the pancreas and account only for 1-2% of the volume or weight of the entire 
gland (Figure 1).  
There are five different types of endocrine cells within pancreatic islets: glucagon-
producing α-cells, insulin-producing β-cells, somatostatin-producing δ-cells, pancreatic 
polypeptide-producing PP-cells and ghrelin-producing ε-cells (Figure 1) (Röder et al., 
2016, Rutter et al., 2015). The distribution and abundance of the different cell types varies 
among species. In rodents, the core of the islet is composed by β-cells (60-80% of the 
total islet), whereas α-cells (10-20% of the total islet cells), δ-cells and PP-cells (~5% of 
the total islet cells) as well as ε-cells (˂1% of the total islet cells) are located preferentially 
in the periphery. In contrast, in humans, the different cell types are scattered and the ratio 
between α- and β- cells is higher. Actually, the final structure of human pancreatic islets 
is believed to result from the folding of a trilaminar sheet composed by a single layer of 
β-cells surrounded by two layers of α-cells. This organization is believed to promote 




greater contact between α- and β- cells, which may contribute to an enhanced regulation 
of insulin secretion (Dolenšek et al., 2015).  
The five types of endocrine cells arise from the same population of endocrine 
precursors, characterized by the expression of the transcription factor Neurogenin 3 
(Ngn3). Indeed, Ngn3 deficiency results in the loss of all pancreatic endocrine cell types. 
These endocrine precursors are differentiated into the 5 different cell types according to 
the expression/repression of several transcription factors (Cano et al., 2014). For instance, 
the opposing activities of paired box gene 4 (Pax4) and aristaless related homeobox (Arx) 
are essential in the cell fate choice between α and β cell lineages. Pax4 silencing leads to 
the loss of β- and δ- cells and an increase in α-cell number. In contrast, Arx inactivation 
results in the complete loss of α-cells and an increase in β- and δ- cell numbers (Collombat 
et al., 2003). Furthermore, ectopic expression of Pax4 and/or inactivation of Arx in α-
cells, promotes the trans-differentiation of these cells into β-cells (Courtney et al., 2013, 
Collombat et al., 2009). Once cell fate has been established, subsequent expression of 
several transcription factors is needed for complete cell maturation and maintenance of 
specific cell function. In this regard, the expression of the Maf basic leucine-zipper 
transcription factor A (MafA) is needed for proper maturation of β-cells, but is not 
required for β-cell fate specification. Actually, MafA knock-out mice have normal 
pancreatic islets at birth but become hyperglycaemic with age (He et al., 2014). Other 
genes, such as paired box gene 6 (Pax6), play a role not only in the differentiation of 
progenitor cells to specific endocrine cell types, but also in maintaining the proper 
functionality of adult endocrine cells, including α- and β- cells (Gosmain et al., 2012).  





Figure 1. Representation of the pancreas anatomy. The majority of the gland is composed 
by acinar cells, while endocrine cells are found forming island-like structures scattered through 
the organ. Representative immunofluorescence image of a pancreatic section from a wild type 
mouse showing insulin (β-cells), glucagon (α-cells) and somatostatin (δ-cells). Modified from 
(Röder et al., 2016). 
Each of the hormones secreted by the different cell types have a distinct function. 
Glucagon is secreted in response to low circulating glucose concentration in order to 
stimulate glycogenolysis and gluconeogenesis in the liver (Thorel et al., 2011). In 
contrast, insulin is released when glucose levels in blood are high to promote glucose 
uptake in its target tissues as well as to inhibit hepatic glucose production (Samuel and 
Shulman, 2016). Somatostatin inhibits both insulin and glucagon, preventing large 
fluctuates in blood glucose levels (Hauge-Evans et al., 2009). Pancreatic polypeptide acts 
as a long-term satiety signal and inhibits glucagon release (Aragon et al., 2015), whereas 
ghrelin inhibits insulin release and stimulates appetite (Dezaki, 2013). The coordinated 
action of the different hormones, particularly glucagon and insulin, maintains the 




concentration of circulating glucose within a narrow physiological range of 4–6 mM 
(Röder et al., 2016).  
1.1.1 Insulin biosynthesis and secretion 
The biologically active form of insulin is a monomer with a molecular weight of 
5.8 kDa composed by two chains bound by three disulphide bonds. The “A” chain is 21 
amino acids long, while the “B” chain consists in 30 amino acids. However, insulin gene 
encodes a 110 amino acids protein called pre-proinsulin. This protein contains a N-
terminal signal that promotes its translocation to the endoplasmic reticulum (ER), where 
the N-terminal is removed by a signal peptidase (Fu et al., 2013, De Meyts, 2004). The 
product, so-called proinsulin, is further processed within the ER, where the disulphide 
bonds are formed and the protein is folded into its native three-dimensional structure (Sun 
et al., 2015). Proinsulin is then transported to the Golgi apparatus, where it is finally 
cleaved into insulin and C-peptide by the prohormone convertases PC1/3 and PC2 as well 
as carboxypeptidase E (CPE) (Liu et al., 2015). Both, insulin and C-peptide are stored in 
secretory granules. In rodents, β-cells contain approximately 13,000 insulin granules and 
each granule stores approximately 200,000 molecules of insulin. However, insulin 
content within β-cells is dynamic, and varies in response to several stimuli. Indeed, insulin 
biosynthesis is rapidly induced in response to glucose at both, transcriptional and 
posttranscriptional levels. Therefore, insulin content in β-cells increases in the presence 
of nutrients and decreases during nutrient deprivation (Fu et al., 2013).  
Although insulin secretion can be induced to some extent by free fatty acids and 
amino acids, the main stimuli to trigger insulin secretion is the increase in circulating 




glucose concentration (Fu et al., 2013, Röder et al., 2016). In rodents, β-cells only express 
the glucose transporter 2 (GLUT2), whereas in humans the main glucose transporter 
found in β-cells is GLUT1 (although they also express GLUT3 and GLUT2) (McCulloch 
et al., 2011). After entering into the β-cell, glucose is phosphorylated by glucokinase 
(GCK). This hexokinase responds to changes in circulating glucose, acting as a glucose 
sensor, and is the rate-limiting enzyme for glycolysis in β-cells. There are two main 
characteristics that differentiate GCK from other hexokinases: 1) its low affinity for 
glucose and 2) it is not inhibited by its product (Kaufman et al., 2015, Fu et al., 2013). 
Interestingly, mutations in this gene resulting in increased enzyme activity are associated 
not only with a lower threshold for glucose induced insulin secretion, but also with an 
increase in β-cell proliferation and apoptosis (Kassem et al., 2010). In contrast, 
inactivating mutations in the gene that encodes for GCK cause hyperglycaemia (MODY 
2) (Gloyn et al., 2004, Gloyn et al., 2005). Once glucose is phosphorylated, it follows the 
glycolytic pathway, producing two molecules of pyruvate. Pyruvate is then transferred 
into the mitochondria, and it is subsequently metabolized to acetyl coenzyme A by the 
pyruvate dehydrogenase complex. Then, acetyl coenzyme A enters into the tricarboxylic 
acid (TCA) cycle to produce nicotinamide adenine dinucleotide (NADH) and flavin 
adenine dinucleotide (FADH2) to feed the mitochondrial electron transport chain for the 
production of adenosine triphosphate (ATP) in the mitochondrial complex V. The 
subsequent increase in ATP:ADP ratio leads to the closure of the ATP-sensitive K+(KATP) 
channels, which promotes the depolarization of the plasma membrane and the opening of 
voltage-dependent Ca2+ channels. The following increase of Ca2+ concentration within β-
cells induces the fusion of the insulin granules with the plasma membrane followed by 




the secretion of their content. The fusion of the secretory granules with the plasma 
membrane is mediated by a number of proteins belonging to the family of the soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins. SNARE 
proteins form the so-called SNARE complex together with Sec1/Munc18-like protein. In 
addition, synaptotagmins (Syts) proteins, that act as Ca2+ sensors, are attached to SNARE 
complexes and induce the fusion of the secretory vesicles to the plasma membrane when 
bound to Ca2+ (Figure 2) (Gauthier and Wollheim, 2008).  
 
Figure 2. Schematic representation of insulin secretion in β-cells. Glucose enters into the 
β-cell by GLUT2 in mice or GLUT1/GLUT2 in humans. Afterwards, it is phosphorylated by 
GCK into glucose-6-phosphate which is metabolized during glycolysis to form pyruvate. 
Pyruvate is translocated to the mitochondria where is used to produce acetyl coenzyme A for 
the TCA cycle, which produces the substrate for the production of ATP by the respiratory chain. 
The increase in ATP/ADP results in the closure of KATP channels and subsequent depolarization 
of the plasma membrane as well as opening of the voltage-dependent Ca2+ channels. The 
increased concentration of intracellular Ca2+, induces the fusion of the insulin granules with the 
plasma membrane (PM) and the subsequent release of insulin. The figure was generated using 
images from Servier Medical Art. 




Insulin secretion is biphasic, with a first peak of insulin secretion five minutes 
after the glucose stimuli, and a second phase in which insulin is secreted in a slower and 
constant manner (Röder et al., 2016, Dolai et al., 2016). During the first phase, insulin is 
secreted from a small pool of granules already pre-docked to the plasma membrane (so-
called readily releasable pool). In contrast, during the second phase, secretory vesicles 
from a reserve pool within β-cells must be translocated and subsequently docked to the 
plasma membrane. Interestingly, the proteins that form the SNARE complex from the 
pre-docked secretory vesicles (Syn-1A, VAMP2, and Munc18a) are distinct from the 
ones found in the reserve pool (Syn-3, VAMP8, and Munc18b), while Syt-7 seems to be 
the major Ca2+ sensor in both cases (Dolai et al., 2016, Henquin, 2009). The second phase 
is, at least to some extent, independent of the closure of the KATP channels, being 
stimulated by intermediates of the TCA cycle, NADPH and glutamate that act as 
amplifying signals for glucose induced insulin secretion (Henquin, 2009, Fu et al., 2013, 
Maechler and Wollheim, 1999). 
1.1.2 Insulin action in main metabolic tissues. 
The main target tissues of insulin are: skeletal muscle, white adipose tissue 
(WAT), liver, brain, β-cells, kidneys and macrophages. The first three are often referred 
as peripheral tissues and have been the most widely studied in terms of insulin signalling. 
Insulin exerts its effects on target tissues via Insulin Receptor (IR), which becomes auto-
phosphorylated on tyrosine residues upon binding with its ligand (Haeusler et al., 2017). 
Subsequently, IR substrate (IRS) proteins, are recruited and phosphorylated on multiple 
tyrosine residues by the active IR. IRS1 phosphorylation on tyrosine residues generate 
binding sites for proteins containing Src-homology 2 (SH2) domains, such as 




phosphoinositide 3-kinase (PI3K). The binding of the two SH2 domains in the regulatory 
subunits of PI3K to IRS1 results in activation of its catalytic subunit. Active PI3K 
phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to form the lipid second 
messenger phosphatidylinositol (3,4,5)-triphosphate (PIP3). Then, 3-phosphoinositide-
dependent protein kinase-1 (PDK1) is recruited to the plasma membrane and binds to 
PIP3 through its Pleckstrin homology (PH) domain. The binding of PDK1 to PIP3, induces 
a conformational change in PDK1 that is necessary for its access to substrates, including 
AKT. AKT is also recruited to the plasma membrane by its PH domain, where it is 
activated by its phosphorylation at Thr308 by PDK1 and at Ser473 by mammalian target 
of rapamycin complex 2 (mTORC2) (Boucher et al., 2014, Bayascas, 2010).  
In the skeletal muscle and WAT, one of the principal actions of insulin is to induce 
the translocation of GLUT4 to the plasma membrane, promoting glucose uptake. In the 
absence of insulin, only 5% of the total GLUT4 is found at the plasma membrane, with 
the majority of this protein located in specific GLUT4 storage vesicles (GSVs), 
endosomes and the trans-Golgi network. Insulin induced translocation of GLUT4 to the 
plasma membrane is mediated by two different pathways: 1) PI3K dependent pathway 
downstream AKT phosphorylation and 2) The APS–insulin signalling pathway (Leto and 
Saltiel, 2012). 
1) The PI3K dependent pathway, which has been observed in adipocytes as well as 
in skeletal muscle, requires the phosphorylation of the AKT substrate of 160 Kda 
(AS160) Rab GTPase-activating protein (GAP) by AKT. AS160 protein 
maintains in the GDP-bound inactivate state a number of Rab proteins (Rab8A, 
Rab10 and Rab14) that are located in GSVs. AKT phosphorylation inhibits AS160 




GAP activity, allowing its target Rab proteins to change to the GTP-bound 
activate state and thus triggering translocation of GSVs (Osorio-Fuentealba et al., 
2013, Gonzalez and McGraw, 2006, Mîinea et al., 2005). Moreover, AKT also 
regulates the fusion of GSVs with the plasma membrane. GSV fusion is mediated 
by SNARE complexes formed by the vesicle-associated protein 2 (VAMP2), 
syntaxin 4 (STX4), which is localized in the plasma membrane, and synaptsomal 
associated protein 23 (SNAP23). AKT phosphorylates the protein Synip, which 
is normally bound to STX4, interfering with its interaction with VAMP2 in the 
approaching vesicle. AKT phosphorylation decreases Synip affinity to STX4, thus 
allowing it to interact with VAMP2 and inducing GSV fusion (Figure 3) (Leto 
and Saltiel, 2012). 
2) The APS–insulin signalling pathway has only been shown to be necessary for 
GLUT4 translocation in adipocytes, while its role in skeletal muscle is unclear 
(Leto and Saltiel, 2012). This pathway is mediated by IR direct phosphorylation 
of the adapter protein containing PH and SH2 domains (APS) on Tyr-618. APS, 
which is constitutively bound to c-Cbl associated protein (CAP), promotes the 
phosphorylation of the CAP/c-Cbl complex on Tyr-700 and Tyr-774. Once 
phosphorylated, the CAP/Cbl complex migrates to lipid rafts in the plasma 
membrane and recruits the CrK/C3G complex to this microdomain. Subsequently, 
C3G activates a member of the RHO-family of small GTPases, TC10 (Katsanakis 
and Pillay, 2005). TC10 has been reported to be needed in adipocytes for insulin 
induced actin rearrangements that are crucial for GLUT4 translocation (Figure 3) 
(JeBailey et al., 2004). 





Figure 3. Schematic representation of insulin signalling in peripheral tissues. In Skeletal 
muscle insulin promotes GLUT4 translocation and subsequent glucose uptake as well as glycogen 
synthesis. In adipocytes, insulin induces glucose uptake as well as lipogenesis. In liver, insulin 
inhibits gluconeogenesis and promotes lipogenesis. The figure was generated using images from 
Servier Medical Art. 
Another important effect of insulin in WAT is to inhibit lipolysis. Insulin induced 
inhibition of lipolysis is mediated by PI3K. Phosphorylated AKT activates 
phosphodiesterase 3B (PDE3B), leading to increased degradation of cyclic AMP 
(cAMP), which otherwise activates lipolytic enzymes (Ahmed et al., 2010).  
Moreover, insulin induces lipid synthesis in both WAT and liver. This is mediated 
by AKT activation of mammalian target of rapamycin (mTOR) and subsequent induction 
of sterol regulatory element binding protein -1c (SREBP-1c) expression (Blüher et al., 
2002, Xu et al., 2013) (Figure 3). SREBP-1c is considered as a master transcriptional 
regulator of fatty acid and triglyceride synthesis, since it regulates the expression of 




several genes involved in lipid synthesis such as fatty acid synthase (FASN) (Figure 3) 
(Xu et al., 2013). Of note, in adipocytes, insulin may also increase FASN expression 
directly without affecting SREBP-1c expression (Palmer et al., 2002).  
In the liver, one of the principal functions of insulin is to inhibit hepatic glucose 
production. During fasting, hepatic glucose production is fundamental to maintain 
circulating glucose levels within it physiological range and to avoid hypoglycaemia. In 
contrast, upon feeding, inhibition of hepatic glucose production by insulin is necessary to 
prevent hyperglycaemia. Glucose is produced in the liver by two processes: 1) 
gluconeogenesis, which is the formation of glucose from pyruvate/lactate and 2) 
glycogenolysis, which is the breakdown of glycogen to produce glucose (Sharabi et al., 
2015). Insulin inhibition of hepatic glucose production is mediated by activated AKT, 
which phosphorylates FOXO1, resulting in its translocation from the nucleus to the 
cytoplasm. Therefore, AKT effectively inhibits the transcription of FOXO1 target genes, 
including those needed for gluconeogenesis, such as phosphoenolpyruvate carboxykinase 
(PEPCK) and glucose-6-phosphatase (G6Pase) (Li et al., 2010) (Figure 3). Additionally, 
although the major suppressor of glycogenolysis is glucose itself, insulin has also been 
shown to inhibit glycogenolysis in human hepatocytes (Petersen et al., 2017). Activated 
AKT also phosphorylates and inhibits Glycogen synthase kinase 3 beta (GSK3β), which 
is an inhibitor of glycogen synthase. Therefore, AKT effectively activates glycogen 
synthase and promotes glycogen synthesis in both liver and skeletal muscle (Haeusler et 
al., 2017, Samuel and Shulman, 2016) (Figure 3). Finally, insulin also induces the 
expression of GCK, the rate-limiting enzyme for glucose utilization in the liver, and 
promotes glycolysis (the pathway by which glucose is metabolized to generate pyruvate). 




Actually, insulin promotes the dephosphorylation and subsequent activation of 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 (PFKFB1), which is a key enzyme 
involved in glycolysis (Noguchi et al., 2013).  
 In β-cells, insulin has been suggested to promote both β-cell proliferation and 
survival though the PI3K-AKT pathway (Haeusler et al., 2017, Samuel and Shulman, 
2016). Transgenic mice expressing a constitutively active form of AKT specifically in β-
cells exhibit increased β-cell mass due to β-cell hyperplasia and increased number of 
pancreatic islets. Furthermore, the constitutively active form of AKT protected β-cells 
from Streptozotocin (STZ) induced apoptosis (Tuttle et al., 2001). In addition, insulin 
contributes to maintain the differentiated state of β-cells through AKT mediated 
inhibition of FOXO1. Actually, FOXO1 has been shown to negatively regulate the 
expression of the pancreatic and duodenal homeobox 1 (Pdx1). gene, a transcription 
factor required for normal β-cell function (Talchai et al., 2012).   
Insulin has also been proposed to promote macrophage survival through the 
upregulation of the antiapoptotic protein B-cell lymphoma 2 (Bcl-2) (Rask-Madsen and 
Kahn, 2012, Mauer et al., 2010). Interestingly, insulin has been reported to activate 
nuclear factor kappa B (NF-κB), which induces Bcl-2 expression, inhibiting apoptosis in 
macrophages isolated from obese mice (San José et al., 2009, Hill et al., 2015). On the 
other hand, insulin mediated AKT activation and subsequent inhibition of FOXO1 may 
also regulate the secretion of pro-inflammatory cytokines by macrophages. Actually, 
FOXO1 upregulation in activated macrophages increases interleukin-1β (IL-1β) 
expression (Su et al., 2009).  




In the brain insulin action reduces food intake by decreasing the expression of the 
orexigenic neuropeptides Agouti-related peptide (AgRP) and neuropeptide Y (NPY), as 
well as by increasing the expression of anorexigenic neuropeptides proopiomelanocortin 
(POMC) and cocaine- and amphetamine-regulated transcript (CaRT). In addition, insulin 
action in the brain affects body temperature. Keinridders et al. showed that insulin 
injections into the preoptic area of the brain in rodents can activate brown adipose tissue 
(BAT) and increase body temperature, whereas the effect is lost in neuron specific IR 
knock-out mice (Kleinridders et al., 2014).  
1.2 Diabetes Mellitus 
Diabetes Mellitus (DM) is a major health problem worldwide. According to the 
World Health Organization, there are approximately 422 million people suffering the 
deleterious effects of DM and it is predicted to become the 7th leading cause of death in 
the world by the year 2030  (World Health organization). This metabolic disease is 
characterized by the dysregulation of glucose homeostasis and hyperglycaemia. The 
diagnostic criteria for diabetes include fasting circulating glucose levels higher than 7 
mmol/L (126 mg/dl), abnormal glucose-tolerance during an oral glucose tolerance test 
(OGTT) and increased glycated haemoglobin (HbA1C), which indicates the average of 
circulating glucose concentration over 3 months, (e.g. equal or greater than 6.5%) 
(Atkinson et al., 2014).  
Increased levels of circulating glucose long term lead to several complications 
such as retinopathy, nephropathy, neuropathy (microvascular), ischemic heart disease, 




peripheral vascular disease, cerebrovascular disease (macrovascular), blindness and 
lower limb amputation (Cade, 2008, Organization, 2015, World Health organization).  
The most prevalent types of DM are: 1) type I, 2) type II and 3) gestational 
diabetes. Additionally, there are also other subtypes of DM, known as “maturity onset of 
the diabetes of the young” (MODY), neonatal diabetes, “mitochondrial related diabetes 
and deafness” and “latent autoimmune diabetes in adults” (Gloyn et al., 2005, Gloyn et 
al., 2004, Siddiqui et al., 2015, Vandenouweland et al., 1994).  
1.2.1 Type 1 diabetes mellitus 
Type 1 diabetes mellitus (T1DM), is an autoimmune disease caused by a direct 
attack of immune cells that selectively destroys pancreatic β-cells, resulting in the 
development of hyperglycaemia. Currently, there is no cure for T1DM, and patients 
largely rely on insulin treatment to maintain circulating glucose levels constant. 
Normally, the progress of this disease is preceded by a long latency period (over 
several months or years), where patients are asymptomatic but still present several 
autoantibodies against islet autoantigens such as insulin, glutamic acid decarboxylase 65 
(GAD 65), islet antigen-2 (IA-2) and Zinc transporter 8 (ZnT8) (Paschou et al., 2017). 
Antibody production by B cells is mainly dependent on the action of a subset of CD4+ 
CXCR5+ T helper cells, so-called follicular T helper cells (Thf), that are crucial for the 
development of the disease (Viisanen et al., 2017, Walker and von Herrath, 2016). 
Pancreatic islets from T1DM patients are infiltrated with Thfs together with other T helper 
cells (Th1 and Th17), B cells, macrophages and antigen presenting cells (APCs). This 
infiltration of immune cells, so-called insulitis, is a major hallmark of T1DM. Th1 and 




Th17, which are the most abundant cell types within insulitis, play a crucial role in 
inducing β-cell apoptosis via the secretion of pro-inflammatory cytokines such as tumour 
necrosis factor -α (TNF-α), interferon-γ (IFNγ) and IL-1β as well as granzyme B and 
perforin (Walker and von Herrath, 2016, Li et al., 2014, Atkinson et al., 2014). However, 
infiltration of immune cells in pancreatic islets does not always lead to diabetes. In fact, 
it has been suggested that in non-autoimmune prone individuals, initial islet infiltration 
may promote repair and regeneration of β-cells (Hill et al., 2007). 
Compelling data indicate that both genetic and environmental factors are required 
for the development and progression of T1DM. To date, more than 50 loci have been 
associated with increased susceptibility to this disease. The main genes associated with 
increased risk of T1DM are located on chromosome 6 within the Major 
Histocompatibility Complex (MHC), which accounts for 40-50% of the genetic 
predisposition to this disease (Paschou et al., 2017). The incidence of T1DM is increasing 
rapidly, without any significant change in the genetic pool, indicating a strong 
environmental component. In this regard, infections with Helicobacter Pylori or the 
hepatitis A virus have been associated with a protective role against T1DM, whereas other 
viral infections, specially enteroviruses, are considered as triggers of the disease 
(Kondrashova and Hyöty, 2014). 
1.2.2 Type 2 diabetes Mellitus 
Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance in 
peripheral tissues coupled to a decrease in insulin secretion due to β-cell dedifferentiation 
and apoptosis (Donath and Halban, 2004). This type of diabetes is the most prevalent 




form, accounting for 80-90% of all the cases worldwide (World Health organization). 
Additionally, its incidence is increasing rapidly mainly due to the increase in obesity, 
which is a major risk factor for T2DM together with aging. There are several mechanisms 
by which obesity promotes insulin resistance (Ye, 2013). 
First, obesity is associated with a chronic low-grade inflammation. Indeed, an 
increase of pro-inflammatory cytokines such as TNF-α, IL-1β and interleukin-6 (IL-6) 
have been reported in both WAT and the circulation of obese patients as well as in animal 
models for obesity (Ye, 2013). TNF-α activates the Jun NH2-terminal kinase (JNK) which 
phosphorylates IRS-1 at the serine 307, impairing tyrosine phosphorylation by IR 
(Aguirre et al., 2000). Moreover, IL-1β downregulates IRS-1 expression at the 
transcriptional level in adipocytes (Figure 4) (Jager et al., 2007). The increase in pro-
inflammatory cytokines is partially explained by the increase in macrophage infiltrations 
in WAT observed during obesity. Actually, reducing macrophage infiltrations in WAT 
has been found to enhance insulin sensitivity (Ye, 2013).  
Moreover, lipotoxicity has been shown to induce insulin resistance in both liver 
and skeletal muscle. The main function of adipose tissue is to store fatty acids. 
Nevertheless, when the storage ability of adipocytes is overwhelmed, ectopic 
accumulation of lipids in the liver and skeletal muscle occurs, leading to inflammation, 
apoptosis and insulin resistance. In addition, adipocytes that have reached their maximal 
expansion capacity also present insulin resistance. The most common lipid species within 
ectopic fat depositions in both skeletal muscle and liver are triglycerides.  




     
 
Figure 4. Schematic representation of the main contributors to insulin resistance. 
Cytokines inhibit insulin signalling at the IRS1 level. DAGs also inhibit the phosphorylation 
of IRS-1 by the insulin receptor, whereas ceramides inhibit AKT phosphorylation. Moreover, 
ROS inhibit insulin signalling in a process mediated by JNK and PKCδ activation. Inhibition 
of insulin signalling results in enhanced gluconeogenesis in the liver and impaired glucose 
uptake in the skeletal muscle and WAT. The figure was generated using images from Servier 
Medical Art. 
However, other lipid intermediates such as diglycerides (DAG) and ceramides, 
are believed to play a more important role in the development of insulin resistance (Brøns 
and Grunnet, 2017). DAGs activate protein kinase C Ɵ (PKCƟ), which phosphorylates 
IRS-1 at Ser1101, impairing IR-dependent tyrosine phosphorylation of IRS-1 and thus 
insulin signalling (Jelenik et al., 2017). Likewise, ceramides may inhibit IRS-1 
phosphorylation via the activation of Mixed-lineage protein kinase 3 (MLK3), which in 
turns activates JNK. In addition, ceramides also reduce AKT phosphorylation by 




activating protein phosphatase 2 (PP2A). Moreover, ceramides bind and activate PKCζ, 
which phosphorylates a serine or threonine residue (depending on the AKT isoform) at 
the site 34 in the PH domain of AKT, preventing its recruitment to the plasma membrane 
(Figure 4) (Galadari et al., 2013). 
In the liver, insulin resistance involves the inhibition of the AKT-FOXO1 branch, 
whereas the mTOR/SREBP-1c branch that induces lipogenesis may be less affected, 
contributing to the accumulation of fatty acids in this tissue (Czech, 2017). Additionally, 
ectopic accumulation of lipids in both liver and skeletal muscle may result from an 
increased uptake of fatty acids due to continued lipid excess uptake and/or to a reduced 
rate of the beta-oxidation of fatty acids (Brøns and Grunnet, 2017). In this regard, several 
studies indicate that insulin resistance is associated with mitochondrial dysfunction, 
although there are contradictory results (Rector et al., 2010, Holmström et al., 2012, 
Jelenik et al., 2017, Brøns and Grunnet, 2017, Richardson et al., 2005). Rector et al. 
showed that OLEFT rats (a model for obesity and T2DM) had reduced hepatic 
mitochondrial content even before the appearance of insulin resistance (Rector et al., 
2010). Likewise, mitochondrial function in both liver and soleus muscle was altered in 
db/db mice, which are a model for obesity and T2DM (Holmström et al., 2012). 
Additionally, lipid infusions in healthy humans were reported to decrease the expression 
of Peroxisome proliferator-activated receptor γ coactivator-1α (PGC1α), which is 
involved in mitochondrial biogenesis (Richardson et al., 2005). In contrast, an 
independent study failed to detect any alteration in the expression of PGC1α in young 
healthy subjects after high-fat diet (HFD) feeding (Brøns and Grunnet, 2017). Moreover, 
Jelenik et al. did not detect mitochondrial dysfunction in two different models of hepatic 




steatosis with insulin resistance. Conversely, they observed a temporary increase in β-
oxidation and TCA cycle–linked maximal respiratory capacity, which was later 
associated with an increase in reactive Oxygen species (ROS) production (Jelenik et al., 
2017). In a different study, Pereira et al. found that lipid infusions induced hepatic insulin 
resistance in a process dependent of ROS production (Pereira et al., 2014). Interestingly, 
ROS have been shown to activate JNK and PKCδ, which phosphorylate IRS1 at Ser307 
and Ser357 respectively, thus inhibiting insulin signalling (Ye, 2013, Waraich et al., 2008, 
Pereira et al., 2014). In addition, 4-hydroxy-2-nonenal (4-HNE), which results from ROS 
attack on the double bonds of polyunsaturated fatty acids (lipid peroxidation), has been 
found to impair insulin signalling in the skeletal muscle of mice (Pillon et al., 2012). 
The classic paradigm stablishes that insulin resistance is the first step in the 
development of T2DM, followed by an increase of insulin production by β-cells in an 
attempt to maintain glucose levels under physiological range. During this period, patients 
exhibit hyperinsulinemia but not hyperglycaemia. Although there are compelling 
evidences that support this model, there are also several studies that indicate that 
hyperinsulinemia is the first step in the development of T2DM. According to the later 
model, over-nutrition would itself enhance insulin secretion by β-cells, which would 
result in hyperinsulinemia and this would cause insulin resistance. This hypothesis is 
supported by data indicating that hyperinsulinemia induces inflammatory pathways that 
lead to insulin resistance in peripheral tissues (Shanik et al., 2008, Marín-Juez et al., 2014, 
Vikram and Jena, 2010). Indeed, reducing hyperinsulinemia by STZ or diazoxide 
treatment in obese mice, results in decreased WAT inflammation and enhanced insulin 
sensitivity. Nonetheless, it should be noted that the two hypotheses are not mutually 




exclusive and probably act in parallel. In this scenario, hyperinsulinemia firstly induced 
by insulin resistance, further increases insulin resistance, propelling the vicious cycle of 
T2DM (Czech, 2017). 
The last step in the pathogenesis of T2DM, is the reduction of insulin secretion 
due to β-cell dedifferentiation/dysfunction and apoptosis. There is still an interesting 
debate regarding the relative contribution of β-cell mass loss and β-cell dysfunction to the 
development of the disease (Martinez-Sanchez et al., 2016). Apoptosis of β-cells in 
T2DM is caused, at least in part, by an increase in ROS production resulting from the 
increased metabolic activity of β-cells in the pre-diabetic state characterized by 
hyperinsulinemia (Elumalai et al., 2017, Tachibana et al., 2015). Nonetheless, increased 
ROS may impair β-cell function by promoting MafA degradation as well as by interfering 
with the DNA binding capacity of Pdx1 (Gerber and Rutter, 2017). Moreover, 
hyperglycaemia itself promotes the dedifferentiation of β-cells, since it has been shown 
to reduce the expression of genes required for proper β-cell function such as Pdx1 and 
Pax6, whereas it enhances the expression of the endocrine progenitor marker Ngn3 
(Brereton et al., 2016). Therefore, T2DM is the result of insulin resistance coupled to β-
cell apoptosis, dedifferentiation and dysfunction.  
1.2.3 Gestational diabetes  
Gestational diabetes mellitus (GDM), defined as diabetes appearing specifically 
during pregnancy, is a relatively common disease that affects approximately 10% of all 
pregnancies. Importantly, GDM is associated with several health complications for both 
mother and foetus, such as preeclampsia, perinatal hypoglycaemia, respiratory distress 




syndrome and macrosomia (Pasek and Gannon, 2013). Moreover, women with GDM are 
seven times more likely to develop T2DM later on in life (Pasek and Gannon, 2013) and 
their offspring are also at increased risk for the development of obesity and T2DM 
(Chiefari et al., 2017).  
During pregnancy, several maternal adaptations are required in order to secure the 
viability of the mother and the fetus. The immune system of the mother must adapt to 
tolerate the fetus while maintaining efficient immune responses (Le Bouteiller and 
Bensussan, 2017). Moreover, inflammation is increased to promote insulin resistance in 
the mother in order to assure nutrient flow to the growing foetus. This increase in 
inflammation is caused, at least to some extent, by the expansion and functional changes 
that occur in WAT during gestation. Actually, during pregnancy there is an increase in 
several serum adipokines, such as leptin, whereas adiponectin is decreased (Rojas-
Rodriguez et al., 2015, Vivas et al., 2016). In order to counterbalance insulin resistance 
and prevent maternal hyperglycaemia (GDM), the endocrine pancreas must adapt (Figure 
5) (Chiefari et al., 2017). This adaptation consists in the augmentation of insulin secretion 
via both β-cell enhanced functionality (enhanced glucose-induced insulin secretion) and 
β-cell mass expansion.  
Seminal reports have established the transcriptional profile of murine pancreatic 
islets during pregnancy. Genes modulated during pregnancy include the two isoforms of 
the serotonin producing enzyme tryptophan hydroxylase (Tph1 and Tph2), genes 
involved in placental lactogens signalling such as the prolactin receptor, proliferative 
markers such as Ki67 and pro-survival genes such as Baculoviral IAP Repeat-Containing 
5 (Birc5) (Rieck et al., 2009). Remarkably, disruption of the serotonin receptors Htr2b 




and Htr3 prevent β-cell mass expansion and enhanced glucose induced insulin secretion 
during gestation, respectively, leading to the development of GDM in mice (Kim et al., 
2010, Ohara-Imaizumi et al., 2013). These studies highlight the importance of both 
mechanisms in the pathogenesis of GDM. In addition, several studies have found that 
single nucleotide polymorphisms (SNPs) in genes that regulate β-cell function, such as 
GCK, are associated with higher risk of GDM (Zhang et al., 2013).  Although these 
studies indicate a strong genetic component in the pathogenesis of GDM, environmental 
factors may also be involved in the development of the disease. In this regard, viral 
infections, such as hepatitis B, have been associated with an increased risk of developing 
GDM (Lao et al., 2007). 
 
Figure 5. Schematic representation of the pathogenesis of GDM. During pregnancy, there is 
an increase of inflammation due, at least in part, to the expansion and functional changes in WAT. 
Inflammation promotes the appearance of insulin resistance. GDM develops when pancreatic 
islets are unable to adapt to the increased insulin demand.  
1.3 Pax genes 
Paired box genes (Pax) are a family of transcription factors characterized by the 
presence of a 128-aminoacid DNA binding domain called the “paired domain”. This gene 




family is subdivided into four groups, according to the presence or absence of an 
octapeptide domain and the presence, absence or truncation of a homeodomain (Figure 
6). The paired domain consists of two subdomains, each of which structurally resembles 
a helix–turn–helix motif. The homeodomain is a highly conserved 60-amino acid helix-
loop-helix DNA-binding domain, commonly found in genes involved in animal 
development such as HOX genes. On the other hand, the octapeptide motif consists in an 
8-amino acid motif that may facilitate transcriptional inhibitory activity (Lang et al., 
2007, Robson et al., 2006). 
 
Figure 6. Classification of the Pax gene family according to the presence and structure of its 
domains. Group I is defined by the presence of the octapeptide motif and the absence of the 
homeodomain. Groups II and III, which are considered as tumour promoting, exhibit both an 
octapeptide domain and the homeodomain, although the homeodomain of group II is truncated. 
Members of the subgroup IV, Pax4 and Pax6, are characterized by the absence of the octapeptide 
domain. 
These transcription factors are involved in early animal development and play a 
crucial role in organogenesis, tissue specification and cell differentiation. Actually, Pax 
genes are normally expressed during development and their expression is downregulated 




in adult tissues. However, specific Pax genes remain expressed in the central nervous 
system, thymus, thyroid, kidney and the endocrine pancreas (Lang et al., 2007, Robson 
et al., 2006). 
 1.3.1 Pax genes expressed in pancreatic islets 
Members of the group IV, Pax4 and Pax6, which lack the octapeptide domain, are 
essential for the organogenesis and maturation of pancreatic islets. Overexpression of 
Pax4 has been shown to protect against hyperglycaemia induced by STZ and against an 
experimental model of autoimmune diabetes (Mellado-Gil et al., 2016, He et al., 2011). 
However, Pax4 overexpression also decreases insulin secretion and promotes a 
dedifferentiated state through the repression of MafA (He et al., 2011). Pax6 deletion in 
β-cells during adulthood causes the development of hyperglycaemia in mouse and 
reduces the expression of genes essential for β-cell function such as MafA and Ins2 
(Mitchell et al., 2017). Furthermore, expression of the group II member, Pax2, has been 
detected in human islets and during murine pancreatic development, reaching its maximal 
expression around E12.5. A detailed study of the pancreases of Pax21Neu mutant mice at 
E18.5, revealed that these mice have an increased volume of β-cells (note that total 
number was not measured), accompanied by an increase in the total area occupied by 
pancreatic islets. Nevertheless, the architecture of pancreatic islets, differentiation of α- 
and β- cells as well as insulin and glucagon content were not affected. Although further 
studies are required to confirm the role of Pax2 in pancreatic islet physiology, the mild 
effect of Pax2 deficiency on the pancreas could stem from the compensatory role of other 
Pax genes expressed in this organ.  





Pax8, which belongs to group II, is expressed during development in the 
midbrain–hindbrain boundary in early central nervous system, the inner ear, kidney, 
urogenital tract, placenta and thyroid (Harter et al., 2015, Bouchard et al., 2010, Mittag 
et al., 2007, Tong et al., 2009, Ferretti et al., 2005). In contrast, in adult tissues it is only 
expressed in thyroid and kidney (Ferretti et al., 2005, Tong et al., 2009). Of particular 
importance is the role of Pax8 in thyroid development, where it is needed for the thyroid 
follicle formation. The thyroid follicle is the structural and functional unit of the thyroid 
gland and comprises a single layer of follicular cells enclosing a central lumen where 
thyroid hormones (THs) are synthesized and stored (Ferretti et al., 2005). Moreover, Pax8 
expression is maintained in adult thyroid follicular cells and is required for the expression 
of thyroid specific genes, including thyroglobulin (Tg), thyroperoxidase (TPO), and 
sodium/iodide symporter (NIS), which are essential for the synthesis of active THs 
(Marotta et al., 2014, Arauchi et al., 2017). Remarkably, Pax8 knock-out mice die at 
weaning (around 21-26 days old), but thyroxine (T4) supplementation allows these mice 
to survive until 6 months of life (Mansouri et al., 1998, Christ et al., 2004). Likewise, in 
humans, heterozygous mutations in Pax8 are associated with hypothyroidism (Montanelli 
and Tonacchera, 2010). In addition, Pax8 null mutant mice are infertile due to defects in 
the urogenital tract and have structural and functional abnormalities in the outer and 
middle ear, despite T4 supplementation (Mittag et al., 2007, Christ et al., 2004, Wistuba 
et al., 2007). Major defects in other tissues such as the kidney or the midbrain-hindbrain 
region have not been observed. This fact is most likely explained by a partial redundancy 
of the highly homologous Pax2 and Pax5 genes (Mittag et al., 2007, Wistuba et al., 2007).  




Pax8 is also found in a translocation mutation t(2;3)(q13;p25) that results in a 
fusion protein with peroxisome proliferator-activated receptor γ (PPARγ) to form what 
has been termed the PAX8-PPARγ oncogene. This oncogene is associated with follicular 
thyroid carcinomas and adenomas (Raman and Koenig, 2014). Additionally, Pax8 is 
aberrantly expressed in the majority of thyroid adenocarcinomas as well as in other 
cancers such as Wilms tumours, renal, ovarian and placental cancers (Robson et al., 
2006). Pax8 has also been proposed as a biomarker for pancreatic neuroendocrine 
tumours (PNTs) (Sangoi et al., 2011). However, it was later shown that this gene is not 
expressed in PNTs, since previous studies reporting its expression in PNTs used a 
polyclonal antibody that cross reacted with Pax6 (Lorenzo et al., 2011). A specific 
monoclonal antibody for Pax8 did not reveal Pax8 expression in PNTs, which was 
consistent with the data from Q-RT-PCR that did not detect Pax8 transcripts in murine 
islets, while scarcely detected them in human islets. Therefore, these results raised serious 
concerns on the reliability of the use of Pax8 as a marker for PNTs (Lorenzo et al., 2011).  
The role of Pax8 in tumorous cells is to promote cell replication and survival. In 
this sense, Pax8 has been shown to interact with the promoter of E2F transcription factor 
1 (E2F1), which acts as an activator for G1/S transition. Silencing of Pax8 in renal, 
thyroid and ovarian cancers, causes cell cycle arrest that ultimately leads to senescence 
of tumorous cells (Li et al., 2011). Pax8 has also been reported to activate the transcription 
of the anti-apoptotic proto-oncogene Bcl-2 in the kidney, which inhibits the 
permeabilization of the mitochondrial membrane and subsequent apoptosis (Hewitt et al., 
1997). In addition, all the Pax proteins that belong to the group II (Pax2, Pax5 and Pax8) 




inhibit the transcription of the tumour suppressor gene p53 by binding its first exon, 
resulting in the promotion of cell survival (Stuart et al., 1995). 
Interestingly, several studies indicate that Pax8 may be involved in the regulation 
of glucose homeostasis. A genome wide study reported that a SNP in the vicinity of this 
gene was correlated to higher prevalence of developing T2DM in an Afro-American 
population (Elbein et al., 2009). In parallel, another study revealed that Pax8 is also 
robustly expressed in murine pancreatic islets during pregnancy, a situation in which there 
is an increase in β-cell proliferation and survival in order to adapt to the high insulin 
demands produced by the presence of the foetus (Rieck et al., 2009). Previous work from 
our lab, confirmed that Pax8 expression is strongly induced during pregnancy in murine 
pancreatic islets, with a major peak at day 14 of gestation, after the induction of 
proliferation of pancreatic islet cells in vivo (Karnik et al., 2007, Kim et al., 2010, Jiménez 
Moreno, 2015). Remarkably, the expression profile of Pax8 during pregnancy differed 
from Tph1, another pregnancy-induced gene involved in the biosynthesis of serotonin, 
which promotes β-cell proliferation and enhances glucose induced insulin secretion (Kim 
et al., 2010, Jiménez Moreno, 2015). In addition, prolactin treatment induced the 
expression of Pax8 in human islets, with a major peak at 72 hours, also differing from 
Tph1 expression  and induction of proliferation (Jiménez Moreno, 2015).  
The fact that Pax8 is expressed in pancreatic islets during gestation suggests that 
this gene might be expressed as a part of the machinery that promotes beta-cell 
proliferation, functionality and/or survival during pregnancy. Unfortunately, the 
physiological implications of the induction of Pax8 and of the genes transcriptionally 
regulated by itself in pancreatic islets during pregnancy are unknown. In order to address 




this issue, our lab performed a transcriptional analysis of murine pancreatic islets 
overexpressing Pax8. Interestingly, a large number of up-regulated genes in murine Pax8 
overexpressing islets (Rsad2, Cxcl10, Ifit3, Iigp1, Ddx60 and Ifit1) belong to the 
interferon inducible gene network. Consistently, Pax8 was shown to modulate canonical 
pathways involved in immune response and cellular proliferation. Moreover, a further 
analysis of annotated “Diseases and Functions” associated the transcriptional profile of 
islets over-expressing Pax8 to several immune-related diseases, endocrine/metabolic 
disorders and cell cycle/cell death/cancer (Jiménez Moreno, 2015). 
Curiously, a heterozygous novel Pax8 mutation associated with congenital 
hypothyroidism was identified in a Portuguese family of Azores and the only pregnant 
female of this family harbouring this Pax8 mutation developed gestational diabetes 
(Jiménez Moreno, 2015). This polymorphism consists in the substitution of proline to 
arginine at codon 25 (P25R) located in the paired domain, and results in impaired 
functionality (Carvalho et al., 2013). As mentioned before, Pax8 is required for THs 
production. Interestingly, both subclinical hypothyroidism and low concentration of 
circulating THs have been associated with the development of GDM (Guzman-Gutierrez 
et al., 2014, Karakosta et al., 2012, Tudela et al., 2012). Therefore, current evidences 
suggest that Pax8 might be involved in diabetogenesis and glucose homeostasis, either 
directly by its expression in pancreatic islets, indirectly via the action of THs or due to a 
combination of both. However, the role of Pax8 in pancreatic islets physiology and 
glucose homeostasis has not been studied yet.  
 




1.4 Thyroid hormones  
The main THs produced by the thyroid gland are triiodothyronine (T3) and T4 
(Schweizer et al., 2017). The synthesis of THs occur in structures called thyroid follicles, 
which are formed by a monolayer of polarized follicular cells that are organized in a tri-
dimensional ovoid structure surrounding the follicle lumen. The interior of the follicle, 
so-called colloid, contains high levels of the protein Tg. The first step in TH synthesis is 
the iodide oxidation and incorporation into tyrosine residues of Tg. Then, tyrosine 
residues are further oxidized to form monoiodotyrosine (MIT) and diiodotyrosine (DIT), 
which are combined to form T4 and T3 in a process mediated by the enzyme TPO. The 
final step involves the cleavage of Tg within vesicles containing proteolytic enzymes in 
order to produce the final forms of T3 and T4 that are secreted (Figure 7A) (Ortiga-
Carvalho et al., 2016, Carvalho and Dupuy, 2017).  
TH production and secretion, and thus, circulating TH levels, are tightly regulated 
under physiological conditions by the hypothalamus-pituitary-thyroid (HPT)-axis. The 
hypothalamus secretes thyrotropin-releasing hormone (TRH) that stimulates the 
transcription of the α-glycoprotein hormone subunit (α-GSU) and βTSH genes in the 
anterior pituitary. These two genes encode for the two subunits that form thyrotropin, also 
called thyroid-stimulating hormone (TSH). TSH then stimulates the production of T4 and 
T3 in the thyroid, which in turn inhibit both TRH and TSH synthesis (Figure 7B) (Ortiga-
Carvalho et al., 2016). Alterations in this regulatory mechanism may result in the 
appearance of hypothyroidism (low TH levels, high TSH) or hyperthyroidism (high TH 
levels, low TSH), both of which lead to serious health complications.  





Figure 7. Thyroid hormones synthesis and regulation by the HPT axis. (A) THs are 
produced after the uptake of iodide by NIS in a process that involves the iodination of the 
tyrosyl residues of Tg. (B) TH levels in circulation are mainly regulated by the HPT axis, that 
involves TRH stimulation of TSH synthesis and subsequent induction of THs synthesis. THs 
then inhibit both TRH and TSH production in a negative feedback loop. From (Ortiga-Carvalho 
et al., 2016).  
In humans, 80% of the THs secreted by the thyroid gland is T4 and 20% is T3, 
while in rodents approximately 50% of the THs secreted is T4 and 50% is T3 (van der 
Spek et al., 2017). T4 has a half-life in circulation of approximately 6 days, while T3 has 
a half-life of 1 day (Grozinsky-Glasberg et al., 2006), thus T4 is more stable than T3 in 
circulation. T4 is converted by deiodinase enzymes into T3 within cells. There are 3 types 
of deiodinases (D1, D2 and D3), which differ in in their pattern of expression within 




tissues. D1 is able to remove an iodine atom from both the outer and the inner ring of 
THs, D2 only deiodinases the outer ring, while D3 only acts on the inner ring. T3 can be 
further deiodinased to form 3,5-diiodo-L-thyronine (T2) (Figure 8) (van der Spek et al., 
2017). Classically, it has been considered that T3 is the active form, since it binds to 
nuclear thyroid hormone receptors (TR) with greater affinity than T4 or T2. However, 
several studies indicate that, both T4 and T2 may have important biological effects in 
several tissues, specially through non-genomic actions that do not involve the binding of 
THs to TR (Senese et al., 2014, Schroeder and Privalsky, 2014).  
 
Figure 8. Deiodination of thyroid hormone isoforms. Deiodination of the outer ring of T4 by D1 
or D2 produces the active form T3, which can be further deiodinase in the inner ring by D1 or D3 to 
produce T2. The functional groups as well as the outer and inner rings are labelled in T4. IRD: inner 
ring deiodination; ORD: outer ring deiodination. 
1.4.1 Genomic actions of thyroid hormones 
The classic, genomic mechanism of THs action is mediated by nuclear TRs. TRs 
are encoded by two genes, THRA and THRB, located on chromosomes 17 and 3, 
respectively. THRA encodes for the thyroid hormone receptor-α1 (TRα1), which is the 
major isoform expressed in heart, brain, bone and intestine, although lower levels of 
expression are also found in skeletal muscle and liver, among others. TRβ1 is the major 
isoform expressed in the liver, kidney, and thyroid, although to a lesser extent is also 




present in brain, heart, thyroid, skeletal muscle, lungs, and spleen. TRβ2 is expressed in 
the hypothalamus, pituitary, and retina, and is involved in the regulation of the HPT axis 
(Senese et al., 2014, Lanni et al., 2016). These receptors act as transcription factors upon 
binding with its ligand. They contain multiple functional domains, including a DNA-
binding domain. The DNA-binding domain is highly conserved and interacts with 
specific DNA segments that are known as “thyroid-hormone response elements” (TREs). 
TRs interact with TREs, which are normally formed by doublets of the half-site 
AGGCTA, as homodimers or forming heterodimers with the retinoid X receptor (RXR). 
Normally, TRs are bound to these sequences in DNA independently of THs. However, 
interaction of THs with TR causes conformational changes in TR and subsequent 
activation/suppression of target genes (Paquette et al., 2014).  
1.4.2 Nongenomic actions of thyroid hormones 
THs have been shown to exert non-genomic actions that are rapid in onset 
(minutes to hours) compared to transcriptional dependent mechanisms. These non-
genomic actions are dependent on TRs located at the plasma membrane, cytoplasm and/or 
the mitochondria.  
The thyroid receptor at the plasma membrane is located on the integrin αvβ3 and 
activates mitogen-activated protein kinase (MAPK) through phospholipase C (PLC) and 
protein kinase C (PKC) as well as PI3K via Src kinase (Davis et al., 2016, Cheng et al., 
2010). Moreover, PI3K is also activated by non-genomic actions of THs by truncated 
forms of TRs found in the cytoplasm. Activated MAPK and PI3K by non-genomic actions 
of THs have been shown to promote angiogenesis via the induction of hypoxia inducible 




factor-1α (HIF-1α) expression and to modulate Ca2+ and Na2+ concentration within cells 
via the modulation of the activity of Ca2+ ATPase and Na2+ ATPase (Lin et al., 2012, 
Davis et al., 2016). Furthermore, activation of PI3K results in the phosphorylation of AKT 
and subsequent translocation of GLUT4 to the plasma membrane in the skeletal muscle 
and adipocytes (Senese et al., 2014, Davis et al., 2016). MAPK activation by THs results 
in the induction of proliferation of several cell types, including human bone cells, 
epicardial progenitor cells, embryo hepatocytes and several types of cancer cells (Deng 
et al., 2017, Davis et al., 2016, Alisi et al., 2004).  
In the mitochondria, there are two truncated TRα1 receptors with molecular 
masses of 43 and 28 kDa, thus so-called p43 and p28, respectively. The function of p28 
is still unknown, while p43 binds to TRE sequences within the mitochondrial DNA. 
Therefore, p43 induces the expression of several mitochondrial genes, such as 
cytochrome c oxidase subunit 2 (MT-COX II) and mitochondrial encoded NADH 
dehydrogenase 2 (MT-ND2). As a consequence, p43 increases mitochondrial activity 
(Wrutniak-Cabello et al., 2017, Casas et al., 2008). 
1.4.3 The role of thyroid hormones in differentiation and maturation of metabolic 
tissues  
THs play a significant role in the differentiation of the vast majority of somatic 
cells (Sirakov et al., 2013, Obregon, 2008). Interestingly, during the last years, extensive 
research has focused on the role of THs in the differentiation, maturation and functionality 
of several metabolic tissues (Obregon, 2008, Bloise et al., 2017, Mastracci and Evans-
Molina, 2014). In this regard, T3 modulates the expression of several genes whose 




expression is dramatically increased during adipocyte differentiation, including 
glycerophosphate dehydrogenase (GPD), malic enzyme (ME) and PEPCK (Obregon, 
2008). Likewise, physiological levels of THs are important for the normal pattern of 
different types of fibre distribution in skeletal muscle. Skeletal muscle is composed of 
two main types of different fibres, classified according to twitch speed: type I, so-called 
slow fibres and type II, so-called fast fibres. Remarkably, hypothyroid rats present a delay 
in the switch to adult myosin in fast fibres, but not in slow ones. Indeed, T3 has been 
shown to play a crucial role in the transition of neonatal fibre to type II (Bloise et al., 
2017). Furthermore, T3 supplementation enhances postnatal pancreatic islet development 
via the induction of MafA and attenuates hyperglycaemia in STZ-treated as well as in 
leptin-receptor deficient mice (Aguayo-Mazzucato et al., 2013, Lin and Sun, 2011, Verga 
Falzacappa et al., 2011). In addition, T3 administration increases the expression of 
endocrine markers in acinar and ductal cell lines as well as in pancreatic explants (Misiti 
et al., 2005, Aïello et al., 2014). Remarkably, newly developed in vitro protocols aiming 
to differentiate human embryonic stem cells towards insulin-secreting β-cells, use T3 in 
specific steps of the differentiation protocol (Pagliuca et al., 2014, Rezania et al., 2014). 
These data indicate that THs are involved in the differentiation and the maturation of 
pancreatic precursor cells into functional endocrine cells. 
1.4.4 Effects of thyroid hormones in metabolism 
One of the main physiological roles of THs is the regulation of basal metabolic 
rate (BMR), defined here as the rate of energy expenditure per time at rest, which accounts 
for about 60–75% of the calories burned in a healthy subject (Johannsen et al., 2012). 
Remarkably, BMR is the main source of energy expenditure in humans and a reduced 




BMR is associated with weight gain and obesity (Mullur et al., 2014). Specifically, THs 
increase oxygen consumption, while reducing the maximal capacity to produce ATP 
(Johannsen et al., 2012). 
Mitochondria are the main site of ATP synthesis, which is coupled to oxygen 
consumption via dissipation of the proton electrochemical gradient that occurs across the 
inner mitochondrial membrane, where the respiratory chain is located. The respiratory 
chain (or electron transport chain) is composed by 4 complexes. Complex I (NADH-
ubiquinone oxidoreductase) oxidises NADH to form NAD+ and reduces coenzyme Q 
(CoQ). Complex II (succinate-ubiquinone-oxidoreductase) catalyses the oxidation of 
succinate to also reduce CoQ. Complex III (ubiquinone cytochrome c-reductase) uses the 
electrons donated by CoQ to reduce cytochrome c, which transfers electrons from 
complex III to complex IV. Complex IV (cytochrome c-oxidase) reduces O2, forming 
H20. During this process, superoxide is produced, mainly at complexes I and III, and it is 
converted to hydrogen peroxide by superoxide dismutases (SOD) (Figure 9A) (Zhong 
and Yin, 2015). The electrons transport is accompanied by the transfer of protons (H+) 
from the mitochondrial matrix to the intermembrane space at complexes I, III, and IV, 
which creates an electrochemical gradient (Δψm). Protons re-enter into the mitochondrial 
matrix through complex V, which uses the proton-motive force to generate ATP from 
ADP and inorganic phosphate (Lanni et al., 2016). Noteworthy, some protons re-enter the 
mitochondrial matrix by other means, lowering Δψm without producing ATP. This proton 
flux across the inner mitochondrial membrane that is not translated into ATP synthesis is 
called proton leak (Figure 9A). Proton leak has been shown to be important for energy 
dissipation in the form of heat and accounts for a significant part of the BMR in animals. 




The main proteins contributing to proton leak are uncoupling proteins 1, 2, 3 and 4 
(UCP1, UCP2 UCP3 and UCP4). UCP1 is mainly expressed in brown adipose tissue and 
is involved in thermogenesis. UCP2 and UCP3 are expressed in several tissues, including 
WAT, skeletal muscle and liver, while UCP4 is almost exclusively expressed in the brain 
with low levels of expression in the spinal cord and medulla (Rousset et al., 2004, 
Lindquist et al., 2017, Lanni et al., 2003, Andrews et al., 2005). Interestingly, UCP2, 
UCP3 and UCP4 have been shown to decrease ROS generation in several cell types 
including L6-muscle cells and neurons (Lanni et al., 2003, Andrews et al., 2005, Nabben 
et al., 2008). In this sense, uncoupling is thought to lead to greater oxygen consumption 
and reduce the proton motive force by reducing the mitochondrial membrane potential, 
which subsequently reduces ROS production. Moreover, it has been suggested that UCP2 
can also act as a channel, promoting the transport of mitochondrial ROS to the cytosol 
where they can be reduced by antioxidant defensive mechanisms. Consistent with a role 
of UCP2 in decreasing ROS production, UCP2 null mice have decreased lifespan 
compared to WT mice (Andrews and Horvath, 2009).  
THs enhance mitochondrial respiration by both genomic and non-genomic actions 
(Figure 9B). Genomic actions involve the induction of expression of genes such as the 
nuclear-encoded mitochondrial transcription factor A (TFAM) and PGC1-α. TFAM binds 
to mtDNA to regulate the transcription of several mitochondrial genes and PGC1α is 
considered a master regulator of mitochondrial biogenesis (Lanni et al., 2016). In 
addition, as mentioned before, THs bind to p43 within the mitochondria to induce the 
expression of several mitochondrial genes, including COXII and ND2 (Figure 9B) (Casas 
et al., 2008).  





Figure 9. Schematic representation of the main effects of thyroid hormones in cellular 
metabolism. (A) THs increase oxidative phosphorylation (OXPHOS), but also decrease the 
efficiency of ATP production and ROS production during mitochondrial respiration by 
inducing UCPs expression. (B) THs promote mitochondrial biogenesis and mitophagy. In 
addition, they increase both lipid synthesis and lipid catabolism. The figure was generated using 
images from Servier Medical Art. 




In contrast, THs also decrease the efficiency of mitochondrial respiration, since 
they induce the expression of UCP1, UCP2 and UCP3 (Lanni et al., 2003). Since UCP2 
and UCP3 have antioxidant capacities, the induction of these proteins by THs also 
indicate a role of these hormones in the redox state of the mitochondria. Actually, Chi et 
al. found that treatment with T3 supressed the development of hepatocellular carcinoma 
by lowering ROS production, while hypothyroidism induced by 0.02% methimazole and 
0.1% sodium perchlorate treatment accelerated the development of this type of cancer in 
hepatic HBx transgenic mice. Noteworthy, the authors found that T3 treatment enhanced 
mitochondrial turnover by inducing both mitochondrial biogenesis and mitophagy. As a 
result, the quality of cellular mitochondria was improved and ROS production was 
reduced (Chi et al., 2017).  
Maintaining a healthy population of mitochondria is also relevant for a proper 
lipid metabolism, since the majority of fatty acid β-oxidation occurs within this organelle. 
THs promote lipid synthesis via the activation of mTOR, which induces the expression 
of SREBP-1c, a master regulator of lipid synthesis. However, one of the most widely 
studied effects of THs is the reduction of cholesterol and lipid levels (Damiano et al., 
2017, Finan et al., 2016). On the other side, hypothyroidism is strongly associated with 
non-alcoholic fatty liver disease (NAFLD), while the use of THs and thyromimetics is a 
promising strategy to treat it (Finan et al., 2016, Ferrandino et al., 2017).  
Fatty acids are converted into fatty acyl-CoA within cells in order to use them as 
fuel for mitochondrial metabolism by β-oxidation, or for other purposes, such as 
membrane synthesis. AMP-activated protein kinase (AMPK) acts as a sensor of the 
energy status of the cell and, depending on its activity, acyl-CoA would be used to 




produce energy or would be stored. Remarkably, THs induce the activating 
phosphorylation of AMPK (Thr 172), which in turns promotes the membrane localization 
of fatty acid transport protein (FATP) and fatty acid translocase cluster determinant 36 
(CD36), enhancing fatty acids uptake to the cell. Moreover, phosphorylated AMPK 
inhibits the enzyme acetyl-CoA carboxylase (ACC) via Ser79 phosphorylation, which 
catalyses the synthesis of malonyl-CoA from acetyl-CoA. Malonyl-CoA inhibits the 
carnitine palmitoyl transferase 1 (CPT1), a protein needed for the entrance of fatty acyl-
CoA into the mitochondria. In addition to cytoplasmic AMPK, several reports have 
suggested that direct targets of THs within mitochondria can also increase β-oxidation 
rate (Sayre and Lechleiter, 2012) (Figure 9B). In this regard, Chocron et al., showed that 
T3 promotes the stabilization of the mitochondrial trifunctional protein (MTP), which 
catalyses the last three reactions (hydration, dehydrogenation, and cleavage) of the β-
oxidation of long fatty acids (Chocron et al., 2012). Through these mechanisms, both T3 
and T2 have been shown to increase fatty acid oxidation. This may explain why THs 
decrease lipid content in tissues, such as skeletal muscle and liver, despite increasing fatty 
acid import (through FATP and CD36) and lipid synthesis by inducing SREBP1c 
expression (Lombardi et al., 2012, Damiano et al., 2017).  
In addition to reducing lipid content in several tissues, THs have also been shown 
to induce several beneficial changes in whole body metabolism, such as weight loss, 
reduction of serum cholesterol and triglycerides (Moreno et al., 2011). However, both 
hypothyroidism and hyperthyroidism have been associated with metabolic problems, 
such as T2DM. Hypothyroidism is associated with decreased glucose absorption by the 
intestinal tract, insulin synthesis and glucose disposal. In contrast, hyperthyroidism 




correlates with increased glucose production and secretion by the liver, hyperinsulinemia 
and insulin resistance (Duntas et al., 2011). Therefore, the effect of THs in metabolic 








       II. OBJECTIVES 
  




Hypothesis: We hypothesize that Pax8 might be involved in diabetogenesis and glucose 
homeostasis, either directly by its expression in pancreatic islets, indirectly via the action 
of thyroid hormones or due to a combination of both. In addition, we also hypothesize 
that T4 supplementation may have a beneficial effect on glucose homeostasis.  
The main objective of this thesis is to determine the role of Pax8 and thyroid 
hormones in metabolic homeostasis and diabetogenesis. In order to do that, the following 
specific aims are addressed: 
1. Determine the role of Pax8 in pancreatic islet physiology and the development of 
gestational diabetes. 
2. Determine the role of Pax8 deficiency in the development of T2DM in male aging 
mice. 
3. Determine the effect of T4 supplementation in healthy C57BL/6 mice as well 












   III. MATERIALS & METHODS 
  




3.1 Mice management  
Procedures involving the use of live animals were approved by the CABIMER 
Animal Committee and performed in accordance with the Spanish law on animal use RD 
53/2013 and the EU Directive 2010/63/EU for animal experiments. Animals were housed 
in individually ventilated cages (Tecniplast, Buguggiate, Italy) (one to five mice per cage) 
in a specific pathogen-free facility and kept under controlled environmental conditions 
(12 hours-light–dark cycle, 23 ± 1 °C with 30–50% relative humidity). Mice were 
provided with standard rodent chow (Envigo, TD2914), unless stated otherwise, and 
sterilized tap water ad libitum. For the HFD study, a chow enriched with 65% of fat was 
used (Envigo, TD06414). 
3.2 Experimental groups 
C57BL/6J mice were used as the control wild type (WT) group in all the studies. 
Likewise, all the transgenic mice used in this thesis have a C57BL/6J genetic background. 
Pax8 knockout mice were obtained from Infrafrontiers mouse repositorium, Italy. These 
animals were originated by the replacement of the second exon of Pax8 gene with a 
neomycin cassette (Mansouri et al., 1998). RIP-B7.1 mice were supplied by Dr Bernhard 
O. Boehm (Ulm University Medical Centre, Ulm, Germany). These mice express the 
B7.1 costimulatory protein under the rat insulin promoter (RIP-B7.1) (Pechhold et al., 
2003). 
Mouse genotyping was performed by PCR in a 0.4 mm tail sample obtained at 
day 10 after birth. Extraction and amplification of genomic DNA was performed using 
the REDExtract-N-AmpTM Tissue PCR Kit (Sigma-Aldrich; 031M6112) and the 




specific primers used for the polymerase chain reaction (PCR) are outlined in table 1 
(Mellado-Gil et al., 2016, Yang et al., 2012). 
For pregnancy studies, WT and Pax8 +/- females between 3 and 6 months of age 
were used. Pax8 -/- female mice could not be used since they are infertile despite T4 
supplementation (Mittag et al., 2007). All the metabolic tests were performed at day 14 
of pregnancy, where the peak in Pax8 expression in pancreatic islets is found. Mating of 
animals was conducted overnight in a ratio of 1 male to 3-4 females. Successful mating 
was confirmed by the presence of a vaginal mucous plug the following morning. In some 
cases, (7.5 μg/g) of Poly I:C (double stranded RNA), which mimics a viral infection, was 
injected intraperitoneally from pregnancy day 1 to 5 and 8 to 14 (Figure 10A) (Moriyama 
et al., 2002). 







In order to study the role of Pax8 in the development of T2DM, WT, Pax8 +/- and 
Pax8 -/- male mice, supplemented or not with T4, were used. T4 supplementation was 
initiated at postnatal day 1 by giving a subcutaneous injection of 18 ng/g of T4 until 
weaning. After weaning 5 μg/ml of T4 was administrated in the drinking water. All the 
metabolic tests were carried out between 7 to 9 months of age. Rotarod and wirehang 
tests were performed in mice ranging from 9 to 15 months old. Moreover, animals were 
weighted monthly. A cohort of animals was sacrificed after 16 hours of fasting at 9 




months old by cervical dislocation and tissues were harvested for further analysis (Figure 
10B). A group of WT and Pax8 +/- male mice were fed with HFD from the second or 
third month of life. In this cohort fed with HFD, metabolic tests were performed between 
6-8 months of life and euthanization was performed at 7-8 months old (Figure 10C).  
In order to study the effect of T4 supplementation in glucose homeostasis in 
healthy mice, WT female mice treated or not with T4 were used. Animals were injected 
subcutaneously with 18 ng/g of T4 from postnatal day 1 until weaning. After weaning, 
50 μg/ml of T4 was administrated in the drinking water. Metabolic tests were performed 
between 2 to 4 months of age and tissues were harvested at 6 months of age (Figure 10D). 
All animals were fasted for 16 hours prior euthanization by cervical dislocation. In 
addition, 4 animals per group received an intraperitoneal dose of 0.75 U/Kg per body 
weight of insulin 15 minutes prior sacrifice. For experiments related to experimental 
autoimmune diabetes (EAD), transgenic RIP-B7.1 mice were used. T4 supplementation 
(5 μg/ml of T4 in the drinking water) was started at 6 weeks of age. EAD was triggered 
by intramuscular immunization at 8 weeks of age with 50 μg of pC1/ppins plasmid DNA 
(1 μg/μl) containing the pre-proinsulin II. At 11 weeks of age, animals were killed by 
cervical dislocation (Figure 10E). For experiments related to chemically induced diabetes 
mellitus, thirty-four-week-old male C57BL/6 mice were treated with T4 (5 μg/ml of T4 
in the drinking water) during two weeks. After 2 weeks of T4 treatment, experimental 
diabetes mellitus was triggered by two intraperitoneal injections (one each day for two 
consecutive days) of STZ (150 mg/kg). STZ was dissolved in 10 mM Na-citrate buffer 
(pH 4.5) each day (Verga Falzacappa et al., 2011). Mice were killed if circulating glucose 
levels were above 500 mg/dl for more than 96 hours (Figure 10F). 





Figure 10. Experimental groups used in this thesis and metabolic tests performed. (A) 
Pregnancy studies. (B-C) Study on Pax8 deficiency in males on standard diet (B) and on HFD 
(C). (D) Effect on T4 supplementation in healthy mice. (E) Effect on T4 supplementation in 
the RIP-B7.1 model of EAD. (F) Effect of T4 supplementation on mice treated with STZ. 
 
 




3.3 T4 determination 
To determine T4 concentration in serum, blood was collected by tail venepuncture 
in eppendorfs and incubated for 30 minutes at room temperature (RT) in order to let blood 
clot. Afterwards, blood was centrifuged at 4000 x g during 20 minutes and serum was 
collected into new tubes. T4 levels were determined using the total T4 enzyme 
immunoassay test kit (MP Biomedicals, 07BC-1007), according to the manufacturer’s 
instructions. Briefly, 25 μl of serum were placed into the antibody-coated wells and 
incubated with 100 μl of the conjugate reagent at RT for 1 hour.  After washing with 
distilled water 5 times, 100 μl of 3,3',5,5'-Tetramethylbenzidine (TMB) were added for 
colour development and incubated for 20 minutes at RT in the dark. Then, stop solution 
was added and absorbance was read at 450 nm using a Varioskan Flash spectrophotometer 
(Thermo Scientific). 
3.4 α-GSU determination.  
To determine α-GSU levels, blood was collected by tail venepuncture in EDTA 
covered tubes and centrifuged immediately at 4 ºC during 20 minutes at 4000 x g to obtain 
plasma. Then, α-GSU was determined using a commercially available kit following the 
manufacturer’s instructions (Abbexa, abx 254594). First, samples were diluted 1:100 in 
the sample diluent buffer and placed into the ELISA plate after performing two washing 
steps. The plate was incubated for 90 minutes at 37 ºC and two further washes were 
performed. Next, 100 μl of the biotin-conjugated antibody working solution were added 
into each well and incubated for 60 minutes at 37 ºC. After washing three more times, 
HRP-Streptavidin Conjugate (SABC) solution was added and left for 30 minutes at 37 




ºC. 5 washing steps were conducted before adding TMB solution and then the plate was 
incubated for 15 minutes at 37 ºC in the dark. Finally, 50 μl of the stop solution were 
added and absorbance was measured at 450 nm using a Varioskan flash 
spectrophotometer (Thermo Scientific). 
3.5 Oral glucose tolerance test (OGTT) 
OGTTs were performed at 4 post meridiem (p.m.). Animals were fasted 6 hours 
prior the experiment and received an oral dose of glucose (3 g/kg of body weight) by 
gavage. Blood glucose levels were determined by tail venepuncture using a glucose meter 
Optimum Xceed (Abbott) at 0, 15, 30, 60 and 120 minutes after the glucose load. For 
insulin measurements, blood was collected in EDTA covered tubes at times 0, 15 and 30 
minutes after the glucose load. Subsequently, blood was centrifuged at 4000 x g during 
20 minutes at 4 ºC and plasma was collected. Insulin was determined by ELISA 
(CrystalChem, 90080), according to the manufacturer’s instructions (Martin-Montalvo et 
al., 2013). 
3.6 Insulin tolerance test (ITT) 
ITTs were performed at 1 p.m. and animals were fasted 3 hours prior the 
experiment. In the studies where females were used, animals received an intraperitoneal 
insulin injection of 0.75 U·Kg-1 of body weight. In contrast, males received an insulin 
injection of 1.5 U·Kg-1 of body weight. Blood glucose levels were then determined by 
tail venepuncture using a glucose meter Optimum Xceed (Abbott) at 0, 15, 30, 60 and 
120 minutes after the insulin injection (Martin-Montalvo et al., 2013). 




3.7 Intraperitoneal pyruvate tolerance test (IPPTT) 
IPPTs were performed at 4 p.m. after mice were fasted for the previous 6 hours. 
Mice received an intraperitoneal injection of 2 g/kg of body weight of sodium pyruvate 
(Sigma-Aldrich). Blood glucose was determined by tail venepuncture using a glucose 
meter Optimum Xceed (Abbott) at 0, 15, 30, 60 and 120 minutes after the pyruvate load. 
3.8 24 hours fasting 
For the 24 hours fasting study, animals were fasted from 8 p.m. and glucose levels 
were measured at 0, 4, 6, 12, 16, 20 and 24 hours during fasting by tail venepuncture 
using a glucose meter Optimum Xceed (Abbott). 
3.9 Homeostatic model assessment: insulin resistance (HOMA-IR) 
In order to determine the HOMA-IR, glucose levels were measured by tail 
venepuncture using a glucose meter Optimum Xceed (Abbott) at 16 hours of fasting. At 
this time, blood was also collected in EDTA covered tubes and centrifuged at 4000 x g 
during 20 minutes to obtain plasma. Insulin was measured in plasma by ELISA 
(CrystalChem, 90080), according to the manufacturer’s instructions. Glucose and insulin 
levels were then used to estimate insulin resistance by the HOMA2 Calculator available 
from Oxford website (Levy et al., 1998).  
3.10 HbA1c  
HbA1c levels were determined in blood samples using Hemoglobin A1c (HbA1c) 
Assay kit (CrystalChem, 80099), according to the manufacturer’s protocol. Briefly, 5 μl 




of whole blood samples were incubated with a lysis buffer for 10 minutes to completely 
lyse the red blood cells. Then, 25 μl of the lysate was incubated in a microplate together 
with 160 μl of protease buffer for 5 minutes at 37 ºC. After that incubation, a first 
absorbance measurement was taken at 700 nm. An enzyme solution (70 μl) was further 
added and final absorbance at 700 nm was measured using a Varioskan flash 
spectrophotometer (Thermo Scientific) after another 5 minutes of incubation at 37 ºC. 
3.11 Rotarod 
Results from rotarod tests are presented as the time to fall from an accelerating 
rotarod (4–40 rpm over 5 minutes). Mice were given a 1-minute habituation trial at 4 rpm 
on the day before the experiment. Results shown are the averages of three trials per mouse 
(Mitchell et al., 2014). 
3.12 Wirehang 
For wirehang test, mice were allowed to grip a horizontal 1-mm wire with four 
paws up to 60 seconds and the latency to fall from the wire was determined. Three 
different trials were performed with each mouse (Gomez et al., 1997).  
3.13 Energy intake determination 
In order to determine the daily energy intake, 150 g of chow were placed in each 
individual cage (n = 5 wt; n = 6 Pax8 +/-). After each week, the weight of the remaining 
chow was measured for individual cages and mouse chow was added to reach 150 g. The 
total amount of chow consumed every week was then divided by the total number of mice 
in each cage. In order to determine the fasting-induced energy intake, animals were fasted 




overnight. Then, animals were individualized and 10 g were placed in each cage. The 
amount of chow consumed by each animal was measured after 4 and 8 hours (Sun et al., 
2016).  
3.14 Determination of the content of lipid in faeces.   
In order to determine faecal lipid content, the bedding of each cage was collected 
after two days in a new, clean cage. The faeces were handpicked and dried at 55 ºC for 3 
days. Then, 5 ml of 0.9 % NaCl were added to 1000 mg of powdered dried faeces. After 
vortex, 5 ml of a solution 2:1 of chloroform-methanol was added. Once centrifuged for 
10 minutes at 1000 x g, the liquid bottom phase that contained the lipids was taken, dried 
and weighted (Kraus et al., 2015). 
3.15 Transaminases determination 
Blood obtained by tail venepuncture was used to measure serum glutamic 
oxaloacetic (GOT), and serum glutamic-pyruvic transaminase (GPT). A drop of blood 
was placed in a strip for each transaminase, Reflotron GPT (ALT) (10745138) and 
Reflotron GOT (AST) (100745120), and measured using reflotron plus (Roche). 
3.16 Cholesterol determination 
Cholesterol and concentrations of high-density lipoprotein (HDL) as well as Low-
density/very low-density lipoprotein (LDL/VLDL) in serum were determined using the 
EnzyChrom AF HDL and LDL/VLDL Assay kit (BioAssay Systems, E2HL-100), 
according to manufacturer’s instructions. First, 20 μl of serum were mixed by vortex with 
20 μl of precipitation reagent. After centrifuging the samples at 9500 x g for 5 minutes, 




HDL was obtained from the supernatant. The pellet was resuspended in PBS to measure 
LDL concentration. Subsequently, 24 μl of each fraction were diluted in 96 μl of assay 
buffer. Total cholesterol was obtained by diluting 12 μl of serum in 108 μl of assay buffer. 
Next, 50 μl of each dilution were placed into a 96-well plate and incubated for 30 minutes 
at RT together with 50 μl of a working solution containing the enzyme mix and dye 
reagent. Finally, absorbance was read at 570 nm using a Varioskan flash 
spectrophotometer (Thermo Scientific).  
3.17 Triglyceride determination  
 Triglycerides were determined using an EnzyChrom Triglyceride Assay Kit 
(BioAssay Systemsm, ETGA-200). In order to measure the concentration of triglycerides 
in plasma, samples were diluted 5-fold in Milli-Q water. In order to determine triglyceride 
content within liver and gastrocnemius, tissues were homogenized in 5% Triton-X100 
(Sigma-Aldrich) using a mortar and pestle. The supernatant was taken after centrifuging 
at 18000 x g during 5 minutes. Next, 10 μl of samples were placed into a 96 well together 
with 100 μl of the working reagent (containing 100 μl of assay buffer, 2 μl of enzyme 
mix, 5 μl of lipase, 1μl of ATP and 1 μl of dye reagent). The plate was then incubated for 
30 minutes at RT and the absorbance was measured at 570 nm using a Varioskan flash 
spectrophotometer (Thermo Scientific).  
3.18 Lipidomics 
In order to determine the different composition of fatty acids in WAT, liver and 
skeletal muscle, 20 mg of each tissue was weighted and homogenized using a polytron 
(PRO250 Homogenizer, PRO Scientific) in 350 μl of a solution 3:2 of hexane-




isopropanol, 0,1% BHT (Hara and Radin, 1978). Tissues were then incubated overnight 
at 4 ºC and, subsequently, 250 μl of sodium sulphate were added. After centrifugation at 
2000 x g for 80 seconds the upper hexane rich layer was analysed for different lipid 
species by gas chromatography by Enrique Force’s group at Instituto de la Grasa.  
3.19 Isolation of islets 
Mice were sacrificed by cervical dislocation and pancreatic islets were isolated by 
injecting 0.7 mg/ml of collagenase type V (Sigma-Aldrich) into the pancreas by 
cannulation of the Winsur duct. After the extraction, the pancreas was incubated for 10 
minutes at 37 ºC in a water bath. Then, islets were handpicked (Jimenez-Moreno et al., 
2015). 
3.20 Human islets 
Human islets were kindly provided by Dr. D. Bosco (The Cell Isolation and 
Transplantation Centre, Department of Surgery, Geneva, Switzerland) and were cultured 
in CMRL-1066 (Cellgro) supplemented with 10% FBS, 100 U/ml penicillin, 100 μg/ml 
streptomycin and 100 μg/ml gentamycin (Sigma-Aldrich) (Jimenez-Moreno et al., 2015). 
The characteristics of the donors used for this thesis are outlined in table 2. 
Table 2. Donors from which human pancreatic islets were obtained. 
Donor Islet Viability Islet Purity Islet Size Average Islet Size 
Number #1 80 % 80 % 50-400 µm 100-200 µm 
Number #2 80 % 80 % 50-400 µm 100-200 µm 
Number #3 88 % 88 % 50-400 µm 100-200 µm 
Number #4 90 % 70 % 50-400 µm 100-200 µm 
Number #5 95 % 90 % 50-400 µm 100-200 µm 
Number #6 95 % 90 % 50-400 µm 100-200 µm 




3.21 Lentivirus production 
For production of lentiviruses, 6 × 106 Hek293T cells were seeded into a 100 mm 
Petri dish (Nunc) and cultured for 24 hours. Then, cells were transfected with 2.29 ug/per 
plate of the transfer vector pHRSIN, harbouring or not the gene of interest (human PAX8 
or murine Pax8) under the Spleen Focus-Forming Virus (SFFV) promoter and the green 
fluorescent protein (GFP) marker under the constitutive ubiquitin promoter, already 
available in our laboratory (Jimenez Moreno, 2015). Transfection was then performed 
using the LipoD293 DNA In Vitro Transfection Reagent (SignaGen Laboratories) (45 μl 
per plate). In addition, two human immunodeficiency virus packaging plasmids were 
added at the following concentrations: pCMVDR8.91 (1.53 μg/ per plate) and pVSVG 
(0.76 μg/ per plate). Lentiviruses were harvested 72 hours post-transfection, passed 
through a 0.45 μm Millex-HV filter (Merck Millipore), and concentrated by 
ultracentrifugation in an Optima TM L-100K ultracentrifuge at 87300 x g for 90 minutes 
at 4 ºC in a swinging rotor SW-28 (Beckman-Coulter). Virus particles were resuspended 
in serum-free DMEM (Invitrogen) and stored at −80 °C until used. In order to determine 
lentiviral particle titers, Hek293T cells were seeded at a confluence of 105 cells, in a 
twelve-well plate. Then, lentiviral particles were added and titer was estimated by flow 
cytometry 72 hours post-infection (FACSCalibur, BD Biosciences) (Jimenez-Moreno et 
al., 2015). 
3.22 Transduction of pancreatic islets  
Freshly isolated islets were cultured for 3 hours for recovery in 2.5 ml of complete 
RPMI medium (Sigma) supplemented with 10% Fetal Bovine Serum (FBS) (Sigma), 100 




U/ml penicillin, 100 μg/ml streptomycin (Sigma-Aldrich), 2 mM glutamine (Sigma-
Aldrich), 1 mM sodium pyruvate (Sigma-Aldrich), 50 μM β-mercaptoethanol (Gibco) 
and HEPES 10 mM (Gibco). Then, islets were incubated with 1000 μl of warm (37 ºC) 
0.5 X trypsin-EDTA (250 mg/L trypsin; 0.48 mM EDTA) for 3 minutes in a cell culture 
incubator (37 ºC, 5% CO2). The 0.5 X trypsin-EDTA was prepared from Trypsin-EDTA 
10 X (5000 mg/l trypsin; 9.6 mM EDTA) (Gibco) diluted in Hanks Balanced Salt Solution 
(HBSS) 1 X (Gibco). In order to inhibit trypsin activity, 1000 μl of RPMI complete 
medium were added and islets were centrifuged at 50 x g for 2 minutes. Afterwards, the 
supernatant was removed and islets were resuspended in 100 μl of serum free RPMI. 
Lentiviruses were added at multiplicity of infection (MOI) 20, assuming that a single islet 
has 1000 cells. Pancreatic islets were incubated over-night in a cell culture incubator (37 
ºC, 5% CO2) and medium was changed to 200-500 μl of complete RPMI medium 
(Jimenez-Moreno et al., 2015). For optimal lentiviral transduction and viability of islets, 
experiments were carried out at 72 hours post-infection. 
3.23 Transcriptomic analysis by RNA microarray 
Total RNA from at least 200 islets of 3 different donors transduced either with a 
lentiviral vector harbouring PAX8 or GFP (control) was extracted using the RNeasy 
Micro Kit (Qiagen, 74034), according to the manufacturer’s instructions. Briefly, islets 
were homogenized in 350 μl of RLT lysis buffer containing β-mercaptoethanol (10 μl of 
β-mercaptoethanol in 1 ml RLT buffer) using a syringe. After centrifuging for 3 minutes 
at 20000 x g the supernatant was taken and 1 volume of ethanol 70% was added. The 
sample, was next transferred to a RNeasy MinElute spin column placed in a 2 ml 
collection tube and centrifuged for 15 s at ≥ 8000 x g. The spin column was further 




centrifuged 15 s at 8000 x g after adding 350 μl of RW1 buffer, which is used to wash 
membrane-bound RNA. Subsequently, 80 μl of a DNase solution were added and 
incubated for 15 minutes at RT. Then, 350 μl of RW1 buffer were added and the spin 
column was centrifuged for 15 s at 8000 x g. Next, 500 μl of RPE buffer, which is also 
used to wash membrane-bound RNA, were added. After another centrifugation for 15 s 
at 8000 x g, 500 μl of 80% ethanol were added and the spin column was centrifuged for 
2 minutes at 8000 x g. Total RNA was eluted in 14 μl of RNase free water.  
Subsequent microarray was performed by the Genomic core facility of CABIMER 
using standard protocols. Briefly, 20 ng of total cRNA per sample were hybridized to 
GeneChip Human Gene 2.0 ST (Affymetrix) and the signal reading was performed with 
the Scanner 3000 7G (Affymetrix). Data were processed with the software Affymetrix 
GeneChip Command Console 2.0, generating the *CEL files (containing the 
hybridization raw data) and *CHP files (containing the normalized data). SST-RMA 
(Signal Space Transformation-Robust Microarray Analysis) was the method followed for 
the normalization, since it makes a background correction and a normalization, enabling 
the expression comparisons. Results were analysed using the platform Ingenuity Pathway 
Analysis (IPA) (Ingenuity, USA) as well as the transcriptome analysis console (TAC) 
software (Affimetrix) by personnel from our laboratory. 
3.24 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
Groups of 35 islets were handpicked to determine the metabolic activity of the 
islets using a Cell Proliferation Kit I (MTT), according to the manufacturer’s protocol 
(Roche, Spain). Briefly, islets were incubated with 0.5% MTT for 4 hours. Then, blue 




formazan crystals were solubilized overnight with 100 μl of solubilization solution. 
Optical density was determined at 550 nm with a reference wavelength of 650 nm, using 
a Varioskan Flash spectrophotometer (Thermo Scientific) (Jimenez-Moreno et al., 2015). 
3.25 Glucose stimulated insulin secretion (GSIS) 
GSIS was performed to assess islet functionality. Groups of 10 islets were washed 
in 500 μL of Krebs-Ringer bicarbonate-HEPES buffer (KRBH) (140 mM NaCl, 3.6 Mm 
KCl, 0.5 mM NaH2PO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 2 mM NaHCO3, 10 mM 
HEPES, 0.1 % bovine serum albumin (BSA)) and pre-incubated at 37 °C for 45 minutes 
in 300 μl of the same buffer. Islets were then centrifuged and KRBH buffer was discarded. 
Subsequently, fresh KRBH supplemented with 2.5 mM glucose was added and islets were 
incubated for 30 minutes. Then, buffer was harvested (basal insulin secretion) and 500 
μL of KRBH supplemented with 22 mM glucose were added. Islets were incubated for 
an additional 30 minutes at 37 °C and the buffer was harvested (glucose induced insulin 
secretion). Insulin levels were measured using a mouse insulin ELISA kit according to 
the manufacturer’s instructions (Crystal Chem, 90080). Stimulation index was expressed 
as the ratio of insulin levels at 22 mM glucose divided by insulin levels at 2.5 mM glucose 
(Mellado-Gil et al., 2016). 
3.26 Cell death determination 
Groups of 10 islets were handpicked to determine the degree of apoptosis using a 
Cell death detection ELISA plus kit, according to the manufacturer’s instructions (Roche, 
Spain). Briefly, islets were lysed with 200 μl of a lysis buffer and centrifuged at 200 x g 
for 10 minutes. Then, 20 μl of the supernatant was placed into the ELISA plaque and 




incubated for 2 hours with 80 μl of the immunoreagent. After the incubation period, 
samples were washed three times with the incubation buffer and incubated for 10 minutes 
with 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid (ABTS) solution for colour 
development. Optical density was determined at 405 nm with a reference wavelength of 
490 nm using a Varioskan Flash spectrophotometer (Thermo Scientific). 
3.27 Genetic screening 
PAX8 genetic screening was performed in collaboration with Dr. José Moreno at 
La Paz hospital in Madrid. In order to determine whether PAX8 genetic variants could be 
associated with the development of GDM in concurrence with gestational thyroid 
dysfunction (GTD), a strict selective inclusion criterion was used to define the human 
cohort of study: 
1. Patients presented hypothyroidism: Free levothyroxine T4 < 0.90 ng/dl or TSH > 2.5 
mU/l during first trimester of pregnancy or TSH > 3 mU/l during the second/third 
trimesters of pregnancy of non-autoimmune nature (negative presence of circulating Tg 
and TPO antibodies). 
2. Patients were diagnosed with GDM by OGTT under internationally accepted criteria.  
3. Patients reported family history of non-autoimmune hypothyroidism and/or T2DM. 
Exclusion criteria were: 
1. Patients not taking iodine supplements. 
2. Obese patients (BMI> 30). 
After obtaining written informed consent, blood was collected and genomic DNA 
was extracted from peripheral leukocytes utilizing the Chemagen DNA Blood Kit in the 




Chemagic TM automated system (Perking Elmer). The entire coding sequence of the 
human PAX8 gene was amplified by PCR under standard conditions. Primers are 
described in table 2. DNA sequencing was performed in an ABI370 Sequencer and 
analysed with Sequencher. The study was approved by the Local Ethical Committee. 
3.28 PAX8 site directed mutagenesis and cloning of PAX8 variants 
The human and murine PAX8 wild type variants cloned into the pHRSIN DUAL-
GFP easy vector were already available in our laboratory. Polymorphisms on PAX8 
(P25R and T356M) were introduced using a technical service provided by GenScript 
(Piscataway, NJ) in the pGEM-T easy vector.  
The pGEM-T easy vectors containing PAX8 variants and the PCDNA3.1 vector 
(already available in our laboratory) were digested with 0.5 μl of BamHI and NotI 
overnight at 4 ºC. Correct digestion was analysed by electrophoresis in a 0.5% agarose 
gel dissolved in TBE 1X and containing 0.1 μg/l of ethidiumbromide. DNA fragments 
were then obtained from the agarose gel and purified using the QIAquick Gel Extraction 
Kit (Qiagen, 28704), according to manufacturer’s instructions. For ligation, 17.5 ng of 
the inserts were ligated with 50 ng of the PCDNA3.1 vector following a molar ratio of 
1:3. Reaction was catalysed by 1 μl of T4 DNA ligase (Promega) and was left for 1 hour 
at 37 ºC. Then, DNA was added to 50 μl of competent cells. The bacteria were maintained 
on ice for 15 minutes before receiving a heat shock at 42 °C for 1 minute. The cells were 
then incubated for 30 minutes at 37 °C with constant shaking in LB Broth. Next, cells 
were plated on a warm LB/agar plate with ampicillin. Successful colonies were selected 
and correct ligation was first verified by digestion. Moreover, the correct sequence of all 




PAX8 constructs was verified by direct sequencing using the service provided by the 
CNIO (Madrid).   
3.30 Luciferase reporter assay 
The Luciferase reporter assay was performed at La Paz hospital in collaboration 
with Dr. José Moreno’s group. Briefly, the human thyroglobulin gene promoter (hTg), 
which is a PAX8 target, was subcloned into the firefly luciferase reporter plasmid. Then 
it was transfected in HEK293T cells along with expression vectors for the Thyroid 
Transcription Factor 1 (TTF1; also known as NKX2.1) in combination with PAX8Wt, 
T356M or P25R using the FuGENE6 reagent (Promega Biotech Iberica, Madrid, Spain). 
To correct for transfection efficiency, Renilla-encoding pRL-CMV vector was co-
transfected in all cases. Cellular extracts were collected 48 hours post-transfection, and 
Dual-Luciferase Reporter Assay (Promega) was performed according to the 
manufacturer’s instructions. The ratio between the luciferase and Renilla activities was 
expressed relative to the ratio obtained in cells transfected with reporter and empty 
expression vector (pcDNA3). 
3.31 PAX8 variants stability and subcellular localization  
MCF-7 cells, which do not express PAX8, were grown in DMEM medium 
supplemented with 10% FBS and 1% penicillin and streptomycin (Invitrogen).  
In order to study the protein stability of PAX8 variants, 3 x 105 MCF-7 cells were 
seeded in 6 well plates and transiently transfected using the PCDNA3.1 constructs 24 
hours later. For transfection in 6 well plates, 4 μg of DNA and 10 μl of lipofectamine 




2000 (Invitrogen) both resuspended in 250 μl of Optimem medium were used for each 
well. 24 hours after transfection, 80 μg/ml of cycloheximide were added. Cells were 
frozen in liquid nitrogen and processed for protein extraction to perform western blots at 
the following times: 24 hours after transfection and before cycloheximide treatment 
(referred as time 0 h); 48 hours post transfection and thus 24 hours after cycloheximide 
treatment (referred as time 24 h); 72 hours post transfection and 48 hours post 
cycloheximide treatment (referred as time 48 h). 
To determine whether the subcellular localization of PAX8 variants was affected, 
3x104 MCF-7 cells were seeded in 12 mm diameter glass coverslips (Menzel-Glaser) in 
24 well plates. Transfection was performed 24 hours later using 1.6 μg of DNA and 2 μl 
of lipofectamine 2000 (Invitrogen), both resuspended in 50 μl of Optimem medium. 24 
hours post transfection, cells were washed with PBS 1X 3 times and fixed with 100% 
Methanol at -20 ºC for immunofluorescence.  
3.32 Western blots 
Cells and tissues were lysed in radioimmunoprecipitation assay buffer (RIPA 
buffer: 20 mM Tris-HCl, 150 mM NaCl, 1 mM Na2-EDTA, 1 mM EGTA, 1% NP-40, 
1% sodium deoxycholate) with 1% Phosphatase Inhibitor Cocktails (P0044 and P5725, 
Sigma-Aldrich), 1% Protease Inhibitor Cocktail (P8340, Sigma-Aldrich) and 1% 
Deacetylation Inhibition Cocktail (SC-362323, Santa Cruz Biotechnology). Cells were 
lysed in 50 μl of RIPA buffer per well using a syringe, whereas approximately 10 mg of 
tissues were homogenized using a Polytron (PRO250 Homogenizer, PRO Scientific) in 




250 μL of RIPA buffer per sample. The resulting lysates were centrifuged at 20.000 x g 
for 10 minutes (4 ºC) and supernatants were harvested. 
Colorimetric assessment at 595 nm using a Varioskan Flash (Thermo Scientific) 
with Quick StartTM Bradford 1x Dye Reagent (BioRad) was used to determine the 
concentration of protein samples. A series of known concentrations of BSA were used 
for the calculation of a standard absorbance-concentration curve. 
Protein solutions were prepared with Laemmli loading buffer (4% SDS, 10% 2-
mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 0.125 M Tris HCl, pH 6.8) 
and then heated at 95 ºC during 4-5 minutes. SDS-PAGE (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis) was performed under reducing conditions at constant 
voltage (100 V) in 1.5 mm 12% polyacrylamide gels with discontinuous buffer system. 
The polyacrylamide gels had two differentiated parts: the stacking gel (5% 
polyacrylamide, 0.1% SDS, 125 mM Tris-HCl, 0.1% ammonium persulfate, 0.025% 
TEMED (N,N,N’,N’-tetramethylethylenediamine), pH 6.8); and the resolving gel (12% 
polyacrylamide, 0.1% SDS, 375 mM Tris-HCl, 0.1% ammonium persulfate, 0.025% 
TEMED, pH 8.8). The stacking gel promotes the compaction of the proteins at the same 
level (the Kohlrausch frontier), enabling an equal beginning of the protein migration 
through the resolving gel. In each gel, 20 μg of proteins were loaded per well.  
Transference from gel to nitrocellulose membrane was performed with Trans-Blot 
Turbo Transfer System (Bio-Rad), following predetermined Bio-Rad protocols. To check 
equal and appropriate loading and transference, ponceau staining was made (0.1% 
Ponceau S (w/v) in 5% acetic acid). Then, membranes were blocked with Tris-buffered 




saline 1X +0.1% Tween (TBST), containing 4% of BSA shaking at 50 rpm for 1 hour in 
a Heidolph Rotamax 120 shaker. Afterwards, primary antibody incubation was made 
overnight on rotation at 4 ºC in TBST-BSA 4%. The antibodies used are outlined in table 
3. Next day, membranes were washed for 15 minutes 3 times with TBST containing 4% 
of skim milk. Horseradish peroxidase (HRP)-conjugated secondary antibody incubation 
was then made for 1 hour in TBST-milk 4% (Table 3). Then, membranes were washed 
three times for 15 minutes each with TBST-milk 4% and three times with TBST. The 
development was made using Clarity Western ECL Substrate (Bio-rad).  
3.33 Immunohistochemistry  
3.33.1 Immunofluorescence in cultured cells 
After fixing the cells with 100% methanol at -20 ºC, cells were washed 3 times 
with Phosphate Buffered Saline (PBS) 1X (8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g 
KH2PO4, pH 7.4, adjust to 1 L with H2O) for 5 minutes (each wash) and blocked with 
PBS + 0.2% Tween, containing 2% of BSA for 45 minutes. Then, cells were incubated 
with the corresponding primary antibodies diluted in PBS + 0.2% Tween-BSA 2% 
overnight at 4 ºC (Table 3). The next day, cells were washed with PBS 1X three times for 
5 minutes each and incubated with matching secondary antibodies conjugated with 
fluorophores diluted in PBS + 0.2% Tween for 1 hour at RT (Table 3). After performing 
three washing steps with PBS 1X, nuclear counterstaining was performed by DAPI 
staining (10 μg/ml; Sigma-Aldrich) diluted 1:1000 in PBS for 5 minutes at RT. Finally, 
cells were washed three times with PBS for 5 minutes each and mounted using DAKO 
fluorescent mounting medium (Dako). 




3.33.2 Immunofluorescence and immunohistochemistry in tissues and cultured islets 
Tissues were fixed in 4% of paraformaldehyde for 24 hours at 4 ºC, while 
approximately 100 mouse islets were fixed in 10% Formalin (Panreac Appli. Chem) for 
48 hours at RT. Subsequently, islets were mixed with approximately 100 μl of 150-300 
μm diameter Affi-Gel blue beads (Bio-Rad) and included in warm (70 ºC) HistoGel 
(Thermo Scientific) (Cozar-Castellano et al., 2004). Histogel containing the islet-bead 
mixture or tissues were then embedded in paraffin following the standard procedures of 
CABIMER Histology Core facility.  
Paraffin blocks were sectioned (5 μm thickness) using a microtome Leica RM 
2255 (Leica Microsystems) and mounted on SuperFrost Plus slides (Menzel-Glaser). 
Sections were deparaffinized/rehydrated in the oven at 60 ºC for 15 minutes followed by 
immersion in decreasing concentrations of ethanol (Xylene 5 minutes/2 x; Ethanol 100% 
1 minute/2 x; Ethanol 96% 1 minute; Ethanol 80% 1 minute; Ethanol 70% 1 minute; 
Distilled water 5 minutes/2 x). After deparaffinization and rehydration, sections were 
subjected to heat-induced antigen retrieval. Antigen retrieval was performed in 10 mM 
sodium citrate buffer (pH 6.0) either in an autoclave for 10 minutes at 121 ºC or in the 
microwave in 3 cycles of 3 minutes (with 2 minutes at RT between heating cycles) at 800 
W, avoiding the boiling of the buffer. Samples were cold down in the same solution for 
20 minutes at RT. For Horseradish peroxidase (HRP) immunohistochemistry, 
endogenous peroxidase was blocked by incubating sections with a solution of 3% 
hydrogen peroxide for 15 minutes. After washing with PBS1 X for 3 times, blocking was 
performed with PBS + 0.2% Triton containing 3% of Donkey serum (Sigma-Aldrich) (for 
immunofluorescence) or 3% BSA (for immunohistochemistry) for 1 hour at RT. Primary 




antibodies at the indicated dilutions were added in PBS + 0.2% Triton X-100 containing 
1% BSA and incubated overnight at 4 ºC in a dark humid chamber (Table 3). 
Subsequently, sections were washed with PBS, followed by PBS + 0.2% Triton X-100 
and PBS for 5 minutes each. Then, samples were incubated with secondary antibodies 
(Table 3) diluted in PBS + 0.2% Triton X-100 containing 0.1% BSA for 1 hour at RT in 
a dark humid chamber. For immunofluorescence, nuclear counterstaining was performed 
by DAPI staining (10 μg/ml; Sigma-Aldrich) diluted 1:1000 in PBS for 5 minutes at RT 
and sections were mounted using DAKO fluorescent mounting medium (Dako). For 
immunohistochemistry, visualization of the immunoreaction was performed using 
Vectastain Elite ABC (Vector Laboratories) and 3,3′-diaminobenzidine (DAB) substrate 
(Vector Laboratories), according with the manufacturer’s instructions. The colour 
reaction was stopped and sections were washed 3 times with PBS 1X. Dehydration of the 
tissues was subsequently performed by placing the slides in an ascending ethanol series 
(70%, 80%, 90%, 96%, 2×100% ethanol for 1 minute each one) and through two changes 
of xylene for 1 and 5 minutes, respectively. Then, sections were mounted with DPX 
(Sigma-Aldrich) and air-dried. After intensity quantification, sections were 
counterstained with hematoxylin (Merck).  
Table 3. Antibodies used in this thesis.  
Antibody Dilution Vendor Catalog number 
Anti-Ki67 1:150 Leica Microsystems NCL-L-Ki67-MM1 
Biotin-rabbit anti-mouse 1:300 Sigma-Aldrich B8520 
Alexa fluor 555 donkey anti-
mouse 
1:800 Thermofisher A31579 
Alexa fluor 647 donkey anti-
rabbit 
1:800 Thermofisher A31573 
Alexa fluor 488 donkey anti-
goat 
1:800 Thermofisher A11055 




Anti-insulin (H-86) 1:500 Santa Cruz Biotecnology SC9168 
Anti-insulin 1:500 Sigma-Aldrich I2018 
Anti-somastotatin 1:100 Santa Cruz 
Biotechnology 
SC-7819 
Anti-glucagon 1:100 Sigma-Aldrich G2654 
Anti-glucokinase 1:50 Santa Cruz 
Biotechnology 
SC-7908 
Anti-Pax8 1:100 WB 
1:20 IF 
Abcam Ab124445 
Anti-cleaved caspase 3 1:150 Cell Signaling 9661S 
Anti-GFP 1:200 Abcam Ab6673 
Anti-MAFA 1:200 Bethyl Laboratories IHC-00352 
Anti-β-catenin 1:200 Cell signaling 9582 
Anti-IR-β 1:200 Santacruz Biotechnology SC-711 
Anti-IRS1 1:200 Santacruz Biotechnology SC-599 
Anti-pTyr 632 IRS1 1:200 Santacruz Biotechnology SC-17196 
Anti-PI3K 1:1000 Cell Signaling 4292 
Anti-pSer473 AKT 1:500 Cell Signaling 9271 
Anti-AKT 1:1000 Cell Signaling 9272 
Anti-pSer256 FOXO1 1:300 Cell Signaling 9461 
Anti-FOXO1 1:1000 WB; 
1:100 IF 
Cell Signaling 2880 
Anti-GSK3β 1:200 Santacruz Biotechnology SC-9166 
Anti-pThr202/pTyr204 ERK 1:1000 Cell Signaling 9106 
Anti-ERK 1:1000 Cell Signaling 9102 
Anti-GAPDH 1:1000 Cell Signaling 2118 
Anti-β-actin 1:5000 Sigma-Aldrich A2228 
Anti-pThr172 AMPK 1:1000 Cell Signaling 2535 
Anti-AMPK 1:1000 Cell Signaling 2532 
Anti-LC3B 1:1000 Cell Signaling 2775 
Anti-UCP2 1:200 Santa Cruz 
Biotechnology 
SC-6526 
Anti-VDAC 1:1000 Abcam 15895 
Anti-PGC1α 1:1000 Santa Cruz 
Biotechnology 
SC-517380 
Anti-4HNE 1:1000 Millipore 393206 
HRP-goat anti-rabbit 1:5000 Sigma-Aldrich A0545 
HRP-rabbit anti-mouse 1:5000 Sigma-Aldrich A9044 








3.34 Tunel assay 
For the terminal deoxynucleotidyl transferase dUTP nick end labelling (Tunel) 
staining, the InSitu Cell Death Detection Kit, Fluorescein was used according to 
manufacturer’s instructions (Sigma-Aldrich). Briefly, paraffin sections were 
deparaffinized/rehydrated as previously described and incubated for 15 minutes at RT 
with Proteinase K. Then, slides were rinsed with PBS 1X 3 times for 5 minutes each and 
incubated for 30 minutes at RT in Tris-HCl, 0.1 M pH 7.5, containing 3% BSA and 20% 
FBS. Afterwards, 50 μl per section of Tunel reaction mixture were added. After 1 hour of 
incubation in a humid chamber, slides were washed with PBS 1X 3 times during 5 
minutes each. Then, slides were incubated with a primary antibody overnight, and the 
protocol described above for immunofluorescence was continued.  
 3.35 Hematoxylin and eosin staining 
Paraffin sections were deparaffinized/rehydrated as previously described and 
slides were immersed into hematoxylin (Merck) for 4 minutes. Then, sections were rinsed 
with abundant tap water. Subsequently, slides were placed in acid ethanol for 
approximately 5-10 seconds and further rinsed with tap water. Samples were immersed 
in eosin (Merck) for 2 minutes followed by another washing step with tap water. Finally, 
sections were dehydrated as described above and mounted with DPX (Sigma-Aldrich).  
3.36 Electron Microscopy  
For electron microscopy, tissues were fixed in 4% PFA with 2% glutaraldehyde 
in PBS for 72 hours at 4 ºC (Hinova-Palova et al., 2014). Then, they were washed with 




PBS three times and stored in PBS with 0.2% sodium azide. Images were taken at the 
Príncipe Felipe Institute in Valencia core facility by Mario Soriano. 
3.37 Image Quantifications 
Western blots were quantified with ImageJ software and normalized to the 
corresponding housekeeping gene (GAPDH). Likewise, the intensity of DAB 
immunohistochemical staining and the area of adipocytes were quantified using ImageJ 
software. Quantifications of cell number/percentage were performed manually using 
adobe photoshop.  
3.38 Mitochondrial electron transport chain activities 
 In order to measure the activity of mitochondrial complexes and superoxide 
generation, 10 mg of liver and gastrocnemius of WT and Pax8 +/- mice were used. Tissues 
were homogenized using a glass conical tissue grinder in 250 μl of a sucrose 
homogenization buffer 250 mM pH 7.4 (0.121 g of Tris, 0.15 g of KCL, 0.038 g of EDTA 
and 4.27 g of sucrose in 50 ml of distilled water) (Spinazzi et al., 2012).  
3.38.1 Complex I+III activity 
 15 μg of gastrocnemius extracts or 50 μg of liver extracts were incubated for 2 
minutes in a 1ml cuvette containing 765 or 755 μl of distilled water, respectively, in order 
to induce an osmotic shock. Subsequently, 100 μl of potassium phosphate buffer (0.5 M, 
pH 7.5), 20 μl of fatty acid-free BSA (50 mg/ ml), 30 μl of KCN (10 mM) (Sigma-
Aldrich) and 50 μl of oxidized cytochrome c (1mM) (Millipore) were added. After mixing 
with a pipette a first read at 550 nm was taken for 2 minutes using a DU-800 




spectophotometer (Beckman Coulter). The reaction was then started by adding 20 μl of 
NADH (10 mM) (Sigma-Aldrich) and the increase in absorbance was measured at 550 
nm for 3 minutes using a DU-800 spectrophotometer (Beckman Coulter). The specific 
activity was calculated assuming a extinction coefficient for reduced cytochrome c of 
18.5 mM-1 cm-1 (Spinazzi et al., 2012).  
3.38.2 Complex II+III activity 
 15 μg of gastrocnemius or 50 μg of liver extracts were incubated for 10 minutes 
in a 1-ml cuvette containing 860 or 850 μl of distilled water (respectively), 40 μl of 
potassium phosphate buffer (0.5 M, pH 7.5), 30 μl of KCN (10 mM) (Sigma-Aldrich) and 
25 μl of succinate (40 mM) (Sigma-Aldrich). The reaction was started by adding 50 μl of 
oxidized cytochrome c (1 mM) (Millipore). Then the increase in absorbance at 550 nm 
was measured for 3 minutes using a DU-800 spectophotometer (Beckman Coulter). The 
specific activity was calculated assuming a extinction coefficient for reduced cytochrome 
c of 18.5 mM-1 cm-1 (Spinazzi et al., 2012).  
3.38.3 Superoxide generation 
50 μg of gastrocnemius extracts or 100 μg of liver extracts were incubated for 2 
minutes in 735 μl of distilled water. Subsequently, 100 μl of potassium phosphate buffer 
(0.5 M, pH 7.5), 20 μl of fatty acid-free BSA (50 mg/ ml), 30 μl of KCN (10 mM) (Sigma-
Aldrich) and 50 μl of partially acetylated cytochrome c (1mM) (Sigma-Aldrich) were 
added. After mixing with a pipette a first read at 550 nm was taken for 2 minutes using a 
DU-800 spectophotometer (Beckman Coulter). The reaction was then started by adding 
20 μl of a solution containing equal amounts of NADH (10 mM) and succinate (400 mM) 




and the increase in absorbance was measured at 550 nm for 3 minutes using a DU-800 
spectrophotometer (Beckman Coulter). The specific activity was calculated assuming an 
extinction coefficient of 18.5 mM-1 cm-1 (Martin-Montalvo et al., 2013). 
3.38.4 Citrate synthase  
 15 μg of gastrocnemius extracts or 50 μg of liver extracts were added to a 1-ml 
cuvette containing 320 or 310 μl of distilled water, 500 μl of Tris (200 mM, pH 8.0) with 
0.2% of Triton X-100 (Sigma-Aldrich), 100 μl of 5,5'-Dithiobis-(2-Nitrobenzoic Acid) 
(DTNB) (Sigma-Aldrich), and 15 μl of acetyl coenzyme A (10 mM) (Sigma-Aldrich). 
After mixing with a pipette, the baseline activity was measured at 412 nm for 2 minutes. 
Then, the reaction was started by adding 50 μl of oxaloacetic acid (10 mM) and 
absorbance was read at 412 nm for 3 minutes using a DU-800 spectrophotometer 
(Beckman Coulter). The specific activity was calculated assuming a extinction coefficient 
of 13.6 mM-1 cm-1 (Spinazzi et al., 2012).  
3.39 RT- PCRs 
Total RNA was extracted from frozen skeletal muscle and liver samples using the 
Easy-blue RNA extraction kit (Intron Biotechnologies). Briefly, tissues were 
homogenized using a Polytron (PRO250 Homogenizer, PRO Scientific) in 200 μl of easy-
BLUE (Trizol). Then, 40 μl of Chloroform were added, vortex, and the sample was 
centrifuged at 18000 x g at 4 ºC for 10 minutes. The upper layer was transferred into 
another tube where isopropanol was added (80 μl) and incubated for 10 minutes at RT. 
After centrifuging samples at 18000 x g for 10 minutes at 4 ºC, the supernatant was 
removed and 75 % ethanol was added to the RNA pellet. Finally, another centrifugation 




step was performed, the pellet was air-dried and diluted in 20 μl of RNase free water. For 
islet experiments RNA was extracted using the RNeasy Micro Kit (Qiagen), according to 
manufacturer’s instructions. Complementary DNA (cDNA) was synthesized using 
random hexamers (Roche) and Superscript II Reverse transcriptase (Invitrogen).  
Genomic DNA for mitochondrial DNA determinations, was extracted using the 
DNeasy Blood & tissue kit (QIAGEN, 60504), according to manufacturer’s protocol. 
Briefly, ~5 mg of gastrocnemius and livers from WT and Pax8 +/- animals were lysed in 
180 μl of ATL buffer and 20 μl of proteinase K, mixed by vortexing and incubated 
overnight at 56 ºC. After vortex, 200 μl of the buffer AL and 200 μl of ethanol (96-100%) 
were added and mixed by vortexing thoroughly. Then, samples were transferred to the 
DNeasy Mini spin column and centrifuged at 6000 x g for 1 minute. Next, 500 μl of buffer 
AW1 were added. After centrifuging at 6000 x g for 1 minute, 500 μl of buffer AW2 were 
added. Subsequently, the spin column was centrifuged for 3 minutes at 20000 x g in order 
to dry the membrane. Finally, in order to elute the DNA, 100 μl of buffer AE were added 
directly into the membrane, incubated for 1 minute at RT and centrifuged for 1 minute at 
6000 x g.  
The RT-PCR was performed on individual cDNAs or genomic DNA (for the 
mitochondrial DNA determination) using SYBR green (Roche). Primer sequences are 
presented in Table 4. The mRNA expression was calculated by the 2−ΔΔCT method and 
normalized to the expression of β-actin or RPS29.  
 
 




Table 4. Primers used for RT-PCR in this thesis.  

























































































































































3.40 Statistical analysis 
For comparisons between two groups, statistical significance was calculated using 
non-paired two-tailed student’s t-test using Excel software, except in the case were values 
were normalized to 1, in which a Mann-Whitney Rank Sum Test was performed. For 
comparisons between more than 2 groups a one-way ANOVA or two-way ANOVA tests 
were performed. If values were relativized to 1, ANOVA on ranks (Kurstal-Wallis) was 
performed. For metabolic tests (OGTT, ITT etc), repeated measurements two-way 
ANOVA tests were performed. Except for the t-tests, all the statistical analyses were 
performed using Graph Pad (Prism 6) and/or SigmaPlot 12.5 software. For all analyses, 
p-value < 0.05 was considered statistically significant. Errors are represented as the 
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AIM 1: Determine the role of Pax8 in pancreatic islet physiology and the 





N.B: Results presented herein are part of a manuscript entitled “A novel association of a 
mutation in PAX8 with Gestational Diabetes Mellitus underlies the transient role of this 
transcription factor in human islet survival” currently under revision in Diabetes in which 
I am second author.  
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4.1.1 Apoptotic signalling is modulated upon PAX8 over-expression in pancreatic 
islets 
In order to investigate cellular processes modulated by PAX8 and its target genes 
in human pancreatic islets, a microarray was performed using human pancreatic islets 
transduced with GFP (mock) or PAX8. Principal Component Analysis (PCA) 
demonstrated a clear effect of PAX8 over-expression on the transcriptional profile of 
human pancreatic islets (Figure 11A). As expected, the most up-regulated gene was 
PAX8, indicating the efficiency of lentiviral-mediated PAX8 over-expression. 
Additionally, translationally controlled tumour protein (TPT1) and HSPA1A were found 
among the most induced genes in PAX8 over-expressing human pancreatic islets (Figure 
11B). Remarkably, TPT1 has been shown to inhibit apoptosis by promoting p53 
degradation, while HSPA1A belongs to the heat shock protein70 gene family and also 
has antiapoptotic properties (Amson et al., 2011, Boia-Ferreira et al., 2017, Dulin et al., 
2012). Moreover, other upregulated genes in PAX8 overexpressing islets, such as 
DNAJC22 and CCT6A, encode for chaperones involved in proper protein folding. A 
comparison of the microarray performed in human pancreatic islets with the previous one 
preformed on murine islets (see introduction), revealed that the most upregulated genes 
and the functional enriched pathways were species specific. However, some genes, such 
as the serotonin receptor HTR3B, were regulated similarly in human and murine islets 
overexpressing PAX8 (Figure 11C). 
  Remarkably, the analysis of human islets revealed changes in apoptosis 
and WNT signalling, which is involved in organogenesis and stem cell proliferation 
(Figure 11D) (Komiya and Habas, 2008). In addition, further analysis using IPA software 
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of annotated “Diseases and Functions” associated preferentially the transcriptional profile 
of human islets over-expressing PAX8 to several endocrine/metabolic disorders and cell 
cycle/cell death/cancer (Figure 11E). Of note, IPA software does not discern between 
potential protections or predisposition to the disease. The overall interpretation of these 
results is that the induction of PAX8 expression in human pancreatic islets exerts 
profound modulations in apoptotic signalling. 
 
Figure 11. PAX8 overexpression in pancreatic islets modulates apoptotic signalling and 
endocrine/metabolic disorders. (A) PCA analysis. (B) Most upregulated genes in human 
islets over-expressing PAX8. (C) Heat map depicting the expression values of shared 
significantly modulated genes in murine and human pancreatic islets over-expressing PAX8. 
(D) Canonical pathways modulated by PAX8 over-expression in human pancreatic islets. (E) 
Diseases associated with PAX8 over-expression. n = 3 per group. 
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4.1.2 PAX8 over-expression reduces apoptosis in murine and human pancreatic 
islets 
In order to further investigate the physiological role of PAX8 in pancreatic islets, 
freshly isolated murine pancreatic isles were transduced with an “empty” lentivirus 
(mock), a Pax8 (murine) lentivirus or a PAX8 (human) lentivirus (Figure 12A-B). Islet 
metabolic activity, determined by MTT, was similar in both Pax8-transduced and PAX8-
transduced murine pancreatic islets when compared to mock-transduced murine 
pancreatic islets (GFP:100 % vs. Pax8:117 ± 35 % and PAX8: 98 ± 14 %, p-value = 0.584 
one-way ANOVA on ranks) (Figure 12C). Additionally, islet functionality, determined 
by glucose-stimulated insulin secretion (GSIS), was unaffected upon Pax8 or PAX8 
transduction of murine pancreatic islets (GFP: 2.65 ± 0.4-fold induction vs. Pax8: 2.65 ± 
0.53-fold induction and PAX8: 2.52 ± 0.82-fold induction, p-value = 0.985 one-way 
ANOVA) (Figure 12D).  
In contrast, consistent with the microarray data, the over-expression of both PAX8 
and Pax8 in murine pancreatic islets produced a reduction on apoptosis, as determined by 
cell death ELISA (GFP: 100% vs. Pax8: 63 ± 11% and PAX8: 77 ± 7%, p-value = 0.008, 
one-way ANOVA on ranks) (Figure 12E). Likewise, human pancreatic islets transduced 
with the human PAX8 lentivirus also exhibited reduced apoptosis when compared to 
mock-transduced human islets (GFP: 100% vs. PAX8: 81 ± 0.46%, p-value = 0.001 Mann 
Whitney Rank Sum test), suggesting that the anti-apoptotic role of PAX8 in pancreatic 
islets is evolutionarily conserved between mice and humans (Figure 12F). In addition, 
immunohistochemical determination of cleaved-caspase 3 expressing cells confirmed the 
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reduction on the percentage of apoptotic cells in murine pancreatic islets (GFP: 17 ± 1.6% 
vs. Pax8: 8.47 ± 2.23%, p-value = 0.035 t-test two tailed) (Figure 12 G-H). 
                                         
Figure 12. Lentiviral mediated PAX8 over-expression reduces apoptosis in human and 
murine pancreatic islets. Human or murine pancreatic islets were transduced with mock (GFP 
control), murine Pax8 (Pax8) or human Pax8 (PAX8) lentiviral vectors. (A, B) Determination 
of the transduction efficiency by flow cytometry. (A) Population of cells analysed according to 
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their size (FSC) and granularity (SSC). FSC: forward scattered light. SSC: side scattered light. 
(B) Flow cytometry histograms showing the number of events plotted against GFP 
fluorescence. The line indicates the threshold for positivity. (C) Determination of metabolic 
activity using the MTT assay in murine islets. n = 4-7 per condition. (D) Determination of GSIS 
in murine islets. n = 3-4 per condition. (E) Determination of the degree of apoptosis measured 
by ELISA in murine islets. n = 5-8 per group. (F) Determination of apoptosis rate by ELISA in 
human islets. n = 3 per group. (G) Determination of the percentage of cleaved Caspase 3 
positive cells in murine pancreatic islets. n = 3 per group. (H) Representative images of GFP 
(marker of positive transduction) and cleaved Caspase 3 staining in murine pancreatic islets. 
Immunofluorescence followed by DAPI staining. Scale bar = 50 μm. Data is represented as the 
mean ± SEM. * p < 0.05 compared to mock transduced islets, one-way ANOVA on ranks 
(Krustal-Wallis) in panels C and E, one-way ANOVA in panel D, Mann Whitney Rank Sum 
test in panel F and t-test two tailed applied to panel G. 
4.1.3 A novel PAX8 detrimental polymorphism associates with GDM and GTD 
Our results indicating that Pax8 expression is induced in islets during gestation 
and that it promotes β-cell survival, suggest that this transcription factor may be involved 
in β-cell adaptation during pregnancy. Moreover, GTD has been associated with GDM 
and PAX8 is essential for proper thyroid function (Tudela et al., 2012, Guzman-Gutierrez 
et al., 2014, Karakosta et al., 2012). Therefore, it is tempting to speculate that detrimental 
polymorphisms in PAX8 may be associated with GDM. In order to address this 
possibility, our collaborators at La Paz Hospital conducted a genetic screening (see 
materials and methods for selective criteria) in patients with GDM and GTD. 
Interestingly, exon sequencing analysis of PAX8 locus in a patient cohort of 7 families, 
identified a woman in pedigree 3 bearing a novel heterozygous variant (c.1067C>T). This 
missense mutation causes a threonine to methionine substitution at codon 356 (p.T356M), 
located at the carboxyterminal region of the protein (Figure 13A-B). The location of the 
mutation on PAX8 is unusual, since almost all the thyroid relevant PAX8 polymorphisms 
known are located at the N-terminal DNA-binding domain. Importantly, the index patient 
was diagnosed with GTD and GDM in her 4 pregnancies. In addition, her father, who 
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also harbours the mutation, was diagnosed with pre-diabetes (HbA1c = 6.7%) at the age 
of 55. Likewise, several family members of the pedigree were diagnosed with T2DM 
and/or non-autoimmune hypothyroidism, although they were not accessible for 
genotyping (Figure 13A). To rule out the possibility of a common polymorphism in 
PAX8, the presence of PAX8-T356M was searched in 100 alleles from individuals of the 
same genetic background. None of these individuals harboured the PAX8-T356M variant 
(Method of Arbitrary Function <0.00034). Moreover, this mutation has not been 
documented in the Exome Variant Server (http://evs.gs.washington.edu/EVS/) or the 
dbSNP (http://www.ncbi.nlm.nih.gov/snp/), further indicating that PAX8-T356M is not 
a common PAX8 variant. Remarkably, an in silico analysis using SIFT, PolyPhen and 
PredictSNP software suggested that this polymorphism might be deleterious (Table 5).  
Table 5. In silico prediction scores for the PAX8 p.T356M (c.1067C>T) variant. 
SIFT PolyPhen-2 PredictSNP 
0.04-damaging1 0.882-possibly damaging2 51%-deleterious3 
• 1 Prediction score from <0.05 (probably damaging) to >0.05 (probably tolerated). 
http://sift.jcvi.org/  
• 2 Prediction score from 0 (probably benign) to 1 (probably damaging). 
http://genetics.bwh.harvard.edu/pph2  
• 3 Expected accuracy score. https://loschmidt.chemi.muni.cz/predictsnp1  
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Figure 13. The novel PAX8-T356M variant identified in the genetic screening is 
pathogenic but does not affect protein stability or subcellular localization. (A) 
Representative image of the family pedigree with gestational diabetes as well as T2DM and 
hypothyroidism in several generations. The arrow indicates the index case. (B) Sequencing 
chromatogram of the mutation in the index patient and wild type sequence in a healthy relative 
as well as schematic representation of PAX8 protein with annotated known mutations, 
including T356M. (C) Luciferase reporter assay. n = 3 per group. (D) Representative western 
blots showing PAX8-Wt, PAX8-T356M, and PAX8-P25R protein levels in transfected MCF-
7 cells at times 0, 24 and 48 hours after cycloheximide treatment (80 μg/ml). n = 3 per condition. 
(E) Densitometric analysis of western blots shown in panel D. (F) Representative 
immunofluorescence image of MCF-7 cells transfected with PAX8-Wt, PAX8-T356M or 
PAX8-P25R showing the subcellular localization of each PAX8 variant. n = 3 per condition. 
Data are represented as the mean ± SEM, * p-value < 0.05 compared to PAX8 Wt one-way 
ANOVA test. 
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We next focused to determine whether mutations on PAX8 associated with GDM 
affect the functionality of this transcription factor. To this end, our collaborators at La paz 
hospital analysed by luciferase reporter assay the transactivation potential of wild-type 
PAX8 (Pax8-Wt), PAX8-T356M and PAX8-P25R (see the introduction) on the Tg gene 
promoter. Importantly, PAX8-P25R was previously shown to lack DNA binding capacity 
while retaining nuclear localization (Carvalho et al., 2013). Remarkably, transfection with 
PAX8-T356M or PAX8-P25R variants resulted in decreased luciferase activity compared 
to Pax8-Wt, indicating that both variants have compromised transcriptional activity 
(Figure 13C). However, protein stability, as determined by protein levels after 
cycloheximide treatment, and the subcellular localization of GDM-associated PAX8 
variants were similar to those of wild-type PAX8 (Figure 13D-F). 
4.1.4 Female Pax8 +/- mice do not develop GDM  
In order to determine whether Pax8 deficiency is associated with GDM in an 
animal model, we next performed several metabolic tests in WT and Pax8 +/- female mice 
under regular physiological conditions and at day 14 of pregnancy (when there is a peak 
in Pax8 expression in murine pancreatic islets). Pax8 -/- mice could not be used since they 
are infertile despite T4 supplementation.  
Surprisingly, non-pregnant Pax8 +/- female mice showed decreased levels of 
circulating glucose 30 minutes after a glucose load compared to non-pregnant WT female 
mice (Figure 14A). However, no significant differences between genotypes were found 
at any other time point measured during the OGTT and in the area under the curve (AUC) 
for this experiment (Figure 14A-B). Likewise, no significant differences between 
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genotypes were found at any time point measured during the ITT and thus in the AUC 
for this experiment (Figure 14C-D). Interestingly, Pax8 +/- pregnant mice had increased 
circulating glucose levels compared to Pax8 +/- non-pregnant mice at 15 and 30 minutes 
after the insulin injection. The same tendency could be observed between non-pregnant 
and pregnant WT mice, which could suggest that there is indeed some degree of insulin 
resistance during pregnancy in both genotypes.  
Since Pax8 overexpression in murine pancreatic islets modulated several genes 
within the interferon pathway (see introduction), we speculated that Pax8 may be 
involved in immune signalling. Remarkably, viral infections have been associated with 
increased risk of developing GDM (Lao et al., 2007). Therefore, we next investigated 
whether Pax8 +/- female mice were more prone to develop GDM when challenged with 
Poly I:C (double stranded RNA that mimics viral infections). To this end, we performed 
an OGTT at day 14 of pregnancy in WT and Pax8 +/- mice who received intraperitoneal 
injections of Poly I:C from pregnancy days 1-5 and 8-14. No differences were observed 
in glucose clearance between treated Pax8 +/- mice and WT animals, while significant 
differences where observed 30 minutes after the glucose load between non-pregnant mice 
from both genotypes and their counterparts during pregnancy (Figure 14E). These results 
suggest that Poly I:C treatment may contribute to the development of glucose intolerance 
during pregnancy. However, no differences were observed in the AUC between the 
different experimental groups (Figure 14F). 
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Figure 14. Pax8 +/- female mice exhibit normal glucose tolerance during pregnancy. (A) 
Circulating glucose levels during an OGTT. n = 11 WT, n = 8 Pax8 +/-, n = 8 WT pregnant, n 
= 11 Pax8 +/- pregnant. (B) AUC for the OGTT. (C) Glucose levels in blood during an ITT. n 
= 10 WT, n = 9 Pax8 +/-, n = 5 WT pregnant, n = 9 Pax8 +/- pregnant. (D) AUC for the ITT. 
(E) Circulating glucose levels during an OGTT performed in animals treated with Poly I:C. n 
= 7 WT + Poly I:C, n = 5 for all the remaining experimental groups. (F) AUC for the OGTT 
performed in mice treated with Poly I:C. Data are represented as the mean ± SEM. * p-value < 
0.05 between WT and Pax8 +/- mice. # p-value < 0.05 between non-pregnant and pregnant 
mice from the same genotype. Repeated measurements two-way ANOVA in A, C and E. Two-
way ANOVA in B, D and F.  
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Noteworthy, circulating T4 levels were similar between Pax8 +/- and WT female 
mice (WT: 5.16 ± 0.21 μg/dl vs. Pax8: 4.92 ± 0.17 μg/dl, p-value = 0.407 t-test two tailed) 
(Figure 15), which could suggest a potential genetic compensation for Pax8 
haploinsufficiency. However, it is also important to note that T4 levels were not measured 
during pregnancy. 
                              
Figure 15. Pax8 +/- female mice have similar circulating T4 levels than WT. Circulating 
T4 levels of WT and Pax8 +/- female mice at 5 months old. n = 6 per group. No significant 
differences were observed in a t-test two tailed (p-value = 0.407). 
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AIM 2: Determine the role of Pax8 deficiency in the development of T2DM in male 





N.B: Results presented herein are part of a manuscript currently under preparation in 
which I am first author. Running title: “The thyroid hormone axis in metabolic health”.  
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4.2.1 Pax8 +/- male mice exhibit reduced circulating T4 levels  
 The analysis of our pedigree might suggest an association of PAX8-T356M with 
prediabetes/T2DM (Figure 13A). Moreover, a polymorphism nearby PAX8 was 
associated with T2DM in an Afro-American population by a genome wide study (Elbein 
et al., 2009). Therefore, we next investigated whether a deficiency in Pax8 could be 
associated with T2DM in mice. To this end, we studied the metabolic status in WT, Pax8 
+/- and Pax8 -/- male mice.  
In contrast to females, untreated Pax8 +/- male mice displayed reduced T4 levels 
in blood compared to WT animals (WT: 3.71 ± 0.10 μg/dl vs. Pax8 +/-: 3.33 ± 0.12 μg/dl, 
p-value = 0.029 t-test two tailed) (Figure 16). Nonetheless, these mice were 8 months old, 
suggesting that the reduction in circulating T4 levels in Pax8 +/- mice may be developed 
with advancing age.  
.                                                  
Figure 16. Pax8 +/- male mice exhibit reduced circulating T4 levels. T4 levels in serum 
from WT and Pax8 +/- male mice. n = 23 WT, n = 15 Pax8 +/-. Data are represented as the 
mean ± SEM. * p-value < 0.05 t-test two tailed. 
Importantly, no differences in T4 levels have been observed in Pax8 +/- mice 
compared to WT at postnatal days 7, 21 and postnatal week 22 (Glaschke et al., 2010). 
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However, Mansouri et al. observed an increase in TSH levels in Pax8 +/- mice and 
Pax8+/−TRα1−/− mice (which also have a deficiency in the thyroid hormone receptor α1) 
exhibit decreased T4 levels around weaning (Mansouri et al., 1998, Mittag et al., 2005) 
4.2.2 Pax8 +/- male mice show glucose intolerance and insulin resistance  
In order to determine whether Pax8 deficiency affects metabolic homeostasis and 
whether it is due to its effect in TH concentration, we performed several metabolic tests 
in WT and Pax8 +/- male mice supplemented or not with T4 from postnatal day 1 (18 
ng/g of body weight per day by subcutaneous injections) until weaning, followed by T4 
administration in the drinking water (5 µg/ml ad libitum). Importantly, the treatment 
increased circulating T4 levels in both genotypes (WT: 3.71 ± 0.10 μg/dl vs. WT+T4: 
12.77 ± 1.62 μg/dl, p-value < 0.0001 and Pax8 +/-: 3.33 ± 0.12 μg/dl vs. Pax8 +/-+T4: 
14.85 ± 2.83 μg/dl, p-value < 0.0001, t-test two tailed).  
Untreated Pax8 +/- male mice exhibited glucose intolerance, as determined by 
increased glucose levels at times 15 and 30 minutes after a glucose load and an increased 
AUC during the OGTT (WT: 25217 ± 894 arbitrary units (a.u.) vs. Pax8 +/-: 30715 ± 916 
a.u., p-value = 0.008 two-way ANOVA). In contrast, no differences were found in 
circulating glucose levels between WT and Pax8 +/- animals treated with T4 (Figure 17A-
B). Insulin levels during the OGTT were not affected in untreated Pax8 +/- mice, whereas 
Pax8 +/- mice treated with T4 had a lower peak of insulin secretion 15 minutes after the 
glucose load and a lower AUC for the experiment (WT: 195 ± 41 a.u. vs. Pax8 T4: 95 ± 
11 a.u., p-value = 0.035 two-way ANOVA) (Figure 17C-D).  
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We next performed an IPPTT to investigate whether gluconeogenesis was affected 
in Pax8 +/- mice. Untreated Pax8 +/- mice had increased glucose levels in blood 
compared to untreated WT animals at 60 and 120 minutes after the pyruvate load and an 
increased AUC during the IPPTT (WT: 21919 ± 1273 a.u. vs. Pax8 +/-: 28168 ± 1941 
a.u., p-value = 0.0153 two-way ANOVA) (Figure 17E-F). Of note, this increase in the 
last time points with an unaffected peak during the IPPTT may be indicative of insulin 
resistance rather than enhanced gluconeogenesis. Consistent with that, untreated Pax8 +/- 
animals displayed severe insulin resistance, as determined by increased glucose levels in 
blood 30, 60 and 120 minutes after an intraperitoneal insulin injection, and increased 
AUC during the ITT (WT: 13451 ± 955 a.u. vs. Pax8: 20277 ± 618 a.u., p-value < 0.0001 
two-way ANOVA) (Figure 17G-H). Importantly, significant differences in the OGTT, 
IPPTT and ITT between untreated Pax8 +/- and WT male mice were maintained even 
when values where relativized by basal glucose levels (Figure 18A-C). 
Further confirming insulin resistance, untreated Pax8 +/- mice had an increased 
value for the HOMA-IR index (WT: 2.84 ± 0.42 a.u. vs. Pax8 +/-: 4.40 ± 0.13 a.u., p-
value = 0.006 two-way ANOVA) (Figure 19A-C). Importantly, no significant differences 
were observed between Pax8 +/- male mice treated with T4 and untreated WT mice in 
the ITT or the HOMA-IR, demonstrating that T4 supplementation prevents the 
development of insulin resistance in Pax8 +/- mice (Figure 17G-H and 19A-C). 
Moreover, untreated Pax8 +/- male mice exhibited increased levels of HbA1c (WT: 5.7 
± 0.55% vs. Pax8 +/-: 7.02 ± 0.43%, p-value = 0.0207 two-way ANOVA), which 
indicates long term-increased glucose levels in blood (Figure 19D). 
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Figure 17. Untreated Pax8 +/- male mice exhibit glucose intolerance and insulin 
resistance. (A) Circulating glucose levels during an OGTT. n = 8 per group. (B) AUC for the 
OGTT. (C) Circulating insulin levels during an OGTT. n = 8 per group. (D) AUC for the insulin 
levels in the OGTT. (E) Circulating glucose levels during an IPPTT. n = 8 per group. (F) AUC 
for the IPPTT. (G) Circulating glucose levels during an ITT. n = 8 per group. (H) AUC for the 
ITT. Data are represented as the mean ± SEM. * p-value < 0.05 between untreated WT and 
untreated Pax8 +/- mice. # p-value < 0.05 between untreated WT and Pax8 +/- mice treated 
with T4. Repeated measurements two-way ANOVA in A, C, E and G and two-way ANOVA 
in all the other panels. 
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Figure 18. Glucose levels in metabolic tests expressed as percentage of basal glucose. (A) 
Glucose concentration in blood during the OGTT expressed as the percentage of basal glucose. 
n = 8 per group. (B) Glucose concentration in blood during the IPPTT expressed as the 
percentage of basal. n = 8 per group. (C) Glucose concentration in blood during the ITT 
expressed as the percentage of basal. n = 8 per group. * p-value < 0.05 Mann-Whitney Rank 
Sum test. 
Consistent with the insulin resistance observed in metabolic tests, western blots 
performed in liver extracts of untreated WT and Pax8 +/- mice revealed a decrease in 
pSer473 AKT (WT: 100 ± 5.84% vs. Pax8 +/-: 82.57 ± 3.63%, p-value = 0.039 t-test two 
tailed), while total AKT levels were not altered (Figure 19E and G). In contrast, pSer473 
AKT levels were increased in gastrocnemius extracts of Pax8 +/- mice compared to WT 
(WT: 100 ± 11.36% vs. Pax8 +/-: 138.31 ±11.72%, p-value = 0.040 t-test two tailed), 
while no differences were observed in total AKT levels (Figure 19F and H). Therefore, 
our results suggest an impairment of insulin signalling preferentially in the liver of Pax8 
+/- male mice. 
                                                                                                                RESULTS  
   
96 
 
              
Figure 19. Pax8 +/- male mice exhibit increased HOMA-IR index and impaired insulin 
signalling in liver. (A) Glucose levels in blood after 16 hours of fasting. n = 8 per group. (B) 
Circulating insulin levels after 16 hours of fasting. n = 8 per group. (C) HOMA-IR. n= 8 per 
group. (D) Percentage of HbA1c. n = 7 per group. (E) Western blots showing total AKT and 
pSer473 AKT in liver extracts of untreated WT and Pax8 +/- mice. (F) Western blots showing 
AKT and pSer473 AKT in gastrocnemius extracts of untreated WT and Pax8 +/- mice. (G) 
Densitometric analysis of western blots shown in panel E. n = 6 per group. (H) Densitometric 
analysis of western blots shown in panel F. n = 6 per group. Mice were fasted 16 hours prior 
sacrifice. Data are represented as the mean ± SEM. * p-value < 0.05. Two-way ANOVA in 
panels A-D. T-test two tailed in panels G-H. 
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Next, we analysed the pattern of expression of Pax8 by RT-PCR in main metabolic 
tissues during adulthood in WT animals, in order to determine whether a deficiency of 
Pax8 expression in any metabolic tissue could contribute to the phenotype observed. 
However, Pax8 expression was not detected in any of the main metabolic tissues tested 
as compared to kidney (Figure 20). These results further indicate that the phenotype 
observed is mainly due to lower circulating T4 levels.  
                                         
Figure 20. Pax8 expression is not detected in main metabolic tissues during adulthood. 
Relative mRNA expression of Pax8 in main metabolic tissues compared to kidney expression. 
Kidneys: n = 6; Liver: n = 6; Gastrocnemius: n = 6; Pancreatic islets: n = 3; WAT: n = 6; BAT: 
n = 6; Brain: n = 6. Data are represented as the mean ± SEM. 
4.2.3 Pancreatic islets from Pax8 -/- and Pax8 +/-  mice are normally developed 
THs are known to promote postnatal pancreatic islet development and maturation 
through MafA (Aguayo-Mazzucato et al., 2013). Moreover, we and others have shown 
that Pax8 expression is induced during gestation in pancreatic islets, suggesting that Pax8 
could be expressed in the endocrine compartment of the pancreas under different 
metabolic circumstances. Therefore, it is tempting to speculate that the lack of one or two 
alleles of Pax8 could result in abnormal islet architecture. In order to determine whether 
pancreatic islets of Pax8 +/- and Pax8 -/- mice are affected, we carried out 
                                                                                                                RESULTS  
   
98 
 
immunohistochemical analyses determining insulin, glucagon and somatostatin positive 
cells in pancreatic sections from WT, Pax8 +/- and Pax8 -/- male mice at postnatal day 
21. No significant differences were found between experimental groups in the percentage 
of these endocrine cells within pancreatic islets. Moreover, the overall morphology of 
pancreatic islets was similar between different genotypes (Figure 21A-D).  
       
 
Figure 21. Pancreatic islets from WT, Pax8 +/- and Pax8 -/- animals exhibit similar 
morphology. (A) Representative immunofluorescence images of pancreatic sections from 
untreated WT, Pax8 +/- and Pax8 -/- male mice at postnatal day 21. n = 4 per group. (B) 
Percentage of insulin positive cells within the islet. n = 4 per group. (C) Percentage of glucagon 
positive cells within the islet. n = 4 per group. (D) Percentage of somatostatin positive cells 
within the islet. n = 4 per group. In all cases, at least 1000 endocrine cells per animal were 
counted. Data are represented as the mean ± SEM.  
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4.2.4 Pax8 +/- male mice exhibit increased body weight  
Remarkably, untreated Pax8 +/- male mice exhibited increased body weight 
compared to WT between 7 to 13 months old, while animals treated with T4 from both 
genotypes displayed reduced body weight from month 6 until they died due to T4 toxicity 
around 12-16 months of age (Figure 22).  
            
Figure 22. Untreated Pax8 +/- male mice exhibit increased body weight. Body weights (g) 
of WT and Pax8 +/- male mice treated or not with T4 as well as Pax8 -/- mice treated with T4. 
Note that untreated Pax8 -/- mice die at weaning. Data are represented as the mean ± SEM. * 
p-value < 0.05 Repeated measurements two-way ANOVA. 
At 9 months of age (when a cohort of untreated WT and Pax8 +/- mice were 
sacrificed) the WAT of Pax8 +/- mice was heavier than the WAT from WT animals (WT: 
1.123 ± 0.23 g vs. Pax8 +/-: 1.77 ± 0.15 g, p-value = 0.043, t-test two tailed), even when 
relativized by total body weight (WT: 3.01 ± 0.49% of body weight, Pax8 +/-: 4.43 ± 
1.99% of body weight, p-value = 0.033 t-test two tailed) (Figure 23A-B). Consistent with 
this, a strong tendency towards increased adipocyte area was observed in Pax8 +/- male 
mice at this age (WT: 1644 ± 200 μm2 vs. Pax8 +/-: 3194 ± 458 μm2, p-value = 0.13 t-
test two tailed) (Figure 23C-D). However, the lipidomic analysis did not reveal any 
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differences between Pax8 +/- and WT mice in the composition of different fatty acid 
species within WAT (Figure 23E).  
      
         
Figure 23. Untreated Pax8 +/- male mice exhibit increased WAT weight. (A) Organs and 
tissues weight at 9 months of age. n = 6 per group. (B) Organs and tissue weight at 9 months 
of age relativized by total body weight. n = 6 per group. (C) Representative images of 
hematoxylin and eosin staining of WAT sections. n = 3 WT, n = 2 Pax8 +/-. Scale bar = 100 
μm. (D) Quantification of adipocyte area. n = 3 WT, n = 2 Pax8 +/-. (E) Lipidomic analysis 
depicting percentage of lipid species in WAT. n = 6 per group. Data are represented as the 
mean ± SEM. * p-value < 0.05 t-test two tailed. 
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4.2.5 Pax8 +/- male mice exhibit compromised performance on rotarod and 
wirehang tests 
Despite having increased body and WAT weight, untreated Pax8 +/- male mice 
did not show increased daily energy intake. In contrast, fasting induced energy intake was 
reduced when compared to WT animals (WT: 5.05 ± 0.22 kcal/8hours, Pax8 +/-: 3.85 ± 
0.29 kcal/8hours, p-value = 0.003 t-test two tailed) (Figure 24A-B). Moreover, faecal 
lipid content was similar in both genotypes (Figure 24C).  
Surprisingly, no significant differences were found in plasma triglycerides, while 
total cholesterol was decreased in Pax8 +/- mice compared to WT (WT: 122 ± 9.53 mg/dl 
vs. Pax8 +/-: 87 ± 6.99 mg/dl, p-value = 0.012, t-test two tailed) (Figure 24D and E). 
However, this was due to a reduction in the high-density lipoprotein (HDL) fraction (WT: 
86 ± 4.10 mg/dl vs. Pax8 +/-: 60 ± 4.07 mg/dl, p-value < 0.0001 t-test two tailed) (Figure 
24E). Next, we measured glutamic oxaloacetic transaminase (GOT) and glutamic-pyruvic 
transaminase (GPT) in serum as markers of liver damage. Unexpectedly, Pax8 +/- animals 
exhibited decreased levels of GPT, while no differences were observed in GOT levels 
(Figure 24F-G). In order to determine the overall health status of Pax8 +/- mice, animals 
were challenged on rotarod and wirehang tests. Pax8 +/- mice performed poorly on 
rotarod test, as determined by the reduced time (s) in falling from an accelerating rotarod 
(WT: 111 ± 2.82 s vs. Pax8 +/-: 88.7 ± 5.25 s, p-value = 0.0005 t-test two tailed) (Figure 
24H). Similarly, a significantly shorter latency to fall in Pax8 +/- mice was observed in 
the wirehang test (WT: 25.7 ± 2.3 s vs. Pax8 +/-: 11.9 ± 2.03 s, p-value < 0.0001 t-test 
two tailed) (Figure 24I). Therefore, our results suggest that Pax8 +/- male mice exhibit an 
overall unhealthy status.  
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Figure 24. Untreated Pax8 +/- male mice exhibit lower HDL content in plasma and 
perform poorly in rotarod and wirehang tests. (A) Basal Daily energy intake. n = 5 cages 
WT, n = 4 cages Pax8 +/-. (B) Fasting induced energy intake. n = 20 WT, n = 14 Pax8 +/-. (C) 
Lipid content in faeces. n = 7 WT, n = 6 Pax8 +/-. (D) Triglycerides concentration in plasma. 
n = 18 WT, n = 13 Pax8 +/-. (E) Total cholesterol in plasma and HDL as well as LDL levels. 
n = 6 per group. (F) Serum levels of GPT. n = 7 per group. (G) Serum levels of GOT. n = 7 
per group. (H) Time to fall from an accelerating rotarod in seconds (s). n = 27 WT, n = 20 Pax8 
+/-. (I) Time to fall in wirehang test (s). n = 27 WT, n = 20 Pax8 +/-. Data are represented as 
the mean ± SEM. * p-value < 0.05 t test-two tailed. 
4.2.6 Pax8 +/- male mice exhibit increased triglyceride content in both liver and 
skeletal muscle 
 Hematoxylin and eosin analyses of the liver of Pax8 +/- animals revealed that 
Pax8 +/- animals displayed increased lipid content in this tissue. Accordingly, triglyceride 
content was increased in the liver of Pax8 +/- mice compared to WT (WT: 33.77 ± 5.49 
nmol/mg of protein vs. Pax8 +/-: 57.17 ± 3.62 nmol/mg of protein, p-value = 0.007 t-test 
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two tailed) (Figure 25A-B).  Likewise, the intramuscular lipid content in the 
gastrocnemius of Pax8 +/- animals was increased as observed by hematoxylin and eosin 
staining as well as by triglyceride determination (WT: 14.77 ± 4.26 nmol/mg of protein 
vs. Pax8 +/: 28.01 ± 2.15 nmol/mg of protein, p-value = 0.033 t-test two tailed) (Figure 
25A and C).  
        
Figure 25. Pax8 +/- mice exhibit increased triglyceride content in both liver and 
gastrocnemius. (A) Representative images of haematoxylin and eosin staining of liver and 
gastrocnemius sections from WT and Pax8 +/- mice. n = 6 per group. Scale bar = 100 μm. (B) 
Triglyceride content per mg of protein in liver. n = 6 WT, n = 4 Pax8 +/-. (C) Triglyceride 
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content per mg of protein in gastrocnemius. n = 5 WT, n = 4 Pax8 +/-. (D) Lipidomic analysis 
depicting percentages of the different species of fatty acids in livers of WT and Pax8 +/- mice. 
n = 5 WT, n = 6 Pax8 +/-. (E) Lipidomic analysis depicting percentages of the different species 
of fatty acids in gastrocnemius of WT and Pax8 +/- mice. n = 6 per group. (F) mRNA 
expression of genes involved in lipid synthesis/import and inflammation in livers from WT and 
Pax8 +/- mice. SREBP1-c: n = 6 per group; SREBP2: n = 6 per group; FASN: n = 6 per group; 
CD36: n = 6 WT, n = 5 Pax8 +/-; LDLR: n = 4 WT, n = 6 Pax8 +/-; SOCS2: n = 4 WT, n = 6 
Pax8 +/-; IL-1β: n = 5 WT, n = 6 Pax8 +/-; TNF-α: n = 5 WT, n = 6 Pax8 +/. (G) mRNA 
expression of genes involved in lipid synthesis/import in gastrocnemius from WT and Pax8 +/- 
mice. SREBP1-c: n = 6 WT, n = 5 Pax8 +/-; CD36: n = 5 WT, n = 6 Pax8 +/-. Data are 
represented as the mean ± SEM. * p-value < 0.05 t-test two tailed.  
Moreover, the lipidomic analysis revealed a significant increase in the percentage 
of 18:1n9 and 18:1n7 fatty acid species in livers from Pax8 +/- mice compared to WT, 
while no significant differences were observed in gastrocnemius (Figure 25D-E). 
Remarkably, the expression of SREBP-1c and CD36, which are involved in lipid 
synthesis and lipid uptake into the cell, respectively, was induced in livers but not 
gastrocnemius of Pax8 +/- mice (Figure 25F-G). However, no significant differences 
were observed in pro-inflammatory markers such as IL-1β in the liver of Pax8 +/- mice 
(Figure 25F).  
4.2.7 Superoxide production is increased in livers from Pax8 +/- male mice, although 
mitochondrial content is not affected  
 Both mitochondrial dysfunction and increased activity have been associated with 
insulin resistance (Holmström et al., 2012, Jelenik et al., 2017). In addition, mitochondria 
are the major site of β-oxidation. Therefore, we next investigated whether mitochondria 
content and function were affected in Pax8 +/- male mice compared to WT.  
Surprisingly, the expression of medium chain acyl-CoA dehydrogenase (MCAD), 
which catalyses the first step in β-oxidation of medium chain fatty acids, was increased 
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in livers of Pax8 +/- mice compared to WT. In contrast, no differences were observed in 
mRNA levels of CPT1 and LCAD, which are involved in the import of fatty acids into 
the mitochondria and long chain fatty acid β-oxidation, respectively (Figure 26A) (Sayre 
and Lechleiter, 2012, Huang et al., 2014).  
Interestingly, both ATP synthase subunit α (ATP5a) and PGC1-α expression were 
increased in liver but not gastrocnemius of Pax8 +/- mice compared to WT (Figure 26A-
D). In contrast, UCP2 expression was decreased in the liver of Pax8 +/- mice as 
determined by both RT-PCR and western blots (WT: 100 ± 12.58 % vs. Pax8 +/-: 58.32 
± 13.81%, p-value = 0.049), while no differences were observed in gastrocnemius extracts 
(Figure 26A-F). The increase in ATP5a coupled to a decrease in UCP2 levels could 
suggest that ATP production is enhanced in the liver of Pax8 +/- mice. Consistent with 
this hypothesis, pThr172 AMPK protein levels, which indicate the energetic status of the 
cell, were reduced in liver (WT: 100 ± 28.61% vs. Pax8 +/-: 22.90 ± 7.21%, p-value = 
0.042 t-test two-tailed) but not in gastrocnemius extracts of Pax8 +/- mice compared to 
WT. However, no differences were found in total AMPK protein levels in any metabolic 
tissue tested (Figure 26C-F).  
Noteworthy, mRNA levels of genes encoding for proteins found at mitochondrial 
complexes were not altered in either liver or gastrocnemius of Pax8 +/- mice compared 
to WT (Figure 26A-B). Likewise, no differences were observed in VDAC protein levels, 
indicating that mitochondrial content is not affected in these tissues (Figure 26C-F). 
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Figure 26. Pax8 +/- mice exhibit increased ATP5A and PGC1-α expression in the liver, 
while UCP2 is downregulated. (A) mRNA expression of genes involved in β-oxidation, 
mitochondrial biogenesis and function in the liver of WT and Pax8 +/- mice. CPT1: n = 5 WT, 
n = 6 Pax8 +/-; LCAD: n = 6 per group; MCAD: n = 6 per group; NDUFAB = n = 6 per group; 
UQCRC1: n = 6 per group; COX5: n = 6 per group; ATP5a: n = 5 WT, n = 6 Pax8 +/-; PGC1α: 
n = 6 per group; UCP2: n = 5 per group. (B) mRNA expression of genes involved in 
mitochondrial biogenesis and function in gastrocnemius of WT and Pax8 +/- mice. NDUFAB: 
n = 5 WT, n = 4 Pax8 +/-; UQCRC1: n = 6 WT, n = 5 Pax8 +/-; COX5: n = 5 WT, n = 4 Pax8 
+/-; ATP5a: n = 5 WT, n = 4 Pax8 +/-; PGC1α: n = 5 WT, n = 4 Pax8 +/-; UCP2: n = 5 per 
group. (C) Western blots showing proteins involved in mitochondrial biogenesis/function as 
well as AMPK and its phosphorylated isoform in livers of WT and Pax8 +/- mice. n = 6 per 
group. (D) Densitometric analysis of western blots shown in panel C. (E) Western blots 
showing proteins involved in mitochondrial function as well as AMPK and its phosphorylated 
isoform in gastrocnemius of WT and Pax8 +/- mice. n = 5 per group. (F) Densitometric analysis 
of western blots shown in panel E. Data are represented as the mean ± SEM. * p-value < 0.05 
t-test two tailed. 
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 Consistent with these results, mitochondrial DNA content to nuclear DNA ratio 
was not altered in any of the metabolic tissues tested (Figure 27A-B). In addition, electron 
microscopy images of gastrocnemius from WT and Pax8 +/- mice revealed normal 
mitochondrial appearance (Figure 27C).  
    
Figure 27. Mitochondrial DNA content is not affected in liver and gastrocnemius of Pax8 
+/- mice. (A) Relative mitochondrial DNA content in livers of WT and Pax8 +/- mice. n = 6 
per group. (B) Relative mitochondrial DNA content in gastrocnemius of WT and Pax8 +/- mice. 
n = 6 per group. (C) Electron microscopy images of gastrocnemius of WT and Pax8 +/- mice 
showing normal mitochondrial appearance. n = 6 per group. Scale bar = 500 nm. Data are 
represented as the mean ± SEM. 
 Further confirming that mitochondrial content is not altered in these tissues, citrate 
synthase activity was not affected in either liver or gastrocnemius extracts of Pax8 +/- 
mice (Figure 28A-B). Likewise, no significant differences were observed between 
genotypes in the specific activities of complexes I+III and II+III in both liver and 
gastrocnemius (Figure 28C-J). However, superoxide generation in the liver of Pax8 +/- 
animals was significantly increased (WT: 7.2 ± 0.2 nmol/mg·min vs. Pax8 +/-: 8.5 ± 0.3 
nmol/mg·min, p-value = 0.009 t-test two tailed), even when relativized to citrate synthase 
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activity (WT: 0.0386 ± 0.0024 nmol/mg·min vs. Pax8 +/-: 0.0454 ± 0.0017 nmol/mg·min, 
p-value = 0.046 t-test two tailed) (Figure 28K-L). In contrast, superoxide generation in 
gastrocnemius extracts of Pax8 +/- and WT mice was similar (Figure 28M-N). 
    
Figure 28. Superoxide generation is increased in livers of Pax8 +/- mice. (A) Citrate 
synthase activity in liver extracts of WT and Pax8 +/- mice. n = 6 per group. (B) Citrate 
synthase activity in gastrocnemius extracts of WT and Pax8 +/- mice. n = 6 per group. (C) 
Complex I+III activity in liver extracts of WT and Pax8 +/- mice. n = 6 per group. (D) Complex 
I+III activity shown in panel C relativized to citrate synthase activity shown in A. (E) Complex 
I+III activity in gastrocnemius extracts of WT and Pax8 +/-mice. n = 6 per group. (F) Complex 
I+III activity shown in panel E relativized to citrate synthase activity shown in B. (G) Complex 
II+III activity in liver extracts of WT and Pax8 +/- mice. n = 6 per group. (H) Complex II+III 
activity shown in panel G relativized to citrate synthase activity shown in A. (I) Complex II+III 
activity in gastrocnemius extracts of WT and Pax8 +/- mice. n = 6 per group. (J) Complex 
II+III activity shown in panel I relativized to citrate synthase activity shown in B. (K) 
Superoxide generation in liver extracts of WT and Pax8 +/- mice. n = 6 per group. (L) 
Superoxide generation shown in panel K relativized to citrate synthase activity shown in A. 
(M) Superoxide generation in gastrocnemius extracts of WT and Pax8 +/- mice. n = 5 WT, n 
= 6 Pax8 +/-. (N) Superoxide generation shown in panel M relativized to citrate synthase 
activity shown in B. Data are represented as the mean ± SEM. * p-value < 0.05 t-test two tailed.  
                                                                                                                RESULTS  
   
109 
 
Determinations by western blot of 4-HNE, which results from lipid peroxidation, 
revealed a significant increase in both liver (WT: 100 ± 6.033% vs. 132.50 ± 8.88%, p-
value = 0.014 t-test two tailed) and gastrocnemius (WT: 100 ± 3.39% vs. Pax8 +/-: 128.63 
± 7.76%, p-value = 0.016 t-test two tailed) of Pax8 +/- mice compared to WT (Figure 
29A-D). 
             
Figure 29. Pax8 +/- mice exhibit increased 4-HNE in liver and gastrocnemius. (A) Western 
blot showing 4-HNE staining in liver extracts of WT and Pax8 +/- mice. n = 6 per group. (B) 
Western blot showing 4-HNE staining in gastrocnemius extracts of WT and Pax8 +/- mice. n 
= 5 per group. (C) Densitometric analysis of the western blot shown in panel A. (D) 
Densitometric analysis of the western blot shown in panel B. (E) Western blots showing LC3B 
(LC3B-I = 16 kDa and LC3B-II = 14 kDa) in liver extracts of WT and Pax8 +/- mice. LE = 
Low exposure. HE = High exposure. n = 6 per group. (F) Densitometric analysis of western 
blots shown in E. Data are represented as the mean ± SEM. * p-value < 0.05 t-test two tailed.  
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 Remarkably, protein levels of LC3B-I and LC3B-II were dramatically reduced in 
liver extracts of Pax8 +/- mice (WT: 100 ±13.82% vs. Pax8 +/-: 53.26 ± 11.16%, p-value 
= 0.026 t-test two tailed and WT: 100 ± 25.84% vs. Pax8 +/-: 23.26 ± 6.42%, p-value = 
0.004 t-test two tailed, respectively). Likewise, there was a tendency towards a decreased 
ratio LC3BII/LC3BI (WT: 0.99 ± 0.16% vs. Pax8: 0.56 ± 0.16%, p-value = 0.086 t-test 
two tailed), indicating that autophagy may be impaired in the liver of Pax8 +/- mice 
(Figure 29E-F).  
  4.2.8 Pax8 +/- male mice fed in HFD do not exhibit exacerbated glucose 
intolerance or insulin resistance 
In order to investigate whether the phenotype observed in Pax8 +/- mice was 
further exacerbated by an environmental stressor, we determined the effects of HFD 
feeding in Pax8 +/- mice. Importantly, circulating T4 levels were significantly reduced in 
Pax8 +/- mice compared to WT mice feed in HFD (WT: 3.28 ± 0.26 µg/dl vs. Pax8 +/-: 
2.62 ± 0.14µg/dl, p-value = 0.047 t-test two tailed) (Figure 30).  
                                        
Figure 30. Pax8 +/- in HFD exhibit reduced circulating T4 levels. T4 levels in serum from 
WT and Pax8 +/- male mice in HFD at 7 months of life. n = 8 WT, n = 9 Pax8 +/-. Data are 
represented as the mean ± SEM. * p-value < 0.05 t-test two tailed. 
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However, Pax8 +/- mice in HFD did not exhibit increased body weight compared 
to WT mice in HFD and no differences were observed in fasting induced energy intake 
(Figure 31A-B). 
 
Figure 31. HFD feeding does not exacerbate body weight gain in Pax8 +/- mice. (A) Body 
weights (g) of WT and Pax8 +/- mice during weeks in HFD. HFD was started at 2-3 months of 
age. n = 15 WT, n = 13 Pax8 +/-. (B) Fasting induced energy intake in WT and Pax8 +/- mice 
fed in HFD. n = 8 WT, n = 9 Pax8 +/-. Data are represented as the mean ± SEM. 
Glucose levels during the OGTT between different genotypes remained similar, 
whereas a tendency towards decreased levels of circulating insulin was observed 15 
minutes after a glucose load in Pax8 +/- mice compared to WT (WT: 8.49 ± 2.47 ng/ml 
vs. Pax8 +/-: 4.58 ± 1.05 ng/ml, p-value = 0.073 t-test two tailed) (Figure 32A-D). 
Remarkably, glucose levels were lower at all the time points measured after a pyruvate 
load in Pax8 +/- animals compared to WT (Figure 32E). Therefore, the AUC for the 
IPPTT was reduced (WT: 42061 ± 1820 a.u. vs. Pax8 +/-: 33.072 ± 3617 a.u., p-value = 
0.0163) (Figure 32F). However, no significant differences were observed during the ITT 
(Figure 32G-H), in the HOMA-IR or in the percentage of HbA1c between different 
genotypes fed on HFD (Figure 33A–D). 
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Figure 32. Pax8 +/- mice in HFD exhibit similar glucose tolerance than WT mice in HFD. 
(A) Circulating glucose levels during an OGTT. n = 13 WT, n = 11 Pax8 +/-. (B) AUC for 
glucose levels during the OGTT. (C) Insulin levels in plasma during an OGTT. n = 8 per group. 
(D) AUC for insulin levels during the OGTT. (E) Circulating glucose levels during the IPPTT. 
n = 13 WT, n = 10 Pax8 +/-. (F) AUC for the IPPTT. (G) Glucose levels in blood during the 
ITT. n = 9 per group. (H) AUC for the ITT. Data are represented as the mean ± SEM. * p-value 
<0.05 repeated measurements two-way ANOVA in panels A, C, E and G. T-test two tailed in 
panels B, D, F and H.  
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Figure 33. HFD feeding does not exacerbate insulin resistance in Pax8 +/- mice. (A) 
Glucose levels in blood after 16 hours of fasting. n = 8 per group. (B) Circulating insulin after 
16 hours of fasting. n = 8 per group. (C) HOMA-IR. n = 8 per group. (D) Percentage of HbA1c 
n = 8 per group. Data are represented as the mean ± SEM.  
 Importantly, Pax8 +/- male mice fed on HFD exhibited an extremely unhealthy 
appearance, even though glucose tolerance and insulin resistance were similar to control 
group on HFD. Moreover, the reduced circulating glucose levels shown during the IPPTT 
by Pax8 +/- male mice in HFD (i.e. impaired gluconeogenesis), could reflect a hepatic 
dysfunction.   
                                                                                                                RESULTS  









AIM 3: Determine the effect of T4 supplementation in healthy C57BL/6 mice as well 





N.B. Results presented herein are published in an article entitled: “Levothyroxine 
enhances glucose clearance and blunts the onset of experimental type 1 diabetes mellitus 
in mice”, published in the British Journal of Pharmacology in which I am first author.  
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4.3.1 T4 supplementation effectively increases circulating T4 levels 
Since according to our previous results reduced circulating T4 levels are 
associated with glucose intolerance and insulin resistance, we next investigated whether 
T4 supplementation could have a beneficial effect on glucose homeostasis. In order to 
determine the metabolic effects of T4 supplementation in mice, we treated female wild-
type C57BL/6 mice with T4 from postnatal day 1 (18 ng/g of body weight per day by 
subcutaneous injections) until weaning, followed by T4 administration in the drinking 
water (50 µg.ml-1 ad libitum) until 24-weeks of age, when mice were euthanized. 
Importantly, the treatment increased circulating T4 concentration (UT: 5.091 ± 0.168 
μg/dl vs. T4: 17.73 ± 0.644 μg/dl, p-value < 0.0001 t-test two tailed) (Figure 34A).  
                  
Figure 34. Circulating T4 levels are increased upon T4 treatment. (A) Circulating T4 levels 
in untreated and T4-treated mice. n = 7 UT, n = 8 T4. (B) Plasma levels of the α-GSU subunit 
of pituitary hormones. n = 7 UT, n = 8 T4. (C) Representative images of the histological 
analysis of the thyroid and pituitary from untreated and T4-treated mice. Thyroid: n = 6 UT, n 
= 7 T4. Pituitary: n = 5 UT, n = 6 T4. Scale bar = 100 μm. UT: untreated; T4: treated with T4. 
Data are represented as the mean ± SEM. * p-value < 0.05 t-test two tailed.  
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Consistent with this, plasma levels of the α-GSU subunit of pituitary hormones, 
such as TSH, were concomitantly reduced in T4-treated mice (UT: 1116 ± 77 uIU/ml vs. 
T4: 921 ± 18 uIU/ml, p-value = 0.045 t-test two tailed) (Figure 34B). Noteworthy, 
histological examinations of the thyroid and the pituitary revealed no major macroscopic 
changes in tissue morphology. However, thyroid sections of T4-treated mice had a 
slightly less intense staining of the colloid in the lumen of the follicle, suggestive of 
reduced endogenous thyroglobulin content (Figure 34C). 
4.3.2 T4 supplementation enhances glucose clearance in healthy C57BL/6 mice 
Glucose tolerance was enhanced by T4 supplementation as determined by reduced 
glucose levels in blood at all time points measured after a glucose load and a lower AUC 
during the OGTT (UT: 27581 ± 1081 a.u. vs. T4: 19333 ± 597 a.u., p-value < 0.0001 t-
test two tailed) (Figure 35A-B). Noteworthy, significant differences in circulating glucose 
during the OGTT were maintained even when glucose levels were expressed as the 
percentage of basal glucose (Figure 36A). Basal circulating insulin levels in the OGTT 
were higher in T4-treated mice, while at 15-30 minutes post-glucose load insulin levels 
were similar to those of untreated animals. However, the increase in basal circulating 
levels were enough to increase the AUC (UT: 28.87 ± 1.97 a.u. vs. T4: 37.60 ± 3.17 a.u., 
p-value = 0.03 t-test two tailed) (Figure 35C-D). In order to determine whether 
gluconeogenesis was affected, animals were challenged with an intraperitoneal pyruvate 
injection (IPPTT). Glucose levels were lower at all the time points measured during the 
IPPTT, as it was the AUC (UT: 25532 ± 899 a.u. vs. T4: 7925 ± 628 a.u., p-value < 0.0001 
t-test two tailed) (Figure 35E-F). However, differences were lost when values were 
relativized to basal glucose (Figure 36B).  
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Figure 35. T4 enhances glucose clearance in wild-type C57BL/6 mice. (A) Glucose 
concentration in blood after an oral glucose load (OGTT). n = 13 per group. (B) AUC of glucose 
levels during the OGTT. (C) Plasma levels of insulin after an oral glucose load (OGTT). n = 7 
UT, n = 8 T4. (D) AUC of insulin levels during OGTT. (E) Glucose concentration in blood 
after an intraperitoneal pyruvate load (IPPTT). n = 7 UT, n = 8 T4. (F) AUC of glucose levels 
during the IPPTT. (G) Glucose concentration in blood after an intraperitoneal insulin injection 
(ITT). n = 12 UT, n = 13 T4. (H) AUC of glucose levels during the ITT. (I) Glucose 
concentration in blood during a 24-hour fasting period. n = 7 UT, n = 8 T4. (J) AUC of glucose 
levels during the 24-hour fasting period. UT: untreated; T4: treated with T4. Data are 
represented as the mean ± SEM. * p-value < 0.05 t-test two tailed. 
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Figure 36. Glucose levels in metabolic test expressed as percentage of basal glucose. (A) 
Glucose concentration in blood during the OGTT expressed as the percentage of basal (time 0) 
glucose. n = 13 per group. (B) Glucose concentration in blood during the IPPTT expressed as 
the percentage of basal glucose. n = 7 UT, n = 8 T4. (C) Glucose concentration in blood during 
the ITT expressed as the percentage of basal glucose. n = 12 UT, n = 13 T4. (D) Glucose 
concentration in blood during a 24-hour fasting period expressed as the percentage of basal 
glucose. n = 7 UT, n = 8 T4. UT: untreated; T4: treated with T4. Data are represented as the 
mean ± SEM. * p-value < 0.05 Mann-Whitney Rank Sum test. 
The AUC for the ITT was also lower in T4-treated animals compared to untreated 
mice (UT: 11515 ± 1502 a.u. vs. T4: 7280 ± 680 a.u., p-value = 0.021 t-test two tailed), 
since circulating glucose levels were significantly lower at any time point measured 
during the experiment (Figure 35 G-H). However, differences were related to the lower 
basal glucose, as determined by the lack of significant differences when glucose levels 
were expressed as the percentage of basal glucose (Figure 36C). We next measured 
circulating glucose levels during a 24-hour fasting period. Glucose levels were 
significantly reduced in T4-treated mice at any time point measured during the 
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experiment, as it was the AUC (UT: 2794 ± 117 a.u. vs. T4: 1825 ± 105 a.u., p-value < 
0.0001 t-test two tailed) (Figure 35I-J and 36D). Consistent with the high insulin levels 
determined during the basal time of the OGTT (6-hour fasting), circulating insulin levels 
were also higher at 16-hours of fasting; while glucose levels were lower (Figure 37A-B).  
  
 
Figure 37. T4 treatment decreases HbA1c levels. (A) Circulating glucose levels after 16 
hours of fasting. n = 7 UT, n = 8 T4. (B) Circulating insulin levels after 16 hours of fasting. n 
= 7 UT, n = 8 T4. (C) HOMA-IR. n = 7 UT, n = 8 T4. (D) Percentage of HbA1c in blood. n = 
9 UT, n = 14 T4. (E) Time to fall from an accelerating rotarod. n = 12 UT, n = 18 T4. UT: 
Untreated; T4: T4-treated. Data are represented as the mean ± SEM. * p < 0.05 compared to 
untreated mice t-test two tailed. 
Interestingly, despite the lower glucose levels during the ITT, a trend towards 
increased HOMA-IR was found in T4-treated mice (UT: 1.38 ± 0.08 a.u. vs. T4: 2.15 ± 
0.37 a.u., p-value = 0.08 in t-test two-tailed) (Figure 37C). Supporting the long-term 
reduction of glucose levels in mice treated with T4, the percentage of HbA1c was found 
to be lower (UT: 4.91 ± 0.13% vs. T4: 3.99 ± 0.12%, p-value < 0.0001) (note that the 
untreated group is within the healthy physiological range) (Figure 37D). Taken together, 
these results indicate that T4 supplementation reduces dramatically glucose concentration 
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in blood, which is associated with increased circulating insulin. Furthermore, rotarod 
performance was improved by T4, indicating the overall healthy status of T4-treated mice 
(Figure 37E). 
Additionally, at 6 months of age, body weight was slightly reduced in T4-treated 
mice compared to untreated animals (Figure 38A), although energy intake was similar in 
both experimental groups, even when divided by body weight (Figure 38B-C). 
Noticeably, at time of euthanization, WAT weight was reduced in T4-treated mice (Figure 
38D-E). In contrast, several organs, including BAT, heart and liver were found to be 
heavier in T4-treated mice, even when divided by body weight (Figure 38D-E). 
     
Figure 38. T4 supplementation reduces body weight. (A) Body weight. Age = 24 weeks. n 
= 12 UT, n = 18 T4. (B) Energy intake. Age = 8 weeks. n = 7 UT, n = 8 T4. (C) Energy intake 
shown in (B) relativized to body weight shown in (A). (D) Organs weight. Age = 24 weeks. 
For liver, heart, WAT, BAT, kidney, brain and spleen n = 12 UT, n = 18 T4. For thyroid and 
pituitary n = 6 UT, n = 7 T4. (E) Organs weight divided by body weight. Age = 24 weeks. For 
liver, heart, WAT, BAT, kidney, brain and spleen n = 12 UT, n = 18 T4. For thyroid and 
pituitary n = 6 UT, n = 7 T4. UT: Untreated; T4: T4-treated. Data are represented as the mean 
± SEM. * p < 0.05 compared to untreated mice t-test two tailed. 
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4.3.3 T4 supplementation increases β-cell insulin content  
The increase in circulating insulin levels observed in T4-treated mice indicated a 
potential effect of the hormone on pancreatic islets. Accordingly, immunohistochemical 
analysis revealed that insulin staining, as determined by mean intensity, was higher in 
pancreatic sections of T4-treated mice compared to control animals (UT: 29.92 ± 4.01 
a.u. vs. T4: 47.46 ± 3.08 a.u., p-value = 0.009 in t-test two tailed), while glucagon was 
unaffected (Figure 39A-C). Increased insulin content in the islets of T4-treated mice was 
further confirmed by ELISA determination using freshly isolated pancreatic islets (UT: 
410 ± 39.14 ng per 10 islets vs. T4: 769 ± 118 ng per 10 islets, p-value = 0.022 in t-test 
two tailed) (Figure 39D). Remarkably, GCK expression was also increased in pancreatic 
islets from T4-treated animals as determined by mean intensity in immunohistochemical 
analysis (UT: 22.14 ± 1.61 a.u. vs. T4: 36.82 ± 4.68 a.u., p-value = 0.01 in t-test two 
tailed) and mRNA expression (UT: 1 ± 0.03 vs. T4: 1.87 ± 0.17, p-value = 0.004 in t-test 
two tailed) (Figure 39E-F).  
Determinations of mRNA expression by real-time PCR also revealed an increase 
in AKT expression, while no significant differences were observed between different 
experimental groups in the expression of MafA and FOXO1, which are markers of β-cell 
differentiation/maturation (Figure 39F) (Aguayo-Mazzucato et al., 2013, Kikuchi et al., 
2012). Moreover, immunofluorescence analysis revealed that the subcellular localization 
of both MafA and FOXO1 was unaffected in T4-treated animals (Figure 39G and I).  
                                                                                                                RESULTS  




Figure 39. T4 increases insulin and GCK expression in pancreatic islets. (A) Representative 
images of insulin (INS), glucagon (GLC) and GCK staining in pancreases from mice treated or 
not with T4. DAB staining followed by hematoxylin counterstaining. (B) Quantification of insulin 
staining (mean intensity). n = 5 per group. (C) Quantification of glucagon staining (mean 
intensity). n = 5 per group. (D) Determination of pancreatic islet insulin content by ELISA. n = 6 
UT, n = 7 T4. (E) Quantification of GCK staining (mean intensity). n = 6 per group. (F) 
Determination of messenger RNA (mRNA) levels of genes involved in pancreatic islet 
metabolism. Values were normalized to islets isolated from untreated mice. n = 6 UT, n = 5 T4. 
(G) Representative images of MafA and insulin immunofluorescence staining. n = 5 per group. 
(H) Determination of GSIS. n = 6 UT, n = 7 T4. (I) Representative images of FOXO1 and INS 
immunofluorescence staining. n = 6 UT, n = 7 T4. UT: untreated mice, T4: mice treated with T4. 
Data are represented as the mean ± SEM. * p < 0.05 compared to untreated mice t-test two tailed. 
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Remarkably, GSIS assays performed in islets isolated from untreated and T4-
treated mice determined that insulin secretion was increased in T4-treated mice when 
islets were cultured under low glucose (2.8 mM) conditions (UT: 0.13 ± 0.02% of total 
insulin vs. T4: 0.27 ± 0.03% of total insulin, p-value = 0.021 in t-test two tailed). 
However, differences in insulin secretion under high glucose (22 mM) conditions did not 
reach statistical significance (Figure 39H).  
4.3.4 T4 supplementation enhances β-cell turnover 
Immunohistochemical analyses performed in pancreatic islets revealed that β-cell 
proliferation, defined here as the percentage of Ki67 positive cells within the insulin-
expressing cell population, was increased in T4-treated animals when compared to 
untreated mice (UT: 0.14 ± 0.033% vs. T4: 0.56 ± 0.075%, p-value = 0.002 in t-test two 
tailed) (Figure 40A-B). As opposed to β-cells, non-insulin-expressing pancreatic 
endocrine cells showed similar proliferation in untreated and T4-treated mice (percentage 
of Ki67 positive cells in islet residing non-insulin expressing cells) (Figure 40C). 
Interestingly, the percentage of apoptotic cells, determined by Tunel staining, was also 
increased by T4 administration specifically in the β-cell population (UT: 0.05 ± 0.11% 
vs. T4: 1.19 ± 0.23%, p-value = 0.049 in t-test two-tailed) (Figure 40D-F). Therefore, our 
results indicate that T4 supplementation effectively promotes β-cell turnover in healthy 
WT animals by increasing both β-cell proliferation and apoptosis.  
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Figure 40. T4 induces β-cell proliferation and apoptosis. (A) Representative 
immunofluorescence image of pancreatic islets from untreated and T4-treated mice showing 
Ki67 and insulin (INS). (B) Quantification of the percentage of Ki67+ INS+ cells. n = 5 per 
group. (C) Quantification of Ki67+INS- cells. n = 5 per group. (D) Representative 
immunofluorescence image of pancreatic islets of T4-treated mice showing Tunel staining. (E) 
Quantification of Tunel + INS+ cells. n = 5 per group. (F) Quantification of Tunel + INS- cells. 
n = 5 per group. In all cases, at least 1000 endocrine cells per animal were counted. UT: 
untreated mice. T4: mice treated with T4. Data are represented as the mean ± SEM. * p-value 
< 0.05 t-test two tailed. 
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4.3.5 T4 induces the activation of IRS1-AKT signalling in insulin-target tissues 
In order to determine the underlying mechanism of T4 action in insulin-target 
tissues, we determined mRNA expression by semi-quantitative real-time PCR of several 
genes involved in the insulin signalling pathway. We found that the transcript levels of 
AKT and FOXO1 were over-expressed in both the skeletal muscle and the liver of T4-
treated mice (Figure 41A-B). Consistent with these data, protein extracts of both, T4-
treated liver and skeletal muscle, exhibited increased protein levels of total AKT, FOXO1 
as well as IRS1 and GSK3-β (Figure 41C-E). Moreover, the phosphorylated isoforms of 
several members of the insulin signalling such as pTyr632 IRS1, pSer473 AKT and 
pSer256 FOXO1, were significantly increased in both, skeletal muscle and liver lysates 
isolated from T4-treated mice (Figure 41C-E). Remarkably, ERK phosphorylation at 
Thr202/Tyr204 in skeletal muscle was reduced in T4-treated samples, indicating the 
specificity of the effect of T4 supplementation in the IRS1-AKT branch of the insulin 
signalling. In order to determine whether T4 supplementation could also increase the 
maximal activation of the IRS1-AKT axis of the insulin signalling, a cohort of mice was 
treated with insulin (0.75 UI.kg-1 of body weight) 15 minutes prior sacrifice (Figure 41F-
H). No differences on insulin-stimulated phosphorylation of Ser473 AKT levels were 
found, indicating that maximal insulin-induced AKT activation is not affected by T4-
treatment.  
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Figure 41. T4 activates insulin signalling in skeletal muscle and liver. (A) Determination of 
mRNA levels of several members of the insulin pathway in the skeletal muscle of mice treated 
or not with T4. IR-β: n = 5 per group; IRS1: n = 6 per group; AKT: n = 5 per group; FOXO1: 
n = 6 per group; GSK3-β: n = 6 per group; ERK: n= 6 per group. (B) Determination of mRNA 
levels of several members of the insulin pathway in the liver. IR-β: n = 6 UT, n = 5 T4; IRS1: 
n = 6 UT, n = 5 T4; AKT: n = 6 per group; FOXO1: n = 6 UT, n = 5 T4; GSK3-β: n = 5 per 
group; ERK: n = 6 UT, n = 5 T4. (C) Western blots indicating activation of insulin signalling 
in the skeletal muscle and liver of T4-treated mice. n = 5 per group. (D) Densitometric analysis 
of western blots performed in skeletal muscle extracts shown in panel C. (E) Densitometric 
analysis of western blots performed in liver extracts shown in panel C. (F) Representative 
images of western blots showing the maximal activation of insulin signalling in T4-treated and 
untreated mice challenged with an insulin injection 15 minutes prior euthanization. (G) 
Densitometric analysis of western blots performed in skeletal muscle extracts shown in F. n = 
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5 UT, n = 6 T4. (H) Densitometric analysis of western blots performed in liver extracts shown 
in F. n = 5 UT, n = 6 T4. UT: Untreated; T4: T4-treated. Mice were fasted for 16 hours prior 
euthanization and in all cases values were normalized to untreated mice. Data are represented 
as the mean ± SEM. * p < 0.05 compared to untreated mice t-test two tailed. The 
undergraduate/master’s students Alvaro Jesus Narbona and Juan Luis Araujo have contributed 
to perform the western blots and RT-PCRs presented in this figure.  
We next investigated whether T4 treatment also modulated the expression of 
genes involved in glucose utilization (e.g. increased glycolysis and gluconeogenesis) as 
well as mitochondrial biogenesis and uncoupling by real time PCR in both skeletal muscle 
and liver. Remarkably, the expression of PEPCK, which is involved in gluconeogenesis, 
was found increased in the liver of T4-treated mice. Additionally, genes involved in 
mitochondrial biogenesis (PGC1α) and uncoupling of the respiratory chain (UCP2), were 
increased in both liver and skeletal muscle extracts from T4-treated mice compared to 
control animals (Figure 42A-B).  
Taken together, these results suggest that T4-induced high insulin levels in 
circulation drive to sustained activation of the IRS1-AKT signalling and subsequent 
increase in glucose uptake in insulin target tissues to maintain their high metabolic 
requirements. Supporting these data, a significant increase on phosphorylated Thr172 
AMPK, which indicates a starvation-like status, was found in T4-treated skeletal muscle 
extracts. Noteworthy, this regulation was not detected in liver samples, suggesting that 
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Figure 42. T4 supplementation increases the expression of genes involved in 
mitochondrial biogenesis and induces a starving-like status in skeletal muscle. (A) 
Determination of mRNA levels of genes involved in energy metabolism in the skeletal muscle 
of untreated and T4-treated mice. GLUT2: n = 5 UT, n = 6 T4; GK: n = 5 UT, n = 6 T4; G6Pase: 
n = 5 UT, n =6 T4; LPK: n = 5, n = 6 T4; PEPCK: n = 5 UT, n = 6 T4; GAPDH: n = 6 per 
group; LDH: n = 5 UT, n = 6 T4; PGC1α: n = 6 per group; PGC1β: n = 6 per group; UCP2: n 
= 5 per group; SREBP1c: n = 5 UT, n = 6 T4. (B) Determination of mRNA levels of genes 
involved in energy metabolism in the liver. GLUT2: n = 5 UT, n = 6 T4; GK: n = 5 per group; 
G6Pase: n = 5 UT, n = 6 T4; LPK: n = 5 UT, n = 6 T4; PEPCK: n = 5 UT, n = 6 T4; GAPDH: 
n = 6 UT, n = 5 T4; LDH: n = 5 per group; PGC1α: n = 5 UT, n = 6 T4; PGC1β: n = 6 per 
group; UCP2: n = 6 UT, n = 5 T4; SREBP1c: n = 6 UT, n = 5 T4. (C) Western blots indicating 
activation of AMPK in skeletal muscle and liver. n = 5 per group. Mice were fasted for 16 
hours prior euthanization and all values are relativized to control group. (D, E) Densitometric 
analysis of western blots shown in panel C. UT: untreated; T4: treated with T4. Data are 
represented as the mean ± SEM.  * p- value < 0.05 t-test two tailed.  
4.3.6 T4 supplementation improves glycaemic control in the RIP-B7.1 model of EAD 
Given the effects of T4 supplementation in the promotion of β-cell proliferation 
and the increase of circulating insulin levels in healthy C57BL/6 mice, we next sought to 
determine whether T4 supplementation could blunt the onset of T1DM in the RIP-B7.1 
model of EAD (Mellado-Gil et al., 2016a, Harlan et al., 1994). To this end, RIP-B7.1 
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mice were treated with T4, (5 µg.ml-1 in the drinking water) starting at 6-weeks of age. 
RIP-B7.1 mice were immunized at 8-weeks of age to trigger the autoimmune attack to 
the β-cells. Determination of circulating T4 levels revealed a significant increase in T4-
treated RIP-B7.1 when compared to untreated RIP-B7.1 immunized mice (RIP-B7.1 UT: 
4.09 ± 0.16 μg/dl vs. RIP-B7.1 T4: 6.68 ± 0.28 μg/dl, p-value <0.0001 t-test two-tailed) 
(Figure 43). Moreover, similar to healthy wild type C57BL/6 mice (Figure 38D-E), the 
weight of several organs, including BAT, was found to be higher at the time of 
euthanization (5 weeks of T4-treatment; 11-weeks of age) (Figure 44A). However, 
differences on the weight of WAT were not apparent.  
                               
Figure 43. T4 treatment increases circulating T4 in RIP-B7.1 mice. Circulating T4 levels 
in untreated and T4-treated RIP-B7.1 mice. n = 9 UT, n = 8 T4. UT: untreated; T4: treated 
with T4. Data are represented as the mean ± SEM. * p-value < 0.05 in t-test two tailed. 
Since, there is a decline in weight associated with diabetes progression in mice, 
RIPB7.1 mice were weighted every week (Huang et al., 2011). Noticeably, T4-treated 
immunized RIP-B7.1 mice gained weight over the course of the experiment, while control 
(untreated) immunized RIP-B7.1 mice reached a plateau. Thus, body weights were 
significantly different from week 4 of T4-treatment, 2 weeks post-immunization (Figure 
44B).  
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Figure 44. T4 supplementation alters organ weight and prevents body weight decline that 
follows hyperglycaemia in RIPB7.1 mice. (A) Organ weight in RIPB7.1 mice treated or not 
with T4. n = 6 UT, n = 9 T4-treated. (B) Body weight. n = 8 UT, n = 9 T4. Data are represented 
as the mean ± SEM. * p-value < 0.05. 
In order to determine the effect of T4 supplementation in the pathogenesis of 
EAD, several metabolic tests were performed. T4-treated immunized RIP-B7.1 mice 
exhibited enhanced glucose clearance compared to untreated immunized RIP-B7.1 mice 
at 2 weeks post-immunization and 4 weeks of T4 treatment as determined by differences 
at several time points measured during an OGTT and a lower AUC for the experiment 
(Figure 45A-B). An ITT performed 3 weeks post-immunization and 5 weeks after T4 
treatment, indicated that circulating glucose was significantly lower in T4-treated 
immunized RIP-B7.1 mice at any time point during the experiment (Figure 45C-D). 
However, these differences were clearly derived from the lower basal glucose levels 
found in T4-treated RIP-B7.1 immunized mice compared to untreated immunized RIP-
B7.1 mice. Post-prandial glucose determinations revealed significant differences from 1-
week post-immunization. Indeed, untreated immunized RIP-B7.1 animals developed 
severe hyperglycaemia at 3-weeks post-immunization, while T4-treated immunized RIP-
B7.1 mice remained normoglycemic (Figure 45E). Remarkably, postprandial circulating 
                                                                                                                RESULTS  
   
131 
 
insulin was dramatically increased in T4-treated RIP-B7.1 immunized mice (UT RIP-
B7.1: 0.51 ± 0.11 ng/ml vs. T4 RIP-B7.1: 3.36 ± 0.48, p-value = 0.0004 t-test two tailed) 
(Figure 45F), which was accompanied with increased phosphorylation of the IRS1 at Tyr 
632 in the liver (Figure 46).  
                        
Figure 45. T4 supplementation blunts the onset of EAD in RIPB-7.1 mice and increases 
the survival in C57BL/6 mice treated with STZ. (A) Glucose concentration in blood during 
an OGTT at 4 weeks of T4-treatment on RIP-B7.1 mice. n = 8 UT, n = 9 T4. (B) AUC of 
glucose levels during the OGTT. (C) Glucose concentration in blood during an ITT at 5 weeks 
of T4-treatment on RIP-B7.1 mice. n = 7 UT, n = 9 T4. (D) AUC of glucose levels during the 
ITT. (E) Postprandial glucose concentration in blood on RIP-B7.1 mice. n = 8 UT, n = 9 T4. 
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(F) Postprandial circulating insulin levels. n = 7 UT, n = 8 T4. (G) Survival of C57BL/6 mice 
challenged with STZ. n = 9 per group. (H) Postprandial glucose concentration in blood on 
C57BL/6 mice challenged with STZ. Alive animals were included. UT: Untreated; T4: T4-
treated; IMM: Immunization. Arrows indicate the time of immunization. Data are represented 
as the mean ± SEM. * p < 0.05 compared to untreated mice, t-test two tailed. A LogRank 
survival test was applied to survival curves 
                
Figure 46. T4 supplementation increases pThyr632 in the liver of RIP-B7.1 mice. (A) 
Western blots showing phospho-tyrosine 632 IRS1, total IRS1 and GAPDH, used as loading 
control, in the skeletal muscle and liver of T4-treated mice. Skeletal muscle n = 6 UT, n= 5 
T4. Liver n = 6 per group. (B) Densitometric analysis of the western blots performed in 
skeletal muscle extracts shown in panel A. (C) Densitometric analysis of the western blots 
performed in liver extracts shown in panel A. Values were normalized to control group. UT: 
Untreated; T4: T4-treated. Data are represented as the mean ± SEM. * p < 0.05 compared to 
untreated mice, t-test two tailed. 
Next, we investigated whether T4 supplementation could improve glucose 
homeostasis in a different mouse model of experimental diabetes, such as STZ treatment. 
To this end, male wild-type C57BL/6 mice were treated with T4, (5 μg.ml-1 in the 
drinking water) starting 2 weeks prior 2 consecutive intraperitoneal injections of STZ 
(150 mg/kg) (Verga Falzacappa et al., 2011). Importantly, the average survival of control 
STZ treated mice was 8 days, whereas the T4-treated group achieved a mean survival of 
34 days, including some mice that survived to STZ (P<0.01, χ2=7,689) (Figure 45G). 
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Furthermore, postprandial glucose levels showed a trend towards reduced glycemia in 
T4-treated mice (Figure 45H). Taken together, our results indicate that T4 blunts the onset 
of T1DM in the RIP-B7.1 model of EAD and promotes survival in STZ-induced 
experimental DM. 
4.3.7 T4 supplementation increases insulin expression in pancreatic islets and β-cell 
proliferation in immunized RIP-B7.1 mice 
In order to determine the underlying effects of T4 supplementation on the pancreas 
of an animal model for EAD, we next performed immunohistochemical analysis in 
pancreatic sections from untreated and T4-treated immunized RIP-B7.1 mice. 
Remarkably, T4-treated mice exhibited a marked increase in insulin expression, as 
determined by the mean intensity of DAB staining (RIPB-7.1 UT: 5.04 ± 0.93 a.u. vs. 
11.37 ± 1.46 a.u., p-value = 0.006 t-test two tailed) with no significant variation in 
glucagon levels (Figure 47A-C). Noteworthy, both values were considerably lower 
compared to healthy C57BL/6 mice. 
We next investigated whether T4 could also increase the proliferation of β-cells 
in the RIP-B7.1 model of EAD. Interestingly, the abundance of islet-residing Ki67 
positive cells was increased in immunized RIP-B7.1 mice when compared to healthy 
C57BL/6 mice, indicating that islet-residing immune cells and/or pancreatic endocrine 
cells proliferate under the immune attack. Nonetheless, T4-treated immunized RIP-B7.1 
mice exhibited a marked increase in proliferating β-cells when compared to untreated 
immunized RIP-B7.1 mice (RIPB-7.1 UT: 2.95 ± 1.28% vs. RIPB-7.1 T4: 7.57 ± 1.49%, 
p-value = 0.041 t-test two tailed) (Figure 47D-E). As expected, the immune attack 
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increased the percentage of apoptotic β-cells in both, T4-treated and untreated immunized 
RIP-B7.1 mice (Figure 47F-G). However, no differences in the percentage of apoptotic 
β-cells were observed between T4-treated and untreated immunized RIP-B7.1 mice. 
These results suggest that increased β-cell proliferation might be the underlying 
mechanism by which T4 blunts the onset of EAD in RIP-B7.1 mice. 
 
Figure 47. T4 increases insulin expression and enhances β-cell proliferation in the RIP-
B7.1 model of EAD. (A) Representative images of insulin (INS) and glucagon (GLC) staining 
in pancreases from immunized RIPB7.1 mice treated or not with T4. DAB staining followed 
by hematoxylin counterstaining. (B) Quantification of insulin staining (mean intensity). n = 6 
UT, n = 5 T4. (C) Quantification of glucagon staining (mean intensity). n = 6 UT, n = 5 T4. 
(D) Representative images of Ki67 and insulin staining in pancreases from immunized RIP-
B7.1 mice treated or not with T4. Immunofluorescence followed by Dapi staining. (E) 
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Percentage of Ki67+Insulin+ cells over total insulin+ cells. n = 5 per group. (F) Representative 
images of Tunel and insulin staining in pancreases from immunized RIP-B7.1 mice treated or 
not with T4. Immunofluorescence followed by Dapi staining. (G) Percentage of 
Tunel+Insulin+ cells over total insulin+ cells. n = 5 per group. UT: Untreated; T4: T4-treated. 
Scale bar = 50 μm. Arrows indicate representative positive staining. Data are represented as 
the mean ± SEM. * p < 0.05 compared to untreated mice t-test two tailed. 
In order to determine whether T4 supplementation could blunt the onset of EAD 
via an effect on the immune system, we next quantified the degree of insulitis in untreated 
and T4-treated immunized RIPB-7.1 mice. Noticeably, pancreatic islets from both 
experimental groups showed the same degree of immune infiltrations (Figure 48). 
    
Figure 48. T4-treated and untreated immunized RIP-B7.1 mice show similar degree of 
insulitis. (A) Representative images of immune infiltrations in T4-treated and untreated 
immunized RIP-B7.1 mice. (B) Insulitis was scored as grade 0–4 according to the percentage 
of infiltrated islet area (0: 0%; 1: <10%; 2: >10% and <55%; 3: >55% and <75%; 4: >75%). 
Scale bar = 50 μm. n = 5 per group. UT: Untreated; T4: T4-treated. Data are represented as the 
mean ± SEM. * p-value < 0.05 compared to untreated mice t-test two tailed. 
In summary, our results suggest that T4 supplementation blunts the onset of EAD 
by increasing β-cell proliferation and insulin content, without affecting the degree of 
insulitis.            
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The uncover of novel target genes capable to induce the regeneration and/or 
protection of β-cells represents a promising strategy to develop novel therapies to treat 
DM. During pregnancy the endocrine pancreas is challenged to adapt to a situation of 
high metabolic demand. Consequently, several genes are induced to increase β-cell 
functionality, proliferation and protection (Rieck et al., 2009). This phenomenon 
represents a unique example of rapid and reversible β-cell mass adaptation occurring in 
mammalian physiology. Therefore, genes induced during pregnancy are candidate target 
genes to treat DM. Moreover, deficiencies in those genes may cause gestational diabetes, 
thus they can be potential biomarkers for this disease. One of such genes is PAX8, which 
expression in the endocrine pancreas of mice has only been detected during pregnancy. 
Previous work from our laboratory showed that there is a major peak in the expression of 
Pax8 in pancreatic islets at day 14 of gestation, after the initiation of islet cell 
proliferation, which might suggest that PAX8 does not play a significant role in the 
induction of β-cell replication. Remarkably, PAX8 expression was also induced in vitro 
in human pancreatic islets upon prolactin treatment, suggesting that PAX8 might be a 
downstream target of placental lactogens during gestation (Jiménez Moreno, 2015).  
Herein we found that the expression of the Htr3b subunit of the serotonin receptor 
Htr3 was induced in both, murine and human pancreatic islets over-expressing PAX8. 
Noteworthy, Htr3 knock-out mice develop gestational diabetes due to the inability of β-
cells to increase its functionality (i.e. decrease the glucose threshold for GSIS) (Ohara-
Imaizumi et al., 2013). However, PAX8 over-expression in islets did not enhance 
metabolic activity or GSIS. In contrast, both murine and human pancreatic islets over-
expressing PAX8 were shown to be protected from apoptosis. Importantly, protection 
                                                                                                               DISCUSSION  
   
138 
 
from apoptosis has been shown to be crucial for the proper adaptation of β-cells during 
pregnancy. Indeed, β-cell-specific knockout mice for the anti-apoptotic gene survivin, 
display glucose intolerance due to attenuated β-cell expansion during pregnancy (Rieck 
et al., 2009, Xu et al., 2015, Rieck and Kaestner, 2010). Therefore, based on our data, we 
speculate that PAX8 could be involved in the protection of β-cells from apoptosis, which 
might be especially important in the pro-inflammatory milieu that occurs during 
pregnancy. Interestingly, the anti-apoptotic attributes of PAX8 have been described in 
other cell types as well as in cancer (Di Palma et al., 2013, Hewitt et al., 1997). Actually, 
lack of Pax8 expression has been associated with increased apoptosis in the 
cardiomyocytes of Pax8 homozygous knockout mice (Yang et al., 2012). Therefore, our 
findings suggest that specific interventions targeting at PAX8 in pancreatic endocrine 
cells could be explored to enhance islet cell survival. 
Our hypothesis suggesting that PAX8 may act as a pro-survival gene in islets 
during gestation is supported by the identification and functional characterization of a 
novel PAX8 mutation (p.T356M) associated with GDM and GTD. The transcription 
factor PAX8 contains a paired domain and a homeodomain, which allows DNA-binding, 
as well as an octapeptide with homology to the engrailed-type repressor sequence (Poleev 
et al., 1997, Kozmik et al., 1993, Buisson et al., 2015). The majority of inactivating PAX8 
mutations described have been located in the highly conserved DNA-binding paired 
domain (amino acids 9-137) (Liu et al., 2017, Montanelli and Tonacchera, 2010b). 
However, PAX8-T356M is located at the c-terminal region of the protein and does not 
affect the paired domain, the octapeptide or the homeodomain. Interestingly, while the 
capacity of DNA-binding would not be expected to be compromised in this variant, 
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promoter transactivation assays determined that the functionality of PAX8-T356M is 
suboptimal. Noteworthy, PAX8-T356M protein stability and subcellular localization 
were not altered compared to PAX8-Wt. Therefore, it is tempting to speculate that this 
variant is ineffective in vivo due to altered protein interactions with co-factors involved 
in the regulation of Pax8 transcriptional activity (Di Palma et al., 2008). Of note, other 
mutations in PAX8 that do not affect the paired homeodomain-binding sites, but exhibit 
impaired DNA binding capacity and loss of transcriptional activity, have already been 
described in the literature (Montanelli and Tonacchera, 2010b). To date, detrimental 
PAX8 polymorphisms in heterozygosis have been reported to be the genetic cause of 
thyroid dysfunction and urogenital malformations (Esperante et al., 2008, Carvalho et al., 
2013b, Al Taji et al., 2007). However, no associations of PAX8 polymorphisms and 
glucose disorders during pregnancy have been established. In this thesis, we have shown 
for first time a possible association between PAX8 and GDM as well as GTD, suggesting 
that this transcription factor could be used as a genetic marker for both pathologies. 
Nonetheless, in order to properly confirm this association a larger cohort of patients 
should be studied. 
Compelling evidences in animal models indicate that Pax8 is expressed in 
different organs such as thyroid, brain and the excretory system during development 
(Plachov et al., 1990). In adulthood, Pax8 expression is restricted to the kidney and the 
thyroid, with barely to undetectable expression levels in the endocrine pancreas (Plachov 
et al., 1990, Lorenzo et al., 2011). Homozygous Pax8 knockout mice show severe 
hypothyroidism and die around weaning, unless they are supplemented with T4. 
Furthermore, despite T4 hormone supplementation, Pax8 knockout mice are infertile due 
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to defects in the urogenital tract (Mittag et al., 2009, Mansouri et al., 1998 Mittag et al., 
2007). Therefore, in order to determine the physiological role of Pax8 in glucose 
homeostasis during pregnancy, we used female Pax8 +/- mice. Curiously, female Pax8 
+/- mice did not develop glucose intolerance or insulin resistance during pregnancy when 
compared to WT pregnant mice. Moreover, no significant differences were observed 
between pregnant WT and Pax8 +/- mice when challenged with Poly I:C (double stranded 
RNA that mimics viral infections), although animals from both genotypes treated with 
Poly I: C displayed glucose intolerance when compared to treated non-pregnant mice. As 
opposed to humans harbouring detrimental PAX8 polymorphisms in heterozygosis, to 
date heterozygous Pax8 mice have not been reported to exhibit any overt phenotype 
(Mansouri et al., 1998). In this context, a dominant negative effect of the protein has been 
proposed as the possible explanation of the human phenotype, suggesting that a 
detrimental copy of PAX8 might be in fact more deleterious than the simply lack of one 
functional allele (Liu et al., 2017, Mansouri et al., 1998). Remarkably, female Pax8 +/- 
mice showed similar levels of circulating T4 when compared to WT animals, although 
they were not measured during pregnancy. In this sense, THs have been shown to be 
involved in postnatal pancreatic islet development and are known to have profound 
effects on metabolism. Moreover, there is an association between subclinical 
hypothyroidism and GDM (Tudela et al., 2012). Therefore, the possibility that TH 
deficiency contributes to the association between detrimental PAX8 polymorphisms and 
GDM cannot be excluded. 
A genome-wide association study detected a SNP in the vicinity of PAX8 with a 
strong association with T2DM in an Afro-American population (Elbein et al., 2009). In 
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addition, the analysis of our pedigree might suggest an association between the new 
detrimental polymorphism and prediabetes/T2DM. Therefore, it is tempting to speculate 
that PAX8 expression may be physiologically relevant in the control of glucose 
metabolism beyond the scope of pregnancy. In order to investigate this possibility, we 
studied metabolic homeostasis in WT and Pax8 +/- male mice. Noteworthy, Pax8 +/- mice 
had significantly, but moderately, reduced levels of circulating T4. Therefore, metabolic 
tests were performed in animals from both genotypes supplemented or not with T4 in 
order to determine whether the effect of Pax8 deficiency on metabolic homeostasis was 
due to the restricted levels of THs. Remarkably, untreated Pax8 +/- male mice displayed 
increased body weight, glucose intolerance and severe insulin resistance, while T4 
supplementation rescued the phenotype. Thus, the phenotype observed appeared to be 
caused by the reduced levels of circulating T4 found. Remarkably, an increase in body 
weight in untreated Pax8 +/- animals is consistent with the lower BMR (defined as the 
rate of energy expenditure per time at rest) associated with hypothyroidism. In addition, 
untreated Pax8 +/- animals exhibited an overall unhealthy status.  
The architecture and proportion of endocrine cells were similar in WT and Pax8 
+/- as well as Pax8 -/- animals at postnatal day 21, excluding the possibility that a major 
defect in pancreatic islet development would account for the phenotype. Moreover, 
insulin secretion after a glucose load was not affected in untreated Pax8 +/- mice, 
suggesting that the phenotype observed is caused by an effect of THs mainly in peripheral 
tissues. Indeed, we observed an increase in WAT weight and a tendency to increased 
adipocyte size, which are correlated with insulin resistance. Furthermore, we found that 
Pax8 +/- animals accumulated higher lipid content in the liver and had increased 
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intramuscular lipid depositions. Since ectopic lipid depositions are strongly correlated 
with insulin resistance, this could contribute to the dysregulation in glucose homeostasis 
and insulin resistance observed in Pax8 +/- male mice. In addition, 4-HNE, which results 
from lipid peroxidation and has also been associated with insulin resistance, was 
increased in both the liver and the gastrocnemius of Pax8 +/- mice. In contrast, superoxide 
production was found increased specifically in the liver. Furthermore, protein levels of 
UCP2, which has been reported to possess antioxidant properties, were also reduced 
specifically in the liver of Pax8 +/- mice (Andrews et al., 2005, Andrews and Horvath, 
2009). These results indicate an increase in ROS levels in the liver of Pax8 +/- mice, 
which may cause hepatic insulin resistance. Consistent with this, insulin signalling was 
preferentially impaired in the liver of Pax8 +/- mice, as determined by the decrease in 
AKT phosphorylation found in this tissue. Moreover, our results also suggest that 
autophagy may be impaired in the liver of Pax8 +/- mice, which may cause an 
accumulation of damaged proteins/organelles. Remarkably, T3 supplementation has been 
reported to reduce ROS production in the liver of hepatic HBx transgenic mice (mouse 
model for hepatocellular carcinoma) by enhancing mitochondrial turnover and thus 
improving the quality of cellular mitochondria (Chi et al., 2017). Therefore, it is tempting 
to speculate that the reduced circulating T4 levels found in Pax8 +/- mice underlies an 
increase in ROS production in the liver that impairs insulin signalling in this organ. 
Whereas mild hypothyroidism causes insulin resistance and glucose intolerance, 
supplementation with TH provides undeniably positive benefits for metabolic health, 
attenuating hyperglycaemia in STZ-treated and leptin-receptor deficient mice (Lin and 
Sun, 2011; Verga Falzacappa et al., 2011; Shoemaker et al., 2012). Therefore, THs or 
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their analogues could represent a promising therapeutic approach for the treatment of 
metabolic complications. However, the detrimental effects of high circulating levels of 
THs (thyrotoxicosis) are well known. Patients suffering thyrotoxicosis exhibit a 
pleiotropy of symptoms that include life-threatening disorders such as cardiovascular 
collapse and thyroid storm, among others (Bahn et al., 2011; Garmendia Madariaga et al., 
2014). Moreover, there is an association between hyperthyroidism and insulin resistance. 
Indeed, in healthy subjects there is a positive correlation between increased HOMA-IR 
and increased TH levels, even within physiological range (Duntas et al., 2011). These 
risks have precluded the investigation of potential therapies based on the use of THs to 
treat metabolic disorders.  
In this thesis, we show that a level of T4 supplementation increases insulin 
concentration in blood and enhances glucose clearance, while maintaining an overall 
healthy status in wild-type C57BL/6 mice. In addition, our results indicate that T4 
supplementation increases insulin content in pancreatic β-cells. Previous reports had 
demonstrated that the T3-TR complex induces MafA transcription through direct binding 
to TH response elements located in the MafA promoter (Aguayo-Mazzucato et al., 2013). 
Moreover, MafA is known to bind to the insulin promoter, inducing insulin expression 
(Olbrot et al., 2002; Matsuoka et al., 2004), providing a plausible molecular mechanism 
by which T4 supplementation enhances insulin expression in pancreatic β-cells. However, 
as opposed to a previous study using 7-day-old mice, our immunohistochemical analysis 
in pancreatic sections from healthy adult mice indicated that MafA is already 
predominantly located in the nucleus of pancreatic β-cells and T4 supplementation does 
not further promote the nuclear localization of this transcription factor. Therefore, our 
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results suggest that T4 supplementation in adulthood increases insulin content by other 
pathways different from the presence/absence of MafA in the nucleus (Aguayo-
Mazzucato et al., 2013).  
Islets isolated from mice treated with T4 exhibited a marked increase in GCK gene 
and protein expression. Remarkably, an upregulation of GCK expression may contribute 
to the increased insulin secretion found under fasting conditions, as observed in GSIS 
tests, since enhanced GCK activity has been previously shown to lower the glucose 
threshold that stimulates insulin secretion (Weinhaus et al., 2007; Kassem et al., 2010). 
Increased circulating insulin in T4-treated animals activated the IRS1-Akt axis of insulin 
signalling, suggesting that glucose uptake is increased in insulin target tissues. T4 is 
known to increase the basal metabolic rate by inducing the expression of several 
mitochondrial uncoupling proteins, such as UCP2 (Lanni et al., 2003; Ramadan et al., 
2011). As a result of increased mitochondrial uncoupling, mitochondrial efficiency is 
lower (defined here as the amount of nutrients used to produce one molecule of ATP) and 
heat production is increased (note that BAT weight in T4-treated animals was increased). 
In order to adapt to this situation, T4-treated cells require higher amounts of nutrients to 
maintain their metabolism. Therefore, it is tempting to speculate that insulin expression 
and secretion in pancreatic islets under fasting conditions is enhanced in mice treated with 
T4 to allow nutrient uptake by insulin-target tissues. Supporting this hypothesis, we found 
that, as opposed to untreated animals, in which a significant increase in insulin levels was 
promoted by a glucose bolus, insulin levels in T4-treated mice were already maximal 
prior glucose load, suggesting that the insulin secretion machinery is already active. 
Moreover, our results also indicate that β-cell proliferation and apoptosis are specifically 
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increased in mice treated with T4. Remarkably, increased GCK activity has been 
associated to increased β-cell proliferation and apoptosis. Therefore, the increase in GCK 
expression induced by T4 administration might contribute to the enhancement of β-cell 
turnover, promoting the existence of a highly insulin-expressing β-cell population, which 
actively secretes insulin into the circulation under basal conditions (Kassem et al., 2000; 
Kassem et al., 2010).  
Given the age of the animals, the length of the treatment (~24 weeks at the end of 
the experiment, which represents ~25% of an average lifespan of this mouse strain) and 
the mouse chow used in this study (a standard healthy diet), we do not believe that the 
increase of insulin expression in pancreatic β-cells found in T4-treated mice was 
indicative of over-stimulation of β-cells, as found in prediabetic individuals. However, 
since hyperinsulinemia itself has been shown to promote insulin resistance, we cannot 
exclude the possibility that a longer T4 treatment could cause insulin resistance, which 
would resemble the phenomenon observed in hyperthyroid patients. However, the 
analysis of insulin-target tissues indicated that the higher insulin concentration in blood 
is able to activate the IRS1-Akt axis of the insulin signalling pathway. Previous reports 
have indicated that T4 exerts non-genomic effects by activating specifically PI3K and its 
downstream targets (Lin and Sun, 2011). Although we cannot exclude that non-genomic 
T4 actions contribute to the activation of PI3K and its downstream targets in vivo, we 
found that T4 supplementation activates insulin signalling as early as the level of IRS1, 
as shown by the increase in pTyr632-IRS1 in skeletal muscles and livers of T4-treated 
mice. Remarkably, we found that both T4-supplemented and control mice treated with 
insulin at the end of the experiment, reached the same level of AKT activation (pSer473-
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AKT levels). Therefore, our results suggest that high insulin levels per se are responsible 
for T4-mediated AKT activation. Hence, although the major effects of reduced circulating 
T4 levels were observed in peripheral tissues, the main target of T4 supplementation 
seems to be the endocrine pancreas (Figure 49).   
 
Figure 49. Schematic representation of the effects of reduced and increased circulating 
T4 levels in metabolism. Reduced circulating T4 levels in mice are associated with glucose 
intolerance, insulin resistance and increased body weight. In contrast, T4 supplementation 
enhances glucose homeostasis and decreases body weight in healthy mice.  
In this thesis, we also show that T4 supplementation blunts the onset of T1DM 
using the RIP-B7.1 model of EAD and increases survival in STZ-induced experimental 
diabetes in wild-type C57BL/6 mice. Previous research has determined that during the 
onset of T1DM, β-cell proliferation is increased in an attempt to compensate β-cell loss 
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(Willcox et al., 2010). In this regard, we observed that, although immune infiltration and 
the percentage of apoptotic β-cells is similarly augmented in untreated or T4-treated 
pancreases during the immune attack, β-cell proliferation is remarkably increased in T4-
treated RIP-B7.1 mice. This process presumably leads to compensation for β-cell loss, 
allowing the production and secretion of enough insulin to maintain normoglycemia. 
Actually, both insulin content and postprandial circulating insulin levels were 
significantly increased in T4-treated immunized RIPB-7.1 mice. Our experimental design 
initiated T4 supplementation 2 weeks prior to induction of diabetes mellitus 
(immunization or STZ treatment), as these research models (EAD and STZ) are very 
aggressive and a significant percentage of mice die within the first 2 weeks after the 
induction of diabetes. In order to evaluate a possible therapeutic benefit, experiments 
aiming to determine whether T4 supplementation after the onset of T1DM could improve 
glucose homeostasis would be required. Notwithstanding, our results indicate that 
interventions based on the use of THs or thyromimetics could open novel venues for the 
treatment of T1DM. Although novel treatments including the use of T4 supplementation 
might not be optimal for the treatment of metabolic diseases due to side effects, certain 
newly developed thyromimetics could affect specific cell types or organs that could 
benefit from these actions of THs, resulting in the improvement of metabolic homeostasis, 
while avoiding side effects (Shoemaker et al., 2012; Coppola et al., 2014; Finan et al., 
2016). Although the profound systemic effects of T4-administration in mice suggest that 
THs and thyromimetics might be useful in ameliorating the abnormal metabolism in 
diabetic patients, the identification of the underlying mechanisms that are critical for the 
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observed improvements on glucose control and potential long-term toxic effects must be 
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1. PAX8 over-expression protects pancreatic islets cells from apoptosis and does not 
have an effect in metabolic activity or GSIS. 
2. A novel PAX8 variant (PAX8-T356M) is associated with GTD and GDM. 
3. PAX8-T356M exhibit compromised functional activity on the activation of Tg 
promoter. 
4. Pax8 +/- female mice exhibit normal circulating T4 levels at 5 months of age. 
5. Pax8 +/- female mice do not display glucose intolerance or insulin resistance 
during pregnancy. 
6. Pax8 +/- male mice exhibit reduced circulating T4 levels at 8 months of life. 
7. Pax8 +/- male mice exhibit increased body weight from 7 to 13 months of life. 
8. Pax8 +/- male mice display glucose intolerance and insulin resistance. 
9. AKT phosphorylation is reduced in the liver of Pax8 +/- male mice. 
10. Pax8 +/- male mice exhibit increased triglyceride content in the liver as well as 
intramuscular lipid depositions. 
11. There is an increase in superoxide generation in the liver of Pax8 +/- male mice, 
while mitochondrial content is not altered. 
12. T4 supplementation enhances glucose clearance in WT mice. 
13. T4 supplementation increases insulin content in pancreatic islets of WT mice. 
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14. T4 supplementation increases GCK expression in pancreatic islets of WT mice. 
15. Insulin secretion at low glucose concentrations in vitro is increased in pancreatic 
islets of WT mice treated with T4. 
16. T4 supplementation increases β-cell proliferation and apoptosis in pancreatic 
islets from healthy mice.  
17. T4 supplementation blunts the onset of T1DM in the RIPB-7.1 model of EAD and 
increases survival in mice challenged with STZ. 
18. T4 supplementation increases insulin content and β-cell proliferation in the 
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Abstract: Successful normalization of blood glucose in patients transplanted with pancreatic islets isolated from ca-
daveric donors established the proof-of-concept that Type 1 Diabetes Mellitus is a curable disease. Nonetheless, major ca-
veats to the widespread use of this cell therapy approach have been the shortage of islets combined with the low viability 
and functional rates subsequent to transplantation. Gene therapy targeted to enhance survival and performance prior to 
transplantation could offer a feasible approach to circumvent these issues and sustain a durable functional β-cell mass in 
vivo. However, efficient and safe delivery of nucleic acids to intact islet remains a challenging task. Here we describe a 
simple and easy-to-use lentiviral transduction protocol that allows the transduction of approximately 80 % of mouse and 
human islet cells while preserving islet architecture, metabolic function and glucose-dependent stimulation of insulin se-
cretion. Our protocol will facilitate to fully determine the potential of gene expression modulation of therapeutically 
promising targets in entire pancreatic islets for xenotransplantation purposes. 
Keywords: Diabetes Mellitus, Gene transfer, Infection, Lentivirus, Pancreatic islet, Transduction. 
INTRODUCTION 
Type 1 Diabetes Mellitus (T1DM) is one of the most 
common multifactorial endocrine and metabolic diseases in 
childhood resulting in persistent hyperglycaemia. Currently, 
approximately 490,000 children have been diagnosed with 
T1DM and 78,000 children under the age of 15 are estimated 
to develop T1DM annually worldwide [1]. More alarmingly, 
a recent epidemiological study has revealed that the inci-
dence rate of T1DM in children in the United Sates has in-
creased dramatically by 29% between 1985 and 2004 sur-
passing by 18 times the incidence of Type 2 Diabetes Melli-
tus (T2DM) in the white population [2]. The most common 
form of T1DM results from the breakdown of β-cell-specific 
self-tolerance by T-lymphocytes precipitating an autoim-
mune attack and eradication of insulin-producing cells [3]. 
Strong genetic and environmental factors contribute to the 
onset of T1DM [4]. Existing treatments for T1DM are pri-
marily focused on insulin supplementation. However, despite 
the beneficial effects of life-long insulin therapy on 
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glucose homeostasis, insulin administration does not elimi-
nate severe diabetic complications such as retinopathy, neph-
ropathy as well as cardiovascular and cerebrovascular dis-
eases [5].  
In the past 10 years, clinical islet transplantation has 
gained much attention as a cell replacement therapy for re-
storing the functional β-cell mass. Unfortunately, the limited 
supply of islets from donors has failed to meet demands im-
posed by the ever-growing number of T1DM patients. An 
additional major hurdle has been the lack of durability of 
islet function with insulin independency in less than 10% of 
patients 5 years after transplantation [6, 7]. Furthermore, 
several post-transplant events, such as instant blood medi-
ated inflammatory reaction and cytokine cascade, seriously 
affect the long-term functionality of islets [8-11]. Ex vivo 
genetic modifications of islets to enhance cell function and 
survival prior to transplantation have been successfully dem-
onstrated in animal models [12, 13]. This strategy can ulti-
mately increase islet viability and performance providing a 
tangible approach to improve human islet transplantation and 
long-term insulin independence. Although protocols de-
signed to modulate gene expression have been extensively 
used in single cells, the complexity of pancreatic islets has 
impeded successful gene delivery. Indeed, due to its tridi-
mensional structure, β-cells embedded within the core of 
islets are sequestered from any significant contact with the 
remote environment [14-19]. During the last years, several 
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non-viral strategies for genetic modification of islet cells, 
such as electroporation, microporation, gene gun particle 
bombardment, cationic liposomes and polymeric particles, 
have been investigated [15, 19-21]. Unfortunately, in most 
cases those techniques provided low gene transfer efficien-
cies and the difficulty of reproducing these protocols have 
hindered their broad use to allow optimized islet gene trans-
fer. More recently, ex vivo infection of islets was proposed in 
order to conduct mechanistic studies and also to transfer 
therapeutically promising genes or alleles prior to islet 
xenotransplantation [22]. Adenoviral vectors have been used 
with this purpose since the efficiency of infection in non-
dividing cells is greater than other vectors and their epi-
chromosomal location reduces the probability of conferring 
insertional mutations. The efficiency of the majority of ade-
novial-based infection protocols has been found to be limited 
to only ~7-30 % of islet cells and infected cells were mostly 
located in the periphery of the islet [14, 15]. Although sev-
eral studies reported infection of 30-90 % of islet cells 
throughout the whole islet [14, 23, 24] excessive viral dosage 
were used which may cause cytotoxicity [14, 25, 26]. Alter-
natively, genetic modifications of adenoviral vectors such as 
the inclusion of Arg-Gly-Asp motif were attempted to en-
hance transduction efficiency up to ~80 % of islet cells at 10 
Plaque Forming Units (PFU) per cell [15]. Unfortunately, the 
drawback for adenoviral transduction was the methodologi-
cal difficulties of these experimental protocols and the tran-
sient modulation of gene expression [23, 27]. 
The use of lentiviral vectors in gene therapy has become 
a powerful tool to safely deliver genetic material with the 
purpose to rectify molecular defects, enhance functional per-
formance or increase viability of cells. Major advantages of 
lentiviral vectors include the capacity to infect both dividing 
and non-dividing cells using repeated dosing, genome inte-
gration and long-term expression as well as low immuno-
genicity [28]. Currently, 89 gene therapy clinical trials using 
lentiviral vectors are ongoing [29] focusing predominantly 
on the treatment of primary immunedeficiencies [30]. Trans-
duction protocols using lentiviruses have also been devel-
oped for islet infection yielding similar efficiency than ade-
noviral vectors (~3-50 % of β -cells) [14, 16-18, 31-33]. 
Given the tremendous attributes of lentiviral vectors com-
bined with their current use in clinical trials, we set out to 
develop a simple and optimal lentiviral transduction protocol 
for intact human and mouse pancreatic islets with the long-
term goal to apply this protocol for gene therapy in islets 
prior to transplantation without compromising their integrity 
and functionality. 
MATERIALS AND METHODS 
Consumables 
Reagents and materials used in this study along with ref-
erence numbers and companies of purchase are outlined in 
Table 1. 
Animals 
Male mice (c57bl/6, 12 week-old) were purchased from 
Janvier Labs (Le Genest-Saint-Isle, France). Mice experi-
mentations were approved by the CABIMER Animal Com-
mittee and performed in accordance with the Spanish law on 
animal use RD 53/2013. 
 




50 x 9 mm Petri dishes BD Falcon 351006 
Affi-Gel blue beads Bio-Rad 153-7301 




CMRL-1066 Cellgro 99-663-CV 
Collagenase Roche C9263 
DAKO fluorescent mounting 
medium 
Dako S3023 
DAPI Sigma-Aldrich 32670 
Donkey serum Sigma-Aldrich D9663 
Fetal Bovine Serum Sigma-Aldrich F7524 
Formaldehyde Panreac AppliChem 252931 
Gentamycin Sigma-Aldrich G1397 
Glutamine Sigma-Aldrich G7513 
Hanks Balanced Salt Solu-
tion 1X 
Gibco 14170088 
HEPES Gibco 15630-056 
HistoGel Thermo Scientific R904012 
micro-Plate 96 welllibiTreat IBIDI 89626 
Millex-HV filter 0.45 µm Merck Millipore SLHV033RS 
PBS Sigma-Aldrich P5368 
Penicillin/Streptomycin Sigma-Aldrich P4333 
Polystyrene Round-bottom 
tube 
BD Falcon 352058 
RPMI-1640 Sigma-Aldrich R0883 
Sodium pyruvate Sigma-Aldrich S8636 
SuperFrost Plus slides Menzel-Glaser J1800AMNZ 
Trypsin-EDTA 10 X Gibco 15400054 
β-mercaptoethanol Gibco 31350-10 
 
Islets Procuration and Culture 
Mice were sacrificed by cervical dislocation and pancre-
atic islets were isolated using the collagenase digestion pro-
cedure with subsequent handpicking as previously described 
[34]. Prior to culture islets were washed with Phosphate 
Buffered Saline (PBS) containing 100 U/ml penicillin and 
100 µg/ml streptomycin to minimize post-isolation contami-
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nations. Subsequently islets were cultured in mouse Com-
plete Media (CM) comprised of RPMI 1640 supplemented 
with 10 % FBS, 100 U/ml penicillin, 100 µg/ml streptomy-
cin, 2 mM glutamine, 1 mM sodium pyruvate, 50 µM β -
mercaptoethanol and 10 mM HEPES. Isolated human islets 
were either kindly provided by the Cell Isolation and Trans-
plantation Centre (Geneva, Switzerland) or purchased from 
Tebu-bio (Le Perray En Yvelines, France). Characteristics of 
human islet preparations are included in Table S1. Islets 
were cultured in human Complete Media (CM) composed of 
CMRL-1066 supplemented with 10 % FBS, 100 U/ml peni-
cillin, 100 µg/ml streptomycin, 2 mM L-glutamine and 100 
µg/ml gentamycin. 
Lentivirus Generation 
We opted for the dual-promoter lentivirus, pHRSIN 
DUAL-GFP also known as pHRSIN-CSGWdINotIpUbEm 
(kindly supplied by Dr. Pintor-Toro, CABIMER, Spain) to 
conduct our studies [35]. This vector allows the cloning 
and expression of a Gene Of Interest (GOI) under the con-
trol of the SFFV promoter while the constitutive Ubiquitin 
(Ubi) promoter regulates expression of the reporter GFP. 
Lentivirus amplification and purification was performed by 
seeding 5 × 106 Hek293T cells into a 100 mm Petri dish 
and subsequently transfected 24 hours later with: 1) 15 µg 
of vector, 2) 10 µg the HIV packaging plasmids 
pCMVDR8.91 and 3) 5 µg of HIV packaging plasmids 
pVSVG (also known as pMDG). Transient DNA transfec-
tion was performed using the CalPhos transfection mam-
malian kit according to the manufacturer’s recommenda-
tions. Viral particles were harvested 72 hours post-
transfection, purified using a 0.45 µm Millex-HV filter, and 
concentrated by ultracentrifugation in an OptimaTM L-100K 
ultracentrifuge at 87300 x g for 90 minutes at 4º C in a 
swinging bucket rotor SW-28 (Beckman-Coulter, Spain). 
Virus particles were resuspended in serum-free DMEM 
(Invitrogen), distributed in aliquots, snapped frozen in liq-
uid nitrogen, and stored at −80 °C. Viral titer was estimated 
by transducing Hek293T cells with increasing amounts of 
pHRSIN DUAL-GFP followed by flow cytometry (FAC-
SCalibur, BD Biosciences, Spain) analysis to determine the 
PFU/ml based on GFP emission.  
Live Imaging and Flow Cytometry 
An ImageXpress Micro System (Molecular Devices) was 
used to monitor GFP fluorescence in living islets. To this 
end, approximately 20 transduced human or mouse islets 
were seeded in µ-Plate 96 welllibiTreat plate in a final vol-
ume of 200 µl of CM. Islets were cultured for 4 days at 37º C 
and images (fluorescence or phase contrast) were automati-
cally captured daily and processed using the MetaXpress 
software. In parallel, islet transduction efficiency was esti-
mated by flow cytometry. In brief, approximately 20 islets 
were transferred into 5 ml polystyrene Round-bottom tube in 
a final volume of 50 µl of CM. Islets were disaggregated 
using 1 X trypsinization for 5 minutes at 37º C and subse-
quently centrifuged at 200 x g for 5 minutes. Cells were re-
suspended in 300 µl of PBS and the number of GFP positive 
cells was estimated as compared to non-infected cells. 
Islet Processing and Immunocytochemistry 
Islet embedding was performed according to the protocol 
developed by Cozar-Castellano et al. [36]. In brief, approxi-
mately 200 human or murine islets were fixed in 10 % for-
maldehyde at room temperature for 48 hours. Islets were 
then washed three times in distilled water prior to adding 
warm (70° C) HistoGel containing 100 µl of 150-300 µm 
diameter Affi-Gel blue beads. After cooling, Histogel con-
taining the islet-bead mixture was embedded in paraffin fol-
lowing the standard procedures of the CABIMER Histology 
Core Facility. Paraffin blocks were sectioned (5 µm thick-
ness) using a microtome Leica RM 2255 (Leica Microsys-
tems, Spain). Sections were mounted on SuperFrost Plus 
slides. After every 10 sections, a slide was stained with he-
matoxylin-eosin to confirm islet integrity and presence of 
islets. Sections were deparaffinized/rehydrated at 60˚ C for 
20 minutes followed by immersion in decreasing concentra-
tions of ethanol (Xylene 5 minutes/2 x; Ethanol 100 % 1 
minute/2 x; Ethanol 96 % 1 minute; Ethanol 80 % 1 minute; 
Ethanol 70 % 1 minute; Distilled water 2 minutes/2 x). After 
deparaffinization and rehydration, sections were subjected to 
heat-induced antigen retrieval using 10 mM sodium citrate 
buffer (pH 6.0) in the microwave in 3 cycles of 3 minutes at 
800 W avoiding boiling of the buffer, with 2 minutes at room 
temperature between heating cycles. Samples were cold 
down in the same solution for 20 minutes at room tempera-
ture. After washing with PBS, samples were incubated in 
PBS + 0.5 % Triton X-100 and then washed again with PBS. 
Blocking was performed with PBS + 0.2 % Triton X-100 
containing 1 % Bovine Serum Albumin (BSA) and 3 % 
Donkey serum for 1 hour at room temperature. Primary anti-
bodies (Table 2) at the indicated dilutions were added in PBS 
+ 0.1 % Triton X-100 containing 1 % BSA and 3 % Donkey 
serum and incubated overnight at 4˚ C in a dark humid 
chamber. Subsequently, sections were washed with PBS for 
5 minutes, PBS + 0.2 % Triton X-100 for 5 minutes and PBS 
for 5 minutes. Samples were then incubated with secondary 
antibodies (Table 2) diluted in PBS + 0.2 % Triton X-100 
containing 0.1 % BSA for 1 hour at room temperature in a 
dark humid chamber. Nuclear counterstaining was performed 
by DAPI staining diluted 1:1000 in PBS for 5 minutes at 
room temperature. Finally, samples were washed three times 
with PBS for 5 minutes each and sections were mounted 
using DAKO fluorescent mounting medium. Wide-field im-
munofluorescence microscopy was performed using a Leica 
microscope (AF6000) (Leica, England). Images were taken 
at 40X magnification. Confocal images were acquired using 
a Leica confocal microscope (TCS SP5). The images were 
scanned under a HCX PL APO lambda blue 63X/ 1.4 OIL 
objective. To analyze the whole section, each sample was 
analyzed using a spatial series through the Z axis. Each spa-
tial series was composed of approximately 5-7 optical sec-
tions with a size of 0.8 µm and a 3D projection of each z-
stack was performed using three sections. 
Viability and Functional Assay 
Islet viability subsequent to transduction was assessed in 
groups of 35 islets using the Cell Proliferation Kit I (MTT) 
according to the manufacturer´s recommendations (Roche, 
Spain). Optical density was determined at 550 nm with a 
reference wavelength of 650 nm using a Varioskan Flash 
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spectrophotometer (Thermo Scientific, Spain). In parallel, 
glucose stimulated insulin secretion was performed to assess 
the functional integrity of islets. Groups of 10 islets were 
washed in 500 µL of Krebs-Ringer bicarbonate-HEPES 
buffer (KRBH) (140 mM NaCl, 3.6 mM KCl, 0.5 mM 
NaH2PO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 2 mM NaHCO3, 
10 mM HEPES, 0.1% BSA) and pre-incubated at 37° C for 
45 minutes in 300 µl of the same buffer. Islets were then 
centrifuged and KRBH buffer was discarded. Subsequently, 
fresh KRBH supplemented with 2.5 mM glucose was added 
and islets were incubated for 30 minutes. Next, buffer was 
harvested (basal insulin secretion) and 500 µL of KRBH 
supplemented with 16.8 mM glucose was added. Islets were 
incubated for an additional 30 minutes at 37° C and then 
buffer was harvested (induced insulin secretion). Insulin lev-
els were measured using a mouse or human insulin enzyme 
immunoassay kit (Mercodia AB, Spain) according to the 
manufacturer´s instructions. Stimulation index was ex-
pressed as the ratio of insulin levels at 16.8 mM glucose di-
vided by insulin levels at 2.5 mM glucose. 
Statistical Analysis 
Results are expressed as the mean± SEM. Statistical dif-
ferences were estimated by two-tailed unpaired student’s t-
test. *Indicates statistical significance, p value <0.05. 
RESULTS 
Elaboration of a High Efficiency Transduction Protocol 
in Mouse Islets 
Modulation of gene expression has been particularly 
challenging in the context of whole pancreatic islets as com-
pared to cell lines due to their three dimensional structure 
composed of approximately 1000 to 2000 compacted cells. 
Sophisticated protocols such as in vivo perfusion or micropo-
ration using adeno and lenti viruses claim to have success-
fully and homogenously transduced up to 70% islet cells 
[24]. As these protocols may be cumbersome to carry out or 
simply not always feasible (i.e. in vivo perfusion of human 
islets) we sought to develop a readily accessible and friendly  
 
Fig. (1). Optimized protocol for lentiviral-mediated islet infec-
tion. Summarized scheme of the transduction protocol described in 
Box 1. 
Table 2. List of antibodies used in this study. 
Antibody Dilution Vendor Catalog Number 
Anti-GFP 1:200 Abcam Ab6673 
Anti-insulin (H-86) 1:500 Santa Cruz SC9168 
Anti-insulin 1:500 Sigma-Aldrich I2018 
Anti-glucagon 1:150 Sigma-Aldrich G2654 
Anti-glucagon 1:200 Cell Signaling 2760S 
Anti-cleaved caspase-3 1:150 Cell Signaling 9661 
Alexa fluor 488 donkey anti-goat  1:800 Invitrogen A11055 
Alexa fluor 555 donkey anti-mouse 1:800 Life technologies A31579 
Alexa fluor 647 donkey anti-rabbit 1:800 Life technologies A31573 
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BOX 1. OPTIMIZED ISLET INFECTION PROTOCOL 
Step 1. Isolation of fresh murine islets by collagenase digestion (0.7-0.9 mg/ml) and subsequent handpicking (for human samples go to step 2). 
Step 2. Culture islets for 3 hours in 50 x 9 mm Petri dishes in 2.5 ml of complete RPMI. For human samples, place islets upon sample arrival in 100 x 9 
mm Petri dishes and culture them over-night in 10 ml of complete CMRL-1066. 
Step 3. Collect medium and islets from the plate in a 15 ml falcon tube. 
Step 4. Centrifuge islets at 50 x g for 2 minutes and remove supernatant. 
Step 5. Incubate islets with 1000µl of warm (37º C) 0.5 X trypsin- Ethylenediaminetetraacetic acid (EDTA) (250 mg/l trypsin; 0.48 mM EDTA) for 3 min-
utes in a cell culture incubator (37º C, 5 % CO2). For trypsin-EDTA preparation: Aliquots of 0.5 % Trypsin-EDTA 10 X (5000 mg/l; 9.6 mM EDTA) are 
diluted in Hanks Balanced Salt Solution (HBSS) 1 X to obtain a final concentration of 0.5 X trypsin-EDTA (250 mg/l; 0.48 mM EDTA)). 
Step 6. Pipette up and down 3 times slowly and carefully with a 1000 µl tip using a micropipette and subsequently add 1000 µl of complete RPMI for mur-
ine islets or complete CMRL-1066 for human islets. 
Step 7. Centrifuge islets at 50 X g for 2 minutes and remove supernatant.  
Step 8. Resuspend 100-300 islets in serum free RPMI (for murine islets) or serum free CMRL-1066 (for human islets). Place islets in a polystyrene Round-
bottom tube or in a µ-Plate 96 welllibiTreat culture plate depending on the desired experiment. Note that final volume must not exceed 200 µl. 
Step 9. Add lentiviruses at 20 Plaque Forming Units per cell (PFU/cell), assuming that a single islet has 1000 cells. Note that final volume must not exceed 
200 µl and virus concentration must be in the range of 1.5-5 x104 PFU/µl. Resuspend islets by gently tapping the polystyrene Round-bottom tube or the µ-
Plate 96 welllibiTreat culture plate three times. 
Step 10. Incubate islets over-night in cell culture incubator (37º C, 5 % CO2) for optimal lentiviral transduction. 
Step 11. Remove medium and add 200-500 µl of complete RPMI (for murine islets) or CMRL-1066 (for human islets). 
Step 12. Incubate islets at 37º C in a cell culture incubator (37º C, 5 % CO2) until the optimal timing for the desired experiment is achieved. 
 
 
Fig. (2). High pHRSIN DUAL-GFP PFU/cell levels compromise islet viability with sub-optimal islet transduction efficiency. Freshly 
isolated murine islets were exposed to increasing PFU/cell of pHRSIN DUAL-GFP. Non-transduced islets (Mock) were used as control. (A) 
Representative images of ex vivo cultured entire live transduced islets. Top; GFP expression was assessed by fluorescence acquisition using 
an ImageXpress Microsystem. Low; Bright field images. Images were captured at 4 days post-infection. Arrows indicate necrotic areas. 
Scale-bars indicate 100 µm. n=4 experiments per condition. (B) Transduction efficiency, defined as the percentage of islet cells expressing 
GFP, was determined by flow cytometry in disaggregated islets at 4 days post-infection. n=6 per condition. (C) Determination of islet meta-
bolic activity using the MTT assay at 4 days post-infection n=4-6 per condition. (D-E) Representative immunofluorescence images of Affi-
Gel bead-embedded pancreatic islets 4 days post-infection. Antibodies against GFP (green), insulin (red) and glucagon (cyan) were employed. 
Of note, in some instances the Affi-Gel beads, emitted a non specific fluorescent signal along with GFP (Green) and insulin (red). (D) Wide-
field fluorescence microscopy. (E) Confocal microscopy. Scale-bars, 50 µm. n=3 per condition. Data are represented as the mean ± SEM. * 
p< 0.05 versus control non-transduced islets. 
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user lentiviral protocol (BOX 1 and Fig. 1). Consistent  with 
previous reports, the mere exposure of islets to increasing 
PFU/cell of pHRSIN DUAL-GFP resulted in enhanced GFP 
fluorescence from living islets corroborating with a greater 
number of islet cells expressing GFP, as assessed by flow 
cytometry of dispersed islets (Fig. 2A-B). However, the 100 
PFU/cell that achieved 80% infection efficiency also consid-
erably reduced islet viability (Fig. 2C) with the appearance 
of necrotic cells in the islet core (Fig. 2A, arrows). Intrigu-
ingly, wide-field and confocal immunocytochemistry re-
vealed that even at high PFU/cell cells at the periphery were 
preferentially infected (e.g. GFP positive) (Fig. 2D-E). In an 
attempt to increase accessibility to cells sequestered within 
the core to viral particles without compromising viability, we 
mildly loosen up islet cells using either 1X (500 mg/L tryp-
sin; 0.96 mM EDTA) or 0.5X (250 mg/L trypsin; 0.48 mM 
EDTA) trypsin-EDTA for 3 minutes prior to transduction. 
Both trypsin concentrations improved the number of GFP-
expressing islet cells at either 5 or 20 PFU/cell (Fig. 3A-B). 
Flow cytometry of disaggregated islets confirmed that the 
number of GFP-positive cells infected at 5 PFU/cell in-
creased from ~30% in control islets to ~50% in islets pre-
treated with trypsin independent of its concentration (Fig. 
3B). Similarly, 20 PFU/cell resulted in 80% of cells express-
ing GFP independent of trypsin concentrations (Fig. 3B). 
Unexpectedly, 1X trypsin jeopardized viability of cells in all 
conditions (Fig. 3C). High-resolution confocal microscopy 
confirmed that 0.5X trypsin-EDTA facilitated infection of 
cells residing within the islet core (Fig. 3D). We next sought 
to determine the temporal evolution of GFP expression sub-
sequent to transduction using 0.5X trypsin. In order to ex-
pose islets to minimal amount of viral particles, we also as-
sessed the transduction efficiency of 7 and 10 PFU/cell. For 
each viral dosage, the percentage of GFP-positive cells re-
mained relatively constant over the 10 day period (Fig. 4A-
B). Of note, at day 10, non-infected (mock) islet cells emit 
low levels of fluorescent, indicative of auto-fluorescence 
produced by apoptotic cells [37]. Consistent with this prem-
ise, islet architecture was strongly compromised at day 10 
with signs of necrosis as compared to islets 4 days post in-
fection (Fig. 4C). In some instances, bacterial contamination 
was also observed 10 days after transduction (data not 
shown). Islets transduced at 20 PFU/cell consistently pre-
sented ~80% of islet cells at day 4 post-infection, as com-
pared to all other PFU/cell tested (Fig. 4B). GFP immu-
nostaining was detected homogeneously throughout the islet 
co-localizing with both insulin as well as glucagon-positive 
cells 4 days post-infections (Fig. 4D-E). More importantly at 
this time point, neither islet viability (Fig. 4F) nor function, 
as measured by glucose-induced insulin secretion (Fig. 4G), 
were altered at 20 PFU/cell as compared to 5, 7, 10 PFU/cell 
or control non-transduced islets. Furthermore, the apoptotic 
rate, as assessed by cleaved-caspase 3 immunostaining, was 
identical in both control and 4 days post-transduction islets 
indicating, that the protocol is not detrimental for islet health 
(Fig. 4H-I) In summary, our data indicate that 80% of mouse 
islet cells express GFP 4 days after exposure to a short and 
mild trypsin treatment and to a viral dosage of 20 PFU/cell. 
Transduction Protocol Validation in Human Islet 
We next validated our transduction protocol in human is-
lets. Live human islets revealed intense GFP expression 
without apparent ultra-structural abnormalities 4 days post 
transduction (Fig. 5A). Consistent with mouse islets, ap-
proximately 70 to 80% of islet cells were GFP-positive, as 
determined by flow cytometry of dispersed islets (Fig. 5B). 
Remarkably, the viability and functionality of transduced 
islets were not altered (Fig. 5C-D). Finally, GFP immu-
nostaining assessed by wide-field and confocal microscopy 
was detected homogeneously throughout islets co-localizing 
with both insulin and glucagon (Fig. 5E-F and Supplemental 
Fig. 1). Taken together, our data indicate that the proposed 
protocol is easy, reliable and allows the transduction of the 
majority of cells residing in entire islets from murine and 
human origin. 
DISCUSSION 
Given the indispensable role of pancreatic islets in glu-
cose homeostasis, the modulation of gene expression in 
transplanted islets could be a promising approach to boost 
islet performance and durability for the treatment of T1DM 
[38, 39]. In this context, non-viral strategies, such as electro-
poration, gene gun particle bombardment, cationic liposomes 
and polymeric particles, have been developed for genetic 
modification of islet cells [15, 19-21]. Unfortunately, these 
techniques provide only low to intermediate gene transfer 
efficiencies, limiting their applicability. In contrast, pub-
lished adenovial-based infection protocols claim to have 
successfully transduced up to 90 % of islet cells using high 
viral doses [14, 15, 23, 25-27]. Although promising, these 
protocols are technically challenging to perform. Moreover, 
these protocols result in transient expression and frequently 
induce cell toxicity. Alternatively, lentiviral vectors have 
emerged as an alternative strategy to modulate gene expres-
sion in intact islets. Up to 50 % of β cells in intact islets have 
been efficiently transduced without adverse viability effects 
[14, 16-18, 31-33]. Based on these initial successes, we have 
devised an easy-to-use and reproducible protocol that be-
stows a significant improvement of murine and human islet 
transduction efficiency. In summary, our optimized easy-to-
use transduction protocol resulted in an infection efficiency 
of ~70-80 % of cells within intact murine and human islets 
without compromising health. In the optimization of our 
protocol three non-mutually exclusive parameters were con-
sidered: 1) PFU/cell, 2) islet architecture, and 3) time post-
transduction. Consistent with other reports, we found that 
high PFU/cell (e.g. 100 PFU/cell or greater) increased trans-
duction efficiency but to the detriment of islet cell function 
and survival [14, 25, 26]. The negative impact of high virus 
dosage has also been substantiated in vivo xenotransplanta-
tion studies [15]. We established that a 20 PFU/cell was the 
optimal viral dosage reaching 50 % cell infection in intact 
islets without jeopardizing either viability or function. This 
PFU/cell is substantially lower to those (100-1000 PFU/cell) 
previously utilized in another published protocol [25]. Addi-
tion of a mild 0.5X trypsin-EDTA treatment to facilitate core 
accessibility greatly improved transduction efficiency while 
preserving islet health and function, reaching approximately 
80 % of the islet cell population. Interestingly, 1X trypsin-
EDTA affected cell viability. Pro-distension agents such as 
collagenase and triton-X-100 were also found to increase 
infection efficiency yet compromised islet functionality [14, 
23]. Thus, although these treatments seemingly appear to be 
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Fig. (3). A Mild Trypsin-EDTA treatment increases transduction efficiency in murine islets. Freshly isolated murine islets were treated 
or not with two concentrations of trypsin-EDTA prior transduction or not with pHRSIN DUAL-GFP. (A) Representative images of live islets 
exhibiting GFP fluorescence subsequent to treatment: Top; GFP expression was assessed by fluorescence acquisition using an ImageXpress 
Microsystem. Low; Bright field images. Images were captured at 4 days post-infection. Arrows indicate necrotic areas. Scale-bars 100 µm. 
n=4 experiments per condition. (B) Transduction efficiency in trypsin-EDTA treated islets was determined by flow cytometry in disaggre-
gated islets at 4 days post-infection. n=3-8 per condition. (C) Determination of islet metabolic activity using the MTT assay 4 days post-
infection. n=4 per condition. (D) Representative confocal immunofluorescence images of Affi-Gel bead-embedded pancreatic islets 4 days 
post-infection with or without 0.5X trypsin-EDTA treatment. Antibodies against GFP (green), insulin (red) and glucagon (cyan) were em-
ployed. Of note, in some instances the Affi-Gel beads, emitted a non specific fluorescent signal along with GFP (green). Scale-bars, 50 µm. 
n=3 per condition. 0 X: Untreated; 0.5 X: 0.5 X trypsin-EDTA treatment (250 mg/l trypsin; 0.48 mM EDTA); 1 X: 1 X trypsin-EDTA treat-
ment (500 mg/l; 0.96 mM EDTA). Data are represented as the mean ± SEM. * p < 0.05 versus control non-transduced trypsin-EDTA un-
treated islets. 
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Fig. (4). Mild trypsinization combined with 20 PFU/cell represents the optimal infection protocol for murine islets. Freshly isolated 
murine islets were treated with 0.5 X trypsin-EDTA (250 mg/l; 0.48 mM EDTA) and subsequently exposed to increasing PFU/cell of 
pHRSIN DUAL-GFP. (A) Representative images of GFP fluorescence emitted from live islets: Top; GFP expression was assessed by fluo-
rescence acquisition using an ImageXpress Microsystem. Low; Bright field images. Images were captured at 4 days post-infection. Scale-bars 
100 µm. n=4 experiments per condition. (B) Transduction efficiency in 0.5 X trypsin-EDTA treated islets at different days after transduction 
was determined by flow cytometry in dispersed islets. n=4 per condition. (C) Representative images of live islets exhibiting GFP fluores-
cence 4 and 10 days post-treatment: Top; GFP expression was assessed by fluorescence acquisition using an ImageXpress Microsystem. Low; 
Bright field images. Scale-bars 100 µm. n=4 experiments per condition. (D-E) Representative immunofluorescence images of Affi-Gel bead-
embedded pancreatic islets trypsin-treated and transduced or not with pHRSIN DUAL-GFP. Antibodies against GFP (green), insulin (red) 
and glucagon (cyan) were employed. Images were captured in samples fixed at 4 days post-infection using either wide-field fluorescence 
microscopy (D) or confocal microscopy (E). Of note, in some instances the Affi-Gel beads, emitted a non specific fluorescent signal along 
with GFP (green) and insulin (red). Filled arrows indicate transduced cells expressing insulin; Non-filled arrows indicate transduced cells 
expressing glucagon. Scale-bars 50 µm. n=3 per condition. (F) Determination of islet metabolic activity subsequent to a 0.5 X trypsin-EDTA 
treatment followed by transduction with 20 PFU/cell. A MTT assay was performed 4 days post-infection. n=3-4 per condition. (G) Glucose-
stimulated insulin secretion was assessed in islet treated with 0.5 X trypsin-EDTA followed by transduction with increasing amount of 
pHRSIN DUAL-GFP. (H) Representative immunofluorescence images of Affi-Gel bead-embedded pancreatic islets 0.5X trypsin-treated and 
transduced or not with pHRSIN DUAL-GFP. Antibodies against GFP (green) and cleaved Caspase 3 (magenta). Images were captured in 
samples fixed at 4 days post-infection using confocal fluorescence microscopy. n=3 per condition. (I) Determination of apoptosis rate by 
quantification of cleaved caspase 3 positive cells in islets 0.5X trypsin-EDTA-treated and transduced or not with pHRSIN DUAL-GFP. n=3 
per condition. Data are represented as the mean ± SEM of n=3. * p < 0.05 versus control non-transduced 0.5 X trypsin-EDTA treated islets. 
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Fig. (5). Human islets are efficiently transduced using the optimized protocol. Human islets obtained from cadaveric donors were initially 
treated with 0.5 X trypsin-EDTA (250 mg/l trypsin; 0.48 mM EDTA) and then transduced with pHRSIN DUAL-GFP at 20 PFU/cell. (A) 
Live imaging reveals GFP expression in human islets 4 days post-infection: Top; GFP expression, assessed by fluorescence acquisition using 
an ImageXpress Microsystem, Bottom; Bright field images. Scale-bars 100 µm. n=3 per condition. (B) Transduction efficiency in 0.5 X tryp-
sin-EDTA treated islets was determined by flow cytometry of dispersed islets at 4 days post-transduction with 20 PFU/cell. n=3 per condi-
tion. (C) Islet metabolic activity was assessed using the MTT assay. n=3 per condition. (D) Glucose-stimulated insulin secretion was assessed 
in either control islets or islet treated with 0.5 X trypsin-EDTA followed by transduction with 20 PFU/cell of pHRSIN DUAL-GFP. n=3 per 
condition. (E-F) Co-immunostaining of GFP (green), insulin (red) and glucagon (cyan) was performed on sections from Affi-Gel bead-
embedded human pancreatic islets subsequent to treatment. Images were captured in samples fixed at 4 days post-infection using wide-field 
fluorescence microscopy (E) or confocal microscopy (F). Scale-bars 50µm. n=3 per condition. Data are represented as the mean ± SEM. * p 
< 0.05 versus control non-transduced 0.5 X trypsin-EDTA treated islets. 
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beneficial, it is of utmost importance to verify that islet func-
tion and viability are preserved post-treatment. We also 
found that time post infection was another critical parameter 
to the successful outcome of the experiment. Indeed, we es-
tablished that islet integrity and health is maintained up to 4 
days post transduction.  
Although islet cell transplantation has demonstrated 
many clinical successes to date, more work is necessary to 
further improve its efficacy and universalize this treatment to 
the vast majority of T1DM patients and to allow long-term 
insulin independency. From the results shown in this report, 
we speculate that human islets infected with our protocol 
may provide a venue to improve health and function prior to 
transplantation and prevent post-transplantation dismay. In-
deed, human islets presented normal metabolic activity and 
functionality, marked insulin and glucagon expression and 
normal islet architecture, suggesting that the proposed proto-
col for islet infection does not compromise human islet 
health. Therefore, lentiviral-mediated gene expression modu-
lation using this protocol could be therapeutically promising 
to generate a functional and stable islet transplanted mass in 
humans. 
CONCLUSION 
Here we present a protocol that represents a reliable easy-
to-use procedure to transduce efficiently human and mouse 
islets with the dual purpose of studying the impact of thera-
peutic genes in islet physiology and ultimately facilitating 
the universalization of islet infection prior transplantation. 
The stable integrating nature of lentiviral vectors supports 
the notion that lentiviral-mediated gene transfer might be an 
optimal method to improve islet function for the treatment of 
T1DM [40]. In this sense, the value of potential benefits 
based on the modulation of gene expression in entire islets 
warrants further experimentation to determine the applicabil-
ity of our protocol for islet infection prior transplantation. 
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PAX4 Defines an Expandable 
β-Cell Subpopulation in the Adult 
Pancreatic Islet
Petra I. Lorenzo1, Esther Fuente-Martín1, Thierry Brun2, Nadia Cobo-Vuilleumier1, 
Carmen María Jimenez-Moreno1, Irene G. Herrera Gomez1, Livia López Noriega1, 
José Manuel Mellado-Gil1, Alejandro Martin-Montalvo1, Bernat Soria3,4 & 
Benoit R. Gauthier1
PAX4 is a key regulator of pancreatic islet development whilst in adult acute overexpression protects 
β-cells against stress-induced apoptosis and stimulates proliferation. Nonetheless, sustained PAX4 
expression promotes β-cell dedifferentiation and hyperglycemia, mimicking β-cell failure in diabetic 
patients. Herein, we study mechanisms that allow stringent PAX4 regulation endowing favorable 
β-cell adaptation in response to changing environment without loss of identity. To this end, PAX4 
expression was monitored using a mouse bearing the enhanced green fluorescent protein (GFP) and 
cre recombinase construct under the control of the islet specific pax4 promoter. GFP was detected 
in 30% of islet cells predominantly composed of PAX4-enriched β-cells that responded to glucose-
induced insulin secretion. Lineage tracing demonstrated that all islet cells were derived from PAX4+ 
progenitor cells but that GFP expression was confined to a subpopulation at birth which declined 
with age correlating with reduced replication. However, this GFP+ subpopulation expanded during 
pregnancy, a state of active β-cell replication. Accordingly, enhanced proliferation was exclusively 
detected in GFP+ cells consistent with cell cycle genes being stimulated in PAX4-overexpressing 
islets. Under stress conditions, GFP+ cells were more resistant to apoptosis than their GFP- 
counterparts. Our data suggest PAX4 defines an expandable β-cell sub population within adult islets.
During embryogenesis, both the exocrine and endocrine compartment of the pancreas arises through 
the interplay of numerous transcription factors that will temporally and spatially bestow the fate of the 
various cell lineages1. Among these, the paired homeodomain nuclear factor Pax4 is indispensable for 
the generation of islet cell progenitors and subsequent β -cell maturation. Although detectable, PAX4 
expression in adult islet β -cells is low as compared to its embryonic expression2. In contrast, aberrantly 
high expression levels for this transcription factor are detected in human insulinomas, lymphomas, head 
and neck squamous cell carcinomas as well as in breast cancer cells3–5. A distinctive attribute of Pax4 is 
that mutations and polymorphisms in this gene are associated with both Type 1 and 2 Diabetes Mellitus 
(T1DM and T2DM), as well as with maturity onset diabetes of the young (MODY) in several ethnic 
populations2, with a strong prominence in the Asian population6–11. Pax4 gene variations also predispose 
to Ketosis-prone diabetes in populations of West African ancestry12. Paradoxically, Pax4 polymorphisms 
were also linked to longevity in the Korean population13.
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Since a hallmark of both T1DM and T2DM, independent of etiology, is the gradual loss of the func-
tional insulin-producing β -cell mass, we and others have demonstrated that PAX4 is not only essential 
for islet development14 but also for survival and expansion of adult β -cells15,16. In mice, conditional 
overexpression of PAX4 in β -cells was shown to protect animals against streptozotocin (STZ)-induced 
hyperglycemia and isolated islets against cytokines induced apoptosis. In contrast, animals expressing the 
diabetes-linked mutant variant R121W (R129W in mice) were more susceptible to develop hyperglyce-
mia and β -cell death upon STZ treatment. Interestingly, sustained expression of PAX4 in vivo resulted 
in loss of islet structure and insulin secretion with the concomitant appearance of a BrdU+/PDX1+/
INSULIN− cell subpopulation suggesting dedifferentiation of β -cells that potentially acquire a prolifer-
ative phenotype17. Intriguingly, β -cell dedifferentiation characterized by the loss of INSULIN granules 
and re-expression of the pancreatic endocrine progenitor marker NGN3 was also recently reported in 
various animal models of T2DM18,19. Restoration of functional β -cells was achieved upon normalization 
of blood glucose levels using insulin therapy indicating that the hyperglycaemic milieu favoured survival 
through loss of β -cell identity at the expense to attempt rescuing glucose homeostasis19. The potential 
implication of PAX4 in this process was recently connoted through data demonstrating that transcript 
levels for this factor were increased in islets isolated from T2DM donors20. The correlation between PAX4 
expression levels and the phenotypic state of β -cells led us to characterize in vivo PAX4 regulation within 
the islets under various physiological and pathophysiological conditions. To this end, we took advantage 
of a transgenic mouse model expressing both the enhanced green fluorescence protein (GFP) and the 
Cre recombinase under the control of the pancreatic islet specific Pax4 gene promoter region21 to mon-
itor in real time the endogenous expression pattern of PAX4 under various metabolic conditions. We 
demonstrate that within mature islets endogenous PAX4 marks predominantly a subset of islet β -cells, 
which on one hand is more susceptible to expansion in response to increased insulin demands such as 
pregnancy, while on the other hand, is more resistant to stress-induced apoptosis.
Results
PAX4 is heterogeneously expressed within adult mice pancreatic islet cells. Previous studies 
performed in vitro as well as in vivo have shown that acute PAX4 expression is important for β -cell sur-
vival and/or expansion while chronic expression triggers dedifferentiation and tumour formation3–5,15,17,22. 
In order to elucidate the mechanism by which β -cells fine tune PAX4 expression without shedding iden-
tity and ultimately inducing hyperglycemia we took advantage of a transgenic mouse model expressing 
both the Gfp and the Cre cDNAs under the transcriptional control of an optimal Pax4 gene promoter 
sequence (pPax4-Cre-IRES-Egfp mice)23. The latter minimal promoter fragment was shown to direct islet 
specific expression of the pax4 gene mimicking the full-length promoter21,24. The pPax4-Cre-IRES-Egfp 
transgenic animals display normal islet architecture as well as glucose homeostasis during their life span 
thereby providing a powerful model to monitor endogenous levels of PAX4 through GFP fluorescence. 
Live imaging of whole islets derived from these mice revealed that only a fraction of cells emitted detect-
able levels of GFP fluorescence, revealing potential cell heterogeneity in PAX4 expression (Fig. 1a). To 
validate this premise, cell suspensions were prepared from islets derived from either wild type C57BL/6 
or pPax4-Cre-IRES-Egfp mice and the various cell populations were discriminated by size or complexity 
against fluorescence intensity using flow cytometry (Fig. 1b). This approach revealed that 14.79 ± 4.06% 
of total islet cells expressed GFP whereas 25.48 ± 6.57% of the total β -cell population expressed GFP 
(Fig. 1c). Despite GFP expression only in a subset of islet cells, genomic amplification confirmed trans-
gene integration in both GFP+ and GFP− subpopulations reinforcing the premise that the Pax4 gene 
promoter driving GFP expression was only active in a subpopulation of islet cells (Fig. 1d). Consistent 
with the latter, endogenous Pax4 transcript levels were 5-fold enriched in the GFP+ cell subpopulation 
(Fig. 1e). Of note, the average Ct value of Pax4 in GFP+ cells was approximately 29 while the Ct values 
for the Cyclophilin control gene was 22. Henceforth, this cell population will be denoted as GFP/PAX4+. 
In order to further characterize this GFP/PAX4+ subpopulation, we next assess expression levels of the 
β -cell markers Pdx1 and Insulin. Transcript levels for either gene remained relatively constant in both 
subpopulations (Fig. 1e). Consistent with the latter, immunostaining of PDX1 revealed expression of the 
transcription factor in the vast majority of GFP/PAX4+ cells as well as in the GFP− cells (Supplementary 
Fig. S1). As DNA methylation is associated with transcriptional silencing of Pax43,20, we assessed the 
methylation status of the 11 GpC sites found within the 409 bp promoter region (Fig.  1f). This region 
was hypomethylated in both the GFP/PAX4+ and GFP− subpopulations as well as in MIN6 cells that 
expressed high levels of PAX4 (Fig. 1f). Thus the methylation profile cannot account for differential GFP 
expression within the two subpopulations. Interestingly, both GFP/PAX4+ and GFP− subpopulations 
displayed similar insulin secretion in response to glucose alone or in combination with IBMX/forskolin 
indicating that GFP/PAX4-expressing cells retained functionality under normal physiological conditions 
(Fig. 1g). Taken together these data suggest that PAX4 expression is restricted to a subpopulation of cells 
phenotypically and functionally similar to β -cells.
PAX4 expression is gradually confined to a subset of islet cells with age, correlating with 
decreased proliferation. To assess in more detail the spatial distribution as well as to determine 
the specific cell types expressing GFP within islets, we performed immunohistochemistry analysis of 
pancreas sections derived from pPax4-Cre-IRES-Egfp adult mice (Fig. 2). Co-immunostaining using an 
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Figure 1. GFP is expressed in a subset of islet cells that are enriched in Pax4 mRNA. (a) Phase contrast 
and fluorescence microscopy images of intact live islets isolated from pPax4-Cre-IRES-Egfp mice showing 
GFP fluorescence only in a subset of islet cells. (b) Representative cytometer plots corresponding to dispersed 
adult islets from C57BL/6 wild type (WT)(upper panels) and pPax4-Cre-IRES-Egfp (lower panels) mice. 
Plots represent GFP fluorescence (Y axis) vs. cell size (X axis left plots) or cell complexity (X axis right plots). 
GFP expressing cells (green) display similar size and complexity as the β -cells. (c) Quantification of the 
cytometry analysis. Each dot corresponds to an independent analysis using islet pools from at least 3 animals 
and presented either per islet or per β -cell population. (d) Agarose gel electrophoresis of PCR-amplified gfp 
fragment confirming transgene insertion in both GFP+ and GFP− islet cell populations (DNA + ). Negative 
controls for PCR are indicated as DNA -. Non-specific primer-dimers are denotes as *. (e) Fold change in 
Pax4, Pdx1 and Insulin transcript levels in sorted GFP+ cells relative to the levels detected in the GFP− 
fraction. *T-Student: p < 0.05. (f) Bisulfite sequencing analysis of the 409 bp pax4 gene promoter region. The 
analysis was performed in parallel in MIN6 cells and in the different sorted islet cell populations, showing 
in all of them less than 20% methylation for each of the CpG sites. (g) Insulin secretion was assessed in 
30 min static incubations in response to 2.5 mM (black bars) and 16.5 mM glucose alone (hashed bars) 
or in combination with 1 μ M IBMX/forskolin (white bars). Insulin released was quantified by ELISA and 
expressed as a percentage of total cellular insulin content. Results are the mean ± SE from 3 independent 
experiments conducted on either GFP+ or GFP− pooled fractions, performed in duplicates.
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antibody against the cell membrane protein E-CADHERIN along with an anti-GFP sera, clearly estab-
lished the presence of a GFP/PAX4+cell subset randomly distributed within islets (Fig. 2a). Analysis of 
GFP co-expression with markers of different islet cell types revealed that more than 90% of the GFP/
PAX4+ subpopulation were insulin-expressing cells (Fig.  2a,b) and comprised approximately 30% of 
the total β -cell population (Fig.  2c). However, 3.73 ± 1.32% and 5.31 ± 1.80% of GFP/PAX4+ cells 
co-immunostained for GLUCAGON and SOMATOSTATIN respectively (Fig. 2a,b), representing roughly 
6% and 10% of the total α - and δ -cell populations (Fig. 2c).
To determine the fate of GFP/PAX4+ cells after birth, we performed lineage-tracing experiments. To 
this end, pPax4-Cre-IRES-Egfp mice were crossed to mice carrying the Rosa26;lox-stop-lox;LacZ reporter 
(R26R). In double transgenic animals (pPax4-Cre-IRES-Egfp;R26R), Pax4 promoter driven expression of 
CRE should result in the excision of the lox-stop-lox cassette hence permanently activating the LacZ gene 
in all PAX4-expressing cells along with their downstream progeny. Accordingly, β -Galactosidase (β -Gal) 
staining was detected in all islet cells at postnatal day 1 (P1) and remained constant until the age of 53 
weeks (Fig. 3a, upper panels). Reciprocally, INSULIN, GLUCAGON and SOMATOSTATIN co-localized 
with β -Gal (Fig.  4a) substantiating previous findings that PAX4 expression is induced early on during 
development in endocrine progenitors that give rise to all islet cells25. These results also demonstrate that 
despite possible limitations of minimal promoter studies, the pax4 gene promoter used in this transgenic 
mouse model is sufficient to recapitulate endogenous PAX4 expression during pancreas development 
and in adulthood. In contrast to β -Gal staining throughout the whole islet, GFP expression was detected 
Figure 2. GFP expression predominantly co-localizes with insulin-producing β-cells in adult islets. 
(a) Immunohistochemistry analysis of paraffin sections from adult pPax4-Cre-IRES-Egfp mice pancreas. 
Representative microscopy images for co-immunofluorescent labeling of GFP (green) together with 
E-CADHERIN (for cellular delimitation) or with the pancreatic islet cell markers INSULIN (red), 
GLUCAGON (red) or SOMATOSTATIN (red). Nuclei counterstaining was performed using DAPI (blue). 
(b) Quantitative analysis (average ± SE) of the GFP+ cell population composition. (c) Quantification of the 
percentage of INSULIN+, GLUCAGON+ and SOMATOSTATIN+ cells that co-express GFP (average ± SE). 
Sections (2 to 4) from 3 to 5 independent animals with an average of 15 islets and 1400 cells per animal 
were used for quantifications.
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in approximately 70 to 80% of these cells at P1 as well as P10 and was thereafter restricted to 30% of 
β -Gal+ cells by the age of 3-weeks (Fig.  3a,b). This fraction of GFP/PAX4+ cells remained relatively 
constant during adulthood until the age of 1 year (53 weeks) at which point GFP expression was fur-
ther reduced to 15% of β -Gal+ cells (Fig.  3a,b). Noteworthy, this decrease in GFP/PAX4+ population 
correlated with the age-dependent reduction in the ratio of proliferating islet cells, from 6.37 ± 1.97% at 
P10 to 0.81 ± 0.27% in adult mice and further decrease to 0.6 ± 0.1% in aged animals (data not shown). 
As expected, INSULIN+ cells encompassed the majority of the GFP/PAX4+ population during adult-
hood (Fig.  3a,c). However during early postnatal stages, P1 and P10, the percentage of GFP/PAX4+ 
Figure 3. Lineage tracing analysis reveals an age dependent decrease in the GFP/Pax4+subpopulation. 
(a) Representative images from IHC of paraffin sections of pPax4-Cre-IRES-EgfpXRosa26;lox-stop-lox;LacZ 
mice at the indicated ages. Co-immunodetection of GFP (green) along with β -GAL (red, upper panels), 
INSULIN (red middle panels) or GLUCAGON (red lower panels). Nuclei counterstaining was performed 
using DAPI (blue). (b) Quantification of β -Gal cells that co-express GFP at the indicated ages (average ± SE). 
(c) Quantitative analysis (average ± SE) of GFP+ cells within the β - and α -cell populations. Sections (2 to 
4) from 3 to 5 animals with an average of 10 islets and 900 cells per animal were used for quantifications. 
**ANOVA:p < 0.01; ***ANOVA:p < 0.001.
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cells that co-express GLUCAGON was approximately 20%, decreasing with maturity to approximately 
3% in adult animals (Fig.  3a,c). Of note, we also detected rare glucagon/insulin co-expressing GFP/
PAX4+ cells (Fig. 4b) indicative of either an early bi-hormonal precursor pool or trans-differentiation of 
GLUCAGON/GFP/PAX4+ cells towards a β -cell phenotype. Together, these lineage-tracing experiments 
show that PAX4 gives rise to all endocrine cells during development and that its expression subsequently 
becomes restricted to a fraction of islet cells predominantly composed of β -cells with residual expression 
in some α - and δ -cells as well as in rare bi-hormonal (GLUCAGON/INSULIN) expressing cells.
Figure 4. GFP/PAX4+ cells contribute to all endocrine cell progeny. (a) Co-immunohistochemical analysis 
of β -Gal (red) along with INSULIN, GLUCAGON and SOMATOSTATIN (green) on pancreatic paraffin 
sections from adult pPax4-Cre-IRES-EgfpXRosa26;lox-stop-lox;LacZ mice. Nuclei were stained with DAPI 
(blue). (b) Triple-immunostaining for INSULIN (red) GLUCAGON (cian) and GFP (green). Inset with 
yellow arrows delineate a representative GFP/PAX4+ cell co-expressing INSULIN and GLUCAGON. Nuclei 
were stained with DAPI (blue).
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PAX4 primes cell cycle genes correlating with the preferential expansion of the GFP/PAX4+ 
cell subset during pregnancy. The fraction of replicative β -cells drastically decreases with age cor-
relating with the observed decline in GFP/PAX4+cells (Fig. 3). The association of these two events com-
bined with our previous finding that PAX4 induces cell replication15 prompt us to investigate whether 
the GFP/PAX4+ subpopulation could represent the β -cell replicative unit of the islet. A recent gene 
expression analysis conducted on PAX4 overexpressing islets revealed a significant functional enrich-
ment in the cell cycle pathway. A more detailed in silico gene analysis within this pathway disclosed that 
PAX4 induced the expression of both cell cycle activators such as CYCLIN A2, B2, D1 and D3, CMYC, 
HDAC and PCNA as well cell cycle inhibitors such as P21, P53, OTUB2 and ERRFI1 (Table 1). These 
data suggest that PAX4 defines a proliferation permissive β -cell subpopulation primed to expansion 
only under conditions that alleviate cell cycle brakes (Fig.  5). To validate this hypothesis, we assessed 
the replicative capacity as well as expansion of the GFP/PAX4+ islet cell subset during pregnancy, a 
physiological condition associated with intense β -cell replication26. Immunohistochemical analysis, using 
antibodies against GFP, INSULIN and GLUCAGON, were performed on pancreas sections derived from 
pregnant pPax4-Cre-IRES-Egfp mice sacrificed at 10.5, 12.5, 14.5 and 17.5 days post coitum (dpc) (Fig. 6). 
In agreement with previous studies27, islet-cell proliferation peaked at 12.5 dpc (Fig.  6e). Consistent 
with the latter, a significant transient increase in the overall number of GFP/PAX4+ cells was observed, 
reaching 45 ± 3% of total islet cell population by 12.5 dpc and decreasing thereafter to 19 ± 1% by 17.5 
dpc (Fig.  6a,b). Accordingly, 52 ± 3% of β -cells were GFP/PAX4+ while 20 ± 6% of α -cells expressed 






Errfi1 ERBB receptor feedback inhibitor 1 2.254 0.020
Cdkn1a cyclin-dependent kinase inhibitor 1A (p21) 1.956 0.011
Ccnb2 cyclin B2 1.478 0.012
Ccna2 cyclin A2 1.447 0.001
Myc myelocytomatosis oncogene 1.412 0.003
Cdk5 cyclin-dependent kinase 5 1.368 0.002
Trp53 transformation related protein 53 1.361 0.013
Ccnd3 cyclin D3 1.339 0.034
Ccnd1 cyclin D1 1.275 0.026
Hdac1 histone deacetylase 1 1.272 0.042
Pcna proliferating cell nuclear antigen 1.271 0.032
Otub2 OTU domain, ubiquitin aldehyde binding 2 1.262 0.047
Table 1.  Significantly up-regulated cell cycle genes after Pax4 overexpression.
Figure 5. PAX4 regulates cell cycle genes. Schematic representation of PAX4 regulated cell cycle activators 
(white boxes) and inhibitors (grey boxes) as determined by RNA microarray analysis performed on PAX4 
overexpressing islets (GSE62846).
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Figure 6. The GFP/PAX4+subpopulation is transiently increased during pregnancy. (a) Representative 
composite images of pancreas sections obtained from pregnant pPax4-Cre-IRES-Egfp females that were 
co-immunostained for GFP (green), INSULIN (red) and GLUCAGON (white). Nuclei counterstaining was 
performed using DAPI (blue). (b) Cell quantification of percent GFP/PAX4+ cells distributed within the 
total islet cell, β -cell and α -cell population. (c) Fold change in endogenous Pax4 mRNA levels measured 
by qt-RT-PCR in whole islets from pregnant C57BL/6 mice. (d) Representative composite images of 
pancreas sections obtained from control and 12.5 dpc pPax4-Cre-IRES-Egfp females that were triple-
immunostained for GFP (green), INSULIN (red) and KI67 (cian). Nuclei counterstaining was performed 
using DAPI (blue). Insets depict KI67+/GFP− cells (white arrow) and KI67+/GFP+ cells (yellow arrow). (e) 
Quantitative analysis (average ± SE) of the proliferative, Ki67+ cells during pregnancy. (f) Cell quantification 
represented as the percentage of GFP+β -cells among the total amount of proliferating KI67+cells. Data 
show the mean ± SE of 3 to 5 animals with an average of 15 islets and 1200 cells per animal were used for 
quantifications.*ANOVA:p < 0.05 as compared to day 0.
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transient increase in endogenous Pax4 transcript levels was also detected in whole islets of pregnant mice 
reaching maximal levels of 2-fold at 12.5 dpc as compared to islets isolated from non-pregnant females 
(Fig. 6c). We next assessed cell proliferation within the GFP/PAX4+ and GFP− subpopulations. To this 
end, immunostaining for the proliferation marker Ki67 along with GFP and INSULIN was performed 
on sections of pregnant mice pancreas (Fig.  6d). In adult non-pregnant mice, 6 ± 3% of Ki67+ cells 
were insulin expressing GFP/PAX4+ (Fig.  6f) while 58 ± 6% were GFP− β -cells. However, in pregnant 
mice by 12.5 dpc the number of GFP/PAX4+ β -cells dramatically increased to 55 ± 20% of the Ki67+ 
proliferating cell population (Fig.  6f) whereas replication of GFP− β -cells remained relatively constant 
(data not shown). This increase was transient as by 17.5 dpc proliferation of the GFP/PAX4+ population 
regressed to control values. Taken together our results suggest that although the fraction of proliferating 
GFP/PAX4+ β -cells is lower than that of the GFP− β -cell fraction in control animals, GFP/PAX4+ β -cells 
are more permissive to proliferation and expansion upon conditions stimulating β -cell replication such 
as during pregnancy.
GFP/PAX4+ islet cells are more resistant to stress-induced apoptosis. High levels of PAX4 
were also shown to protect β -cells against stress-induced apoptosis as well as to act as a survival factor 
in INS-1E insulinoma cells2,15,17. This PAX4-mediated protective effect was recently correlated to improve 
calcium and endoplasmic reticulum (ER) homeostasis (Mellado-Gil et al., manuscript submitted). This 
data led us to postulate that GFP/PAX4+ cells within islets would be more resistant to apoptosis as com-
pared to their GFP− counterpart. To validate this assumption, islets isolated from pPax4-Cre-IRES-Egfp 
mice were cultured in the presence of thapsigargin (THAP), an inhibitor of ubiquitous ER Ca2+-ATPases 
that induces ER-stress dependent apoptosis. Cleaved-CASPASE-3 immunostaining revealed a significant 
2-fold enrichment in apoptotic GFP− cells within THAP-treated islets as compared to untreated con-
trols, while no significant increase in apoptosis was discerned in GFP/PAX4+ cells (Fig.7a,b). In order 
to substantiate these findings in a more physiological context, pPax4-Cre-IRES-Egfp mice were treated 
with streptozotocin (STZ), an agent that specifically destroys β -cells. Animals were sacrificed 24 hours 
post-STZ treatment prior to the development of hyperglycemia with the aim to clearly discriminate 
the impact of STZ on the two GFP subpopulations. As anticipated, the number of GFP/PAX4+ cells 
remained relative constant while the overall β -cell population drastically decreased from 70 to 30% of 
all islet cells in STZ-treated mice (Fig. 7c,d). A more detailed analysis of the various β -cell populations 
based on GFP expression pattern revealed that the decrease in β -cell mass predominantly stemmed from 
the loss of GFP−cells while GFP/PAX4+β -cells were refractory to STZ-mediated destruction (Fig. 7e). Of 
note, we did not observed any gender specific effect of STZ on the two distinct subpopulations. However, 
a slight increase in the percentage of INSULIN− cells in the GFP/PAX4+ subpopulation was discerned 
upon STZ treatment (Fig.  7e) potentially as a result of either re-expression of PAX4 in α -cells or loss 
of β -cell entity. Immunofluorescence analysis revealed that the percentage of GFP/PAX4+ cells among 
glucagon expressing cells remained relatively constant after STZ treatment (Supplementary Fig. S2) 
suggesting that INSULIN+/GFP/PAX4+ cells were undergoing de-differentiation resulting in the loss of 
INSULIN expression.
Discussion
Our work establishes the existence of a bona fide PAX4-enriched cell subpopulation nested within pan-
creatic islets that can, on one hand expand in periods of increased functional demands, and on the other 
hand exhibit improved viability in response to pathophysiological situations. These results foster the 
prospect that PAX4, a critical regulator of embryonic β -cell development, maintains plasticity within a 
pool of cells in adult islets concealed predominantly as β -cells. These cells are dispersed throughout the 
islet without any apparent niche. Heterogeneity among islet β -cells has been well documented and first 
described by Pipeleers as the sociobiology of pancreatic β -cells28. Consistent with the notion of an islet 
β -cell progenitor reservoir contributing to this heterogeneity, several studies using reporter constructs 
to track the fate of β -cells either in vitro or in vivo, revealed the existence of at least three distinct sub-
populations of β -cells within human and mouse islets29–31. Of particular interest was the characterization 
of a proliferative immature PDX1+/INSULINlow β -cell subpopulation that comprised approximately 15 
to 25% of all islet cells and that expressed higher levels of PAX432. This cell population is reminiscent 
to that of PDX1+/INSULINlow/BrdU+ β -cells characterized in PAX4 over-expressing mice17 as well as 
to the endogenous GFP/PAX4+ cell fraction described herein. Nonetheless, GSIS was normal in GFP/
PAX4+ cells whereas it was impaired in both PAX4 over-expressing islets and in the reported PDX1+/
INSULINlow β -cell subpopulation17,32. As the insulin content of both GFP/PAX4+ and GFP− cells was 
identical (as assessed for GSIS presented in Fig. 1g), we propose that pending environmental cues expres-
sion levels of PAX4 will define the fate, state and functionality of endogenous islet cells. Such premise 
is reinforced by the fact that some of the GFP/PAX4+ cells express SOMATOSTATIN, GLUCAGON or 
INSULIN and GLUCAGON together, resembling embryonic cell fate commitment process, where dual 
hormone cells have been detected33,34.
Our data reconcile divergent views regarding an ongoing debate on whether β -cell expansion involves 
an elusive progenitor cell pool or proceeds through self-duplication of resident β -cells35–37. Consistent 
with self-duplication advocates, we find that under normal conditions, both GFP/PAX4+and GFP− 
β -cells are prone to proliferation, a state that is gradually impaired with age38. However, in physiological 
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Figure 7. GFP/PAX4+ cells are more resistant to apoptosis than their GFP/PAX4− counterparts. (a) 
Immunofluorescent detection of GFP (green), cleaved-CASPASE 3 (yellow), and INSULIN (red) as well as 
DAPI nuclear staining (blue) in islets isolated from pPax4-Cre-IRES-Egfp and treated in vitro for 24 hours 
with thapsigargin (THAP). Arrows depict examples of GFP−/cleaved caspase 3+ cells. Non-specific GFP 
labeling of Affi-Gel® beads used for islet mounting is denoted by #. (b) Cell quantification represented as 
the percentage of cleaved caspase 3-positive cells in either GFP/PAX4+or GFP− cells treated or not with 
thapsigargin. Data show the mean ± SE of 3 independent experiments, each representing at least 10 islets 
and 1000 cells per conditions. **ANOVA:p < 0.01. (c) pPax4-Cre-IRES-Egfp mice were injected (i.p.) with 
STZ (200 mg/kg body weight) to promote β -cell apoptosis and pancreas extracted 24 hours post treatment. 
Animals were normoglycemic at this time point. Pancreas sections were then co-immunostained for GFP 
(green) and INSULIN (red). (d) The number of INSULIN+ and GFP/PAX4+cells were counted and results 
presented as the percentage of total islet cells. (e) Percentage of GFP− and GFP/PAX4+ cells between 
INSULIN+ and INSULIN− cells. Data show the mean ± SE of 8 independent animals, each representing an 
average of 15 islets and 1500 cells per animal.
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situation evoking an increase in the β -cell mass, as during pregnancy, we witnessed a specific enrichment 
in the replication of GFP/PAX4+ cells as compared to the GFP− cells advocating in favor of the recruit-
ment of a specialized plastic β -cell pool. This specific mobilization could be a consequence of GFP/
PAX4+ cells being permissive to cell proliferation as revealed by increased cell cycle genes in equivalent 
PAX4-overexpressing islet cells. A similar cell cycle re-entry dependent permissive state was recently 
reported for islets conditionally overexpressing the connective tissue growth factor39. Hence, our study 
demonstrates that both GFP/PAX4+ and GFP− β -cells are susceptible to basal proliferation but that only 
the fraction, defined by expression levels of PAX4, are permissive to increased replication pending stim-
uli. However, this capacity to proliferate declines with age as assessed by both a decrease in the GFP/
PAX4+ subpopulation as well as in cell replication correlating with increased failure to adapt β -cell mass 
with age40.
Additional members of the pax gene family have been shown to convey similar proliferative and sur-
vival phenotypes within adult tissues. For example, PAX6 is essential for the production and subsequent 
maintenance of progenitor cells in the adult hippocampal dentate gyrus while PAX7 expression is critical 
for survival and plasticity of adult skeletal muscle satellite cells in response to environmental cues41,42. In 
addition, PAX3 expressing melanocytic progenitor cells are permissive to injury signals for re-entry into 
cell cycle and initiate regeneration whereas PAX2 re-activation is essential for kidney injury repair43,44. 
Interestingly, pax genes have arisen from a single gene during the early metazoan era emphasizing a 
common ancestral function among the pax members including PAX4. This function that pre-dates gene 
duplication most likely relates to the capability of expressing host cells to respond to a dynamic environ-
ment45. The latter also includes increased survival in response to hostile settings, a premise also demon-
strated by the ability of the GFP/PAX4+ cell subset to preferentially resist STZ and thapsigargin-mediated 
apoptosis as compared to GFP− cells.
Recent studies suggest that in the diabetic state β -cells revert to NGN3+/MAFA−/INSULIN− 
progenitor-like cells rather than undergoing massive apoptosis18,19,46. Re-differentiation of dedifferenti-
ated cells was possible following insulin therapy19. Interestingly, we previously demonstrated that PAX4 
transcript levels are induced by high glucose and are dramatically increased in islets obtained from T2DM 
donors correlating with increased survival2,15. Chronic PAX4 expression was also shown to lead to MAFA 
and INSULIN repression reminiscent of the progenitor-like cells induced by the diabetic milieu19. Of 
particular interest is the finding that NGN3 was increased in islet overexpressing PAX4. Taken together, 
it is tempting to speculate that under pathophysiological conditions, acute increased in PAX4 expression 
will initially protect cells while sustained expression will induce dedifferentiation towards a ‘progeni-
tor phenotype’ as an adaptive mechanism to protect cells against a hostile environment. In support of 
this viewpoint, we observed a small increase in INSULIN− cells within the GFP/PAX4+ subpopulation 
subsequent to STZ treatment (Fig. 7e) while others have reported robust increases in PAX4 expression 
levels in islets of STZ-treated mice47. Once the threat is neutralized, repression of PAX4, by mechanisms 
independent of DNA methylation, will promote re-differentiation towards a β -cell phenotype.
Pax4 could be considered a ‘selfish gene’ safeguarding survival of the fittest cell population within 
islets48. Indeed, by exquisitely fine tuning its levels in response to the microenvironment, PAX4 will act 
as a rheostat in defining the phenotypic characteristic of islet cells to best adapt to their new surround-
ings. Functional impairment associated with PAX4-dependent re-entry into cell cycle would have little 
consequence short term on glucose homeostasis, as the predominant β -cell mass would remain quies-
cent and functional. Disparity in the impact of pax4 gene mutations on the incidence of diabetes could 
potentially be rationalized by the outcome of gene-environment interaction, which will dictate fitness of 
β -cells. In conclusion, strategies to fine-tune PAX4 expression levels may constitute a promising approach 
to simultaneously expand while blocking dedifferentiation of the functional β -cell mass with the aim to 
salvage hyperglycemia in diabetic patients.
Methods
Animals. Mice were maintained on a normal light/dark cycle and studied under conditions approved 
by the Institutional Animal Care Committee of CABIMER. Methods associated with animals were car-
ried out in accordance with the approved guidelines.The pPax4-Cre-IRES-Egfp mice, kindly provided 
by Dr. P. Gruss (Max Planck Institute, Gottingen, DE), were back crossed to C57BL/6 mice (Jackson 
Laboratory). Animals were genotyped with the REDExtract-N-Amp kit (Sigma-Aldrich, Madrid, Spain) 
using specific primers that can be obtained upon request. Lineage tracing experiments were conducted 
on the progeny of pPax4-Cre-IRES-Egfp mice bred to Rosa26;lox-stop-lox;LacZ mice. For in vivo cell 
death analysis, adult (3–4 months) pPax4-Cre-IRES-Egfp mice (average body weight 25 g) were treated 
with a single high-dose of streptozotocin (STZ: 200 mg/kg body weight) by intraperitoneal injection. 
STZ was dissolved in 0.1 M sodium citrate buffer and injected within 5 min of dissolution. Blood glucose 
levels from tail vein samples were determined prior to and 24 hours after STZ injection using a Precision 
Xceed glucometer (Abbott, Madrid, Spain).
Mouse Islet Isolation and Treatment. Mouse pancreatic islets were isolated by intraductal colla-
genase as described elsewhere17. Islets were maintained overnight in 11.1 mM glucose/RPMI-1640 (Life 
Technologies, Madrid, Spain) supplemented with 10% fetal bovine serum (Sigma), 100 Units/ml pen-
icillin and 100 μ g/ml streptomycin (Sigma), 2 mM glutamine (Life Technologies), 10 mM hepes (Life 
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Technologies), 1 mM sodium pyruvate (Sigma), and 50 μ M β -mercaptoethanol (Life Technologies). 
In some instances, GFP fluorescence from living islets was captured using and Image-Xpress device 
(Molecular devices, Spain). Composition of the various islet cell subpopulations was assessed by flow 
cytometry (FACSCalibur, BD Biosciences) while isolation of GFP+ and GFP− islet cells was achieved 
using FACS (FACSAria,BD Biosciences) and FACSDiva software (BD Biosciences). Briefly, isolated islets 
from adult (3–4 months) C57BL/6 WT mice and pPax4-Cre-IRES-Egfp mice were dispersed by trypsini-
zation, resuspended in PBS containing 25 mM Hepes and 2.5 mM EDTA and filtered through cell strainer 
caps (70 μ m). Using fluorescence-activated sorting, β -cells were separated from non-β -cells based on 
their size (FSC channel) and autofluorescence (FL-1 channel-GFP), as previously described49. Purified 
subpopulations were plated on an 804G matrix rich in laminin for 24 hours to improve cell viability 
prior to insulin secretion assay. The latter was performed by incubating cells for 30 min in Krebs-Ringer 
bicarbonate Hepes buffer containing 2.5, 16.5 mM glucose or a mixture of 16.5 mM glucose/1 μ M forsko-
lin/100 μ M isobutylmethylxanthine (IBMX). Supernatants were collected and cells lysed in 1 mM acetic 
acid/ethanol. Secreted and total cellular content of insulin were assessed using an ELISA kit (Linco, St 
Charles, MO). For in vitro thapsigargin-induced cell death assessment, groups of 150 islets were incu-
bated or not during 24 hours with 1 μ M thapsigargin. Islets were then embedded according to the pro-
tocol of Cozar-Castellano et al.50 and processed for IHC analysis.
RNA Isolation and Quantitative PCR. RNA was extracted from GFP+ and GFP− islet cells using 
the RNeasy micro Plus kit (Qiagen Iberia S.L., Madrid Spain). After quantification and analysis of the 
RNA integrity using a 2100 bioanalyzer (Agilent-Eukaryote Total RNA Nano Series), 100 to 200 ng RNA 
was used for cDNA synthesis using Super Script II RT (Life Technologies) and Anchored OligodT as 
primers. For RNA extraction from whole islets, RNeasy micro Plus kit (Qiagen Iberia S.L., Madrid Spain) 
was used. Between 800 ng and 1 μ g of RNA was employed for cDNA synthesis using Super Script II RT 
(Life Technologies) and Anchored OligodT as primers. Quantitative PCR was performed using a 7500 
Real-Time PCR System (Applied Biosystems). Specific primers for the analyzed genes (Pax4, Pdx1 and 
Insulin) were designed to span an intron in order to avoid genomic DNA amplification. The housekeep-
ing genes β -actin and cyclophilin were used as control.
RNA Microarray. Labeled cRNA samples were prepared from pools of at least 100 islets isolated from 
Pax4/rtTA transgenic animals (8-week old females) treated or not with DOX as previously described17. 
Three independent preparations of cRNA per group were then hybridized to the GeneChip Mouse 
Gene 1.0 ST Array chip (Affymetrix, Santa Clara, CA) using standard protocols of the Genomic Core 
Facility of CABIMER. Analysis of the transcriptome profiling is described elsewhere (Mellado Gil et al., 
Manuscript submitted). Raw data are accessible in the Gene Expression Omnibus database under acces-
sion number GSE62846.
Bisulfite Sequencing. DNA was extracted from MIN6 cells as well as from FACS purified non-β , 
GFP+ and GFP− subpopulations. Bisulfite conversion of unmethylated C to U was performed using 
“Cells-to-CpG Bisulfite Conversion” kit (Life Technologies) following guidelines of the manufacturer. 
Converted DNA was amplified using MyTaqHS DNA polymerase (Bioline, Paris, France) along with 
specific primers for the region of interest on the pax4 gene promoter. Amplicons were purified using 
QIAquick PCR purification kit (Qiagen Iberia S.L.), cloned into the pGEMT vector and transformed into 
DH5α E. Coli bacteria. At least 20 colonies per DNA region and cell subpopulation were sequenced and 
analyzed using the BiQ Analyzer software.
Immunohistochemistry. For paraffin sections, pancreata were dissected and fixed overnight in 4% 
paraformaldehyde at 4 °C. Dehydration, embedding, and sectioning at 5 μ m thickness were performed 
by the Histology platform of CABIMER. Sections were rehydrated in decreasing ethanol concentra-
tion solutions and subjected to heat-induced antigen retrieval in 10 mM sodium citrate buffer pH 6. 
Sections were then blocked in PBS containing 5% donkey serum and 0.2%TritonX100 for 1 h at room 
temperature. Primary antibodies were incubated overnight at 4 °C in PBS 1% BSA 0.2% TritonX100, 
except for GFP antibody that was incubated in PBS 0.1% BSA 0.2% TritonX100. The following primary 
antibodies and dilutions were used: Goat anti-GFP 1:200 (Abcam), mouse anti-INSULIN 1:500 (Sigma), 
rabbit anti-INSULIN 1:100 (Santa Cruz), mouse anti-GLUCAGON 1:150 (Sigma), mouse anti-PDX1 
1:150 (Hybridoma bank), rabbit anti-SOMATOSTATIN 1:150 (Santa Cruz), goat anti-SOMATOSTATIN 
1:100 (Santa Cruz), mouse anti-E-CADHERIN 1:250 (BD Transduction laboratories), mouse anti-Ki67 
1:150 (Novocastra), rabbit anti-Ki67 1:150 (Pierce-Thermo Scientific), rabbit anti-β -GAL1:500 (MP 
Biomedicals) and rabbit anti-cleaved CASPASE-3 1:150 (Cell Signaling). Secondary antibodies were incu-
bated for 1 hour at room temperature at a 1:800 dilution in PBS 0.2% TritonX100. The following second-
ary antibodies were employed: Alexa Fluor 488 donkey anti-goat, Alexa Fluor 555 donkey anti-mouse 
and Alexa Fluor 647 donkey anti-rabbit (Life Technologies). Counterstaining was performed with 5 μ g/ml 
DAPI (Life Technologies) and slides finally mounted using fluorescent mounting medium (DAKO). 
Epifluorescence microscopy images were taken with a Leica DM6000B microscope. For image quanti-
fication, slides from 4 to 8 animals per time point were studied with an average of 15 islets per animal.
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Statistical Analysis. Results are expressed as mean ±  SE. Statistical differences were estimated using 
a 2-tailed Student’s test for comparison between 2 groups and 1-way ANOVA for more that 2 groups, 
with Scheffe’s F test for post-hoc analysis.
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Abstract
Aims/hypothesis A strategy to enhance pancreatic islet
functional beta cell mass (BCM) while restraining inflamma-
tion, through the manipulation of molecular and cellular
targets, would provide a means to counteract the deteriorating
glycaemic control associated with diabetes mellitus. The aims
of the current study were to investigate the therapeutic
potential of such a target, the islet-enriched and diabetes-
linked transcription factor paired box 4 (PAX4), to restrain
experimental autoimmune diabetes (EAD) in the RIP-B7.1
mouse model background and to characterise putative cellular
mechanisms associated with preserved BCM.
Methods Two groups of RIP-B7.1 mice were genetically
engineered to: (1) conditionally express either PAX4
(BPTL) or its diabetes-linked mutant variant R129W
(mutBPTL) using doxycycline (DOX); and (2) constitutively
express luciferase in beta cells through the use of RIP. Mice
were treated or not with DOX, and EAD was induced by
immunisation with a murine preproinsulin II cDNA expres-
sion plasmid. The development of hyperglycaemia was
monitored for up to 4 weeks following immunisation and
alterations in the BCM were assessed weekly by non-
invasive in vivo bioluminescence intensity (BLI). In parallel,
BCM, islet cell proliferation and apoptosis were evaluated
by immunocytochemistry. Alterations in PAX4- and
PAX4R129W-mediated islet gene expression were investi-
gated by microarray profiling. PAX4 preservation of endo-
plasmic reticulum (ER) homeostasis was assessed using
thapsigargin, electron microscopy and intracellular calcium
measurements.
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Results PAX4 overexpression blunted EAD, whereas the
diabetes-linked mutant variant PAX4R129W did not convey
protection. PAX4-expressing islets exhibited reduced insulitis
and decreased beta cell apoptosis, correlating with diminished
DNA damage and increased islet cell proliferation. Microar-
ray profiling revealed that PAX4 but not PAX4R129W
targeted expression of genes implicated in cell cycle and ER
homeostasis. Consistent with the latter, islets overexpressing
PAX4 were protected against thapsigargin-mediated
ER-stress-related apoptosis. Luminal swelling associated with
ER stress induced by thapsigargin was rescued in PAX4-
overexpressing beta cells, correlating with preserved cytosolic
calcium oscillations in response to glucose. In contrast, RNA
interference mediated repression of PAX4-sensitised MIN6
cells to thapsigargin cell death.
Conclusions/interpretation The coordinated regulation of
distinct cellular pathways particularly related to ER homeo-
stasis by PAX4 not achieved by the mutant variant
PAX4R129W alleviates beta cell degeneration and protects
against diabetes mellitus. The raw data for the RNA microar-
ray described herein are accessible in the Gene Expression
Omnibus database under accession number GSE62846.
Keywords Beta cell degeneration . ER homeostasis . PAX4 .
RIP-B7.1 . Type 1 diabetes
Abbreviations
BCL-2 B cell CLL/lymphoma 2
BCM Beta cell mass
BLI Bioluminescence intensity
BPTL RIP-B7.1/Pax4/rtTA/MIP-Luc




DsRed Discosoma sp. red fluorescent protein
EAD Experimental autoimmune diabetes
EM Electron microscopy
ER Endoplasmic reticulum
ERAD ER-associated protein degradation
GSIS Glucose-stimulated insulin secretion
KEGG Kyoto Encyclopaedia of Genes and Genomes
Luc Luciferase
MIP Mouse insulin promoter
PAX4 Paired box 4
RER Rough ER
RIP Rat insulin II promoter
rtTA Reverse tetracycline-controlled transactivator
si Small interfering
STZ Streptozotocin
Th1 T helper 1
UPR Unfolded protein response
Introduction
The islet of Langerhans is the core unit of the endocrine
pancreas, which regulates blood glucose homeostasis. Regu-
lation is achieved by the release of insulin from beta cells in
response to increasing levels of glucose and by the secretion
of glucagon from alpha cells under fasting conditions. Imbal-
ance in this circuitry leads to either hyperglycaemia, the hall-
mark of diabetes mellitus, or hypoglycaemia. Loss of beta cell
function coupled to insulin resistance of target tissues, which
usually associates with obesity and chronic low-grade inflam-
mation, defines type 2 diabetes [1]; high-grade T lymphocyte
inflammation mediating autoimmune beta cell destruction is
characteristic of type 1 diabetes [2].
Emerging evidence suggests that alterations in endoplas-
mic reticulum (ER) function contribute to beta cell disarray
in both type 1 and 2 diabetes [3]. In an attempt to restore ER
function and prevent apoptosis, cells activate the unfolded
protein response (UPR) [4]. The crucial role of the UPR in
balancing beta cell death and survival is illustrated in the
human Wolfram and Wolcott–Rallison syndromes, in
which mutations in UPR genes result in unresolved ER
stress, beta cell death and early-onset diabetes [5, 6]. Inter-
estingly, MODY genes such as Pdx1 and Hnf1a regulate
UPR-associated genes [7, 8]. These clinical conditions
suggest that islet-enriched transcription factors involved
in insulin biosynthesis and secretion also preserve the
BCM by limiting ER stress.
Paired box (Pax) genes encode transcription factors critical
for tissue development and cellular differentiation [9]. Paired
box 4 (PAX4) is necessary for the generation of pancreatic
islet cell progenitors and their differentiation towards beta
cells [10, 11]. Pax4 gene mutations have been associated with
type 1 and 2 diabetes as well as with ketosis-prone diabetes,
suggesting a key role of PAX4 in mature islets [12, 13].
Accordingly, overexpression of PAX4 in adult beta cells was
shown to block streptozotocin (STZ)-induced hyperglycaemia
in mice whereas the diabetes-linked variant PAX4R129Wwas
less efficient [14]. Despite differences in nitric oxide synthase
2 (NOS2) levels, both PAX4- and PAX4R129W-expressing
islets exhibited similar levels of cytokine-induced NO produc-
tion, indicating that the nuclear factor-κB (NF-κB) signalling
pathway was fully activated and that additional anti-apoptotic
pathways are involved in islet survival. Consistent with this
premise, PAX4 islets expressed higher levels of B cell CLL/
lymphoma 2 (BCL-2) [14]. Nonetheless, overexpression of
BCL-2 in islets did not prevent autoimmune-mediated beta
cell destruction and development of hyperglycaemia [15].
Thus, although these data highlight the protective function
of PAX4 against a chemical acute stress, whether such an
effect can also be conveyed in the context of a pathophysio-
logical autoimmune attack and the molecular mechanism
involved in this protection remain to be established.
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Herein, we investigated whether PAX4 and PAX4R129W
could promote beta cell health, preventing the development of
hyperglycaemia in the RIP-B7.1 mouse model of experimen-
tal autoimmune diabetes (EAD), and sought to characterise
the PAX4-regulated pathways implicated in islet survival
and expansion.
Methods
Animals and bioluminescence imaging Mouse experiments
were approved by the local ethics committee and performed
according to the Spanish law on animal use RD 53/2013. The
rationale for using RIP-B7.1 (kindly supplied by B. O.
Boehm) rather than NOD mice for the current study is
provided in the electronic supplementary material (ESM)
Methods. BPTL mice were derived as outlined in Fig. 1a, b
and maintained on a C57bl/6 background. This mouse
harbours four transgenes: (1) RIP-B7.1, a construct coding
for the Cd80 gene under control of the rat insulin promoter
(RIP); (2) the tetracycline response element (TRE)/
cytomegalo mosaic virus (CMV) Pax4, a tetracycline-
inducible CMV promoter driving Pax4 expression; (3) the
RIP-reverse tetracycline trans-activator (rtTA), a construct
allowing selective expression of Pax4 in beta cells exposed
to DOX; and (4) the MIP-Luciferase (Luc), a construct that
expresses luciferase under the mouse insulin promoter (MIP),
allowing assessment of BCM using non-invasive in vivo im-
aging technology. Induction of Pax4 or Pax4R129W gene
expression using doxycycline (DOX) was performed as pre-
viously described [14], while EAD was achieved by i.m.
immunisation of 9-week-old BPTL animals with 50 μg of
pC1/ppins plasmid DNA (1 μg/μl) encoding the murine
preproinsulin II. Blood glucose levels were measured using
a Precision Xceed glucometer (Abbott, Madrid, Spain).
Bioluminescence imaging was performed using a Xenogen
IVIS 50 imaging system as previously described [16].
Islet isolation and treatment Islets were isolated and cultured
as previously described [14]. Total RNAwas extracted using
the RNeasy Micro Kit (Qiagen, Madrid, Spain) and quantita-
tive (q)-PCR was performed as described previously [17].
Primer sequences can be obtained on request. For studies on
thapsigargin-induced ER stress and apoptosis, islets from ei-
ther Pax4/rtTA or Pax4R129W/rtTA transgenic mice were
treated with 1 μg/l DOX for 96 h or left untreated [14]. Fluo-
rescence of theDiscosoma sp. red fluorescent protein (DsRed)
correlating with Pax4 or Pax4R129W expression was moni-
tored using an ImageXpress Micro System (Molecular
Devices, Wokingham, UK). Islets were then treated or not
with 1 μmol/l thapsigargin for 48 h and apoptosis was
assessed by ELISA (Roche Diagnostics, Mannheim,
Germany). Glucose-stimulated insulin secretion (GSIS) was
performed as previously described [18].
Intracellular Ca2+ measurements Isolated islets were incu-
bated for 1 h at room temperature with 2 μmol/l Fura-2
(Qiagen). Fluorescence recordings were performed using an
inverted epifluorescence microscope (Axiovert 200; Zeiss,
Jena, Germany) equipped with 360 nm and 380 nm band-
pass filters. Recordings were expressed as the ratio of
fluorescence at 360 nm and 380 nm (F360/380). Images were
taken every 3 s. Intracellular [Ca2+] changes in response to
stimuli were analysed as previously described [19].
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Fig. 1 Characterisation of the BPTL mice. (a) Schematic diagram
showing the generation of the BPTL mouse. (b) Genotyping of BPTL
mice by PCR using primer sets for Cd80, Pax4, Luc and rtTA. (c) The
bioluminescent signal was correlated with age in BPTL male (white
diamonds, n = 5) and female (black rectangles, n = 5) mice. (d) BCM
calculated as a percentage of total islet cells and compared with
8-week-old animals was assessed in both sexes. On average, cells from
at least 25 islets were counted per animal, with each group comprising at
least 5–6 mice. (e) Blood glucose levels were measured for up to 35 days
in BPTL mice (n = 3) immunised (black circles) or not (control, white
squares). (f) Pancreatic sections of BPTL mice at the indicated time after
immunisation were co-immunostained for glucagon (green) and insulin
(red). Nuclei were stained with DAPI (blue). Scale bar, 25 μm. GCG,
glucagon; INS, insulin
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MIN6 cell culture and RNA interference MIN6 cells were
cultured as previously described [20] and transfected with
either 50 μmol Pax4 small interfering (si)RNA (Sigma) or
scramble siRNA using Oligofectamine (Life Technologies,
Madrid, Spain). Cells were either processed for RNA or
treated with thapsigargin (Sigma-Aldrich, Madrid, Spain) to
assess apoptosis 48 h after transfection.
Immunohistochemistry and electronmicroscopyDissected
pancreases were fixed in 4% paraformaldehyde and processed
at the Histology Core Facility, Andalusian Center for
Molecular Biology and Regenerative Medicine (CABIMER).
A detailed immunocytochemistry protocol along with the list
of antibodies used is provided in ESM Methods and ESM
Table 1. Validation of antibodies was performed on appropri-
ate control samples. The BCM and islet cell number were
assessed as described elsewhere [21]. Apoptosis, proliferation
and DNA damage were quantified by counting caspase-3-,
Ki67- and p53BP1-positive cells, respectively, in at least 20
to 50 islets from three independent pancreatic sections from
3–4 mice per group. Insulitis scoring was performed as
previously outlined [22]. For electron microscopy (EM), pan-
creatic islets were processed using a standard Spurr protocol
[23]. Images were acquired with an electron-multiplying
charge-coupled device (EMCCD) camera (TRS 2 k×2 k).
RNA microarray Labelled cRNA samples were prepared
from pools of at least 100 islets isolated from either Pax4/
rtTA or Pax4R121W/rtTA transgenic animals (8-week-old
females) treated with DOX or not treated [14]. Three prepara-
tions of cRNA per group were then hybridised to the
GeneChip Mouse Gene 1.0 STArray chip (Affymetrix, Santa
Clara, CA, USA) using the standard protocols of the Genomic
Core Facility, CABIMER. Raw data are accessible in the
Gene Expression Omnibus database under accession number
GSE62846, while its analysis is described in ESM Methods.
Statistical analysis Results are expressed as mean ± SEM.
Statistical differences between two conditions were estimated
using the unpaired Student’s t test. One-way ANOVA was
used for comparison of more than two groups with Bonferroni
post hoc test or non-parametric Mann–Whitney test (*p<0.05
and **p<0.01).
Results
PAX4 expression blunts EAD in immunised BPTL mice
We first monitored in vivo the bioluminescence intensity
(BLI) emitted by beta cells of BPTL mice from 4 to 65 weeks
of age (Fig. 1c). In 4-week-old mice, the bioluminescence
signal was two fold higher in male mice than females.
Consistent with a transient wave of beta cell apoptosis and
decreased rate of islet growth around weaning [24], both sexes
displayed a decline in BLI signal between the fourth and the
ninth week (Fig. 1c). Thereafter, this signal did not significant-
ly change with age (Fig. 1c). Morphometric evaluation
revealed that the volume density of beta cells was similar in
animals aged from 4 to 16 weeks (Fig. 1d). Thus, by 9 weeks
of age the bioluminescent signal reflects the mass and function
of beta cells, which we hereafter refer to as the functional beta
cell mass (BCM). Similar to the RIP-B7.1 animal, immunised
BPTL mice developed hyperglycaemia within 21 days
(Fig. 1e) due to a gradual loss of beta cells (Fig. 1f), whereas
non-immunised mice remained normoglycaemic (Fig. 1e, f).
We next determined whether PAX4 expression could
prevent EAD. Five-week-old BPTL mice were treated with
DOX for 4 weeks prior to immunisation. Compared with
control mice, islets from treated mice revealed a ten fold
increase in Pax4 expression (Fig. 2a), but no change in
Cd80 transcript levels (Fig. 2b). DOX treatment did not alter
the BCM or GSIS of PAX4-expressing islets (Fig. 2c, d).
Nine-week-old untreated controls remained normoglycaemic
and featured no variation in bioluminescent signal for up to
28 days (Fig. 2e). Immunised BPTL mice without DOX
revealed a rapid decrease in BLI, reaching undetectable levels
by day 28 post-immunisation, which coincided with sustained
hyperglycaemia (Fig. 2f). Escalation in blood glucose level
observed 21 days after immunisation correlated with a 60%
decrease in BLI. DOX-treated and immunised BPTL mice
maintained both normoglycaemia and bioluminescent signal
(Fig. 2g). Protection was extended up to 63 days (Fig. 2h), at
which point 65% of immunised and DOX-treated BPTL mice
developed hyperglycaemia, probably because of the robust
immune attack conveyed by CD80 overexpression.
Immunised and DOX-treated RIP-B7.1 mice developed
hyperglycaemia (ESM Fig. 1), excluding a protective effect
mediated by the antibiotic through alteration in the gut
microbiome [25, 26]. Non-DOX-treated BPTL mice suffered
a 40% and 80% reduction in the functional BCM after 21 and
28 days of immunisation, respectively. Such changes were not
observed in DOX-treated mice (Fig. 3a, b). By day 63, the
latter animals retained approximately 50% of the functional
BCM (Fig. 3b).
PAX4 improves beta cell health and mitigates the autoim-
mune attack Insulitis assessment at 28 days after
immunisation revealed that 65% of islets of DOX-treated
BPTLmice were insulitis free (grade 0), whereas 90% of islets
derived from non-DOX-treated BPTL mice displayed severe
insulitis (grades 2–4) (Fig. 4a). Even at 63 days after
immunisation only 50% of islets from DOX-treated BPLT
mice displayed mild insulitis (Fig. 4a). DOX treatment also
diminished the percentage of cleaved CASPASE-3-positive
islet cells in immunised animals (Fig. 4b and ESM Fig. 2a).
DNA damage induced by NO and reactive oxygen species
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(ROS) contributes to beta cell death [27, 28]. Immunostaining
for the double-strand DNA break marker p53BP1 revealed
that PAX4 overexpression reduced DNA damage in islets
from either immunised BPTL or STZ-treated mice (Fig. 4c).
These changes were paralleled by increased cell proliferation
in DOX-treated BPLT islets (Fig. 4d and ESM Fig. 2b).
PAX4 regulates genes important for beta cell proliferation
and ER homeostasis Transcriptome profiling was conducted
on PAX4 and PAX4R129W islets to highlight PAX4 target
genes involved in beta cell health, and those altered by the
diabetes-linked mutant variant R129W. We initially demon-
strated that DOX-treated and immunised mutBPTL mice
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Fig. 2 PAX4 prevents the development of hyperglycaemia in immunised
BPTL mice. Islet (a) Pax4 and (b) Cd80 transcript levels in 5-week-old
BPTL animals treated with DOX for 1 month or not treated (n = 4–6).
Relative mRNA levels were normalised to the transcript levels of the
housekeeping gene β-actin and/or Rps29. Data were calculated as fold
change compared with non-DOX-treated mice. **p < 0.01. (c) BCM was
calculated as a percentage of total islet cells and compared with the (−)
DOX group. On average, cells from at least 25 islets were counted per
animal (n = 4–6). (d) Insulin secretion by isolated BPTL islets treated or
not with DOX was assessed in 30 min static incubations in response to
glucose at 2.5 mmol/l (white bars) and 16.5 mmol/l (black bars). Insulin
released was quantified by ELISA and expressed as a percentage of total
cellular insulin content. n= 4–7, *p< 0.05. BLI (white diamonds) and
blood glucose levels (black circles) was measured weekly for up to
4 weeks in (e) control untreated BPTL mice (n = 4), (f) immunised
non-DOX-treated (n= 6) and (g) immunised DOX-treated BPTL animals
(n = 6). (h) BLI and blood glucose level measurements were extended to
63 days in immunised and DOX-treated BPTL mice (n= 6). BLI results
are presented as per cent change compared with day 0 (t= 0), while blood

















































Fig. 3 PAX4 preserves the functional BCM in immunised BPTL mice.
(a) Immunohistochemical analysis of glucagon (green) and insulin (red)
in pancreases fromBPTLmice treated or not with DOX and killed at days
0, 21, 28 and 63 post-immunisation. Nuclei are stained blue. Scale bar,
25 μm. (b) BCM in control non-immunised and non-DOX-treated (white
bars), immunised and non-DOX-treated (grey bars) and immunised and
DOX-treated (black bars) mice was calculated as a percentage of total
islet cells and compared with the control group at each time point. On
average, cells from at least 25 islets were counted per animal (n= 5–6). As
similar results were obtained for days 28 and 35, the data were combined
as a single time point. ND, not determined, as this group was killed at day
35 to comply with animal welfare guidelines. *p< 0.05 and **p < 0.01.
GCG, glucagon; IMM, immunised; INS, insulin
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approximately 75% by day 28 compared with 100% in non-
DOX-treated immunised animals (Fig. 5b). Transcriptome
analysis revealed that 770 transcripts were upregulated and
449 were downregulated in PAX4 islets, whereas 1437 genes
were upregulated and 1136 downregulated in PAX4R129W
islets. Genes showing the largest changes are listed in ESM
Table 2. Notwithstanding this list, we substantiated by qPCR
our previous findings [14] that Mafa transcript levels were
repressed whereasNos2 levels were unchanged in PAX4 islets
(ESM Fig. 3). However, Bcl2 levels were not increased in
PAX4-overexpressing islets (ESM Fig. 3), arguing against a
role of this factor in protecting from EAD [15].
A functional enrichment analysis disclosed that the cell
cycle and the protein processing in ER pathways were
among the top upregulated Kyoto Encyclopaedia of Genes
and Genomes (KEGG) pathways in islets overexpressing
PAX4, but were among the most significantly downregu-
lated pathways in islets overexpressing PAX4R129W
(adjusted p values < 0.05) (Fig. 5c, d and ESM Tables 3
and 4). To contrast the expression levels of genes contrib-
uting to these pathways, we generated heat maps amenable
to statistical analysis (raw p value < 0.05). Several genes
associated with cell cycle were increased in PAX4 islets,
while remaining unchanged or having lower levels in islets
expressing PAX4R129W (Fig. 5e). Genes encoding
proteins for peptide folding (Hspa5 [also known as Bip],
Calr), ER–Golgi translocation (Lman1, Lman2, Sec23b
and Plaa) and ER-associated protein degradation (ERAD)
(Ufd1l, Derl3, Pdia4, Ssr3, Syvn1 and Dnaja2/Hsp40)
were upregulated after overexpression of PAX4, but were
downregulated after overexpression of PAX4R129W
(Fig. 5f). The UPR-associated genes Mbtps2, Eif2ak3 and
Mapk10 were upregulated in PAX4 islets and were
marginally altered in PAX4R129W islets (Fig. 5f).
PAX4 targets ER integrity and calcium homeostasis,
protecting cells against apoptosis Given that PAX4 but
not PAX4R129W targets genes that are involved in ER
homeostasis, we investigated the contribution of ER to
PAX4-mediated beta cell health. We initially assessed
expression levels of calreticulin (Calr), a major Ca2+
binding protein of the ER lumen and of galectin-9
(Lgals9), a protein involved in immune modulation.
Although Pax4 and Pax4R129W transcript levels were
increased three fold, Calr and Lgals9 expression levels
were only increased in PAX4 islets (Fig. 6a, b). As Ca2+
handling by the ER affects the cell sensitivity to apoptosis,
we assessed whether PAX4 and PAX4R129W could
protect against ER-stress-induced beta cell apoptosis. Islets
treated in vitro with DOX exhibited DsRed fluorescence,
confirming the expression of the transgenes (Fig. 6c).
Thapsigargin exposure prompted a two fold increase in
apoptosis in control mice (Fig. 6d). DOX reduced both
basal and thapsigargin-induced apoptosis only in PAX4
islets (Fig. 6d). However, Pax4 siRNA-mediated
repression in MIN6 cells caused a 60% decrease in Calr
transcript levels, with a concomitant sensitisation to
thapsigargin-induced apoptosis compared with siControl
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Fig. 4 BPTL mice overexpressing PAX4 display reduced insulitis, cor-
relating with decreased islet apoptosis and DNA damage and increased
proliferation. (a) Insulitis was scored as grade 0–4 according to the per-
centage of infiltrated islet area (0: 0%; 1: <10%; 2: >10% and <55%; 3:
>55% and <75%; 4: >75%). n = 5–6, *p < 0.05 vs immunised day 0 and
(−) DOX group; †p< 0.05 vs immunised day 28 and (−) DOX group.
(b) Apoptosis was assessed by immunohistochemical analysis of cleaved
caspase-3 in pancreatic islets from BPTLmice treated (black ovals) or not
(white ovals) with DOX and killed at the time points. As similar results
were obtained for days 28 and 35, the data were combined as a single time
point. n= 5–6, *p < 0.05, (+) vs (−) DOX groups within each time point.
(c) The average number of 53BP1 foci per beta cell was assessed from
pancreatic islets of either 14-day-old immunised BPTLmice or 2-day-old
STZ-treated PAX4 mice exposed (+) or not (−) to DOX. n = 5–6,
*p< 0.05 vs untreated mice; †p< 0.05 vs DOX-untreated immunised or
STZ-treated mice. (d) Cell proliferation was assessed by the combined
immunohistochemical analysis of Ki67 in pancreatic islets from BPTL
mice treated (black ovals) or not (white ovals) with DOX and killed at the
time points. n = 5–6, *p < 0.05, (+) vs (−) DOX groups within the time
point. IMM, immunised
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Perturbation in beta cell ER homeostasis has been linked to
ER dilation [29, 30]. Accordingly, islets from non-DOX-
treated Pax4 transgenic mice exposed in vitro to thapsigargin
displayed distension and fragmentation of the rough ER
(RER) in beta cells, an effect prevented by PAX4 overexpres-
sion (Fig. 7). ER calcium release in response to carbachol was
then measured. Calcium release in PAX4-overexpressing beta
cells from isolated islets was marginally higher than that of
controls cells (Fig. 8a–d). As the higher ER-Ca2+-buffering
capacity induced by PAX4 could mask the carbachol-
stimulated calcium release, we measured cytosolic Ca2+
signals in response to glucose. Glucose-induced calcium
oscillations were improved in isolated islets overexpressing
PAX4 compared with control islets (Fig. 8e, f). The overall
Ca2+ signal was also higher in PAX4-overexpressing cells
(Fig. 8g–i). Thus, PAX4 overexpression leads to improve
ER and Ca2+ homeostasis in the face of beta cell stress as
encountered during the islet isolation procedure or an immune
attack.
Discussion
Inflammation is a common denominator in types 1 and 2
diabetes, and leads to beta cell failure and death, predominant-
ly by apoptosis. As yet, there is no ‘unifying hypothesis’ for
the mechanisms triggering beta cell deterioration [31, 32];
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Fig. 5 ER homeostasis and cell
cycle are key cellular pathways
targeted by PAX4. (a) Blood
glucose levels were measured for
up to 28 days in control non-
DOX-treated (control, white
squares) and immunised DOX-
treated (black circles) mutBPTL
mice (n= 4). (b) Hyperglycaemia
incidence was assessed in control
non-treated (n= 5, white
diamonds), immunised and non-
DOX-treated (n= 6, white circles)
and immunised and DOX-treated
(n = 6, black circles) BPTL mice
as well as in immunised and
DOX-treated mutBPTL mice
(n = 7, black squares). (c, d)
Significantly enriched KEGG
pathways (adjusted p value
<0.05) altered by (c) PAX4 and
(d) PAX4R129W. The dotted line
shows the threshold of
significance. (e, f) Heat maps
displaying t statistic values of
(e) cell cycle and (f) protein
processing in the ER KEGG
pathway genes modulated in
either PAX4 or PAX4R129W
islets vs control. Colours display
the t statistic values for all genes
within the corresponding KEGG
pathway, estimated using the t
statistic value from differential
expression analysis. GPI,
glycosylphosphatidylinositol
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as PAX4—mutations in which are linked to both forms of
diabetes—may help identify common pathways. Herein, we
provide proof-of-concept that PAX4, but not PAX4R129W,
preserves the BCM and delays the development of
hyperglycaemia in the RIP-B7.1 mouse model of EAD. This
highlights the mechanistic differences between the wild type
and mutant variant.
Consistent with previous reports exploiting the RIP-
B7.1 model, 90–100% of immunised non-DOX-treated
RIP-B7.1 mice bearing either the Pax4 or Pax4R129W
transgene developed hyperglycaemia within 3 weeks,
correlating with insulitis and beta cell destruction [33].
DOX-med i a t e d i ndu c t i o n o f Pax4 p r e v e n t e d
hyperglycaemia development in BPTL animals up to
4 weeks after immunisation, whereas Pax4R129W induc-
tion partially reduced the hyperglycaemic incidence in
mutBPTL mice. Thus, PAX4 blunts hyperglycaemia in
an autoimmune context, in contrast to several other
factors such as caspase-3-generated RAS p21 protein
activator 1 (RasGAP) N-terminal fragment (fragment N),
cytokine response modifier A (CRMA) or BCL-2 which,
d e s p i t e i n c r e a s i n g BCM, c o u l d no t p r e v e n t
hyperglycaemia in animal models of type 1 diabetes
[15, 22, 34]. Our data imply that in addition to inhibiting
apoptosis, PAX4 is involved in additional regulatory path-
ways, possibly including immune modulation. Corre-
spondingly, insulitis was reduced after PAX4 overexpres-
sion, an effect not attributable to a non-specific repression
of the Cd80 transgene that facilitates the immune
response. Our observations extend the analogous findings
that inhibition of vascular endothelial growth factor recep-
tor 2 (VEGFR-2) in NOD mice reversed hyperglycaemia
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Fig. 6 PAX4-regulated ER homeostasis prevents cell degeneration. Islet
PAX4, galectin-9 (Lgals9) and calreticulin (Calr) transcript levels were
assessed in (a) PAX4 or (b) PAX4R129W transgenic mice treated (black
bars) or not treated (white bars) with DOX for 1 month. The relative
mRNA levels were normalised to transcript levels of the housekeeping
gene β-actin. Data were calculated as fold change compared with the
values in control, non-DOX-treated animals. n = 3, **p < 0.01 and
*p< 0.05. (c) Pax4 or Pax4R129W induction in DOX-treated islets was
qualitatively assessed through DsRed fluorescence. Scale bar, 10 μm.
(d) Control (white bars), PAX4-expressing (black bars) and
PAX4R129W-expressing (grey bars) islets were then challenged with
1 μmol/l thapsigargin or not challenged and apoptosis was measured by
ELISA. Results expressed as per cent change compared with control
non-thapsigargin-treated islets. n = 5, *p < 0.05. (e) Pax4, Calr and
cyclophylin expression levels were measured in MIN6 cells treated with
siControl (white bars) and siPax4 (black bars). mRNA levels were nor-
malised to the transcript levels of the housekeeping gene β-actin. Data
were calculated as fold change compared with the values in siControl-
treated cells. n = 4, *p < 0.05. (f) Apoptosis was evaluated in control
MIN6 (white bars), and cells treated with siControl (grey bars) or siPax4
(black bars), untreated or treated with thapsigargin. Results are expressed
as fold change compared with control non-thapsigargin-treated cells.
n= 5, *p< 0.05
















Fig. 7 ER integrity is preserved in PAX4-overexpressing islets. Two sets
(upper and lower) of beta cell micrographs from islets isolated from
PAX4 transgenic mice, treated with DOX or not treated, and challenged
with 1 μmol/l thapsigargin or not challenged. Arrows indicate the RER.
Inset is enlarged below each image. Scale bar, 0.5 μm. N, nucleus;
V, insulin vesicles
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[35]. Although the mechanism by which PAX4 acts at the
interface of beta cells and the immune system to blunt
insulitis and improve islet recovery remains undefined,
our genetic analysis revealed that Lgals9 was specifically
upregulated in PAX4 islets. This gene induces apoptosis
of differentiated T helper 1 (Th1) cells [36], and its over-
express ion in NOD mice reduced insul i t i s and
hyperglycaemia [37], prolonging the survival of grafts
[38]. It is therefore plausible that, by enhancing Lgals9
expression, PAX4 may downregulate Th1 function,
partially impeding insulitis and improving islet survival.
Transcriptome profiling revealed that cell-cycle-associated
genes upregulated by PAX4 were downregulated by
PAX4R129W, despite comparable expression levels of both
transgenes. Specifically, the type 2 diabetes-associated cyclin-
dependent kinase inhibitor 2A, which strongly inhibits the
proliferative cyclin-dependent kinase 4 (CDK4) [39], was
enriched in PAX4R129W islets whereas it was decreased in
PAX4 islets. Reciprocally, cyclin D3, which promotes beta
cell survival, was increased in PAX4- but not in
PAX4R129W-overexpressing islets [40]. These findings
provide some molecular insights into the pathogenic effect
of the R129W mutation on beta cell plasticity.
Our data also reveal that PAX4, but not PAX4R129W, is
a key regulator of ER function by a combined targeting of
genes involved in UPR, Ca2+ homeostasis, ER–Golgi
translocation, and ERAD. The functional importance of
the transcriptional changes in these genes was validated
by the capacity of PAX4 to prevent thapsigargin-induced
ER ultrastructural abnormalities and apoptosis of beta
cells, consistent with the finding that PAX4-binding sites
are enriched within the promoter region of palmitate-
modified ER stress response genes [41]. In contrast, re-
pression of PAX4-sensitised MIN6 cells to thapsigargin
cell death correlates with reduced CALR levels.
Calreticulin is a Ca2+ chaperone of the ER, which contrib-
utes to the quality control of protein folding [42]. Overex-
pression of CALR in MIN6 cells enhances ER Ca2+ stores
and prevents NO-induced apoptosis [43]. In this context,
the production of NO and ROS induced by inflammatory
cytokines in the diabetic environment promotes beta cell
death by a variety of mechanisms, including the induction
of irreversible double-strand DNA breaks [27, 44]. We
found that PAX4 blunts DNA damage in two models of
experimental diabetes, pointing to a general protective
mechanism, possibly through preserved ER homeostasis,
implicating CALR [43]. The finding that PAX4-
overexpressing islets exhibited improved glucose-induced
Ca2+ oscillations points to this premise. Loss of oscillatory
capacity is associated with diminished islet glucose sensi-
tivity and increased ER dysfunction [45]. Thus, amplified
Ca2+ content in the CALR-enriched ER of PAX4-
overexpressing beta cells may impact cytosolic calcium
dynamics [43, 46], thereby preventing activation of
downstream apoptotic pathways under stress conditions.
We conclude that PAX4 favours beta cell survival and
regeneration in various deleterious inflammatory and high-
grade inflammatory environments, such as autoimmunity,
through the coordinated regulation of immune modulation,
cell cycle, cell survival, ER homeostasis and DNA repair.
While both PAX4 and PAX4R129W modulate these
pathways, it is the wild-type transcription factor that conveys
pro-survival properties by increasing the expression of
selected adaptive genes.
Fig. 8 PAX4-overexpressing islets exhibit normal calcium oscillation in
response to glucose. Carbachol-stimulated (100 μmol/l) intracellular re-
lease of Ca2+ wasmeasured in intact islets (a) treated with DOXor (b) not
treated. As indicated by the bars, islets were exposed to Ca2+-deficient
medium containing 2 mmol/l EGTA prior to applying 100 μmol/l carba-
chol. (c) Analysis of the AUC for the time of the stimulus with carbachol
from experiments shown in (a) and (b). (d) Analysis of the Ca2+ peak
amplitude in response to carbachol challenge. (n = 5–6). Representative
Ca2+ signals in response to 11 mmol/l glucose measured in intact islets (e)
treated with DOX or (f) not treated. (g) Analysis of the AUC for the last
10 min of the glucose stimulus recording shown in (e) and (f). (h)
Analysis of the amplitude of the first Ca2+ transient in response to the
glucose challenge. (i) Analysis of the basal fluorescence during the first
minute of the experiments. n = 9; **p ≤ 0.01 and ***p ≤ 0.001. ΔF;
fluorescence increase
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Targeting pancreatic expressed PAX genes for the treatment of diabetes mellitus
and pancreatic neuroendocrine tumors
Alejandro Martin-Montalvo*, Petra I. Lorenzo*, Livia López-Noriega and Benoit R. Gauthier
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ABSTRACT
Introduction: Four members of the PAX family, PAX2, PAX4, PAX6 and PAX8 are known to be expressed
in the pancreas. Accumulated evidences indicate that several pancreatic expressed PAX genes play a
significant role in pancreatic development/functionality and alterations in these genes are involved in
the pathogenesis of pancreatic diseases.
Areas covered: In this review, we summarize the ongoing research related to pancreatic PAX genes in
diabetes mellitus and pancreatic neuroendocrine tumors. We dissect the current knowledge at different
levels; from mechanistic studies in cell lines performed to understand the molecular processes con-
trolled by pancreatic PAX genes, to in vivo studies using rodent models that over-express or lack specific
PAX genes. Finally, we describe human studies associating variants on pancreatic-expressed PAX genes
with pancreatic diseases.
Expert opinion: Based on the current literature, we propose that future interventions to treat pan-
creatic neuroendocrine tumors and diabetes mellitus could be developed via the modulation of PAX4
and/or PAX6 regulated pathways.
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1. Introduction: the PAX family
PAX transcription factors, defined by the conserved bipartite
paired box DNA-binding domain (PAIRED), are classified into
four groups according to the presence/absence of an octapep-
tide region, and the presence/absence/truncation of a second
DNA-binding homeodomain [1,2]. This family of 9 genes in
mammals is evolutionarily conserved, with orthologues in
worms, flies, frogs, fish, and birds [3,4]. During embryonic
development, PAX proteins are involved in cell fate commit-
ment while maintaining cells in a proliferative pre-differen-
tiated status. Their actions include the enhancement of cell
proliferation and self-renewal, resistance to apoptosis, and
migration of embryonic precursor cells. Mouse models bearing
the deletion of individual PAX genes in homozygosis exhibit
striking developmental defects causing their death either in
the uterus or within few days after birth (Table 1) [5,6]. The
expression of several PAX members, such as PAX7 and PAX3,
persist in adult progenitor cell populations. In adulthood,
these genes are involved in organ/tissue regeneration [7].
The functional role of PAX proteins conveying proliferative
phenotypes is also a hallmark of tumorigenic proteins.
Indeed, PAX2, PAX3, PAX5, PAX7, and PAX8 are aberrantly
expressed in certain cancers and are currently used as tumor
markers in kidney, prostate, breast, and ovary cancer among
others [8].
To date, PAX2 and PAX8 (group II) as well as PAX4 and
PAX6 (group IV) have been directly or indirectly associated to
pancreas development or function (Figure 1). More impor-
tantly, mutations and/or small-nucleotide polymorphisms
(SNPs) in several of these genes have been associated with
diabetes mellitus (DM) (Figure 2). The above-mentioned
actions of pancreatic expressed PAX genes together with the
well-established fact that the diabetic milieu is a risk factor for
the development of pancreatic tumors prompted us to review
the current knowledge of PAX genes expressed in the pan-
creas and dissect their physiological and pathophysiological
roles with a particularly emphasis on DM and pancreatic neu-
roendocrine tumors (PNTs). We discuss whether pancreatic-
expressed PAX genes, especially PAX6 and PAX4, and their
targets have therapeutic potential for the treatment of these
terrible diseases.
2. PAX genes and the pancreas
2.1. PAX2; to be or not to be
PAX2 expression is essential for the development of the cen-
tral nervous system, eye, ear, kidney, and mammary gland [22–
24]. Seminal reports detected PAX2 mRNA transcripts in adult
rat islets, where two PAX2 isoforms, known as PAX2a and
PAX2b, were found [25]. Further in vitro functional studies
showed that PAX2 interacts with and transactivates the gluca-
gon promoter in islet cell lines and transfected fibroblasts [9].
Based on these data, PAX2 was proposed to be a regulator of
islet proglucagon gene expression. PAX2 mRNA is detected
CONTACT Benoit R. Gauthier benoit.gauthier@cabimer.es
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during murine pancreatic development as early as embryonic
day (E) 10.5, reaching its maximal expression around E12.5
(Figure 1). However, PAX2 expression was too low to be
detected by immunohistochemistry [10]. Noteworthy, PAX2
mRNA was also detected in human islets [10]. Conversely, an
independent report failed to detect PAX2 mRNA either in late
embryonic development (E19) or in adult mice islets [9]. In
addition, similar proglucagon mRNA expression levels were
found in the pancreas of wild type (wt) and homozygous
PAX21Neu mutant mice expressing a truncated nonfunctional
variant of PAX2 (Table 1). These results refute the concept that
PAX2 is involved in α-cell mature function through regulation
of glucagon gene expression. Moreover, the differentiation of
α-cells and β cells and islet architecture were not affected in
PAX21Neu mutant mice, raising concerns on the role of PAX2 in
islet development or function. However, a detailed analysis of
the islets of homozygous and heterozygous PAX21Neu mutant
mice at E18.5 revealed a marked increase in the pancreatic
volume occupied by islets [10]. This increase resulted from an
increase in the number and size of islets. Even though the
total number of islet cells was not quantified, the authors
observed an increase in the volume occupied by β-cells, but
not by α-cells. Interestingly, the increase in β-cell mass was not
associated with a significant increase in total pancreatic insulin
content, suggesting a reduction in the insulin content per cell
[10]. Based on these data, Zaiko et al. speculated that the
absence of PAX2 might favor the expansion of endocrine
cells, involving PAX2 in the endocrine/exocrine commitment
during embryonic development [10]. Nevertheless, the
decrease in insulin content of the β-cells in PAX21Neu mice
pinpoints to an effect of this gene on the functional matura-
tion of the β-cell. In any case, further studies are required to
validate this hypothesis. The mild effect of PAX2 deficiency on
the pancreas could stem from the compensatory role of other
PAX genes expressed in the pancreas. Supporting this hypoth-
esis, several examples have indicated that lack of one PAX
gene can be, to some extent, compensated by other members
of the PAX family [26]. Humans bearing in heterozygosis the
homologous polymorphism of PAX21Neu mice exhibit a detri-
mental phenotype that includes optic nerve and kidney fail-
ures. However, analyses of associations with glucoregulation
or any pancreatic phenotype were not performed in this
report [27]. Remarkably, although PAX2 expression has been
detected in various types of tumors, this gene has not been
associated with any kind of pancreatic tumor and only one
study investigated whether PAX2 immunostaining was posi-
tive in primary ductal adenocarcinomas of the pancreas. The
authors confirmed that none of the samples analyzed
expressed PAX2, suggesting that PAX2 is not involved in the
pathogenesis of this type of tumor [28]. Therefore, the role of
PAX2 in pancreatic physiology and pathophysiology is still
uncertain, revealing the need of further studies to validate
the implication or not of PAX2 in pancreatic diseases.
2.2. PAX8; An uncertain role in PNTs and DM
PAX8 is expressed during embryogenesis in the thyroid and
urogenital system, maintaining its expression in adult kid-
ney and thyroid gland [29–31]. As opposed to other PAX
genes expressed in the pancreas, the current scientific lit-
erature does not involve the expression of this gene in
pancreatic development [32]. PAX8 knock-out (KO) mice
exhibit severe growth retardation and die around weaning
due to thyroid dysgenesis and subsequent thyroid hormone
deficiency. Thyroxine administration can extend the survival
of these animals up to at least 6 months of age, indicating
that the lack of this hormone is the cause of death of these
mice [33]. In humans, detrimental PAX8 polymorphisms in
heterozygosis are also associated with thyroid dysgenesis
and urogenital malformations [34, 35]. To date, humans
harboring deleterious PAX8 variants in homozygosis have
not been found, suggesting that the lack of PAX8 is lethal.
The compromised survival of homozygous PAX8 KO mice
has precluded the evaluation of the plausible physiological
role of PAX8 in glucoregulation during adulthood [33, 36].
Interestingly, several reports have suggested that PAX8 may
be involved in the control of glucose homeostasis under
specific metabolic conditions. The transcriptional profile of
islets isolated from pregnant mice revealed a robust induc-
tion of PAX8 expression (Figure 1) [37]. Remarkably, under
normal conditions (nonpregnant mice fed on a healthy
diet), PAX8 mRNA expression is virtually absent in murine
pancreatic islets while human islets exhibit very low expres-
sion of this transcription factor [38]. These data suggest that
transient expression of PAX8 in islets might be required for
islet adaptation under situations of increased metabolic
demand such as pregnancy. However, there is still a lack
of research focused to determine whether homozygous
PAX8 KO mice treated or not with thyroxine or heterozy-
gous PAX8 mice suffer alterations in glucose control.
Supporting a possible role of PAX8 in islet physiology,
SNPs found in the region of chromosome 2 where PAX8 is
located show a strong association with type 2 DM (T2DM) in
Afro-Americans [39]. Therefore, further investigation is
required to define PAX8 function in pancreatic endocrine
physiology.
Intriguingly, numerous reports have associated PAX8
expression with PNTs, suggesting the possible use of PAX8
as PNTs marker [40–44]. Unfortunately, the anti-PAX8 polyclo-
nal antibody used in these reports was shown to cross-react
with at least PAX5 and PAX6 [38, 45, 46]. Indeed, we found
that a monoclonal antibody specific to PAX8 (e.g. raised
against a highly divergent sequence not found in other PAX
Article highlights
● Four PAX family members (PAX2, PAX4, PAX6, and PAX8) have been
linked to either endocrine pancreas (islets of Langerhans) develop-
ment or mature function.
● PAX4 and PAX6 control islet cell fate differentiation and survival.
● Small nucleotide polymorphisms/mutations in PAX4, PAX6 and PAX8
were shown to be associated with diabetes mellitus.
● Aberrant expression of PAX4 and PAX6 is associated with either islet
malformation or malignancy.
● Changes in the delicate balance PAX4-PAX6 may be involved in the
pathogenesis of DM and PNTs.
This box summarizes key points contained in the article.
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members) failed to reveal PAX8 expression in PNTs as well as
pancreatic tissue. Our results clearly indicated that the high
degree of conservation in the N-terminal part of the protein
among the different PAX proteins was the underlying cause of
the false-positive results associating PAX8 expression with
PNTs. Of note, the antibody used in these studies was raised
against a region that includes the conserved 128 amino acid
paired DNA-binding domain found in all members of the PAX
gene family (Figure 2). Notwithstanding the assumptions of
the literature using polyclonal PAX8 antibodies, the fact that a
PAX gene is expressed in PNTs might be clinically relevant for
the diagnosis of this disease [47]. In summary, despite the
growing interest aimed at delineating whether PAX8 plays a
significant role in diabetogenesis and the formation and pro-
gression of PNTs, a definite answer remains to be established.
2.3. PAX4; a crucial role safeguarding β-cell integrity
PAX4 is predominantly expressed in pancreatic β- and δ-cells
[11]. During murine embryonic development, PAX4 expression
is first detected around E9.5 in the pancreas and the ventral
spinal cord, reaching its maximal expression at embryonic
E13.5–15.5, when β-cell differentiation is initiated [11]. After
birth, and coinciding with the decline in β-cell proliferation,
PAX4 expression is decreased, albeit still detectable, in adult
rexpression of PAX4 under the control of the Pdx islets
(Figure 1) [48–51]. Homozygous PAX4 KO mice, despite being
born at Mendelian ratios, die within 3 days after birth with
severe hyperglycemia (Table 1) [11, 52, 13]. These animals lack
β- and δ-cells, and have an increased α-cell mass [11, 12].
Noteworthy, heterozygous PAX4 KO mice exhibit insulin-produ-
cing β-cells and do not develop DM, indicating that a single
copy of PAX4 is sufficient to promote normal β-cell develop-
ment and function [11]. Despite the specific requirement of
PAX4 for only β- and δ-cell formation, lineage-tracing analysis
demonstrated that all islet cells are derived from PAX4 expres-
sing progenitors [53, 54]. These data suggest that a minimum
threshold level of PAX4 is required to determine the commit-
ment of the endocrine cells towards β- and δ-cells. Collombat
and coworkers further demonstrated the crucial role of PAX4 in
β-cell commitment/differentiation by in vivo overexpression of
PAX4 under the control of the Pdx1, PAX6, or glucagon pro-
moters. These authors demonstrated that ectopic PAX4 over-
expression in murine endocrine precursor cells induces the
formation of β-cells at the expense of the other islet cell popu-
lations [55]. Moreover, PAX4 overexpression under the control
of glucagon promoter during embryonic development or post-
natal life results in the trans-differentiation of α-cells toward β-
like cells [55, 56], likely through PAX4-mediated transcriptional
inhibition of Arx [57]. Similarly, viral-mediated PAX4 expression
in human islets induced α-cell-to-β-cell phenotypic conversion
[58]. Functional in vitro studies conducted to determine PAX4
mechanism of action revealed that PAX4 overexpression in
either rodent or human islets stimulates β-cell proliferation
and protects β-cells from cytokine-induced apoptosis [50, 59].
These results were validated in vivo using a conditional β-cell
specific PAX4 overexpression in adult mice. PAX4 overexpres-
sion protects against streptozotocin (STZ)-induced DM as well
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[59, 60]. Remarkably, these reports have provided substantial
knowledge on the cellular mechanisms orchestrated by PAX4
that protect β-cells. Transcriptome profiling of islets overexpres-
sing PAX4 in β-cells revealed that PAX4 controls the expression
of different groups of genes that act at different cellular tasks,
conferring multiple layers of protection to promote β-cell survi-
val. Of particular interest, PAX4 preserves the integrity of the
endoplasmic reticulum preventing thapsigargin-induced cell
death, a treatment that inhibits the sarcoplasmic/endoplasmic
reticulum Ca2+-dependent ATPase pump. DNA damage induced
Figure 2. Schematic representation of human pancreatic-expressed PAX genes with annotated mutations associated with impaired glucose homeostasis, DM or pancreatic tumors.
Schematic representation of the four human pancreatic PAX genes. Chromosomes location is indicated under the gene name, together with the NCBI reference
number. Exons are depicted as rectangles, with the coding region indicated in grey and the specific domains indicated in colors: Paired Domain (green), octapeptide
(blue) homedomain (purple) and negative regulatory region (orange). Disease-associated (impaired glucose homeostasis, DM or pancreatic tumors) mutations are
indicated in the figure: point mutations are represented by black dots with the resulting amino acid change indicated above. Mutation causing truncated variants of
the protein are indicated underneath the gene and represented by brown arrows. Point mutations causing the generation of a stop codon (represented by the ‘X’ in
the amino acid change indication) appear underneath the gene. The relative size of the exons is depicted in the figure. Non-coding exons appear as broken
rectangles indicating longer relative size. Full color available online.
Figure 1. Relative expression of mouse pancreatic PAX genes. Representation of the relative expression of PAX2 and PAX8 (group II) as well as PAX4 and PAX6 (group IV) in
mouse islets during embryonic development and postnatal life. In the upper part of the figure the main stages of islet organogenesis and postnatal development
are indicated: formation of the precursor cells (E9.5 to E11.5), secondary transition with the formation of the endocrine cells (E12.5 to E 15.5), adult fully functional
islet, islet adaptation in response to the increased insulin demand (e.g. during pregnancy). Colored curves underneath indicate the relative expression levels of each
PAX gene at the specific time points. The relative expression is not comparable among the four PAX members. Dotted lines indicate probable expression, still not
confirmed.
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by diabetogenic treatments (STZ and autoimmune attack) was
also reduced in PAX4 overexpressing islets [60]. Intriguingly,
long-term PAX4 overexpression in these mice resulted in
blunted insulin secretion and the appearance of a proliferative
BrDU+/Pdx1+/insulin− cell population that suggests that PAX4
promotes the dedifferentiation of mature β-cells [59].
Supporting these data, PAX4 overexpression decreases the
expression of MafA and insulin, markers of mature β-cells [59,
61]. Interestingly, β-cell dedifferentiation has been proposed to
underlie the functional alterations of pancreatic islets during
T2DM development [62, 63]. Based on these data, we hypothe-
sized that, when β-cells are challenged, the induction of PAX4
expression promotes β-cell dedifferentiation to potentiate pro-
liferation and protection in order to recover/protect the β-cell
mass. Supporting this hypothesis, an increase in PAX4 expres-
sion has been observed in nonobese T2DM patients with a BMI
between 22 and 26 [51]. Intriguingly, we and others have
demonstrated that PAX4 expression is maintained in adult
islets, which might be potentially detrimental for β-cell func-
tionality given the dedifferentiative potential of this gene [48,
54]. However, the use of a transgenic mouse model that
expresses GFP under the control of PAX4 promoter allowed us
to determine that PAX4 is not homogeneously expressed in all
β-cells, but specifically in a β-cell subpopulation. During post-
natal development, the expression of PAX4 becomes restricted
to a subpopulation of β-cells that decreases with age, correlat-
ing with the decrease in the proliferative capacity of pancreatic
β-cells [54]. Remarkably, in adult animals, PAX4-expressing cells
are more resistant to apoptosis compared to those lacking
PAX4 expression when challenged in vitro with thapsigargin
or in vivo with STZ. Moreover, the PAX4-expressing β-cell sub-
population is prone to proliferation during pregnancy, when
endogenous PAX4 levels transiently increase correlating with
the increase in β-cell proliferation [54]. The fact that PAX4 is
only expressed in a subset of β-cells in adult islets is consistent
with the proliferative heterogeneity of β-cells [64]. All together,
these studies clearly indicate the central role of PAX4 in both
development and adult endocrine pancreatic physiology.
The capacity of PAX4 to maintain a β-cell subpopulation in
a proliferation-prone status while enhancing resistance to
apoptosis suggests a potential role in tumor formation and
progression. In this line, high PAX4 expression levels have
been reported in human insulinomas [65] as well as in
approximately 42% of human PNTs [66]. Noteworthy, in
human insulinoma samples, in addition to PAX4 overexpres-
sion, a deletion of exon 7 originating a mutated protein that
lacks the negative regulatory domain (NRD) has been reported
[65]. A similar protein truncation was also detected in a rat
insulinoma cell line [67]. Remarkably, the repression of PAX4 in
an insulinoma cell line (INS-1E) induces an increase in sponta-
neous apoptosis, suggesting that PAX4 expression is required
for the survival of insulinoma cells [68]. However, long-term
PAX4 overexpression (4 months) in mice did not induce PNTs,
suggesting that per se PAX4 overexpression does not confer
tumorigenic potential [59]. Taken together, these results indi-
cate that high PAX4 expression may not be the root cause of
PNT development, but that sustained overexpression of this
transcription factor may rather facilitate the dedifferentiation
and survival of PNT cells. Accordingly, PAX4 was shown to
increase cell cycle activators, including c-myc and cyclin D,
as well as inhibitors, such as p21 and Mig6 [54]. These results
may support that PAX4-expressing β-cells are prone to prolif-
eration upon alleviation of the cell cycle brakes. It is tenable
that chronic hyperglycemia and hyperinsulinemia, known
inducers of PAX4 expression, as well as hallmarks of T2DM,
could suffice to override these brakes favoring cell prolifera-
tion [51].
Taking into consideration the critical role of PAX4 in β-cell
formation and plasticity, it is not surprising that detrimental
polymorphisms in PAX4 have been associated with type 1 DM
(T1DM), T2DM, ketosis-prone DM (KPDM), and maturity onset of
the diabetes of the young (MODY) in humans (Figure 2) [31, 69–
73]. Genome-wide association studies (GWAS) have identified,
in Asian populations, two T2DM susceptibility loci (rs6467136
and rs10229583) located in intergenic regions in the proximity
of PAX4 [74, 75]. Further analysis of PAX4 polymorphisms
located within the PAX4 gene revealed that, the majority of
PAX4 polymorphisms predisposing to DM are located within
the evolutionarily conserved DNA-binding domains (amino
acids 2 to 222) likely affecting its binding to target genes
(Figure 2) [76, 77]. One of the most studied polymorphisms
affecting the DNA-binding domain is PAX4 R121W, which has
been associated with T2DM in Japanese populations. Patients
harboring this polymorphism in homozygosis showed severe
defects in first-phase insulin secretion whereas patients harbor-
ing the same polymorphism in heterozygosis exhibit impaired
insulin secretion. This β-cell dysfunction associated to PAX4
R121W has been correlated with earlier onset of DM [76–79].
Extensive research has been conducted in mice harboring the
equivalent polymorphism, the PAX4 R129W variant [59, 60]. In
vitro studies using primary pancreatic islets overexpressing
PAX4 R129W determined that PAX4-mediated protection
against cytokine-induced as well as thapsigargin-induced apop-
tosis is restricted when compared to the overexpression of the
wt PAX4. In agreement with these data, in vivo overexpression
of PAX4 R129W confers only partial protection against STZ as
well as in a model of experimental autoimmune DM when
compared to the overexpression of wt PAX4 [59, 60]. Besides
this well-studied mutation, two PAX4 rare variants, PAX4 R133W
and PAX4 R37W, have been found among patients of West
African ancestry with KPDM, a rare form of T2DM [72]. These
two variants correlated with severe alterations on pancreatic β-
cell functionality. Remarkably, PAX4 R133W has been associated
with predisposition to KPDM [72]. However, the low incidence
of PAX4 R37W has impeded the performance of association
analyses for this polymorphism. Interestingly, polymophisms in
PAX4, affecting β-cell functionality and survival, have also been
associated with DM in Asian families with unknown MODY
reinforcing the premise of PAX4 as MODY9. PAX4 R164W var-
iant, associated with DM in Thai MODY families, exhibits com-
promised PAX4 transcriptional activity resulting in increased
glucose-induced apoptosis in INS-1 cells [71, 80]. Another
PAX4 polymorphism associated with MODY patients, PAX4
R192H, is located within the homeodomain of the protein.
The expression of this variant impairs PAX4 transcriptional
repressor activity and reduces β-cell survival under glucotoxic
82 A. MARTIN-MONTALVO ET AL.
conditions [71, 81–83]. Additionally, a PAX4 polymorphism
affecting the splice acceptor site in intron 7, known as IVS7-
1G>A, has been identified in heterozygosis in a MODY family
with severe diabetic complications [71]. This isoform results in
defective PAX4 protein structure and function, with impaired
transcriptional activity and blunted PAX4-mediated protection
of INS-1 cells from apoptosis when cells are grown on high
glucose [80]. Similarly, a PAX4 polymorphism resulting in a 39-
base deletion in exon 3 that causes splicing changes leading to
a truncated PAX4 protein that lacks transcriptional repressor
activity has been described in a Japanese MODY family [84].
Intriguingly, this polymorphism renders different diabetic phe-
notypes in different individuals harboring this variant, indicat-
ing that other diabetogenic genes or environmental factors
might contribute to the phenotype of these patients. In addi-
tion to the association of PAX4 detrimental polymorphisms
with T2DM, KPDM, and MODY, a polymorphism in PAX4 has
also been associated to T1DM. Although it is under debate, the
H321P variant in homozygosis was suggested to be a predis-
position marker for T1DM in two independent Caucasian popu-
lations [70]. However, this correlation was not detected in
Finish, Hungarian, and Asian populations [85, 86]. Taken
together, substantial clinical evidences indicate that PAX4 is
central orchestrating the regulation of molecular networks
within the β-cell subpopulation that ensure cell survival and
controlled expansion in the adaptation to environmental
changes. However, these adaptive mechanisms include at
long term the dedifferentiation and proliferation of β-cells,
which may under specific conditions benefit the progression
of PNTs.
2.4. PAX6; essential and untouchable
During early development, PAX6 is expressed in the eye and
brain as well as in pancreatic islet cells. Within the developing
murine pancreas, PAX6 is expressed early on throughout the
dorsal pancreatic bud. Later on, its expression is restricted to
the endocrine cell precursors to promote their differentiation
[17, 14, 19]. In adult mice, PAX6 expression is maintained in all
the endocrine cells of the pancreas (Figure 1) [19]. PAX6 KO
mice as well as mice harboring two independent PAX6 dele-
terious mutations (Sey1Neu and the naturally occurring SeySey)
in homozygosis have strong developmental abnormalities and
die immediately after birth (Table 1). These animals fail to
develop eyes, nasal structures and display abnormal forebrain
patterning and altered pancreatic islet morphology [17, 14, 15,
87]. Islets from homozygous null-mutant PAX6 mice are dis-
organized, lacking α-cells while the other hormone-expressing
cell populations are greatly reduced, with the exception of
ghrelin expressing cells that are increased [16]. Moreover,
these islets exhibit restricted secretion of several pancreatic
endocrine hormones [17, 14]. Mice bearing a pancreatic endo-
crine-specific PAX6 ablation in homozygosis display abnormal
glucoregulation [19]. These mice die within 3–6 days after
birth exhibiting overt diabetic phenotype, with severe growth
retardation, hyperglycemia, and hypoinsulinemia.
Immunohistochemical analysis of the pancreas of these mice
revealed decreased number of glucagon and insulin expres-
sing cells, but surprisingly, pancreatic peptide and
somatostatin expressing cells were not affected [19]. A sepa-
rated report also indicated that the lack of PAX6 expression
specifically in adulthood produces a severe decrease in insulin,
glucagon, and somatostatin production [21]. These data
clearly demonstrate that PAX6 plays an essential role both
during pancreatic embryogenesis as well as in the adult islets.
Functional studies determined that, at the molecular level,
PAX6 directly regulates the expression of genes required for
the maintenance of metabolic homeostasis, such as insulin,
incretins, prohormone convertases, glucagon, and somatosta-
tin [17, 88–91]. Consequently, PAX6 was proposed to be
involved in hormone production, rather than in the develop-
ment of endocrine cells. Mice harboring a PAX6 R266Stop
mutation (a truncated PAX6 that lacks the transactivation
domain) in heterozygosis exhibit normal glucose regulation
up to 4 months of age. However, animals older than 6 months
exhibit impaired glucose tolerance. These animals were shown
to produce less prohormone convertase 1/3, a direct target of
PAX6, suggesting that defective proinsulin processing is the
cause of the pancreatic phenotype in heterozygous PAX6 mice
[20]. Consistent with this premise, heterozygous PAX6 mutant
rats rSey, that lack most of the transactivation domain of
PAX6, exhibit impaired first phase glucose-induced insulin
secretion [92]. PAX6 also regulates production of incretins,
which suggest that effects in pancreatic endocrine physiology
could stem, at least in part, from the effect of non-pancreatic
tissues. In mice, PAX6 is needed for the differentiation of
intestine cells producing the gastric inhibitory peptide (GIP),
glucagon-like peptide 1 (GLP1) and GLP2 [93]. Circulating
GLP1 and its transcript levels in the intestines were markedly
reduced in heterozygous mice expressing a PAX6 variant that
impairs the homeodomain-binding activity [18]. Interestingly,
exendin-4 (a long-lasting GLP1 analog) supplementation in
PAX6 heterozygous mice rescued the aberrant phenotype
(e.g. abnormal food intake, glycemic excursion, and insulin
secretion). Therefore, Ding et al. suggested that the mechan-
ism underlying the detrimental effects on adult PAX6 hetero-
zygous mutant mice was related to the reduced expression of
GLP1, an important incretin that potentiates insulin secre-
tion [18].
Heterozygous PAX6 mutations in mice and humans pro-
duce microphthalmia, also known as the small eye phenotype,
and aniridia [94, 95]. Interestingly, in some instances, aniridia
patients harboring in heterozygosis PAX6 variants that impede
its transcriptional activity develop abnormal glucose tolerance,
impaired insulin secretion, as well as decreased glucagon and
GIP concentrations (Figure 2) [96–98]. Patients harboring one
copy of the PAX6 R240 stop variant, which lacks the transacti-
vation domain and a small portion of the homeodomain
(Figure 2), exhibit reduced insulin secretion upon glucose
challenge and impaired proinsulin processing, as reflected by
the increased proinsulin/C-peptide ratio [20, 98]. Interestingly,
2 h after the glucose challenge, insulin levels were similar in
individuals bearing detrimental PAX6 variants when compared
to healthy individuals. In contrast, circulating glucose levels
remained high in these patients, suggesting defects in insulin
signaling. However, insulin sensitivity was unaffected in an
insulin tolerance test, and the proinsulin/C-peptide ratio was
higher in patients with PAX6 detrimental polymorphisms [20].
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These results suggested that, similar to mice, defective proin-
sulin processing might be the cause of impaired glucoregula-
tion in humans harboring PAX6 detrimental polymorphisms in
heterozygosis. Supporting these data, in vitro studies using
human islets indicated that islets expressing the impaired
glucoregulation-associated PAX6 SNP rs685428 ‘G’ in hetero-
zygosis (known as AG) had lower mRNA levels of PCSK1, the
gene encoding prohormone convertase, when compared to
islets expressing the fully functional A allele in homozygo-
sis [96].
In addition to mutations directly affecting PAX6 expression,
a separated report has indicated that polymorphisms affecting
cis-regulatory response elements located in the promoters of
direct target genes of PAX6, and possibly PAX4, are associated
with the development of DM in humans [99]. Human pancrea-
tic islets harboring in heterozygosis the T2DM-associated
rs11603334 SNP, located in the ankyrin repeat and PH domain
1 (ARAP1) promoter (known as ‘C’ allele), exhibit increased
ARAP1 expression. Interestingly, although the mechanism by
which ARAP1 expression favors the development of T2DM
remains elusive, PAX6 was shown to bind preferentially to
the non-T2DM-associated SNP (known as the ‘T’ allele) in a
protein-DNA complex that could also contain PAX4 [99]. The
authors speculated that the competitive binding of PAX6, and
possibly PAX4, to this site dictates physiological levels of
ARAP1 expression, while loss of binding results in aberrantly
high expression levels. Supporting this hypothesis, the com-
petition of PAX6 and PAX4 for the same binding sites has
been reported in insulin and glucagon promoters [61, 100,
101]. Taken together, these reports indicate that PAX6-
mediated ARAP1 expression might be a molecular mechanism
contributing to T2DM susceptibility, suggesting that direct
targets of PAX genes could have therapeutic potential.
As opposed to the majority of studies investigating the
physiological role of PAX6 deficiency, minimal work has
been conducted in animal models overexpressing PAX6. Of
particular interest is an elegant work published by Yamaoka
et al. [102]. This report demonstrated that mice overexpres-
sing PAX6 under the control of the PDX1 promoter exhib-
ited increased proliferation of islet cells. Interestingly, islet
neogenesis from ductal epithelial cells was also detected in
the vicinity of dilated pancreatic ducts. However, concomi-
tantly with an increased in cell proliferation, many apoptotic
cells were detected in islets. As a result, islet hypotrophy
was observed due to the simultaneous decrease of β-cell
and α-cell area. Moreover, the authors also observed a
decrease in whole pancreas weight, indicative of hypoplasia
of the exocrine pancreas. However, PAX6 overexpression
later in development (driven by the insulin promoter)
neither induced islet neogenesis nor increased the prolifera-
tion of islet cells. Additionally, a decrease on the β-cell area
was detected without any effect on the α-cell area [102].
Interestingly, in PAX6 overexpressing mice, the incidence of
hyperglycemia ranged from 22 to 46%, suggesting that
additional factors are required to trigger impaired glucore-
gulation in these mice. Nevertheless, the overexpression of
PAX6 under both PDX1 or insulin promoters disturbs the
normal development of β-cells. Remarkably, only pPDX1/
PAX6 overexpressing mice exhibited an increase in the
ductal epithelium and the development of pancreatic cystic
adenomas. The authors speculated that PAX6 might play a
dual action in pancreatic development controlling on one
side the proliferation of primitive ductal epithelia and islet
progenitor cells and on the other side the induction of α-
cell phenotypes. These findings also indicated that the
maintenance of high PAX6 expression is detrimental for
the normal development of the endocrine and the exocrine
pancreas.
The role of PAX6 in tumor formation and proliferation
remains controversial both in animal models and humans.
Indirect evidence indicates that high PAX6 expression was
found specifically in insulinomas in a transgenic animal
model in which the simian virus 40T antigen was under
the control of the glucokinase promoter [103]. Interesting
studies using human samples have described that 70% of
adenocarcinomas, preferentially poorly differentiated,
express PAX6 [38, 104]. In differentiated tumors, PAX6
was expressed in the atypical ductules while non-tumorous
adjacent pancreatic ducts did not express PAX6. In sum-
mary, data in the scientific literature raise concerns regard-
ing the use of strategies aiming to modulate PAX6
expression for the development of novel therapies to
treat DM and pancreatic tumors since both the overexpres-
sion and restricted expression of PAX6 is associated with
impaired glucoregulation and/or the development of dif-
ferent types of pancreatic tumors.
3. Conclusion
Several members of the PAX family of transcription factors
orchestrate essential tasks in pancreatic physiology and patho-
physiology. Despite discrepancies regarding the role of PAX2
and PAX8 in pancreatic development and function, altered
expression of PAX4 and PAX6, has been repeatedly associated
with DM and PNTs. Remarkably, while the expression of loss of
function variants of both PAX4 and PAX6 is associated with
DM, aberrant expression of PAX4 and/or PAX6 is found in
certain PNTs. Similar to the pro-proliferative effect of PAX4
and PAX6 during development, increased expression of both
PAX4 and PAX6 in PNTs may promote their progression, sug-
gesting that blockage of PAX4/PAX6 expression could repre-
sent a promising strategy to treat PNTs. Accumulated
evidences indicate that the modulation of PAX6 expression
might not be optimal for the treatment of DM since both
overexpression and restricted expression of this transcription
factor is associated with the development of DM. However,
research using transgenic PAX4 overexpressing mice indicates
that interventions based on the short-term or intermittent
overexpression of PAX4 could be promising to develop novel
therapies for the treatment of the different types of DM. In
addition, direct targets of PAX4 and PAX6, such as ARAP1,
might also be promising candidates for the development for
novel therapies to treat these terrible diseases. The data in the
scientific literature indicate that increased understanding of
the mechanisms controlled by pancreatic PAX genes would
offer the potential to develop mechanism-based interventions
to prevent and cure DM and PNTs.
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4. Expert opinion
Lessons learnt from animal models (Table 1) as well as from
human studies have provided sufficient evidence to argue
against a role of PAX2 in the pathogenesis of both DM and
PNTs. Although the involvement of PAX8 in PNTs has been
undoubtedly refuted, punctual expression of this transcription
factor under specific conditions indicate a physiological func-
tion of PAX8 in the islet of Langerhans, which deserves further
investigation. In contrast, there are strong indications that
involve changes in expression levels of PAX6 and PAX4 and
the occurrence of certain types of pancreatic tumors and DM.
Indeed, either gain or loss of PAX6 function results in β-cell
death and impaired glucose metabolism while aberrant
expression under the control of PDX1 promoter produces
pancreatic cystic adenomas [102]. In the case of PAX4, the
lack of this gene and the expression of non-fully functional
PAX4 variants lead to DM. Long-term PAX4 overexpression
prompts β-cell dedifferentiation and hyperglycemia without
any apparent development of PNTs [59]. However, research
reports indicate that certain insulinomas express high levels of
PAX4 and PAX6 [103]. The current scientific literature supports
that PAX4 and PAX6 are the main players, within the PAX
family, in the development, plasticity, and functionality of
the pancreas. Interestingly, PAX4 was originated from duplica-
tion of the PAX6 gene early in vertebrate evolution. Such
event is usually followed by interplays in their function [105].
However, although of common origin, a striking feature of
PAX4 is its sharp repression of PAX6 targets, such as insulin,
MAFA, and GLUT2, in the islets of Langerhans. This process
involves both direct protein–protein interaction as well as
competitive binding to the same cis-regulatory DNA elements
within the promoters of their targets. Thus, the ratio of PAX6
to PAX4 likely defines expression levels of common molecular
targets that will ultimately dictate the fate of islet β-cell differ-
entiation, proliferation, and/or survival (Figure 3). Such model
would reconcile most published data demonstrating that
PAX4 is essential for β-cell differentiation yet inhibits most
mature β-cell markers. In addition to common islet specific
targets, PAX4 and PAX6 also regulate distinct sets of genes.
Non-fully functional variants of PAX4, such as the R121W,
would result in restricted expression of both direct PAX4
targets such c-myc (cell proliferation) but also in the modula-
tion of the expression of PAX6 interactive targets, resulting in
dysfunctional and apoptosis-prone β-cells. Physiological stres-
ses such as obesity-induced insulin resistance and hyperglyce-
mia and/or the presence of non-fully functional variants of
these genes may lead to a discontinuity in the balance
Figure 3. The PAX6/PAX4 balance dictates islet β-cell fate in health and disease. Under normal physiological conditions, balanced expression levels in PAX4 and PAX6 specify
a healthy and functional β-cell phenotype with low proliferation capacity and minimal apoptosis (middle panel). However, increases in PAX6 or decreases in PAX4
expression levels due to mutations will tilt the balance towards PAX6, resulting in dysfunctional β-cells with impaired insulin processing and increased susceptibility
to apoptosis. Sustained Pax6 over-expression may lead to impaired glucoregulation. Pancreatic tumors might be favoured as found in mice over-expressing Pax6
under the control of PDX promotor (upper panel). In contrast, conditions favouring increased PAX4 expression levels to the detriment of PAX6 will impose a
protective dedifferentiated phenotype to β-cells with proliferating properties. Sustained Pax4 over-expression may lead to impaired glucoregulation. Although long-
term Pax4 over-expression did not cause pancreatic tumors it might favor their progression (lower panel).
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between PAX4 and PAX6 [51, 54, 59, 60]. In conclusion, we
present arguments indicating that changes in this delicate
balance may be involved in the pathogenesis of DM and
certain types of pancreatic tumors.
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BACKGROUND AND PURPOSE
Thyroid hormones induce several changes in whole body metabolism that are known to improve metabolic homeostasis.
However, adverse side effects have prevented its use in the clinic. In view of the promising effects of thyroid hormones, we
investigated the effects of levothyroxine supplementation on glucose homeostasis.
EXPERIMENTAL APPROACH
C57BL/6 mice were treated with levothyroxine from birth to 24 weeks of age, when mice were killed. The effects of levothyroxine
supplementation on metabolic health were determined. C57BL/6 mice treated with levothyroxine for 2 weeks and then chal-
lenged with streptozotocin to monitor survival. Mechanistic experiments were conducted in the pancreas, liver and skeletal
muscle. RIP-B7.1 mice were treated with levothyroxine for 2 weeks and were subsequently immunized to trigger experimental
autoimmune diabetes (EAD). Metabolic tests were performed. Mice were killed and metabolic tissues were extracted for
immunohistological analyses.
KEY RESULTS
Long-term levothyroxine supplementation enhanced glucose clearance and reduced circulating glucose in C57BL/6 mice.
Levothyroxine increased simultaneously the proliferation and apoptosis of pancreatic beta cells, promoting the maintenance of a
highly insulin-expressing beta cell population. Levothyroxine increased circulating insulin levels, inducing sustained activation of
IRS1-AKT signalling in insulin-target tissues. Levothyroxine-treated C57BL/6 mice challenged with streptozotocin exhibited ex-
tended survival. Levothyroxine blunted the onset of EAD in RIP-B7.1 mice by inducing beta cell proliferation and preservation of
insulin-expressing cells.
CONCLUSIONS AND IMPLICATIONS
Interventions based on the use of thyroid hormones or thyromimetics could be explored to provide therapeutic benefit in patients
with type 1 diabetes mellitus.
Abbreviations
BAT, brown adipose tissue; EAD, experimental autoimmune diabetes; GK, glucokinase; GSIS, glucose-stimulated insulin
secretion; GSK3β, glycogen synthase kinase 3β; IPPTT, intraperitoneal pyruvate tolerance test; ITT, insulin tolerance test; STZ,
streptozotocin; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; T3, triiodothyronine; T4, levothyroxine; TR,
thyroid hormone receptors; THs, thyroid hormones; WAT, white adipose tissue; α-GSU, α-glycoprotein subunit
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Introduction
Glycaemic control is exquisitely orchestrated by the hor-
mones secreted by the islets of Langerhans, which exert
effects on many target tissues. In the pathogenesis of type 2
diabetes mellitus (T2DM), insulin-target tissues gradually de-
velop insulin resistance. As a result of compromised insulin
sensitivity, there is an increased demand of insulin produc-
tion to maintain circulating glucose concentration within
the physiological range. Under these circumstances, pancre-
atic beta cells overproduce insulin, which in late stages of
the disease results in overstimulation of beta cells and their
apoptosis. In type 1 diabetes mellitus (T1DM), as opposed to
T2DM, there is a direct and specific attack of immune cells
that selectively destroys pancreatic beta cells. In both T1DM
and T2DM, the lack of a functional beta cell mass produces
hyperglycaemia, propelling a vicious cycle of metabolic
disorders.
The use of thyroid hormones (THs) and newly generated
thyromimetics is promising to improve metabolic homeosta-
sis given their potent effect on weight loss and the reduction
of cholesterol levels (de Lange et al., 2011; Lin and Sun, 2011;
Moreno et al., 2011). Triiodothyronine (T3) and
levothyroxine (T4), produced in the thyroid gland, are the
main THs. T4 is converted into T3 within cells by deiodinases.
Interestingly, T4 is less active but more stable (190 h) than T3.
The average activity of T3 is about three to five times higher
than T4, but the stability is 19 h in euthyroid patients.
Other THs or thyromimetics, such as triac, tetrac,
thyrinnamines, reverse T3, 3,5-diiodo-l-thyronin and conju-
gated glucagon/T3, also exist and are recently attracting at-
tention in the scientific community as promising drugs for
the treatment of several pathologies (Ball et al., 1997; Shang
et al., 2013; Goglia, 2014; Senese et al., 2014; Finan et al.,
2016). One of the main physiological roles of THs is the regu-
lation of basal metabolic rate, defined here as the rate of en-
ergy expenditure per time at rest, which accounts for about
60–75% of the calories burned in a healthy subject. Specifi-
cally, THs increase oxygen consumption and rates of ATP hy-
drolysis, while lowering coupled state of the mitochondria
and the maximal capacity to produce ATP (Johannsen et al.,
2012). Actually, THs are known to induce the catabolism of
all types of energy sources (Weinstein et al., 1991). THs in-
duce the reduction of circulating triglycerides and cholesterol
containing lipoproteins, as well as the induction of hepatic
gluconeogenesis and glycogenolysis (Bahn et al., 2011). En-
hanced gluconeogenesis and glycogenolysis support tissues
with sufficient fuel to maintain their energy requirements
(Dimitriadis and Raptis, 2001; Klieverik et al., 2008).
The mechanistic insights of THs action in cells involve
the modulation of gene expression in a process mediated by
their binding to TH receptors (TR). TH-TR complexes
bound to specific DNA sequences modulate the expression
of more than 80 genes (Dong et al., 2009; Shoemaker et al.,
2012). In this context, essential cellular processes are orches-
trated by THs, such as mitochondrial biogenesis in the ner-
vous system and the contractile apparatus of the
endoplasmic reticulum in the heart (Iwen et al., 2013;
Vargas-Uricoechea et al., 2014). Additionally, non-genomic
effects of TH have also been described (e.g. activation of
Akt signalling, through the TR-β) (Verga Falzacappa et al.,
2009; Vicinanza et al., 2013). Moreover, THs play a significant
role in the differentiation of the vast majority of somatic cells
(Obregon, 2008; Sirakov et al., 2013). Interestingly, during the
last years, extensive research has focused on the role of TH in
the differentiation, maturation and functionality of meta-
bolic tissues (Mastracci and Evans-Molina, 2014). Thus, T3
supplementation enhanced postnatal pancreatic islet devel-
opment, via the induction of the transcription factor MAFA,
and attenuated hyperglycaemia in streptozotocin (STZ)-
treated and leptin-receptor deficient mice (Lin and Sun,
2011; Verga Falzacappa et al., 2011; Aguayo-Mazzucato et al.,
2013). In addition, T3 administration increased the expres-
sion of endocrine markers in acinar and ductal cell lines as
well as in pancreatic explants (Misiti et al., 2005; Aiello
et al., 2014). Remarkably, newly developed in vitro protocols
aiming to differentiate human embryonic stem cells towards
insulin-secreting beta cells use T3 in specific steps of the dif-
ferentiation protocol (Pagliuca et al., 2014; Rezania et al.,
2014). These data indicate that THs are involved in the differ-
entiation and the maturation of pancreatic precursor cells
into functional endocrine cells.
In this report, we set out to investigate whether a long-
term supplementation with T4 enhanced glucose clearance
in healthy and in STZ-challenged C57BL/6 wild-type mice,
as well as improving metabolic homeostasis in the RIP-B7.1
mouse strain, which provides a model of experimental auto-
immune diabetes (EAD). We found that T4 improved meta-
bolic control in these murine models via the induction of
the proliferation of pancreatic beta cells, as well as the
production of insulin, which was associated with higher cir-
culating insulin levels and the subsequent activation of the
IRS1-Akt axis of insulin signalling in target tissues for insulin.
Methods
Animals
All animal care and experimental procedures complied with
national and European Union legislation (Spanish RD
53/2013 and EU Directive 2010/63) for the protection of ani-
mals used for scientific purposes. The CABIMER animal facil-
ity is an SPF-certified facility. Animal studies are reported in
compliance with the ARRIVE guidelines (Kilkenny et al.,
2010; McGrath and Lilley, 2015).
Mice were housed in individually ventilated cages
(Tecniplast, Buguggiate, Italy). Souralit plus 29/12 bedding
(Souralit, Gerona, Spain) was sterilized by autoclave and
added to each cage. Mice were group-housed (one to four
mice per cage), maintained on a 12 h light/dark cycle and
had access to rodent chow TD2914 (Envigo, Barcelona,
Spain) and water ad libitum.
For experiments in C57BL/6 mice, the offspring of five
pairs of mice were used (Janvier, Le Genest-Saint-Isle,
France). C57BL/6 mice are considered an optimal model to
study glucose homeostasis. Female mice were treated or not
with T4 starting at birth (s.c. injection of 18 ng·g1 of body
weight daily until weaning). After weaning, mice were sup-
plemented with T4 in drinking water (50 μg·mL1) (Spencer
and West, 1961; Weinstein et al., 1991; Weinstein et al.,
1994; Wistuba et al., 2007; Dong et al., 2010; Mysliwiec
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et al., 2011; Buras et al., 2014). Five untreated and six
T4-treated animals per group were injected with insulin
(0.75 U·kg1 of body weight) before killing. At 24 weeks of
age, animals were fasted for 16 h and killed by cervical
dislocation.
For experiments related to EAD, transgenic RIP-B7.1 mice
were used (Harlan et al., 1994; Mellado-Gil et al., 2016); these
mice were supplied by Dr Bernhard. O. Boehm (Ulm
University Medical Centre, Ulm, Germany). RIP-B7.1 mice
are a well-established model of EAD. T4 supplementation
(5 μg·mL1 of T4 in the drinking water) was started at 6 weeks
of age. EAD was triggered by intramuscular immunization at
8 weeks of age with 50 μg of pC1/ppins plasmid DNA
(1 μg·μL1) containing the preproinsulin II. At 11 weeks of
age, animals were killed by cervical dislocation. For experi-
ments related to chemically induced diabetes mellitus, STZ
was used following a previously published protocol (Verga
Falzacappa et al., 2011). Briefly, Thirty-four-week-old male
C57BL/6 mice were treated with T4 (5 μg·mL1 of T4 in the
drinking water). At 2 weeks of T4 treatment, experimental di-
abetes mellitus was triggered by two injections (one each day
for two consecutive days) of STZ (i.p., 150 mg·kg1), freshly
dissolved in 10 mM Na-citrate buffer (pH 4.5). Mice were
killed if circulating glucose levels were above 5 g·L1 for more
than 96 h.
Blinding, group size and randomization
The data analyst was blinded, whereas the operator was not
blind to the group assignment of animals. Mice were selected
from the pool eligible for inclusion in the study and were ran-
domly divided into the experimental groups (n = 26 un-
treated mice and n = 28 T4-treated mice for C57BL/6 mice;
n = 8 for the untreated group and n = 9 for the T4-terated
group for RIP-B7.1 mice; n = 9 for the untreated group and
n = 9 for the T4-treated group for STZ-treated C57BL/6 mice).
The number of biological replicates was similar (n untreated-
= n ± 1 T4-treated) in the different experiments, experimental
loss leading to greater differences in the number of biological
replicates within the different experimental groups occurred
in the experiments shown in Figures 1L, 2A, B, D, E and 5B
and Supporting Information Figure S5B. Quantitative analy-
sis of gene and protein expression was normalized to the
mean of the control group to facilitate representation and
understanding of the results. Quantitative-PCR data were
adjusted by using a reference gene (β-actin). The experiments
shown in Supporting Information Figure S1B–E were normal-
ized to glucose levels at time 0 (%) to determine whether
differences in metabolic test stem from differences in basal
glucose levels (Curtis et al., 2015). Measured glucose values
are shown in Figure 1A, E, G, I.
Immunohistochemistry
Dissected tissues were fixed in 4% paraformaldehyde.
Pancreatic sections (7 μm thick) were deparaffinized and
rehydrated. Antigen retrieval was performed in 0.01 M
sodium citrate buffer (pH 6). After 1 h blocking at room
temperature, sections were incubated overnight at 4°C with
primary antibodies (Supporting Information Table S1).
Subsequently, slides were incubated with secondary anti-
bodies (Supporting Information Table S1) for 1 h at room
temperature. For immunofluorescence, DAPI-nuclear
staining (Life Technologies,Carlsbad, USA) was used. For
diaminobenzidine staining, biotinylated secondary
antibodies were used (VectorLab, Burlingame, VT, USA).
Counterstaining with haematoxylin (Panreac, Barcelona,
Spain) was performed. Insulin staining was quantified using
Image J as mean value/pixel after background subtraction.
Thyroid and pituitary sections were stained with
haematoxylin and eosin (Panreac).
Semi-quantitative RT–PCR
Total RNAwas extracted from frozen skeletal muscle and liver
samples using the Easy-blue RNA extraction kit (Intron
Biotechnology, Gyeonggi-doQiagen, Korea). For islet experi-
ments, the RNeasy Micro Kit was used (Qiagen). CDNA was
synthesized using the Superscript II (Invitrogen, Carlsbad,
CA, USA). The RT-PCR was performed on individual cDNAs
using SYBR green (Roche). Primer sequences are presented
in Supporting Information Table S2. The mRNA expression
was calculated by the 2ΔΔCT method and normalized to the
expression of β-actin.
Western blot
Samples were lysed in radioimmunoprecipitation assay buffer
(20 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA,
1 mM EGTA, 1% NP-40, 1% sodium deoxycholate) with pro-
tease, phosphatase and deacetylase inhibitors P0044, P5725,
P8340 and SC-362323. Western blots were performed accord-
ing to standard methods, which involved incubation with a
primary antibody of interest, followed by incubation with a
horseradish peroxidase-conjugated secondary antibody
(Supporting Information Table S1). Blots were quantified
with ImageJ, and the bands of interest were normalized to
Ponceau S and/or GAPDH staining, as previously validated
(Bello et al., 2003).
In vivo insulin and glucose determinations
To determine glucose levels, blood samples were taken by
venepuncture using a Precision Xceed glucometer (Abbott,
Madrid, Spain) (Martin-Montalvo et al., 2013). Insulin was
measured in plasma using ELISA kits (Crystal Chem, Downers
Grove, IL, USA). For the oral glucose tolerance test (OGTT),
mice were fasted from 6 h at 10 a.m. and received an oral dose
of glucose (3 g·kg1) by gavage. For the intraperitoneal pyru-
vate tolerance test (IPPTT), mice were fasted for 6 h from
10 a.m. and received aninjection of sodium pyruvate (i.p., 2-
g·kg1) by gavage. For the insulin tolerance test (ITT), mice
were fasted for 3 h from 10 a.m. and were injected with insu-
lin (0.75 IU·kg1, i.p). For glucose determination during a
24 h fasting period, mice were fasted from 8 p.m.
Rotarod
Results from rotarod tests are presented as the time to fall
from an accelerating rotarod as previously described
(4–40 rpm over 5 min) (Mitchell et al., 2014). Mice were given
a 1 min habituation trial at 4 rpm on the day before the
experiment. Results shown are the averages of three trials
per mouse.
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Figure 1
T4 enhances glucose clearance in wild-type C57BL/6 mice. (A) Glucose concentration in blood after oral glucose load (OGTT). Age = 10 weeks.
n = 13 per group. (B) AUC of glucose levels during the OGTT. (C) Plasma levels of insulin after oral glucose load (OGTT). Age = 9 weeks. n = 7 un-
treated; n = 8 T4-treated. (D) AUC of insulin levels during OGTT curve. (E) Glucose concentration in blood after intraperitoneal pyruvate load
(IPPTT). Age = 8 weeks. n = 7 untreated; n = 8 T4-treated. (F) AUC of glucose levels during the IPPTT. (G) Glucose concentration in blood after
i.p. insulin injection (ITT). Age = 11 weeks. n = 12 untreated; n = 13 T4-treated. (H) AUC of glucose levels during the ITT. (I) Glucose concentration
in blood during a 24 h fasting period. Age = 12weeks. n = 7 untreated; n = 8 T4-treated. (J) AUC of glucose levels during the 24 h fasting period. (K)
Sixteen-hour fasting circulating insulin levels. Age = 12 weeks. n = 7 untreated; n = 8 T4-treated. (L) Percentage of glycated haemoglobin (HbA1c)
in blood. Age = 23 weeks. n = 9 untreated; n = 14 T4-treated. UT, untreated; T4, T4-treated. Data shown are the means ± SEM. *P < 0.05, signif-
icantly different from untreated mice; two tailed Student’s t-test.
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Islet isolation, culture and glucose-stimulated
insulin secretion (GSIS)
Islets from 24-week-old female wild-type C57BL/6 mice were
isolated by intraductal collagenase perfusion as previously
described (Jimenez-Moreno et al., 2015). For semi-
quantitative RT-PCR purposes, pancreatic islets were proc-
essed upon collection. For insulin determination, similar
amounts of islet equivalents (10 in each technical replicate)
were lysed in HCl-ethanol (5% HCl in 96° ethanol) for 16 h
at 4°C. For GSIS studies, islets were cultured overnight in
RPMI-1640 medium (2 g·L1 glucose). Then, groups of 10 is-
lets were washed in 500 μL of Krebs-Ringer bicarbonate-
HEPES buffer (KRBH) (140 mM NaCl, 3.6 mM KCl, 0.5 mM
NaH2PO4, 0.5 mM MgSO4, 1.5 mM CaCl2, 2 mM NaHCO3,
10 mM HEPES, 0.1% BSA). Subsequently, fresh KRBH supple-
mented with 2.8 mM glucose was added, and islets were incu-
bated for 30 min. Next, buffer was harvested (“2.8 mM
insulin secretion”), and 500 μL of KRBH supplemented with
22 mM glucose was added. Islets were incubated for an addi-
tional 30 min at 37°C, and then, buffer was harvested
(“22 mM insulin secretion”). Following the incubations,
islets were lysed with HCl-ethanol to obtain the insulin
content. In all cases, insulin was measured using ELISA kits
(Crystal Chem).
T4 determination
T4 concentration in serum was determined using a T4
commercial kit (MP Biomedicals, Santa Ana,CA, USA).
Homeostasis model assessment of insulin
resistance (HOMA-IR)
Insulin resistance was estimated using the HOMA2 Calcula-
tor available from the Oxford website (Levy et al., 1998).
Glycated haemoglobin
HbA1c levels were determined in blood samples according to
the manufacturer’s protocol (CrystalChem).
α-glycoprotein subunit (α-GSU) determination
The α-GSU of pituitary hormones was determined using a
commercially available kit following the instructions of the
manufacturer (Abbexa, Cambridge, United Kingdom).
TUNEL assay
For the TUNEL staining, the In Situ Cell Death Detection Kit,
Fluorescein, was used using proteinase K (Sigma-Aldrich, St.
Louis, MO, USA).
Data and statistical analysis
The data and statistical analysis in this study comply with the
recommendations on experimental design and analysis in
pharmacology (Curtis et al., 2015). Data are shown as means
± SEM. Statistical significance was calculated using unpaired,
two-tailed Student’s t-test as two experimental groups (un-
treated and T4-treated) were compared (Excel 2007,
Microsoft). The Mann–Whitney rank sum test was applied
when data were normalized to basal glucose levels (SigmaPlot
Figure 2
T4 reduces body weight and increases rotarod performance. (A) Body weight. Age = 24 weeks. n = 12 untreated; n = 18 T4-treated. (B) Time to fall
from an accelerating rotarod. Age = 21 weeks. n = 12 untreated; n = 18 T4-treated. (C) Energy intake. Age = 8 weeks. n = 7 untreated; n = 8 T4-
treated. (D) Organs weight. Age = 24 weeks. For liver, heart, WAT, BAT, kidney, brain and spleen n = 12 untreated; n = 18 T4-treated. For thyroid
and pituitary n = 6 untreated; n = 7 T4-treated. (E) Organs weight divided by body weight. Age = 24 weeks. For liver, heart, WAT, BAT, kidney,
brain and spleen n = 12 untreated; n = 18 T4-treated. For thyroid and pituitary n = 6 untreated; n = 7. UT, untreated; T4, T4-treated. Data shown
are the means ± SEM. *P < 0.05, significantly different from untreated mice; two tailed Student’s t-test.
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12.5, Softonic, Barcelona, Spain). A LogRank statistical test
was applied for survival curves (SigmaPlot 12.5, Softonic).
For all analyses, P < 0.05 was considered statistically
significant.
Materials
T4, glucose, sodium pyruvate, STZ and the enzyme inhibitors
P0044, P5725 and P8340 were purchased from
Sigma-Aldrich. SC-362323 was supplied by Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Unless otherwise
stated, other reagents were purchased from Sigma-Aldrich.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.
org, the common portal for data from the IUPHAR/BPS Guide
to PHARMACOLOGY (Southan et al., 2016), and are perma-
nently archived in the Concise Guide to PHARMACOLOGY
2015/16 (Alexander et al., 2015a, b).
Results
T4 supplementation enhances glucose
clearance in healthy C57BL/6 mice
In order to determine the metabolic effects of T4 supplemen-
tation in mice, we treated female wild-type C57BL/6 mice
with T4 from postnatal day 1 (18 ng·g1 of body
weight·day1; s.c. injections) until weaning, followed by T4
administration in the drinking water (50 μg·mL1 ad libitum)
until 24 weeks of age, when mice were killed (Spencer and
West, 1961; Weinstein et al., 1991; Weinstein et al., 1994;
Wistuba et al., 2007; Dong et al., 2010; Mysliwiec et al.,
2011; Buras et al., 2014). Analysis of serum samples indicated
that T4 concentration was increased in T4-treated mice
(Supporting Information Figure S1A).
Glucose tolerance was enhanced by T4 supplementation
as determined by the lower AUC in an OGTT, even when glu-
cose levels were expressed as the percentage of basal glucose
(Figure 1A–B and Supporting Information Figure S1B). Re-
markably, basal circulating insulin levels were higher in T4-
treated mice in the OGTT, while levels were similar to those
of untreated animals at 15–30 min post-glucose load
(Figure 1C–D). Glucose levels were also lower at all time
points during an IPPTT, indicating that hepatic gluconeogen-
esis, although significant (e.g. significant increase in glucose
levels promoted by pyruvate administration), was not able
to normalize glucose levels in T4-treated mice (Figure 1E–F
and Supporting Information Figure S1C). In order to
determine whether insulin sensitivity was affected, animals
were challenged with an ITT. Circulating glucose levels were
significantly lower in T4-treated mice at any time point dur-
ing the ITT, although these differences were related to the
lower basal glucose levels, as shown by the lack of significant
differences when glucose levels were expressed as the
percentage of basal glucose (Figure 1G–H and Supporting
Information Figure S1D). We next measured circulating glu-
cose levels during a 24 h fasting period. Glucose levels were
significantly reduced in T4-treated mice at any time point
during the experiment (Figure 1I–J and Supporting
Information Figure S1E). Consistent with the high insulin
levels determined during the basal time of the OGTT (6 h
fasting), circulating insulin levels were also higher at 16 h of
fasting (Figure 1K). Interestingly, despite the lower glucose
levels during the ITT, a trend towards increased HOMA-IR
was found in T4-treated mice (P = 0.08 in two-tailed Student’s
t-test) (Supporting Information Figure S1F). Supporting the
long-term reduction of glucose levels in mice treated with
T4, the percentage of glycated haemoglobin was lower (note
that the untreated group is within the healthy physiological
range; ~5%) (Figure 1L). Taken together, these results indicate
that T4 supplementation markedly reduced the glucose
concentration in blood, which was associated with increased
circulating insulin.
We next assessed the effects of T4 supplementation on
whole body physiology. Body weight was slightly reduced in
T4-treated mice (Figure 2A). Rotarod performance was im-
proved by T4, indicating the overall healthy status of the
animals (Figure 2B). Interestingly, energy intake was similar
in both experimental groups, even when corrected for
changes in body weight (Figure 2C and Supporting
Information Figure S2A). Noticeably, at killing, gonadal white
adipose tissue (WAT) and thyroid weights were reduced in T4-
treated mice (Figure 2D–E). In contrast, several organs, includ-
ing the brown adipose tissue (BAT), were heavier in T4-treated
mice, even when corrected for body weight (Figure 2D–E).
Histological examinations of the thyroid and the pituitary
revealed no major macroscopic changes in tissue morphology
(Supporting Information Figure S2B). Thyroid sections of T4-
treated mice had a slightly less intense staining of the colloid
in the lumen of the follicle, suggestive of reduced endogenous
thyroglobulin content. In addition, serum concentration of
the α-GSU of pituitary hormones was concomitantly reduced
in T4-treated mice (Supporting Information Figure S2C).
T4 supplementation enhances beta cell
turnover and increases beta cell insulin content
T4-mediated increases in circulating insulin levels implied ef-
fects of the hormone on pancreatic islets. Accordingly, insu-
lin staining was greater while glucagon was unaffected, in
pancreatic sections of T4-treated mice, compared with con-
trol mice (Figure 3A–C). Increased insulin content in the islets
of T4-treated mice was confirmed by ELISA determination
using freshly isolated pancreatic islets (Figure 3D). Determi-
nations of mRNA expression by real-time PCR in pancreatic
islets from T4-treated and untreated mice indicated that Akt
and glucokinase (GK) expression were also significantly in-
creased in the islets of T4-treated mice, whereas no changes
were observed in MAFA and FOXO1 gene expression
(Supporting Information Figure S3A). Immunohistochemical
analysis confirmed that GK expression was increased, while
the subcellular localization of FOXO1 and MAFA remained
unaffected in T4-treated mice (Figure 3A, E and Supporting
Information Figure S3B–C) (Kikuchi et al., 2012; Aguayo-
Mazzucato et al., 2013). Remarkably, GSIS assays performed
in islets isolated from T4-treated mice showed that insulin
secretion was increased, when islets were cultured under
low glucose (2.8 mM) conditions (Figure 3F). However, differ-
ences in insulin secretion under high glucose (22 mM) condi-
tions did not reach statistical significance. Interestingly, beta
cell proliferation, defined here as the percentage of Ki67
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positive cells within the insulin-expressing cell population,
was increased in T4-treated animals, compared with that in
untreated mice (Figure 3G–I). As opposed to beta cells, non-
insulin-expressing pancreatic endocrine cells showed similar
proliferation (percentage of Ki67 positive cells in islet resid-
ing non-insulin expressing cells) (Figure 3G, I). Remarkably,
the percentage of apoptotic cells, determined by TUNEL
staining, was also increased by T4 administration, specifically
in the beta cell population (Figure 3J–L).
T4 induces the activation of IRS1-Akt
signalling in insulin-target tissues
In order to determine the underlyingmechanism of T4 action
in insulin-target tissues, we measured mRNA expression by
semi-quantitative real-time PCR. We found that the tran-
script levels of several members of the insulin signalling path-
way were over-expressed in skeletal muscle and in the liver of
T4-treated mice (Figure 4A–B). Consistent with these data,
protein extracts of both T4-treated liver and skeletal muscle,
Figure 3
T4 increases insulin expression and enhances the proliferation of pancreatic beta cells. (A) Representative images of insulin (INS), glucagon (GLC) and
glucokinase (GK) staining in pancreas frommice treated or not with T4. Diaminobenzidine staining followed by haematoxylin counterstaining. Scale
bar = 50 μm. INS; n = 5 per group. GLC; n = 5 per group. GK; n = 6 per group. (B) Quantification of insulin staining (mean intensity). (C) Quantification
of glucagon staining (mean intensity). (D) Determination of pancreatic islet insulin content by ELISA. n = 6 untreated, n = 7 T4-treated. (E) Quantifi-
cation of glucokinase staining (mean intensity). (F) Determination of GSIS. n = 6 untreated, n = 7 T4-treated. (G) Representative images of Ki67
and insulin staining in pancreases from mice treated or not with T4. Immunofluorescence followed by DAPI staining. Scale bar, 50 μm. n = 5 per
group. (H) Percentage of Ki67+-Insulin+ cells over total insulin+ cells. (I) Percentage of Ki67+-Insulin cells over total insulin cells residing in pancreatic
islets. (J) Representative images of TUNEL and insulin staining in pancreas from mice treated or not with T4. Immunofluorescence followed by DAPI
staining. Scale bar = 50 μm. n = 5 per group. (K) Percentage of TUNEL+-Insulin+ cells over total insulin+ cells. (L) Percentage of TUNEL+-Insulin cells
over total insulin cells residing in pancreatic islets. UT, untreated; T4, T4-treated. Arrows indicate representative positive staining. Data shown are the
means ± SEM. *P < 0.05 significantly different from untreated mice; two tailed Student’s t-test.
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exhibited increased levels of total Akt, FOXO1 and glycogen
synthase kinase 3β (GSK3-β) (Figure 4C–E). Moreover, the
phosphorylated isoforms of several members of the insulin
signalling such as pTyr632-IRS1, pSer473-Akt and
pSer256-FOXO1 were significantly increased in both, skeletal
muscle and liver lysates isolated from T4-treated mice
(Figure 4C–E). Remarkably, ERK phosphorylation at Thr202/
Tyr204 in skeletal muscle was reduced in T4-treated samples,
indicating the specificity of the effect of T4 supplementation
in the IRS1-Akt branch of insulin signalling. In order to
determine whether T4 supplementation could also increase
the maximal activation of the IRS1-AKT axis of insulin signal-
ling, a cohort of mice was treated with insulin (0.75 UI·kg1
of body weight) 15 min before killing (Figure 4F–H and
Supporting Information Figure S4A). No differences on
insulin-stimulated phosphorylation of Ser473-Akt levels were
found, indicating that maximal insulin-induced Akt activa-
tion was not affected by T4-treatment. T4 treatment also
modulated the expression of genes involved in glucose utili-
zation (e.g. increased glycolysis and gluconeogenesis) and
Figure 4
T4 activates insulin signalling in skeletal muscle and liver. (A) Determination of mRNA levels of several members of the insulin pathway in the skel-
etal muscle of mice treated or not with T4. Mice were fasted for 16 h before they were killed. Values were normalized to untreatedmice. IR-β; n = 5.
IRS1; n = 6. Akt; n = 5. FOXO1; n = 6. GSK3-β; n = 6. ERK; n = 6. (B) Determination of mRNA levels of several members of the insulin pathway in the
liver of mice treated or not with T4. Mice were fasted for 16 h before they were killed. Values were normalized to untreated mice. IR-β; n = 6 un-
treated, n = 5 T4-treated. IRS1; n = 6 untreated, n = 5 T4-treated. AKT; n = 6. FOXO1; n = 6 untreated, n = 5 T4-treated. GSK3-β; n = 5. ERK; n = 6
untreated, n = 5 T4-treated. (C) Western blots indicating activation of insulin signalling in the skeletal muscle and the liver of T4-treatedmice. Mice
were fasted for 16 h before they were killed. n = 5 per group. (D) Densitometric analysis of the Western blots using skeletal muscle extracts shown
in panel C. Values were normalized to untreated mice. (E) Densitometric analysis of the Western blots using liver extracts shown in panel C. Values
were normalized to untreated mice. (F) Representative images of Western blots showing the maximal activation of insulin signalling in T4-treated
and untreatedmice challenged with an insulin injection (0.75 U·kg1 of body weight) 15min prior euthanization. Mice were fasted for 16 h before
they were killed. (G) Densitometric analysis of the Western blots using skeletal muscle extracts shown in Supporting Information Figure S4A. n = 5
untreated, n = 6 T4-treated. Values were normalized to untreated mice. (H) Densitometric analysis of the Western blots using liver extracts shown
in Supporting Information Figure S4A. n = 5 untreated, n = 6 T4-treated. Values were normalized to untreatedmice. UT, untreated; T4, T4-treated.
Data shown are the means ± SEM. *P < 0.05, significantly different from untreated mice; two tailed Student’s t-test.
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mitochondrial uncoupling, in both skeletal muscle and liver
(Supporting Information Figure S4B–C). Taken together,
these results suggest that high circulating levels of insulin,
induced by T4, lead to sustained activation of IRS1-Akt
signalling and subsequently increased glucose uptake in
insulin target tissues, to maintain their high metabolic
requirements. Supporting these data, a significant increase
of pThr172-AMPK, which indicates a starvation-like status,
was found in extracts isolated from T4-treated skeletal mus-
cles (Supporting Information Figure S4D–E). Noteworthy,
such a change was not detected in liver samples, suggesting
that energy metabolism is preferentially affected in tissues
with higher metabolic demands (Supporting Information
Figure S4D, F).
T4 supplementation improves glycaemic
control in the RIP-B7.1 model of EAD and
increases survival in STZ-treated mice
Given the effects of T4 supplementation in the promotion of
beta cell proliferation and the increase of circulating insulin
levels in healthy C57BL/6 mice, we next sought to determine
whether T4 supplementation could blunt the onset of T1DM
in the RIP-B7.1model of EAD (Harlan et al., 1994;Mellado-Gil
et al., 2016). To this end, RIP-B7.1 mice were treated with T4,
(5 μg·mL1 in drinking water) starting at 6 weeks of age.
RIP-B7.1 mice were immunized at 8 weeks of age to trigger
the autoimmune attack on the beta cells. Assay of circulating
T4 levels revealed a significant increase in T4-treated RIP-B7.1
immunized mice when compared to untreated RIP-B7.1 im-
munized mice (Supporting Information Figure S5A).
Noticeably, T4-treated immunized RIP-B7.1 mice gained
weight over the course of the experiment, while control
(untreated) immunized RIP-B7.1 mice reached a plateau
(Figure 5A). Thus, body weights were significantly different
from week 4 of T4-treatment. Similar to healthy wild-type
C57BL/6 mice (Figure 2D–E), the weight of several organs,
including the BAT, was higher at the end of the experiment
(5 weeks of T4-treatment; 11 weeks of age) (Figure 5B).
However, differences on the weight of gonadal WAT were
not apparent, even when corrected for body weight
(Figure 5B and Supporting Information Figure S5B).
In order to determine the effect of T4 supplementation in
the pathogenesis of EAD, several metabolic tests were per-
formed. An OGTT performed 2 weeks post-immunization re-
vealed enhanced glucose clearance in T4-treated immunized
RIP-B7.1 mice (Figure 5C–D). An ITT performed 3 weeks
post-immunization indicated that circulating glucose was
significantly lower in T4-treated immunized RIP-B7.1 mice
at any time point during the experiment (Figure 5E–F).
However, these differences seem to stem from the lower basal
glucose levels in T4-treated RIP-B7.1 immunized mice. Post-
prandial glucose determination revealed that, while
untreated immunized RIP-B7.1 animals developed
hyperglycaemia at 5 weeks of treatment (3 weeks post-
immunization), T4-treated immunized RIP-B7.1 mice
remained normoglycaemic (Figure 5G). Remarkably, post-
prandial circulating insulin was dramatically increased in
T4-treated RIP-B7.1 immunized mice, which was associated
with increased phosphorylation of the IRS1 at Tyr632, in the
liver (Figure 5H and Supporting Information Figure S5C–E).
In order to determine whether T4 supplementation could
improve glucoregulation in a different mouse model of
experimental diabetes, STZ chemically induced diabetes
mellitus was used. To this end, male wild-type C57BL/6 mice
were treated with T4 (5 μg·mL1 in the drinking water),
starting 2 weeks before injection of STZ (Verga Falzacappa
et al., 2011). The average survival of control STZ-treated mice
was 8 days, whereas the T4-treated group achieved a mean
survival of 34 days, including some mice that survived STZ
(Figure 5I; P < 0.05, χ2 = 7,689). Postprandial glucose levels
showed a trend towards reduced glycaemia in T4-treatedmice
(Figure 5J). Taken together, our results indicate that treatment
with T4 delayed the onset of T1DM in the RIP-B7.1 model of
EAD and increased survival in STZ-induced experimental dia-
betes mellitus.
Immunohistochemical analyses were performed in order
to determine the underlying effects of T4 supplementation
on the pancreas of immunized RIP-B7.1 mice. Although both
immunized untreated and T4-treated RIP-B7.1mice displayed
a similar level of lymphocyte infiltration, T4-treated mice
exhibited a marked increase in insulin staining with no
significant variation in glucagon staining (Figure 6A–C and
Figure S6A–B). We next investigated whether T4 could also
increase the proliferation of beta cells in the RIP-B7.1 model
of experimental T1DM. Interestingly, the abundance of
islet-residing Ki67 positive cells was increased in immunized
RIP-B7.1 mice when compared to healthy C57BL/6 mice,
indicating that islet-residing immune cells and/or pancre-
atic endocrine cells proliferate under the immune attack
(Figures 3D and 6D). Nonetheless, T4-treated immunized
RIP-B7.1 mice exhibited a marked increase in proliferating
beta cells when compared to untreated immunized RIP-B7.1
mice (Figure 6D–E). As expected, the immune attack
increased the percentage of apoptotic beta cells in both,
T4-treated and untreated immunized RIP-B7.1 mice
(Figures 3G–H and 6F–G). However, no differences were
observed between T4-treated and untreated immunized
RIP-B7.1 mice. These results suggest that increased beta cell
proliferation might be the underlying mechanism by which
T4 blunts the onset of experimental T1DM in mice.
Discussion
Supplementation with THs provides undeniably positive
benefits for metabolic health, attenuating hyperglycaemia
in STZ-treated and leptin-receptor deficient mice (Lin and
Sun, 2011; Verga Falzacappa et al., 2011; Shoemaker et al.,
2012). Therefore, THs or their analogues could represent a
promising therapeutic approach for the treatment of meta-
bolic complications. However, the detrimental effects of high
circulating levels of THs (thyrotoxicosis) are well known. Pa-
tients suffering thyrotoxicosis exhibit a pleiotropy of symp-
toms that include life-threatening disorders such as
cardiovascular collapse and thyroid storm, among others
(Bahn et al., 2011; Garmendia Madariaga et al., 2014). These
risks have precluded the investigation of potential therapies
based on the use of THs to treat metabolic disorders.
In this report, we show that a level of T4 supplementation
modulates the thyroid-pituitary axis, increases insulin con-
centration in blood and enhances glucose clearance, while
maintaining an overall healthy status in wild-type C57BL/6
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Figure 5
T4 blunts the onset of T1DM in the RIP-B7.1 model of EAD and increases survival in STZ-challenged C57BL/6 mice. (A) Body weight of RIP-B7.1
mice. n = 8 untreated; n = 9 T4-treated. (B) Organs weight of RIP-B7.1 mice. n = 6 untreated; n = 9 T4-treated. (C) Glucose concentration in blood
during an OGTT at 4 weeks of T4-treatment of RIP-B7.1 mice. n = 8 untreated; n = 9 T4-treated. (D) AUC of glucose levels during the OGTT. (E)
Glucose concentration in blood during and ITT at 5 weeks of T4-treatment of RIP-B7.1 mice. n = 7 untreated; n = 9 T4-treated. (F) AUC of glucose
levels during the ITT. (G) Postprandial glucose concentration in blood on RIP-B7.1 mice. n = 8 untreated; n = 9 T4-treated. (H) Circulating insulin
levels in fed conditions. n = 7 untreated; n = 8 T4-treated. (I) Survival of C57BL/6 mice challenged with STZ. n = 9 per group. (J) Postprandial glu-
cose concentration in blood from C57BL/6 mice challenged with STZ. Alive animals were included (see Figure 5I for n in each time point). UT,
untreated; T4, T4-treated; IMM, immunization. Arrows indicate the time of immunization. Data shown are the means ± SEM *P < 0.05, signifi-
cantly different from untreated mice; two tailed Student’s t-test. A LogRank survival test was applied to survival curves.
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mice. Our results indicate that T4 supplementation increases
insulin content in pancreatic beta cells. The mechanism
underlying the increase in insulin content may rely on a
TH-dependent regulation of expression of the transcription
factor MAFA. Previous reports have demonstrated that the
T3-TR complex induces MAFA transcription through direct
binding to TH response elements located in the MAFA pro-
moter (Aguayo-Mazzucato et al., 2013). Moreover, MAFA is
known to bind to the insulin promoter, inducing insulin ex-
pression (Olbrot et al., 2002; Matsuoka et al., 2004), providing
a plausible molecular mechanism by which T4
supplementation enhances insulin expression in pancreatic
beta cells. However, as opposed to a previous study using
7-day-old mice, our immunohistochemical analysis in pan-
creatic sections of adult mice indicated that MAFA is predom-
inantly located in the nucleus of pancreatic beta cells and T4
supplementation does not further promote the nuclear local-
ization of MAFA, suggesting that the presence/absence of
MAFA in the nucleus of pancreatic beta cells does not control
insulin expression in adulthood (Aguayo-Mazzucato et al.,
2013). Remarkably, islets isolated from mice treated with T4
exhibited a marked increase in GK gene and protein
Figure 6
T4 increases insulin expression and enhances beta cell proliferation in the RIP-B7.1 model of EAD. (A) Representative images of glucagon (GLC)
and insulin (INS) staining in pancreases from immunized RIP-B7.1 mice, with or without T4. Diaminobenzidine staining followed by haematoxylin
counterstaining. Scale bar, 50 μm. n = 6 untreated; n = 5 T4-treated. (B) Quantification of insulin staining (mean intensity). (C) Quantification of
glucagon staining (mean intensity). (D) Representative images of Ki67 and insulin staining in pancreas from immunized RIP-B7.1 mice, with or
without T4. Immunofluorescence followed by DAPI staining. Scale bar = 50 μm. n = 5 untreated; n = 5 T4-treated. (E) Percentage of Ki67+-Insulin+
cells over total insulin+ cells. (F) Representative images of TUNEL and insulin staining in pancreases from immunized RIP-B7.1mice, with or without
T4. Immunofluorescence followed by DAPI staining. Scale bar = 50 μm. n = 5 per group. (G) TUNEL Insulin+ cells, as % total insulin+ cells. UT, un-
treated; T4, T4-treated. Arrows indicate representative positive staining. Data shown are the means ± SEM. *P < 0.05, significantly different from
untreated mice; two tailed Student’s t-test.
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expression. Increased GK expression might contribute to the
increased insulin secretion under fasting conditions, as ob-
served in GSIS tests, because increased GK activity has been
previously shown to lower the glucose threshold that stimu-
lates insulin secretion (Weinhaus et al., 2007; Kassem et al.,
2010). Increased circulating insulin activates the IRS1-Akt
axis of insulin signalling, suggesting that glucose uptake is in-
creased in insulin target tissues. T4 is known to increase the
basal metabolic rate by inducing the expression of several mi-
tochondrial uncoupling proteins, such as UCP2 (Lanni et al.,
2003; Ramadan et al., 2011). As a result of increased mito-
chondrial uncoupling, mitochondrial efficiency is lower (de-
fined here as the amount of nutrients used to produce one
molecule of ATP) and heat production is increased (note that
BAT weight in T4-treated animals was increased). In order to
adapt to this situation, T4-treated cells require higher
amounts of nutrients to maintain their metabolism. There-
fore, it is tempting to speculate that insulin expression and
secretion in pancreatic islets under fasting conditions is en-
hanced in mice treated with T4 to allow nutrient uptake by
insulin-target tissues. Supporting this hypothesis, we found
that, as opposed to untreated animals, in which a significant
increase in insulin levels was promoted by a glucose bolus, in-
sulin levels in T4-treated mice were already maximal before
glucose load, suggesting that the insulin secretion machinery
is already active. Moreover, our results also indicate that beta
cell proliferation and apoptosis are specifically increased in
mice treated with T4. Remarkably, increased GK activity has
been associated to increased beta cell proliferation and apo-
ptosis, suggesting that the increase in GK expression induced
by T4 administration might contribute to the enhancement
of beta cell turnover, promoting the existence of a highly
insulin-expressing beta cell population, which actively se-
cretes insulin into the circulation under basal conditions
(Kassem et al., 2000; Kassem et al., 2010). Given the age of
the animals, the length of the treatment (~24 weeks at the
end of th experiment, which represents ~25% of an average
lifespan of this mouse strain) and the mouse chow used in
this study (a standard healthy diet), we do not believe that
the increase of insulin expression in pancreatic beta cells
found in T4-treated mice was indicative of over-stimulation
of beta cells, as found in pre-diabetic individuals (Martin-
Montalvo et al., 2013). The analysis of insulin-target tissues
indicates that the higher insulin concentration in blood is
able to activate the IRS1-Akt axis of the insulin signalling
pathway. Previous reports have indicated that T4 exerts
non-genomic effects by activating specifically PI3K and its
downstream targets (Lin and Sun, 2011). Although we cannot
exclude that non-genomic T4 actions contribute to the acti-
vation of PI3K and its downstream targets in vivo, we found
that T4 supplementation activates insulin signalling as early
as the level of IRS1, as shown by the increase in pTyr632-
IRS1 in skeletal muscles and in livers of T4-treated mice. Re-
markably, we found that both T4-supplemented and control
mice treated with insulin at the end of the experiment,
reached the same level of Akt activation (pSer473-Akt levels).
Therefore, our results suggest that high insulin levels per se
are responsible for T4-mediated AKT activation.
In this report, we also show that T4 supplementation
blunts the onset of T1DM using the RIP-B7.1 model of EAD
and increases survival in STZ-induced experimental diabetes
in wild-type C57BL/6mice. Previous research has determined
that during the onset of T1DM, beta cell proliferation is in-
creased in an attempt to compensate beta cell loss (Willcox
et al., 2010). We observed that, although immune infiltration
and the percentage of apoptotic beta cells is similarly
augmented in untreated or T4-treated pancreases during the
immune attack, beta cell proliferation is remarkably
increased in T4-treated RIP-B7.1 mice. This process presum-
ably leads to compensation for beta cell loss, allowing the
production and secretion of enough insulin to maintain
normoglycaemia. Our experimental design initiated T4 sup-
plementation 2 weeks prior to induction of diabetes mellitus
(immunization or STZ treatment), as these research models
(EAD and STZ) are very aggressive and a significant percent-
age of mice die within the first 2 weeks after the induction
of diabetes. In order to evaluate a possible therapeutic benefit,
experiments aiming to determine whether T4 supplementa-
tion after the onset of T1DM could improve glucoregulation
would be required. Our results indicate that interventions
based on the use of THs or thyromimetics could open novel
venues for the treatment of T1DM.Whereas novel treatments
including the use of T4 supplementation might not be opti-
mal for the treatment of metabolic diseases due to side effects,
certain newly developed thyromimetics could affect specific
cell types or organs that could benefit from these actions of
THs, resulting in the improvement of metabolic homeostasis,
while avoiding side effects (Shoemaker et al., 2012; Coppola
et al., 2014; Finan et al., 2016). Although the profound sys-
temic effects of the T4-administration in mice suggest that
THs and thyromimetics might be useful in ameliorating the
abnormal metabolism in diabetic patients, the identification
of the underlying mechanisms that are critical for the ob-
served improvements on glucose control and potential
long-term toxic effects must be addressed before results in
mice could be extrapolated to humans.
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Figure S1 Glucose levels in metabolic test expressed as per-
centage of basal glucose. (A) Circulating T4 levels in fed con-
ditions. Age = 13 weeks. n = 7 untreated; n = 8 T4-treated. (B)
Glucose concentration in blood during the OGTT expressed
as the percentage of basal (time 0) glucose. n = 13 per group.
(C) Glucose concentration in blood during the IPPTT
expressed as the percentage of basal glucose. n = 7 un-
treated; n = 8 T4-treated. (D) Glucose concentration in blood
during the ITT expressed as the percentage of basal glucose.
n = 12 untreated; n = 13 T4-treated. (E) Glucose concentra-
tion in blood during a 24-hour fasting period expressed as
the percentage of basal glucose. n = 7 untreated; n = 8 T4-
treated. (F) Homeostatic assessment of insulin resistance
(HOMA-IR) index. Age = 12 weeks. n = 7 untreated; n = 8
T4-treated. UT: Untreated; T4: T4-treated. Data are repre-
sented as the mean ± SEM. * P < 0.05 significantly different
from untreated mice. A two tailed t-test was applied to
panels A and F. A Mann–Whitney Rank Sum test was ap-
plied to panels B-E.
Figure S2 Energy intake and histology of the thyroid and the
pituitary of in T4-treated mice. (A) Energy intake divided by
body weight. n = 7 untreated; n = 8 T4-treated. (B) Representa-
tive images of the histological analysis o the thyroid and pitu-
itary of T4-treated and untreated mice. Thyroid; n = 6
untreated; n = 7 T4-treated. Pituitary; n = 5 untreated; n = 6
T4-treated. (C) Determination of the α-GSU of pituitary hor-
mones in the serum of T4-treated and untreated mice. n = 7
untreated; n = 8 T4-treated. UT: Untreated; T4: T4-treated.
Data are represented as the mean ± SEM. * P < 0.05 signifi-
cantly different from untreated mice (two tailed t-test).
Figure S3 The subcellular localization of MAFA and FOXO1
is not affected by T4 supplementation. (A) Pancreatic islets
were isolated from animals treated or not with T4. Determi-
nation of messenger RNA (mRNA) levels of genes involved
in pancreatic islet metabolism. Values were normalized to is-
lets isolated from untreated mice. n = 6 untreated; n = 5 T4-
treated. (B) Representative images of MAFA and insulin
(INS) immunofluorescence staining in pancreases from mice
treated or not with T4. Scale bar = 50 μm. n = 5 per group.
(C) Representative images of FOXO1 and INS immunofluo-
rescence staining in pancreases frommice treated or not with
T4. Scale bar = 50 μm. n = 5 per group. UT: 2 Untreated; T3: T3-
treated; T4: T4-treated. Data are represented as the mean ±-
SEM. * P < 0.05 significantly different from untreated mice
(two tailed t-test).
Figure S4 T4 induces a starvation-like state in the skeletal
muscle. (A) Western blots indicating activation of AKT in
the skeletal muscle and the liver of T4-treated mice. Mice
were fasted for 16 hours and then injected with insulin
(0.75 UI.kg-1 of body weight) 15 minutes before the end of
the experiment. n = 5 untreated; n = 6 T4-treated. (B) Determi-
nation of mRNA levels of genes involved in energy metabo-
lism in the skeletal muscle of mice treated or not with T4.
Values were normalized to untreated mice. GLUT2; n = 5 un-
treated, n = 6 T4-treated. GK; n = 5 untreated, n = 6 T4-treated.
G6Pase; n = 5 untreated, n = 6 T4-treated. LPK; n = 5 untreated,
n = 6 T4-treated. PEPCK; n = 5 untreated, n = 6 T4-treated.
GAPDH; n = 6. LDH; n = 5 untreated, n = 6 T4-treated. PGC1α;
n = 6. PGC1β; n = 6. UCP2; n = 5. SREBP1c; n = 5 untreated,
n = 6 T4-treated. (C) Determination of mRNA levels of genes
involved in energy metabolism in the liver of mice treated
or not with T4. Values were normalized to untreated mice.
GLUT2; n = 5 untreated, n = 6 T4-treated. GK; n = 5. G6Pase;
n = 5 untreated, n = 6 T4-treated. LPK; n = 5 untreated, n = 6
T4-treated. PEPCK; n = 5 untreated, n = 6 T4-treated. GAPDH;
n = 6 untreated, n = 5 T4-treated. LDH; n = 5. PGC1α; n = 5 un-
treated, n = 6 T4-treated. PGC1β; n = 6. UCP2; n = 6 untreated,
n = 5 T4-treated. SREBP1c; n = 6 untreated, n = 5 T4-treated.
(D) Western blots indicating activation of AMPK in the skele-
tal muscle and the liver of T4-treated mice. Mice were fasted
for 16 hours prior euthanization. n = 5 per group. (E) Densito-
metric analysis of the western blots using skeletal muscle ex-
tracts shown in Supporting Information Figure S4D. Values
were normalized to untreated mice. (F) Densitometric analy-
sis of the western blots using liver extracts shown in
Supporting Information Figure S4D. Values were normalized
to untreated mice. UT: Untreated; T4: T4-treated. Data are
represented as the mean ± SEM. * P < 0.05 significantly differ-
ent from untreated mice (two tailed t-test).
Figure S5 T4 supplementation increased circulating T4, al-
ters organs weight andmodulates insulin signalling in immu-
nized RIP-B7.1 mice. (A) Circulating T4 levels in fed
conditions. n = 9 untreated; n = 8 T4-treated. (B) Organs
weight divided by body weight. n = 6 untreated; n = 9 T4-
treated. (C) Western blots showing the amount of phospho-
tyrosine 632 IRS1, total IRS1 and GAPDH, used as loading
control, in the skeletal muscle and the liver of T4-treated
mice. Skeletal muscle n = 6 untreated, n = 5 T4-treated. Liver
n = 6 per group. (D) Densitometric analysis of the western
blots using skeletal muscle extracts shown in Supporting 3 In-
formation Figure S5C. Values were normalized to untreated
mice. (E) Densitometric analysis of the western blots using
liver extracts shown in Supporting Information Figure S5C.
Values were normalized to untreated mice. UT: Untreated;
T4: T4-treated. Data are represented as the mean ± SEM. *
P < 0.05 significantly different from untreated mice (two
tailed t-test).
T4 improves glucose homeostasis in mice BJP
British Journal of Pharmacology (2017) 174 3795–3810 3809
Figure S6 T4-treated and untreated immunized RIP-B7.1
mice show similar degree of insulitis. (A) Representative im-
ages of immune infiltrations in T4-treated and untreated im-
munized RIP-B7.1 mice. (B) Insulitis was scored as grade 0–4
according to the percentage of infiltrated islet area (0: 0%; 1:
<10%; 2: >10% and <55%; 3: >55% and <75%; 4: >75%).
Scale bar = 50 μm. n = 5 per group. UT: Untreated; T4: T4-
treated. Data are represented as the mean ± SEM. * P < 0.05
significantly different from untreated mice (two tailed t-test).
Table S1 Antibodies used in this study.
Table S2 Primer pair sequences used for quantitative RT-PCR
analysis.
BJP L López-Noriega et al.
3810 British Journal of Pharmacology (2017) 174 3795–3810
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The type 2 diabetes-associated HMG20A
gene is mandatory for islet beta cell
functional maturity
Jose M. Mellado-Gil1, Esther Fuente-Martín1, Petra I. Lorenzo1, Nadia Cobo-Vuilleumier1, Livia López-Noriega1,
Alejandro Martín-Montalvo1, Irene de Gracia Herrera Gómez1, Maria Ceballos-Chávez2, Laura Gómez-Jaramillo3,
Antonio Campos-Caro3, Silvana Y. Romero-Zerbo4, Júlia Rodríguez-Comas5, Joan-Marc Servitja5,6,
Gemma Rojo-Martinez4,6, Abdelkrim Hmadcha 1,6, Bernat Soria1,6, Marco Bugliani 7, Piero Marchetti7,
Francisco J. Bérmudez-Silva4,6, Jose C. Reyes2, Manuel Aguilar-Diosdado3,8 and Benoit R. Gauthier 1
Abstract
HMG20A (also known as iBRAF) is a chromatin factor involved in neuronal differentiation and maturation. Recently
small nucleotide polymorphisms (SNPs) in the HMG20A gene have been linked to type 2 diabetes mellitus (T2DM) yet
neither expression nor function of this T2DM candidate gene in islets is known. Herein we demonstrate that HMG20A
is expressed in both human and mouse islets and that levels are decreased in islets of T2DM donors as compared to
islets from non-diabetic donors. In vitro studies in mouse and human islets demonstrated that glucose transiently
increased HMG20A transcript levels, a result also observed in islets of gestating mice. In contrast, HMG20A expression
was not altered in islets from diet-induced obese and pre-diabetic mice. The T2DM-associated rs7119 SNP, located in
the 3′ UTR of the HMG20A transcript reduced the luciferase activity of a reporter construct in the human beta 1.1E7 cell
line. Depletion of Hmg20a in the rat INS-1E cell line resulted in decreased expression levels of its neuronal target gene
NeuroD whereas Rest and Pax4 were increased. Chromatin immunoprecipitation confirmed the interaction of HMG20A
with the Pax4 gene promoter. Expression levels of Mafa, Glucokinase, and Insulin were also inhibited. Furthermore,
glucose-induced insulin secretion was blunted in HMG20A-depleted islets. In summary, our data demonstrate that
HMG20A expression in islet is essential for metabolism-insulin secretion coupling via the coordinated regulation of key
islet-enriched genes such as NeuroD and Mafa and that depletion induces expression of genes such as Pax4 and Rest
implicated in beta cell de-differentiation. More importantly we assign to the T2DM-linked rs7119 SNP the functional
consequence of reducing HMG20A expression likely translating to impaired beta cell mature function.
Introduction
Type 2 Diabetes Mellitus (T2DM) is a metabolic disease
characterized by impaired insulin secretion and/or action
in target organs that leads to elevations in blood glucose
levels. Environmental factors as well as strong genetic
components contribute to the pathogenesis of T2DM.
Thus far, 100–120 susceptibility loci have been associated
to T2DM by Genome Wide Association Studies
(GWAS)1–3. Although functional defects remain to be
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assigned, many of these loci point to primary defects in
beta cell function rather than to insulin resistance4. In this
context, several SNPs within the HGM20A gene (also
known as iBRAF) have been associated to T2DM5–8. Of
particular interest is the rs7119 SNP located within the 3′
UTR of the HMG20A transcript. In silico analysis revealed
that rs7119 modifies a functional microRNA (miRNA)
cis-regulatory element9. However, the molecular con-
sequences of this SNP on the expression of HMG20A
and/or its regulation and impact on islet physiology are
still unknown.
HMG20A is a member of the high mobility group
(HMG) box-containing genes that binds to chromatin and
exerts global genomic changes through establishing active
or silent chromatin10. HMG20A is highly expressed in
mature neurons and plays a key role in promoting neu-
ronal differentiation during development11. In this con-
text, HMG20A relieves the transcriptional repression
imposed by the complex LSD1–CoREST histone deme-
thylase12, which function is to silence neuronal genes in
non-neuronal tissues through its interaction with the
transcription factor REST. In analogy, epigenetic repres-
sion of the Rest gene in pancreatic precursors was shown
to coincide with the activation of the core beta cell pro-
gram13. Mature pancreatic beta cells do not express REST
while forced expression results in inhibition of neuronal
proteins of the insulin exocytotic machinery such as
SNAP25 and SYNAPTOTAGMIN VII (SYT7) leading to
impaired glucose-induced insulin secretion14. Interest-
ingly, REST was shown to repress expression of key beta
cell development genes, such as NEUROD and PAX415,16.
NEUROD is a bona fide target gene of HMG20A in
neuronal cells11 and mutations in this gene predispose
individuals to maturity onset diabetes of the young 6
(MODY6)17.
HMG20A is also implicated in epithelial-to-
mesenchymal transition (EMT) through interaction with
specific key regulators of this process such as SNAIL18.
EMT is an example of cell plasticity and a key process
during embryonic development, and together with the
reverse transformation, the mesenchymal-to-epithelial
transition (MET), are required for the formation of
organs in the final destinations of embryonic migratory
cells19,20. Both processes occur during pancreatic and islet
development and require extensive reorganization of the
epigenetic information of the cells. Remarkably, not only
in development but also in response to different physio-
logical demands, beta cells may de-differentiate in order
to acquire plasticity capabilities and increase survival21,22,
two processes that may implicate PAX423,24.
Based on these findings, we hypothesized that HMG20A
may contribute to the regulation of key genes such as
NeuroD and Pax4 which are essential for beta cell func-
tional maturity as well as survival. Towards this goal,
herein we investigate the expression profile and the gene
regulatory function of HMG20A in pancreatic islets, as
well as determine whether the SNP rs7119 associated with
T2DM impacts HMG20A expression. We report that
T2DM-associated SNP rs7119 leads to altered HMG20A
expression, and that HMG20A regulates metabolism-
secretion coupling genes as well as functional maturity of
beta cells.
Results
HMG20A is expressed in pancreatic islets and transcript
levels are decreased in islets from T2DM donors
As a first step to assign a potential role of the HMG20A
gene in pancreatic islet physiology, we determined its
transcript levels in islets as compared to other tissues.
Mouse pancreatic islets displayed comparable expression
levels of Hmg20a to other organs such as adipose tissue
(white and brown), brain and muscle whereas the liver
displayed highest levels (Fig. 1a). HMG20A co-stained
with INSULIN (beta cells), GLUCAGON (alpha cells) and
SOMATOSTATIN (delta cells) whereas its expression
was rarely detected in exocrine pancreas (Fig. 1b). A
similar endocrine cell expression pattern was detected in
human islets (Fig. 1c). We next assessed whether
expression levels of HMG20A were altered in islets iso-
lated from T2DM donors. The rational was to establish a
correlation between HMG20A levels and the hypergly-
cemic environment that may be altered by T2DM-linked
SNPs. HMG20A transcript levels were decreased by ~60 %
in islets from T2DM patients as compared to islets pur-
ified from normoglycemic control donors (Fig. 1d).
Metabolic stressors modulate HMG20A expression in islets
As HMG20A transcript levels were decreased in T2DM
islets, we reasoned that lipids and/or glucose might alter
its expression. Towards addressing this premise, we used
(see figure on previous page)
Fig. 1 HMG20A is expressed in both mouse and human islets and is decreased in islets from T2DM donors. a HMG20A transcript levels were
assessed by qPCR in islets, brain, liver, muscle, white adipose tissue (WAT), and brown adipose tissue (BAT) from mice (n = 6). Representative images
of b mouse and c human islets co-stained for HMG20A (green) along with INSULIN (INS), GLUCAGON (GLUC) or SOMATOSTATIN (SMT) (red). Nuclei
are stained using DAPI (blue). Magnification 40×. White boxes define areas enlarged in panels bellow. d HMG20A mRNA levels were measured by
qPCR in human islets isolated from normoglycemic (control) or type 2 diabetic (T2DM) organ donors (n = 7). Data are depicted as dot plots with
means ± S.E.M. p values were determined using unpaired two-tailed Student's t-test. **p < 0.01
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our mouse model of 45% high fat diet (HFD)-induced
obesity and pre-diabetes to assess the contribution of
lipids. These mice exhibit a typical 20% increase in body
weight, develop glucose intolerance with the concomitant
increases in insulin and leptin levels and decreased adi-
ponectin levels25. Although these mice developed insulin
resistance, glycaemia is normal due to increased insulin
levels (Fig. 2a, b). Under these conditions, HMG20A
protein levels were not significantly changed in islets as
compared to levels in chow-fed control mice (Fig. 2c). In
contrast, short-term exposure of INS-1E cells to palmitate
resulted in a transient reduction in HMG20A transcript
levels (Fig. 2d).
We next assessed the direct action of high glucose on
HMG20A levels in isolated islets. In human islets,
HMG20A expression levels were transiently increased by
approximately twofold at 72 h returning to basal levels by
96 h (Fig. 3a). A similar transient induction pattern, albeit
attaining maximum levels at 48 h, was also observed in
mouse islets and in INS-1E beta cells (Fig. 3b,c). Inter-
estingly, a significant decrease was detected INS-1E cells
at 72 h of high glucose exposure (Fig. 3c). It is noteworthy
that expression levels of NEUROD, a bona fide target of
HMG20A, mirrored those of HMG20A in human islets as
well as in INS-1E (Fig. 3d,f), following the same tendency
in mouse islets (Fig. 3e). In order to satisfy metabolic
demand by fetus and mother, glucose metabolism is
altered during pregnancy inducing metabolic stress that, if
ill adapted, will lead to gestational diabetes. We therefore
pondered whether Hmg20a expression levels were
modulated during pregnancy. Consistent with this pre-
mise, transcript and protein levels of the Hmg20a gene
were increased reaching a peak of maximum signal at 12.5
and 14.5 days post coitum, respectively, and thereafter
declining (Fig. 4a–c). Pregnant females displayed mild
glucose intolerance at 14.5 correlating with the peak in
HMG20A protein levels (Fig. 4d). Taken together, these
data suggest that increased glucose levels both in vitro and
in vivo stimulate HMG20A expression.
The rs7119 SNP variant within the 3′ untranslated region
(UTR) of human HMG20A reduces activity of a luciferase
reporter gene
Although GWAS have highlighted a panoply of SNPs
correlating with T2DM, few have been assigned a func-
tional consequence to the associated gene. Towards
addressing this question, we assessed whether the human
HMG20A SNPs associated to T2DM may impact
HMG20A levels. Of particular interest is the SNP rs7119
located in the 3′ UTR of the HMG20A transcript that is
encoded in part by exon 10 and the entirety of exon 11
(Fig. 5c). The SNP rs7119 causes a “C” (reference allele
“wt”) to “T” (“mut” allele) substitution. In silico analysis of
Fig. 2 HMG20A protein expression is not altered in islets of high
fat diet (HFD)-induced obesity and pre-diabetic mice. a Insulin
tolerance test (ITT) and area under the curve (AUC) analysis in both
control (CT) and HFD mice (CT, n = 10; HFD, n = 15). b Fasting blood
glucose levels in both control and HFD mice (CT, n = 10; HFD, n = 15).
c Representative images of pancreatic sections from HFD and CT mice
stained and quantified for HMG20A (n = 4). d Hmg20a mRNA levels
were assessed by qPCR in INS-1E cells cultured with 0.05 mM
palmitate for 24, 48, 72 or 96 h (n = 3 independent experiments
performed in triplicates). Data are represented as means + S.E.M. p
values were determined by ordinary one-way ANOVA. *p < 0.05, **p <
0.01, ***p < 0.0001
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the HMG20A 3′UTR revealed the binding site of a single
miRNA (miR-571) to the wt allele whereas the “mut” allele
results in the ablation of this miRNA binding site
(Table 1). Interestingly expression of miR-571 was not
detected in mouse islets as compared to the highly
expressed miR375 (data not shown). Notwithstanding, the
Fig. 3 HMG20A is regulated by glucose. a–c HMG20A and d–f NEURODmRNA levels were assessed by qPCR in human (n = 3 donors performed in
triplicates) and mouse islets (three independent preparations of pooled islets from three different isolation) as well as INS-1E cells cultured in 24 mM
glucose for 24, 48, 72, or 96 h (n = 3 independent experiments of all time points executed in triplicates). Data are represented as means + S.E.M. p
values were determined by ordinary one-way ANOVA. *p < 0.05, compared to the control 0 time point
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Fig. 4 HMG20A is transiently increased in mouse islets during pregnancy. a Representative images of pancreatic sections from pregnant mice
co-stained for HMG20A (green) and INSULIN (INS) (red). Nuclei were stained using DAPI (blue). Magnification 40×. White boxes define areas enlarged
in panels below. p.c. post coitum. b Quantification of integrated fluorescence intensity for HMG20A in beta cells of islets from pregnant mice (n = 3
mice per time point with 35-71 islets counted per time point). Data are depicted as dot plots with means ± S.E.M. c HMG20A mRNA levels in islets
from pregnant mice (n = 5 mice) at 12.5 and 14.5 days of pregnancy. d Oral glucose tolerance test (OGTT) and area under the curve (AUC) analysis of
non-pregnant (NP) and pregnant (day 14.5 of pregnancy; D14.5) mice (NP, n = 8; D14.5, n = 6). Data are represented as means ± S.E.M. p values were
determined by the unpaired two-tailed Student´s t-test (d for AUC and c) or ordinary one-way ANOVA with Dunnet’s multiple comparison test (b). *p
< 0.05, **p < 0.01, ****p < 0.0001, compared to the control 0 time point
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Fig. 5 The rs7119 SNP within the HMG20A 3′ UTR decreases protein levels. Expression profile of putative miRNAs binding to the “mut” allele of
the HMG20A transcript in a human 1.1E7 cells and b mouse islets. Data are presented respect to miR375 expression levels. c Schematic
representation of the HMG20A gene depicting the promoter region (HMG20A promoter), transcription starting site (tss) and 11 exons. Gaussia
luciferase (GLuc) reporter constructs harboring the 3′ UTR corresponding to either wild type (wt) or rs7119 mutant (mut) allele under pSV40 promoter
are shown below. d HMG20A mRNA levels assessed by qPCR in the human pancreatic beta cell line 1.1E7 cultured in 24 mM glucose for 24, 48, 72, or
96 h (n = 5 independent experiments performed in triplicates). e Human pancreatic beta 1.1E7 and f RPE1 cell lines were transfected with the reporter
construct bearing either wt or rs7119 mut variant of the HMG20A 3′ UTR. Both the Gaussia Luciferase activity and SEAP activity were determined 24 h
post transfection (n = 3 independent experiments). Data are represented as means + S.E.M. p values were determined by ordinary one-way ANOVA
(d) or unpaired Student's t-test (e, f). *p < 0.05
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“mut” allele generates binding sites for six alternative
miRNAs (Table 1) of which four, miR-143 (3p and 5p),
miR-490-3p, miR-1246, and miR-1261, were expressed in
the human 1.1E7 pancreatic cell line (Fig. 5a). In contrast
mouse islets only expressed miR-143 and very low levels
of miR-1246 (Fig. 5b). The latter findings suggest that the
“mut” variant may alter expression of the HMG20A
transcript due to the action of those miRNAs. To assess
this premise, we generated two Gaussia luciferase (Gluc)
reporter constructs harboring either the “wt” or “mut” 3′
UTR of the human HMG20A transcript. Expression of
these constructs was under the transcriptional regulation
of the SV40 basal promoter (Fig. 5c). Transient transfec-
tions were then performed in the human pancreatic beta
1.1E7 and retinal pigmented epithelial RPE1 cell lines.
The rational of using human cell lines was to maintain
species-specific effects targeting the human 3′ UTR of the
HMG20A transcript, which is distinct than that of the
mouse Hmg20a transcript. We initially confirmed that
glucose also stimulated HMG20A expression in 1.1E7 beta
cells (Fig. 5d). The “mut” variant displayed significantly
less Gluc activity as compared to the construct bearing
the “wt” variant 48 h post transfection in either cell lines
(Fig. 5e, f). These results suggest that the diabetes-linked
SNP rs7119 alters expression of the human HMG20A.
HMG20A regulates the expression of beta cell genes
involved in metabolism-secretion coupling and beta cell
maturity
To determine the specific contribution of HMG20A to
islet beta cell function and the impact of its reduced levels
in T2DM islets, we silenced HMG20A expression by RNA
interference and then assessed transcript levels of key
factors involved in beta cell identity and function. A 60%
depletion of Hmg20a in INS-1E cells (Fig. 6a, b) resulted
in a concomitant 60% inhibition of NeuroD transcript
levels (Fig. 6c). Mafa, which is essential to maintain the
beta cell phenotype, was decreased by 50% whereas Pdx1
was unaltered. Interestingly, Pax4 as well as Rest were
increased by 1.8- and 1.5-fold, respectively, subsequent to
Hmg20a silencing (Fig. 6c). We previously demonstrated
that chronic overexpression of Pax4 leads to loss of beta
cell identity characterized by decreased Mafa and Insulin
expression23. We thus, pondered whether HMG20A
could directly regulate Pax4 thereby maintaining its
expression within a range that would not interfere with
beta cell function. To validate this premise, chromatin
immunoprecipitation (ChIP) experiments were performed
using the islet specific Pax4 gene promoter24. As expected
H3K4me2, a marker for active promoters and enhancers
specifically occupied this region (Fig. 6d)26. More
importantly, HMG20A also occupied the Pax4 gene
promoter region as well as exon 1 while control anti-IgG
exhibited no binding (Fig. 6e). Since NEUROD and
MAFA are involved in metabolism-secretion coupling in
beta cell, genes implicated in this process were assessed
after Hmg20a silencing. Glucokinase (Gck) and Insulin
transcript levels were significantly repressed by 30%
(Fig. 6f). In contrast, Pi3k and Glut2 levels were increased
1.8 and 2.6-fold, respectively (Fig. 6f). Transcript levels of
Syt7 and Snap25, two factors involved in insulin granule
membrane docking and fusion were not altered in
Hmg20a-repressed INS-1E cells (Fig. 6f). The modulation
of key HMG20A target genes was validated using a second
independent siHMG20A (Fig. 6g). Taken together our
results indicate that HMG20A coordinates expression of
genes that will establish the mature beta cell phenotype.
Glucose-stimulated insulin secretion is impaired by
Hmg20a depletion
We next assess the cellular and functional consequences
of Hmg20a depletion in beta cells. Neither cell death nor
proliferation was altered by HMG20A depletion in INS-
1E cells (Fig. 7a, b). In contrast, glucose-stimulated insulin
secretion (GSIS) was blunted in these cells (Fig. 7c).
Similarly, subsequent to a 40% depletion of Hmg20a in
mouse islets (Fig. 7d), cell proliferation was unaltered
while GSIS was drastically decreased as compared to
control islets (Fig. 7e, f). Taken together, Hmg20a
expression is essential for insulin secretion.
Discussion
The overall aim of the current study was to assign a
functional role of the putative diabetes-linked HMG20A
gene to islet physiology, and determine the pathophysio-
logical consequence of the rs7119 SNP associated with
this disease. We find that: (1) HMG20A is expressed in
pancreatic islet beta cells, (2) HMG20A levels are
decreased in T2DM islets, (3) high glucose stimulates
HMG20A expression, (4) the T2DM-associated SNP
within the 3′ UTR of the HMG20A transcript decreases
luciferase activity, (5) HMG20A regulates key genes in
beta cell function and maturity, and (6) HMG20A
TABLE 1 In silico identification of miRNAs binding sites
within the rs7119 SNP located in the 3′UTR of HMG20A
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Fig. 6 HMG20A regulates metabolism-secretion coupling genes in INS-1E cells. a Hmg20a was silenced by specific siRNA in INS-1E cells (n = 6
independent experiments, each performed in triplicates). b Representative images of INS-1E cells immuno-stained for HMG20A (green) and DAPI
(blue) confirming decreased protein level after treatment with siHMG20A. Magnification 40×. c Beta cell development and maturity genes, as Neurod,
Pax4, Mafa, Pdx1, and Rest transcripts levels after silencing of Hmg20a in INS-1E cells (n = 4 independent experiments performed in triplicates). d
H3K4m2 and e HMG20A occupancy of promoter, exon 1 and ATG regions of the Pax4 gene after chromatin immunoprecipitation using anti-H3K4m2
or anti-HMG20A antibodies, with IgG as a control for non-specific interactions (n = 4 independent experiments performed in triplicates). f Beta cell
metabolism-secretion coupling genes transcripts levels after silencing of Hmg20a in INS-1E cells (n = 4 independent experiments, performed in
triplicates). g Alteration in the expression of key genes was confirmed in INS-1E cells using a second siHMG20A (n = 4 independent experiments
performed in triplicates). Data are represented as means + S.E.M. p values were determined by one-way ANOVA with Tukey’s multiple comparisons
test (a, c, f, g). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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depletion impairs GSIS. Therefore, we provide first evi-
dence that HMG20A is a key regulator of mature beta cell
function.
Our results indicate that variations in glucose levels are
a main rheostat of islet HMG20A expression, which in
turn appears to modulate islet adaptive measures by
increasing insulin biosynthesis. The latter premise is
supported by our findings that NEUROD expression levels
mirrored those of HMG20A, being stimulated by high
glucose and inhibited under siRNA-mediated Hmg20a
downregulation. Mutations in the NEUROD gene
predispose individuals to develop maturity onset diabetes
of the young (MODY6)17 while adult mouse islets lacking
Neurod respond poorly to glucose27. We also found
reduced expression levels of Mafa as a consequence of
Hmg20a depletion. This transcription factor along with
NEUROD activates expression of the Gck and Insulin
gene27–29, consistent with reduced levels of both tran-
scripts in Hmg20A-silenced cells. Intriguingly, Glut2 was
increased following Hmg20a repression perhaps as a
compensatory mechanism to increase cellular glucose
influx due to decreased GCK-mediated phosphorylation
Fig. 7 Hmg20a silencing impairs insulin secretion in INS-E1 cells as well as in mouse islets without affecting cell death or proliferation. a
Cell death (n = 3), b proliferation (n = 3), and c glucose-induced insulin secretion (GSIS, n = 4) were assessed subsequent to siRNA-mediated HMG20A
depletion in INS-1E cells. d Effect of siRNA-mediated HMG20A depletion on e cell proliferation (n = 6 islet preparations) and f GSIS in mouse islets (n
= 6 islet preparations). Data are represented as mean + S.E.M. p values were determined by unpaired two-tailed Student's t-test. *p < 0.05, **p < 0.01
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and glycolysis30. Thus, the coordinated regulation of
NeuroD and Mafa by HMG20A may be a key molecular
hub essential for beta cell function and adaptation to
physiological stress such as during pregnancy in which
glucose metabolism is altered. Interestingly, although
HMG20A was repressed by palmitate in vitro, expression
levels were not significantly altered in islets of a mouse
model of high fat diet-induced obesity and pre-diabetes.
Thus, it is tempting to speculate that in vivo, glucose and
lipids may have opposite effect on HMG20A expression
nullifying any significant increased in expression, which
may in long-term hinder islet adaptation, precipitating
beta cell dysfunction and T2DM. The latter hypothesis
may rationalize the observed association of HMG20A risk
variants with T2DM in obese cases8.
Our study also identifies the Pax4 gene as a direct target
repressed by HMG20A. Although the Pax4 gene pro-
moter was shown to interact with REST15, the absence of
this “disallowed” gene in beta cells suggest that HMG20A
acts independent of the LSD1–coREST complex that
requires REST to be recruited onto DNA14. Rather, our
results are in agreement with recent findings that
HMG20A in cohort with LSD1 is sufficient to repress
Snail1 and induce TGF beta-triggered EMT, demon-
strating a mechanism independent of REST as well as the
capacity of HMG20A for binding directly to DNA18.
Notwithstanding, Hmg20a silencing also evoked REST re-
expression indicating that in cohort with PAX4, these two
factors may promote de-differentiation of beta cells con-
veying increased survival under unfavorable physiological
conditions such as chronic hyperglycemia.
To date, regulation of the endogenous Pax4 gene in
mature islets conveying protection and adaptation in
response to physiological or pathophysiological condi-
tions has remained obscure. Our data suggest that
HMG20A may be an important epigenetic regulator of
Pax4 gene expression that will dictate the faith of beta
cells under stress conditions such as in T2DM. In accord
with this premise, we previously demonstrated that PAX4
expression was increased in islets derived from T2DM
patients31. We now demonstrate that HMG20A levels are
repressed in T2DM islets. These combined human data
are in line with increased expression of Pax4 subsequent
to Hmg20a silencing in either islets or INS-1E cells
without altering apoptosis and proliferation. Accumulat-
ing evidence suggest that the main characteristic event in
T2DM is not massive beta cell death but rather beta cell
de-differentiation32. We previously demonstrated that
chronic expression of Pax4 is implicated in this process
through downregulation of Mafa and Insulin expres-
sion33. Our current data substantiate these findings as we
detected a decrease in Mafa expression after Hmg20a
silencing. Thus, the role of HMG20A may be to supress
Pax4 transcription thereby permitting expression of Mafa
as well as Insulin. Such cross talk between the two factors
is highlighted also during pregnancy. Indeed, we pre-
viously found a peak of Pax4 expression and beta-cell
proliferation at 10.5 days and 12.5 days of pregnancy
respectively24. Herein, we now find that HMG20A
expression in islets is increased at 14.5 days of pregnancy,
just after the peak of proliferation and correlating with
decreased Pax4 and increased Mafa expression levels.
These findings are consistent with the premise that beta
cells after proliferation have to re-differentiate to reach
their metabolic mature phenotype and adequately secrete
insulin, a process requiring MAFA34. A similar regulatory
cross talk between HMG20A and PAX4 may also be
operative in early stages of hyperglycemia, which is
characterized by active beta cell adaptation. Nonetheless,
long-term exposure may favor de-differentiation and
survival (without altering proliferation) to the detriment
of function, as we observed in vitro in which HMG20A
expression was transiently increased but then inhibited by
glucose. Although further studies will be needed to specify
the mechanism by which HMG20A regulates those islet-
enriched genes, our work provides the basis for the
involvement of a non-mutually exclusive cross regulation
of HGM20A and PAX4 in islet/beta cell physiology.
A significant finding of our study is the potential
decreased in HMG20A levels associated with the
diabetes-linked rs7119 SNP within the 3′ UTR of the
transcript. This SNP opens the putative binding site of
several new miRNAs as compared to the normal wild type
allele. Although a previous study has linked T2DM-
associated genes to islet-expressed miRNA35, our study, to
the best of our knowledge, provides first evidence that a
diabetes-linked SNP alters the putative binding site for
miRNAs resulting in the deregulate repression of the
target transcript. Further indication for a dysfunctional
role of the rs7119 variant in aberrant HMG20A repression
was highlighted by the expression of SNP-associated
miRNAs, the most abundant being miR-143 and 1246, in
human 1.1E7 cells and mouse islets. In contrast, miR-571
associated with the wild type allele miRNA binding site
was not express suggesting the potential absence of post-
transcriptional regulation conveyed by the normal allele.
Although scarce details are available on the role of miR-
143 and 1246 in islet function, miR-143 was shown to be
among the ten most abundant miRNAs expressed in
human islets beta cells whereas miR-1246 was pre-
dominantly expressed in other islet cell types35. Else-
where, miR-143 expression was found to be essential for
human pre-adipocyte differentiation partly through
repression of its target gene ERK5 involved in cell growth
and proliferation36. Although it remains to be validated,
the potential serendipitous binding of miR-143 to the
HMG20A rs7119 gene variant may induce aversely de-
differentiation through activation of Pax4 and Rest.
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The overall data presented in this work clearly describes
a functional link between HMG20A and islet physiology.
HMG20A regulates metabolism-secretion coupling genes
in beta cells and could be also involved in beta cell plas-
ticity through PAX4 and REST, regulating phenotypic
changes needed for beta cells in order to respond to dif-
ferent physiological situations as pregnancy and obesity.
Failure on those HMG20A-mediated processes could lead
to the development and establishment of T2DM. As
consequence, our study opens a venue to consider tar-
geting of HMG20A expression and/or regulation as
potential therapies for T2DM.
Materials and methods
Animals
The experimental mouse procedures were approved by
the Institutional Animal Care Committee of the Andalu-
sian Center of Molecular Biology and Regenerative Medi-
cine (CABIMER) and by the ethic committee of the
University of Malaga, Biomedical Research Institute of
Málaga (IBIMA) and performed according to the Spanish
law on animal use RD 53/2013. Animal studies were per-
formed in compliance with the ARRIVE guidelines37. Mice
were housed in ventilated plastic cages and maintained on
a 12-h light–dark cycle with ad libitum access to pelleted
chow and water. C57BL/6J of both genders were used to
obtain pancreatic islets and other tissues (liver, adipose
tissue, skeletal muscle, and brain) and females for preg-
nancy studies. For diet-induced obesity studies, 8-weeks-
old male C57BL/6J mice (Janvier Labs, Saint-Berthevin
Cedex, France) were housed in individual cages under a 12
h light/dark cycle (8:00 pm light off) in a room with con-
trolled temperature (21± 2 °C) and humidity (50± 10%).
For induction of obesity, groups of ten mice were fed a high
fat diet (D12451 Research Diets Inc., New Brunswick, NJ,
USA), containing 45% of Kcal from saturated fat, for
15 weeks. In parallel, groups of ten age-matched mice were
fed a control diet containing 10% of Kcal from fat (D12450
Research Diets Inc.). Circulating glucose levels were mea-
sured from tail vein blood samples using an Optium Xceed
glucometer (Abbott Scientifica SA, Barcelona, Spain).
Insulin tolerance tests (ITT) and glucose tolerance test
(OGTT) were performed as previously described38. At
15 weeks, mice were sacrificed by cervical dislocation and
pancreas extracted for histological processing.
Pancreatic islet and cell line cultures
Mouse pancreatic islets were isolated from 2 to 4-
months-old C57BL/6J mice by intraductal collagenase as
previously described24,39 . After isolation, mouse islets
were cultured in 5.5 mM glucose/RPMI 1640 medium
(Life Technologies, Madrid, Spain) supplemented with 10
% Fetal bovine serum (FBS, Sigma-Aldrich, Madrid,
Spain), 100 U/ml penicillin, 100 μg/ml streptomycin
(Sigma-Aldrich), 2 mM L-glutamine (Life Technologies),
1 mM sodium pyruvate (Sigma-Aldrich), 50 μM β-
mercaptoethanol (Life Technologies), and 10mM
HEPES (Life Technologies) prior to different experimental
treatments. Islets from non-diabetic or T2DM organ
donors were obtained in Pisa or purchased from Tebu-Bio
(Barcelona, Spain). After reception, human islets were
cultured in CMRL-1066 (Gibco) medium containing 5.5
mM glucose and supplemented with 10% FBS, 100 U/ml
penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine,
and 100 μg/ml gentamycin. To assess glucose influence in
HMG20A expression, both human and mice islets were
cultured in normal (5.5 mM) or high (24.4 mM) glucose
concentrations for 24, 48, 72, and 96 h, and lately har-
vested for RNA extraction.
The rat insulinoma INS-1E beta cell line (kindly pro-
vided by Dr. P Maechler, Geneva, CH) was cultured
between passages 50–90 and maintained in 11.1 mM
glucose/RPMI 1640 medium (Life Technologies) supple-
mented with 10% FBS, 100 U/ml penicillin, 100 μg/ml
streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate,
50 μM β-mercaptoethanol, and 10mM HEPES. Following
overnight glucose deprivation (3 mM), cells were cultured
in 11.1 mM or 24.4 mM glucose RPMI 1640 medium for
24, 48, 72, and 96 h. Alternatively INS-1E cells were also
exposed to 0.5 mM palmitate for up to 96 h. Cells were
harvested at each time point for RNA extraction.
The human retinal pigmented epithelial RPE1 (ATCC,
CRL-4000) and the islet beta 1.1E7 cell lines (The Eur-
opean Collection of Authenticated Cell Cultures) were
cultured in F-12 Ham and RPMI media, respectively, prior
to luciferase reporter assays. The 1.1E7 cell line was also
cultured in the presence of either 11.1 or 24.4 mM glucose
for up to 96 h. RNA was extracted at 24, 48, 72, and 96 h
post treatment.
RNA interference
Mouse pancreatic islets and INS-1E cells were cultured
as previously described40 and transfected with either 50
μmol of two independent HMG20A small interfering (si)
RNAs (5′-AGGCAAAUCUCAUAGGCAA-3′ and 5′-
UCACAAGGAUGUUGGGCAA-3′) or scramble siRNA
(Sigma-Aldrich) using Oligofectamine (Life Technolo-
gies). Samples were processed for RNA, immuno-
fluorescence, GSIS, cell proliferation and death
assessment 72 h after transfection.
RNA extraction and quantitative-PCR expression analysis
Qiagen RNeasy Micro and Mini kits (Qiagen, Madrid,
Spain) were used for the extraction of total RNA from the
different tissues, islets and cell line samples. After quan-
tification of the RNA concentration using a NanoDrop
1000 Spectrophotometer (Wilmington, DE, USA), single-
stranded cDNA was synthesized with the Superscript II
Mellado-Gil et al. Cell Death and Disease  (2018) 9:279 Page 12 of 15
Official journal of the Cell Death Differentiation Association
First-Strand cDNA synthesis kit (Invitrogen, Carlsbad,
CA, USA) and Anchored OligodT as primers (Sigma-
Aldrich). Quantitative PCR was performed on a 7500
Real-Time PCR System (Applied Biosystems). Gene-
specific primers (HMG20A, NEUROD1, PDX1, PAX4,
REST, GLUKOKINASE, INSULIN, PI3K, MAFA, GLUT1,
GLUT2, SNAP25, and SYT7) were designed using Power
Primer3 (Supplementary Table 1, 2 and 3). Expression
levels of the housekeeping genes β-ACTIN or CYCLO-
PHILIN were used for normalization. The relative gene
expression was calculated using the 2−ΔΔCt method24. For
miRNA expression profiling, microRNAs were extracted
from the 1.1E7 beta cell line and mouse pancreatic islets
using the miRNAeasy kit (Qiagen) and cDNA synthesis
was conducted using the Universal cDNA Synthesis Kit
(Exiqon) as previously described41. ExiLENT SYBR Green
Master Mix Kit and primers for each assay to perform
quantitative-PCR (qPCR) were obtained from Exiqon.
Immunofluorescence and immunohistochemistry studies
Dissected pancreases were fixed overnight in 4% par-
aformaldehyde at 4 °C and processed for embedding in
paraffin at the Histology Core Facility, CABIMER. Pan-
creatic sections from non-pregnant/pregnant mice sacri-
ficed at 10.5, 12.5, 14.5, and 17.5 days post coitum were
analyzed by immunohistochemistry using specific anti-
bodies against HMG20A, insulin, glucagon, and soma-
tostatin (Supplemental Table 4). Counterstaining was
performed with 5 μg/ml DAPI (Life Technologies) to stain
the nuclei and slides were mounted using fluorescent
mounting medium (DAKO). Images were acquired using
either the epifluorescence (Leica AF6000, Leica, England)
or confocal (Leica TCS SP5) microscopes. Expression of
HMG20A in beta cells was quantified using Metamorph
Analysis Software (Molecular Devices). Single frames
were acquired using a confocal TCS SP5 microscope
(Leica). Same illumination settings were applied for all the
samples (image parameters including pinhole size, pho-
tomultiplier offset and gain, and laser intensity were first
set for non-pregnant control samples, and then, the same
settings were used for all conditions). For Image analysis/
quantification, the integrated intensity values (∑ pixel
intensity at region of interest) were measured as pre-
viously described42–44. Integrated intensity of nuclear
HMG20A in islet cells co-expressing insulin were mea-
sured, and the average of intensity per islet was calculated.
Three independent animals and an average of 50 islets
were used for each time point. Pancreatic sections from
control and HFD mice were performed and analyzed as
previously described25.
Luciferase 3′ UTR reporter assays
The effect of the 3′ UTR SNP rs7119, previously linked
to T2DM was evaluated by luciferase reporter assays. 3′
UTR constructs containing the wt allele (reference allele)
“C” or the DMT2-linked allele (“mut” allele) “T” cloned
downstream of the luciferase gene were obtained from
GeneCopoeia. Luciferase contained in these constructs is
a secreted one; therefore luciferase activity can be mea-
sured in the medium. These constructs also have a
secreted embryonic alkaline phosphatase (SEAP) gene
driven by a constitutive promoter, used as internal con-
trol. The Secrete-Pair TM Dual Luminescence Assay Kit
(GeneCopoeia) was used as luciferase reporter system
according to manufacturer’s instructions. RPE1 and 1.1E7
cell lines were chosen for transfection studies using those
constructs. Both are cell lines of human origin and from
different tissues. RPE1 are cells from retina pigmentosum
ephitelia45 meanwhile 1.1E746 is a human beta cell line.
The RPE1 and 1.1E7 cell lines were transfected and
luciferase activity was measured 48 h after in the collected
culture media.
Glucose-stimulated insulin secretion assays
Insulin secretion in response to 2.8 mM or 22mM
glucose was measured in static incubations as previously
described47,48 in both mouse pancreatic islets and INS-1E
cells. Following the incubations, supernatants were col-
lected and islets and cells were lysated with HCl-ethanol
to obtain the insulin content. Insulin from supernatants
and cell contents was measured by ELISA (Mercodia,
Uppsala, Sweden). All experiments were run in triplicate.
Cell death and proliferation
Cell death (apoptosis) and proliferation was measured
using either the Cell Death Detection ELISA kit or the 5-
Bromo-2′-deoxy-uridine labeling and detection kit (Roche
Diagnostics, Madrid, Spain) as described by the
manufacturer.
ChIP assays
ChIP assays were performed as previously descri-
bed12,18. INS-1E cells were treated with 1% formaldehyde
for 15 min at 37 °C for crosslinking. Chromatin was
sonicated to an average fragment size of 400 to 500 bp
using the Diagenode Bioruptor. Immunoprecipitations
were performed using the following reagents: Dynabeads
Protein A (Invitrogen), rabbit polyclonal anti-HMG20A
(Sigma-Aldrich) and rabbit monoclonal to Histone H3 (di
methyl K4) (Abcam). Rabbit IgG (Sigma) was used as a
control for non-specific interactions. Input was prepared
with 10% of the chromatin used for immunoprecipitation.
Quantification of immunoprecipitated DNA was per-
formed by real-time PCR with the Applied Biosystems
7500 FAST real-time PCR system, using Applied Biosys-
tems Power SYBR green master mix. Each sample was
quantified in triplicate. Provided data are the average of at
least three independent experiments.
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Statistical analysis
The Ruth Lenth's power of analysis was applied to the
different animal models to ensure that adequate numbers
of animals had been studied to detect significant changes.
Results are expressed as mean± SEM (line plots as a
function of time) or as mean+ SEM (bar graphs). Statis-
tical analyses were performed using the GraphPad Prism
software version 7 (GraphPad Software, La Jolla, USA).
Acknowledgements
This work was supported by the Consejería de Salud, Fundación Pública
Andaluza Progreso y Salud, Junta de Andalucía (PI-0727-2010 to B.R.G., PI-0085-
2013 to P.I.L., PI-0006-2016 to E.F.-M. and PI-0574-2012 to S.Y.R.-Z.), the
Consejería de Economía, Innovación y Ciencia (P10.CTS.6359 to B.R.G. and P09-
CTS-5445 to A.C.-C.), the Ministerio de Economía y Competitividad, Instituto de
Salud Carlos III co-funded by Fondos FEDER (PI10/00871 and PI13/00593 to B.R.
G., and BFU2014-5343-P to J.C.R.) and the Red TerCel program (RD12/0019/
0028 to B.S. and K.H.). E.F.M. is recipient of a Juan de la Cierva Incorporación
Fellowship from the Ministerio de Economía y Competitividad (IJCI-2015-
26238). S.Y.R.Z is a recipient of a postdoctoral fellowship from Consejería de
Salud, Junta de Andalucía (RH-0070-2013). F.J.B.S. is recipient of a “Nicolás
Monardes” research contract from Consejería de Salud Junta de Andalucía, (C-
0070-2012). A.M.M. is supported by CP14/00105 and PI15/00134 from the
Instituto de Salud Carlos III co-funded by Fondes FEDER. CIBERDEM is an
initiative of the Instituto de Salud Carlos III. We thank Noelia García-
Rodriguez, Lourdes Sanchez-Salido, and Leopoldo Perez-Rosendo for their
excellent technical assistance. B.R.G. is the guarantor of this work and, as such,
had full access to all the data in the study and takes responsibility for the
integrity of the data and the accuracy of the data analysis.
Author details
1Department of Cell Regeneration and Advanced Therapies, Andalusian Center
of Molecular Biology and Regenerative Medicine-CABIMER, Junta de
Andalucia-University of Pablo de Olavide-University of Seville-CSIC, Seville,
Spain. 2Department of Genome Biology, Andalusian Center of Molecular
Biology and Regenerative Medicine (CABIMER) JA-CSIC-UPO-US, Seville, Spain.
3Research Unit, University Hospital “Puerta del Mar”, Instituto de Investigación e
Innovación en Ciencias Biomédicas de la Provincia de Cádiz (INiBICA), Cádiz,
Spain. 4Unidad de Gestión Clínica Intercentros de Endocrinología y Nutrición,
Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional
Universitario de Málaga, Universidad de Málaga, Málaga, Spain. 5Diabetes &
Obesity Research Laboratory, Biomedical Research Institute August Pi I Sunyer
(IDIBAPS), Barcelona, Spain. 6Centro de Investigación Biomédica en Red de
Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain.
7Department of Translational Research and of New Surgical and Medical
Technologies, University of Pisa, Pisa, Italy. 8Endocrinology and Metabolism
Department University Hospital “Puerta del Mar”, Instituto de Investigación e
Innovación en Ciencias Biomédicas de la Provincia de Cádiz (INiBICA), Cádiz,
Spain
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41419-018-0272-z).
Received: 4 August 2017 Revised: 20 December 2017 Accepted: 27
December 2017
References
1. Frayling, T. M. & Hattersley, A. T. Physiology helps GWAS take a step closer to
mechanism. Diabetes 63, 1836–1837 (2014).
2. Prasad, R. B. & Groop, L. Genetics of type 2 diabetes-pitfalls and possibilities.
Genes (Basel) 6, 87–123 (2015).
3. Mohlke, K. L. & Boehnke, M. Recent advances in understanding
the genetic architecture of type 2 diabetes. Hum. Mol. Genet. 24, R85–R92
(2015).
4. Perry, J. R. & Frayling, T. M. New gene variants alter type 2 diabetes risk
predominantly through reduced beta-cell function. Curr. Opin. Clin. Nutr.
Metab. Care 11, 371–377 (2008).
5. Kooner, J. S. et al. Genome-wide association study in individuals of South
Asian ancestry identifies six new type 2 diabetes susceptibility loci. Nat. Genet.
43, 984–989 (2011).
6. Sim, X. et al. Transferability of type 2 diabetes implicated loci in multi-ethnic
cohorts from Southeast Asia. PLoS Genet. 7, e1001363 (2011).
7. Fukuda, H. et al. A single nucleotide polymorphism within DUSP9 is associated
with susceptibility to type 2 diabetes in a Japanese population. PLoS ONE 7,
e46263 (2012).
8. Perry, J. R. et al. Stratifying type 2 diabetes cases by BMI identifies genetic risk
variants in LAMA1 and enrichment for risk variants in lean compared to obese
cases. PLoS Genet. 8, e1002741 (2012).
9. Arnold, M., Ellwanger, D. C., Hartsperger, M. L., Pfeufer, A. & Stumpflen, V. Cis-
acting polymorphisms affect complex traits through modifications of micro-
RNA regulation pathways. PLoS ONE 7, e36694 (2012).
10. Bianchi, M. E. & Agresti, A. HMG proteins: dynamic players in gene regulation
and differentiation. Curr. Opin. Genet. Dev. 15, 496–506 (2005).
11. Wynder, C., Hakimi, M. A., Epstein, J. A., Shilatifard, A. & Shiekhattar, R.
Recruitment of MLL by HMG-domain protein iBRAF promotes neural differ-
entiation. Nat. Cell Biol. 7, 1113–1117 (2005).
12. Ceballos-Chavez, M. et al. Control of neuronal differentiation by sumoylation of
BRAF35, a subunit of the LSD1-CoREST histone demethylase complex. Proc.
Natl Acad. Sci. USA 109, 8085–8090 (2012).
13. van Arensbergen, J. et al. Derepression of polycomb targets during pancreatic
organogenesis allows insulin-producing beta-cells to adopt a neural gene
activity program. Genome Res. 20, 722–732 (2010).
14. Martin, D. & Grapin-Botton, A. The importance of REST for development and
function of beta cells. Front. Cell Dev. Biol. 5, 12 (2017).
15. Kemp, D. M., Lin, J. C. & Habener, J. F. Regulation of Pax4 paired homeodomain
gene by neuron-restrictive silencer factor. J. Biol. Chem. 278, 35057–35062
(2003).
16. Martin, D. et al. REST represses a subset of the pancreatic endocrine differ-
entiation program. Dev. Biol. 405, 316–327 (2015).
17. Malecki, M. T. et al. Mutations in NEUROD1 are associated with the devel-
opment of type 2 diabetes mellitus. Nat. Genet. 23, 323–328 (1999).
18. Rivero, S., Ceballos-Chavez, M., Bhattacharya, S. S. & Reyes, J. C. HMG20A is
required for SNAI1-mediated epithelial to mesenchymal transition. Oncogene
34, 5264–5276 (2015).
19. Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-
mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178–196 (2014).
20. Nieto, M. A. Epithelial plasticity: a common theme in embryonic and cancer
cells. Science 342, 1234850 (2013).
21. Talchai, C., Xuan, S., Lin, H. V., Sussel, L. & Accili, D. Pancreatic beta cell ded-
ifferentiation as a mechanism of diabetic beta cell failure. Cell 150, 1223–1234
(2012).
22. Wang, Z., York, N. W., Nichols, C. G. & Remedi, M. S. Pancreatic beta cell
dedifferentiation in diabetes and redifferentiation following insulin therapy.
Cell Metab. 19, 872–882 (2014).
23. Hu, He. K. H. et al. In vivo conditional Pax4 overexpression in mature islet beta-
cells prevents stress-induced hyperglycemia in mice. Diabetes 60, 1705–1715
(2011).
24. Lorenzo, P. I. et al. PAX4 defines an expandable beta-cell subpopulation in the
adult pancreatic islet. Sci. Rep. 5, 15672 (2015).
25. Romero-Zerbo, S. Y. et al. The cannabinoid ligand LH-21 reduces anxiety and
improves glucose handling in diet-induced obese pre-diabetic mice. Sci. Rep.
7, 3946 (2017).
26. Wang, Z. et al. Combinatorial patterns of histone acetylations and methyla-
tions in the human genome. Nat. Genet. 40, 897–903 (2008).
Mellado-Gil et al. Cell Death and Disease  (2018) 9:279 Page 14 of 15
Official journal of the Cell Death Differentiation Association
27. Gu, C. et al. Pancreatic beta cells require NeuroD to achieve and maintain
functional maturity. Cell. Metab. 11, 298–310 (2010).
28. Moates, J. M., Nanda, S., Cissell, M. A., Tsai, M. J. & Stein, R. BETA2 activates
transcription from the upstream glucokinase gene promoter in islet beta-cells
and gut endocrine cells. Diabetes 52, 403–408 (2003).
29. Wang, H., Brun, T., Kataoka, K., Sharma, A. J. & Wollheim, C. B. MAFA controls
genes implicated in insulin biosynthesis and secretion. Diabetologia 50,
348–358 (2007).
30. Remedi, M. S. & Nichols, C. G. Hyperinsulinism and diabetes: genetic dissection
of beta cell metabolism-excitation coupling in mice. Cell. Metab. 10, 442–453
(2009).
31. Brun, T. et al. The diabetes-linked transcription factor Pax4 is expressed in
human pancreatic islets and is activated by mitogens and GLP-1. Hum. Mol.
Genet. 17, 478–489 (2008).
32. Hunter, C. S. & Stein, R. W. Evidence for loss in identity, de-differentiation, and
trans-differentiation of islet beta-cells in type 2 diabetes. Front. Genet. 8, 35
(2017).
33. Lorenzo P. I., Juarez-Vicente F., Cobo-Vuilleumier N., Garcia-Dominguez M.,
Gauthier B. R. The diabetes-linked transcription factor PAX4: from gene to
functional consequences. Genes (Basel) 8, E101 (2017).
34. Kaneto, H. et al. Role of MafA in pancreatic beta-cells. Adv. Drug Deliv. Rev. 61,
489–496 (2009).
35. van de Bunt, M. et al. The miRNA profile of human pancreatic islets and beta-
cells and relationship to type 2 diabetes pathogenesis. PLoS ONE 8, e55272
(2013).
36. Esau, C. et al. MicroRNA-143 regulates adipocyte differentiation. J. Biol. Chem.
279, 52361–52365 (2004).
37. Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving
bioscience research reporting: the ARRIVE guidelines for reporting animal
research. PLoS Biol. 8, e1000412 (2010).
38. Lopez-Noriega, L. et al. Levothyroxine enhances glucose clearance and blunts
the onset of experimental type 1 diabetes mellitus in mice. Br. J. Pharmacol.
174, 3795–3810 (2017).
39. Mellado-Gil, J. M. et al. PAX4 preserves endoplasmic reticulum integrity pre-
venting beta cell degeneration in a mouse model of type 1 diabetes mellitus.
Diabetologia 59, 755–765 (2016).
40. Brun, T., Duhamel, D. L., Hu He, K. H., Wollheim, C. B. & Gauthier, B. R. The
transcription factor PAX4 acts as a survival gene in INS-1E insulinoma cells.
Oncogene 26, 4261–4271 (2007).
41. Rodriguez-Comas, J. et al. Stress-induced microRNA-708 impairs beta-cell
function and growth. Diabetes 66, 3029–3040 (2017).
42. Mahoney, E. et al. ER stress and autophagy: new discoveries in the mechanism
of action and drug resistance of the cyclin-dependent kinase inhibitor flavo-
piridol. Blood 120, 1262–1273 (2012).
43. Monteiro, P. et al. Endosomal WASH and exocyst complexes control
exocytosis of MT1-MMP at invadopodia. J. Cell Biol. 203, 1063–1079 (2013).
44. Wheelock, M. S., Wynne, D. J., Tseng, B. S. & Funabiki, H. Dual recognition of
chromatin and microtubules by INCENP is important for mitotic progression. J.
Cell Biol. 216, 925–941 (2017).
45. Rambhatla, L., Chiu, C. P., Glickman, R. D. & Rowe-Rendleman, C. In vitro
differentiation capacity of telomerase immortalized human RPE cells. Invest.
Ophthalmol. Vis. Sci. 43, 1622–1630 (2002).
46. McCluskey, J. T. et al. Development and functional characterization of insulin-
releasing human pancreatic beta cell lines produced by electrofusion. J. Biol.
Chem. 286, 21982–21992 (2011).
47. Gauthier, B. R. et al. PDX1 deficiency causes mitochondrial dysfunction and
defective insulin secretion through TFAM suppression. Cell. Metab. 10,
110–118 (2009).
48. Jimenez-Moreno, C. M. et al. A simple high efficiency intra-islet transduction
protocol using lentiviral vectors. Curr. Gene Ther. 15, 436–446 (2015).
Mellado-Gil et al. Cell Death and Disease  (2018) 9:279 Page 15 of 15
Official journal of the Cell Death Differentiation Association
ARTICLE
LRH-1 agonism favours an immune-islet dialogue
which protects against diabetes mellitus
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Type 1 diabetes mellitus (T1DM) is due to the selective destruction of islet beta cells by
immune cells. Current therapies focused on repressing the immune attack or stimulating beta
cell regeneration still have limited clinical efficacy. Therefore, it is timely to identify innovative
targets to dampen the immune process, while promoting beta cell survival and function. Liver
receptor homologue-1 (LRH-1) is a nuclear receptor that represses inflammation in digestive
organs, and protects pancreatic islets against apoptosis. Here, we show that BL001, a small
LRH-1 agonist, impedes hyperglycemia progression and the immune-dependent inflammation
of pancreas in murine models of T1DM, and beta cell apoptosis in islets of type 2 diabetic
patients, while increasing beta cell mass and insulin secretion. Thus, we suggest that LRH-1
agonism favors a dialogue between immune and islet cells, which could be druggable to
protect against diabetes mellitus.
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Type 1 diabetes mellitus (T1DM) is a CD4
+ and CD8+ T-
cell-dependent autoimmune disease that targets beta cell
destruction, ultimately leading to hyperglycemia and
insulin dependence. The collapse in tolerance to self-antigens,
such as insulin, is precipitated by genetic and environmental
factors1,2. To date, therapies aimed at inhibiting the immune
system using anti-CD3 monoclonal antibodies or at neutralizing
pro-inflammatory cytokines, have had limited success3,4. One of
the reasons may be that inhibiting the immune and inflammatory
reactions in the pancreas impairs the repairing and regeneration
capabilities of a functional beta cells mass5,6, as observed during
wound healing7. Novel agents that could guide a pro-
inflammatory autoimmune destructive environment toward an
anti-inflammatory milieu facilitating islet regeneration, would
define a novel class of antidiabetic therapies.
The liver receptor homolog-1 (LRH-1, or NR5A2) is a member
of the NR5A family of nuclear receptors, which plays a pivotal
role in early embryonic development, and specifies the endo-
dermal lineage8. In the liver, LRH-1 modulates the expression of
genes involved in cholesterol and bile acid metabolism, as well as
in glucose homeostasis9, attenuates the hepatic acute phase
response, which is triggered upon increases of pro-inflammatory
cytokines, and protects against endoplasmic reticulum stress10,11.
In the intestine, LRH-1, modulates the enterocyte renewal and
regulates the local immune system via production of glucocorti-
coids12. In the pancreas, LRH-1 regulates the expression of genes
involved in digestive functions, and protects the endocrine islets
against cytokine- and streptozotocin-induced apoptosis13,14, while
stimulating the production of enzymes involved in glucocorticoids
biosynthesis14. In view of the above, specifically of the possibility
that LRH-1 could elicit an islet-driven anti-inflammatory micro-
environment, we posited that upregulating LRH-1 activity could
have beneficial therapeutic effects in diabetes mellitus (DM).
Natural phospholipids physiologically stimulates LRH-1
activity15,16, decreasing hepatic steatosis and improving glucose
homeostasis in animal models of insulin resistance17. Given that
LRH-1 can also be activated by smaller, non-polar bicyclic
compounds18, we have synthesized a compound termed BL001,
which we have tested in mouse models of T1DM, as well as in
pancreatic islets from patients affected by Type 2 DM (T2DM).
Here we report that the long-term in vivo administration of
BL001 prevents the development of diabetes in mice, through the
combined maintenance of a functional islet beta cell mass and the
release of anti-inflammatory factors, which contribute to the islet
regeneration effect. We further report that BL001 also protects
human islet cells from apoptosis and improves impaired insulin
secretion as well as beta cell survival in the pancreatic islets of
T2DM patients. The data define LRH-1 as a novel therapeutic
target for the treatment of T1DM.
Results
BL001 activates LHR-1 without cytotoxic or metabolic effects.
The chemical structure of BL001, which specifically binds to and
activates LRH-118, is depicted in Supplementary Fig. 1a. The
effects of the drug on LRH-1 activity, cell viability, and toxicity
are described in Supplementary Fig. 1b–e. Pharmacokinetic and
safety profiling of BL001 were studied in C57BL/6 and RIP-B7.1
mice, respectively. An i.p. injection of 10 mg/kg b.w. BL001 led to
peak plasma concentrations of 3.6 μg/ml (≈8 μM) after 0.2 h, and
a half-life of 9.4 h. Daily injections during 24 weeks did not reveal
macroscopic organ alterations in BL001-treated RIP-B7.1 mice
(Supplementary Fig. 2a, b), which also featured normal plasma
levels of total cholesterol and triglycerides up to 8 weeks of
treatment (Supplementary Fig. 3a, b). Insulin sensitivity was not
altered by this BL001 treatment (Supplementary Fig. 3c).
BL001 blunts apoptosis and attenuates diabetes in mice. To
assess the anti-apoptotic effect of BL001, mouse islets were
exposed to 10 μM BL001 in the presence of 2 ng/ml IL1beta, 28
ng/ml TNFalpha and 833 ng/ml IFNgamma. The drug prevented
the cytokine-induced islet cell death (Fig. 1a). A substantial loss of
LRH-1 transcript and protein by RNAi, sensitized BL001-treated
islets to the cytokine-induced apoptosis (Fig. 1b–d). The anti-
diabetic role of BL001 was next evaluated in animal models of
T1DM. C57BL/6 male mice that received 150mg/kg b.w. strep-
tozotocin (STZ) developed diabetes within 4 weeks (Fig. 1e,
Supplementary Fig. 4a). The incidence of diabetes was decreased
after a 5 day pre-treatment with 10 mg/kg b.w. BL001 (Fig. 1e,
Supplementary Fig. 4a), which decreased the loss of insulin-
containing beta cells (Fig. 1g), and increased the proportion of
cells staining for both insulin and glucagon (Fig. 1h, i). Moreover,
30% of the mice that developed diabetes returned to normogly-
cemia 4 weeks after a daily injection of 10 mg/kg b.w. BL001,
starting 1 week after the STZ injection (Fig. 1f, Supplementary
Fig. 4b).
To evaluate the effect of BL001 against an autoimmune attack,
we studied RIP-B7.1 mice, a model mimicking the etiology of
T1DM19, without gender influence20. Eighty percent of RIP-B7.1
mice immunized against insulin developed diabetes within
8 weeks (Fig. 1j, Supplementary Fig. 4c), when receiving only a
vehicle solution. This proportion dropped to 43% in mice treated
with 10 mg/kg b.w. BL001 for 5 days prior to immunization
(Fig. 1j, Supplementary Fig. 4c). Still, a similar increase in the
proliferation of T cells in response to insulin was also detected in
the splenocytes of mice treated or not with BL001, both 4 and
8 weeks after the insulin immunization (Fig. 1k), confirming that
all mice had mounted an in vivo autoimmune attack. At these
time points, immunostaining showed a near-complete destruction
of beta cells in the islets of the control immunized mice, and the
persistence of sizable numbers of these cells in the immunized
mice treated with BL001 (Fig. 1l). In the presence of
hyperglycemia, the latter animals also featured islets with a
significant increase in the number of PDX1+ cells as compared to
immunized mice (Fig. 1m, n).
Mice in which the BL001 treatment was initiated 5 days after
the immunization, featured an incidence of diabetes similar to
that of controls for the first 5 weeks (Fig. 1o, Supplementary
Fig. 4d). Thereafter, however, the incidence of diabetes was lower
(~30%) in the BL001-treated mice than in immunized controls
(~80%; Fig. 1o, Supplementary Fig. 4d). A similar decrease in
diabetes incidence was observed in female NOD mice treated with
BL001 from week 12 (Fig. 1p), an age at which these animals
feature an ongoing autoimmune attack, and reduced insulin
content. To establish whether the in vivo effects of BL001 were
mediated via LRH-1, we generated mice in which the Lrh1 gene
was selectively disrupted in beta cells. To this end, Lrh1 lox/lox
mice were crossed with RIP-Cre mice. We found that all mice
carrying two deleted alleles (βLRH-1−/−), and 75% of the
progenies carrying one normal allele (βLRH-1−/+) died within
3 weeks of life (Supplementary Fig. 5a). Immunofluorescence
staining of islets from day 1 neonatal pups, showed an atypical
islet morphology, with a normal proportion of insulin-containing
beta cells surrounded by an increased proportion of glucagon-
containing alpha cells in homozygous mice (Supplementary
Fig. 5b–e).
BL001 inhibits insulitis and alters serum cytokine profile. To
unravel the mechanism whereby BL001 impedes the progression
of diabetes, we evaluated the lymphocytic infiltration of islets
(insulitis) in mice pre-treated or not with BL001. Four weeks after
immunization, a sizable insulitis was detected in the pancreas of
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both BL001-treated and control mice (Fig. 2a, b). However,
4 weeks later, the normoglycemic BL001-treated mice were nearly
free of insulitis, in contrast to controls which displayed strong
infiltration (Fig. 2c, d). Accordingly, no CD4+ or CD8+ T cells
were found in the islets of the former animals (Supplementary
Fig. 6), which also showed significantly higher levels of circulating
IL10, IL5, IL6 (Fig. 2e, f), CCL2, CCL4 (Fig. 2g, h), and TGFbeta
(Fig. 2i, j) than immunized controls at 8 but not 4 weeks. In
contrast, no significant differences were observed in levels of
INFgamma (0.6965 ± 0.0931 versus 0.4989 ± 0.0733 p= 0.1072,
unpaired Student’s t test), TNFalpha (5.925 ± 0.815 versus 6.648
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0.0913 versus 0.3461 ± 0.0579 p= 0.1092, unpaired Student’s
t test) and IL2 (1.306 ± 0.181 versus 1.111 ± 0.154 p= 0.4221,
unpaired Student’s t test) between immunized untreated and
BL001-treated mice at 8 weeks.
BL001 elicits a tolerogenic environment within the pancreas.
To analyze how BL001 remodeled the immune cell environment,
we performed flow cytometry studies on pancreatic cell suspen-
sions (gating strategy shown in Supplementary Fig. 7). The pro-
portions of CD4+/CD25+/FoxP3+ Tregs and CD4+/IL4+ Th2
cells were higher in the pancreas of the immunized and BL001-
treated RIP-B7.1 mice than in the cognate controls (Fig. 3a, c),
whereas CD4+/IFN gamma+ Th1 cells were decreased, and CD4
+/IL17+ Th17 cells were unaffected (Fig. 3b, d). Furthermore, the
number of CD103+/IDO+ tolerogenic dendritic cells, F4/80
+/CD11b+ macrophages, and their M2-like anti-inflammatory
subtype (F4/80+/CD11b+/CD206+) were also increased in
BL001-treated mice (Fig. 3e–g). Accordingly, transcriptome
profiling revealed that BL001 significantly increased the expres-
sion of key genes associated with the M2 genetic signature,
including, Clec7a (Dectin-1), Clec10a (CD301), Chst7, Tiam1,
Cd300ld, and Olfm1 (Noelin-1 or Pancortin)21 (Fig. 3h).
BL001 favors a M2 macrophage phenotype via LRH-1. To
further delineate the role of BL001 in promoting a M2 macro-
phage phenotype resulting in increased IL10 secretion, peritoneal
macrophages were isolated and treated in vitro with the com-
pound. BL001 dose-dependently increased transcript levels and
the secretion of IL10 and TGFbeta (Fig. 4a–d). Exposure to LPS,
also enhanced the expression and secretion of IL10, but not of
TGF beta by these cells (Fig. 4e–h). To substantiate that BL001-
mediated M2 polarization was conveyed by direct LRH-1 acti-
vation, the latter receptor was knock down using siRNA. Silen-
cing of LRH-1 transcript and protein levels by ~70% in primary
macrophages (Fig. 4i, j), significantly blunted the BL001-mediated
increase in expression of the M2 signature genes, Clec7a, Clec10a,
and Olfm1 as well as Il10 (Fig. 4k, l, p, q), independent of LPS
treatment. Transcript levels of Chst7, Tiam1, and Cd300ld were
also repressed, albeit in macrophages either treated or not with
LPS (Fig. 4m–o). In contrast, TGFbeta expression was not altered
in LRH-1 silenced cells (Fig. 4r). As IL10 biosynthesis and
secretion in alternatively activated macrophage has been linked to
Clec7a stimulation22,23, secretion levels of this cytokine was next
evaluated in LRH-1 knockdown cells. Accordingly, IL10 secretion
was decreased in BL001-treated macrophages independent of LPS
treatment (Fig. 4s) indicating that LRH-1 is involved in the
BL001-dependent polarization and cytokine secretory function of
M2 macrophages.
BL001 increases the number of bi-hormonal cells in islets. To
assess whether the BL001 treatment favored the survival and
replenishment of islet cells, we morphometrically evaluated the
mass of beta and alpha cells, as well as islet numbers and sizes.
Eight weeks after immunization, all these parameters were
increased in the BL001-treated mice (Fig. 5a–d, Supplementary
Fig. 8a–c). This increase was not associated to enhanced pro-
liferation or decreased apoptosis of beta cells, as assessed using
different methods (Fig. 5e–h, Supplementary Fig. 9a, b). In con-
trast, the immunized mice, which did not receive BL001, featured
higher levels of beta cell proliferation and apoptosis as a result of
the ongoing autoimmune attack (Fig. 5e–h). Eight weeks after
immunization, the mass of alpha cells was also increased in
BL001-treated mice in the absence of enhanced proliferation
(Fig. 5c, d, i, j, Supplementary Fig. 9c). At this time point, islets of
these mice, also contained increased numbers of cells co-
expressing insulin and glucagon, as well as PDX1 and glucagon
(Fig. 5k–n and supplementary Fig. 10). Since the data suggest the
potential activation of a genetic beta cell program in alpha cells,
we investigated whether a 48-h BL001 treatment could suppress
the expression of ARX, whose down-regulation triggers beta-to-
alpha cell trans-differentiation24. Accordingly, a 2-day exposure
to BL001 decreased the expression of ARX, glucagon, and MafB
transcripts in the alpha cell-derived TC1–6 cell line (Fig. 5o).
BL001 protects human islet from apoptosis improving func-
tion. Having validated the proof-of-concept in mice that BL001
protects islets and prevents both chemically and autoimmune-
induced diabetes, we next sought to determine whether these
beneficial effects were translated to human islets under stress
conditions. Ten to twenty μM BL001 did not reveal any cytotoxic
effects on islets obtained from normoglycaemic donors (Supple-
mentary Fig. 11a). In the same islets, the expression levels of
LRH-1 were also unchanged, whereas that of its target gene shp
was increased (Supplementary Fig. 11b). However, 10 μM BL001
decreased the apoptosis of islet beta cells, 24 and 72 h after an
exposure to either cytokines (Fig. 6a, c) or streptozotocin (Fig. 6b,
d). Glucose-stimulated insulin secretion (GSIS) of islets from non
diabetic donors (Supplementary Table 1) was not modified by
BL001 (Fig. 6e). In contrast, GSIS of islets from type 2 diabetic
donors (Supplementary Table 2) was significantly increased after
exposure to BL001 (Fig. 6f). Under these conditions, the pro-
portion of apoptotic beta cells was significantly decreased (Fig. 6g,
Fig. 1 BL001 improves islet survival and blunts development of diabetes in three mouse models. a Exposure to 10 μM BL001 (BL) for 72 h blocked cytokine-
induced apoptosis (CK; 2 ng/ml IL1beta, 28 ng/ml TNFalpha and 833 ng/ml IFNgamma) in mouse islets. Cell death was assessed by ELISA quantification
of mono and oligonucleosomes released by apoptotic cells. This blockade was blunted in islets transfected with siRNAs (d) which decreased LRH-1
transcript (b) and protein levels (LRH1, red; scale bar: 25 µM) (c). Data are means+ s.e.m. values of six independent experiments using six different islet
preparations and performed in triplicates. siSC, pool of siRNAs against scrambled sequence. BL001 (10mg/kg b.w.) also decreased the incidence of
diabetes in C57Bl/6 male mice treated with a single dose of streptozotocin (STZ;150mg/kg b.w.), irrespective of whether the former drug was given prior
to (e) or 1 week after (f) STZ. Values are means ± s.e.m. of n= 5 (STZ)-14 mice (BL/STZ). After these 2 protocols, insulin-containing beta cells (red) and
glucagon-containing alpha cells (green) were preserved in islets of STZ and BL001-treated mice (g), which also featured an increase number of cells
containing both hormones (h, arrowheads). Nuclei were stained with DAPI (blue). Scale bars: 25 µM. i Quantification of insulin- and glucagon-positive
cells. j A 5-day BL001 pre-treatment of RIP-B7.1 mice prior to immunization decreased the diabetes incidence. Values are means ± s.e.m. C (vehicle treated,
n= 26 male and female mice); BL (BL001, n= 26 male and female mice); IMN (immunized, n= 50 male and female mice), and BL IMN (BL001-treated and
immunized, n= 50 male and female mice). k Immunization increased the proliferation of RIP-B7.1 splenocytes, an effect that was not modified by the
BL001 treatment. Values are median (lines in the boxes) ± median errors of 5–12 preparations. l The 8-week-long BL001 treatment preserved insulin- (red)
and glucagon-containing cells (green) in islets of immunized RIP-B7.1 mice (scale bar: 25 µM). m, n BL001-treated and immunized RIP-B7.1 mice that
developed hyperglycemia contained a higher number of PDX1+ cells as compared to untreated and immunized animals (scale bar: 25 µM). o Diabetes
incidence of RIP-B7.1 mice that were immunized at days 0 and 7 and subsequently injected daily, starting at week 1 and for up to 8 weeks, with either
vehicle (IMN, n= 38 male and female mice) or BL001 (BL IMN, n= 38 male and female mice). p Diabetes incidence in female NOD mice receiving (BL, n
= 8) or not (C, n= 14) BL001 from 12 weeks. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, one-way ANOVA (a, d, k, i) or Student’s t test (b, n)
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Fig. 2 BL001 decreases insulitis and modulates the blood cytokine profile. Histology (representative images, scale bar: 25 µM) and morphometry at a, b 4
and c, d 8 weeks revealed that treatment with 10 mg/kg b.w. BL001 decreased the incidence and severity of insulitis in immunized RIP-B7.1 mice. At
8 weeks, BL001-treated and immunized mice that developed hypeglycemia exhibited a similar degree of insulitis to the BL001-treated and immunized mice
that were normoglycemic at 4 weeks. Impact of BL001 treatment on the profile of cytokines, chemokines and TGFbeta at 4 weeks (e, g, i) and 8 weeks (f,
h, j). Plots show individual mice values. *p < 0.05, **p < 0.01, and ***p < 0.001, one-way ANOVA
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03943-0 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1488 | DOI: 10.1038/s41467-018-03943-0 |www.nature.com/naturecommunications 5
a b c d
h
Th1 Th2 Th17



















































































n = 5 n = 7 n = 7









































































































C BL IMN BL IMN C BL IMN BL IMN
C BL IMN BL IMN C BL IMN BL IMNC BL IMN BL IMN
C BL IMN BL IMN C BL IMN BL IMN
Fig. 3 BL001 promotes a pancreatic anti-inflammatory/tolerogenic environment. RIP-B7.1 male and female mice were pre-treated or not with BL001 for
5 days and then immunized. Treatment with BL001 was pursued for an additional 8 weeks at which point animals were sacrificed and pancreas extracted
and processed for flow cytometry quantification of a Tregs (n= 10–16 mice), b Th1 (n= 5–11 mice), c Th2 (n= 5–11 mice), d Th17 (n= 5–11 mice), e
dentritic cells (n= 5 mice), f macrophages (n= 7 mice), and g M2-like macrophages (n= 7 mice). h Heatmap displaying expression values of a subset of
M2 macrophage genes in F4/80+/CD11b+/CD206+ pancreatic subpopulations isolated from immunized mice treated or nor with BL001 (IMN and IMN
BL). Also depicted are raw p-values and the graphical representation of logFC from the differential expression analysis (IMN BL versus IMN). *p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001, one-way ANOVA (a–g)
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h) and paralleled by reduced cleaved caspase-3 activity (Fig. 6i, j
and Supplementary Fig. 12).
To assess whether comparable effects could be observed during
an ongoing, in vivo immune attack, mimicking a T1DM
environment, we transplanted human islets under the kidney
capsule of immune competent C57BL/6 mice, treated or not with
BL001. Two days after xenotransplantation, mice were treated
with daily injections of BL001 or vehicle for 7 days. At this time
point, rejection of the human islets is anticipated25,26. Consistent
with the protective effect of BL001, grafts from BL001-treated
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Fig. 4 LRH-1 is required for BL001-mediated M2 polarization. Primary macrophages were exposed in culture to increasing concentration of BL001 for 24 h.
Media was collected and RNA isolated to perform QT-PCR. Transcript and secreted levels of a, b Il10 and c, d Tgfb were then determined (n= 9 mice). e–h
Primary macrophages were incubated for 24 h with increasing concentrations of BL001 alone or in combination with 1.0 µg/ml lipopolysaccharide (LPS).
Transcript and secreted levels of e, f IL10 and g, h TGFbeta were then measured (n= 9 mice). i siRNA-mediated repression of LRH-1 transcript and j
protein levels in mouse primary macrophages as assessed by QT-PCR and immunostaining (LRH-1, green; scale bar: 25 µM). Relative expression levels of
M2 signature genes, k Clec7a, l Clec10a, m Chst7, n Tiam1, o Cd300ld, and p Olfm1 in control or LRH-1-silenced macrophages treated or not with 10 µM
BL001 and LPS (n= 4). q Il10 and r Tgfb transcript levels in siLRH1-treated or not macrophages in the presence or absence of 10 µM BL001 and LPS (n= 5).
s Secreted levels of IL10 in silenced or not macrophages. Results are expressed as the averages+ s.e.m. (a–i and k–s). *p < 0.05, **p < 0.01, ***p < 0.001,
and ****p < 0.0001, one-way ANOVA (a–h) and Student’s t test (i, k–s)
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mice showed greater numbers of beta cells than the controls
(Fig. 6k, l).
Immune-related biological processes are targeted by BL001. To
evaluate the effects of BL001 on a larger scale, we profiled gene
expression via DNA microarray analysis in mouse islets exposed
to BL001 for 2 days. We found that 277, 23, and 195 gene
ontology (GO) terms were enriched in islets exposed to 0.1, 1.0,
and 10 µM BL001, respectively (Fig. 7a). Seven of these GO terms
were common to all conditions, whereas no common down-
regulated GO terms was found in the same samples (Fig. 7a). The
seven enriched GO terms were related to genes involved in































































4 weeks 4 weeks8 weeks 8 weeks


























C BL IMN BL
IMN
C BL IMN BL
IMN
C BL IMN BL
IMN
C BL IMN BL
IMN
C BL IMN BL
IMN
C BL IMN BL
IMN
C BL IMN BL
IMN













































































































































































































































































ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03943-0
8 NATURE COMMUNICATIONS |  (2018) 9:1488 | DOI: 10.1038/s41467-018-03943-0 |www.nature.com/naturecommunications
immune functions (Fig. 7b). Heat maps of those genes which
were consistently modified, identified 33 genes (Fig. 7c). Those
encoding for the CCL2, CCL3, CCL7 chemokines, the cytokine
IL6 and the prostaglandin-endoperoxide synthase-2 (PTGS2)
were the most induced by the BL001 exposure, whereas the gene
coding for the IL1 beta receptor (IL1R1) was the most down-
regulated (Fig. 7c). Quantitative PCR of these genes, confirmed
that the CCL2, CCL3, and PTGS2 transcripts were upregulated by
the BL001 exposure (Fig. 7d–f), whereas the IL1R1 transcript was
downregulated under the same conditions (Fig. 7g).
Discussion
In spite of major efforts, the available strategies to restore/pre-
serve a functional beta cell mass through immunomodulation
and/or beta cell regeneration/replacement treatments have so far
shown limited efficacy for the long-term improvement of gly-
caemia in T1DM patients27. This frustrating situation calls for
innovative approaches to this complex problem; identify novel
“druggable” targets that could promote the regeneration of a
functional beta cell mass, while attenuating the autoimmune
attack, and preserving the anti-inflammatory locale that appears
necessary for beta cell renewal. Here, we show that BL001, a small
agonist of the LRH-1 receptor, has such characteristics, which
prevent and revert diabetes in three different mouse models of
T1DM.
Our data first document that, by activating LRH-1, BL001
primes macrophages toward the anti-inflammatory M2 pheno-
type (as revealed by the enhanced M2 genetic signature) resulting
in direct stimulation of IL10 expression and secretion23. BL001-
treated mice also featured increased numbers of pancreatic Tregs,
whose expansion is induced by IL1028, and which are essential in
maintaining self-immune tolerance including in T1DM29. Cir-
culating levels of CCL2 as well as its expression in islets were
increased in BL001-treated and immunized RIP-B7.1 mice.
Although the impact of CCL2 as a pro or anti-inflammatory
chemokine is disease- and cell-dependent30, our results suggest
that in the context of autoimmune diabetes, increased levels of
local CCL2 appears to be associated with the recruitment of
macrophages to the pancreas which, in turn are further polarized
towards the M2-like subtype under the influence of IL10 pro-
duction. CCL2 through enhanced IL4 production also fosters an
environment that favors expansion of Th231, a cell type and
cytokine that were increased in the pancreas and in the circula-
tion of immunized, BL001-treated RIP-B7.1 mice. Immunized
mice treated with BL001 also displayed increased circulating
TGFbeta levels correlating with the presence of a larger number
of CD103+/IDO+ dentritic cells, which convey immunosup-
pressive and tolerogic functions32,33. Given that the adoptive
transfer of M2 macrophages as well as the upregulation of CCL2
enhance beta cell survival in NOD mice34,35 and that the auto-
logous transfer of Tregs improves islet survival and function in
T1DM patients36, the immune changes we observed converge to
demonstrate that BL001 significantly inhibits the aggressive
autoimmune process favoring tolerance, which presumably con-
tributes to its beneficial effects. In this context, BL001-treated and
immunized mice that develop diabetes retained islets with a sig-
nificant number of PDX1+ cells and reduced insulitis at 8 weeks
as compared to immunized mice. Although speculative, the latter
results indicate that BL001 dosage or activity was suboptimal in
favoring an anti-inflammatory and tolerogenic environment
resulting in beta cell destruction and hyperglycemia in these
animals.
Blood analysis further showed that BL001 increased circulating
levels of the IL5 and IL6 cytokines, and of the chemokine CCL4,
which have anti-inflammatory actions. IL6 enhances insulin
secretion via the release of GLP1 by alpha cells37,38 while IL5 and
CCL4 shift pro-inflammatory Th1 cells towards the anti-
inflammatory Th2 subset and stimulate expansion of Tregs39,40.
Accordingly, we found reduced numbers of Th1 cells but
increased numbers of Th2 and Tregs cells in the pancreas of the
immunized and BL001-treated mice. In contrast, circulating levels
of IFNgamma, TNFalpha, IL1beta and IL2 remained constant
suggesting that production of these cytokines were not directly
impacted by the compound. BL001 treatment also stimulated the
islet expression of PTGS2, an inducible prostaglandin synthase,
whose PGE2 metabolite also inhibits Th1 cells and protects
against T1DM41–43. In addition, IL6 and the potential secretion of
PTGS2-derived PGE2 by islets along with IL4 and IL10 released
by Th2 as well as Tregs, will further contribute to M2 polarization
within the pancreas independent of the direct activation of LRH-1
in macrophages by BL00144–47. These data highlight that, in
addition to a direct sizable action on the immune system, BL001
also promotes the release of pancreatic islet-derived factors
favoring an anti-inflammatory environment that will further
induce tolerogenecity. Future work will focus on dissecting the
mechanism whereby the BL001/LRH-1 signaling pathway
achieves these beneficial effects.
Our study further documents that the LRH-1 receptor is
essential for the proper organization of pancreatic islets. Thus,
the beta cell loss of the LHR-1 receptor modifies the proportion
of islet cells characterized by an increase in the number of alpha
cells, and the retention of a sizable beta cell mass, which
associate with a rapid, post-natal death of transgenic mice. Our
parallel experiments also show that BL001-mediated activation
of LRH-1 stimulates the regeneration of beta cells, in the islets
of both control and diabetic mice, an effect which is not attri-
butable to a change in the proliferation and apoptosis of these
Fig. 5 BL001 promotes beta and alpha cell mass expansion in immunized RIP-B7.1 mice. The control (C) mass of beta (a, b) and alpha cells (c, d) of RIP-
B7.1 mice was decreased after immunization (IMN), an alteration that was prevented by 10mg/kg b.w. BL001 daily treatment for 8 weeks (BL IMN). Dot
plots show the results from 8 (4 weeks) and 16 (8 weeks) pancreas per group, each dot corresponding to the cell mass of an entire pancreatic section. e–j
Representative immunofluorescence images of islets co-stained and quantified for e, f insulin (INS, red) and Ki67 (green), g, h insulin (red) and Tunel
(green), i, j glucagon (GLUC, red) and Ki67 (green). All values are means of 5 mice per group. Scale bars: 25 µM. Right panels are enlargements of boxed
area, and arrow heads point to example of cells simultaneously stained for 2 proteins. k Representative confocal images showing the distribution of the
insulin- (red) and glucagon-bihormonal cells (green) as well as l quantification in islets of the different animal groups. Nuclei were stained with DAPI
(blue). Scale bar: 25 µM. Right panel show enlargements of boxed areas. Arrow heads point to cells co-stained for the two depicted markers. m A
representative image depicting co-immunostaining of PDX1 (red) and glucagon (green) in a pancreas of a normoglycemic immunized BL001-treated
mouse, and n quantification of such cells in the various groups. Bottom left panels are enlargements of boxed area. Bottom right panels, are without DAPI
staining. White arrows point to PDX1+/GLUC+ cells, # identifies a PDX1-/GLUC+ cell and * highlights a PDX1+/GLUC- cell. n= 15 pancreatic slices
obtained from five independent mice per group. Scale bar: 25 µM. o After a 24-h exposure to 10 μM BL001 (BL), alpha TC-1.6 cells featured decreased
expression of the Arx, glucagon (Ggc) and MafB transcripts. Six independent experiments were performed and subsequent QT-PCR conducted in
triplicates. Values are means+ s.e.m. (f, h, j, l, n, o). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, one-way ANOVA (a–d, f, h, j, l, n) and the
Student’s t test as compared to control (o)
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cells. The underlying mechanism may or may not directly target
beta cells, and remains to be ascertained. A possible explanation
may be an alpha-to-beta cell trans-differentiation48, as sug-
gested by (1) the frequent occurrence of cells containing both
insulin and glucagon after the BL001 administration, (2)
repression of the alpha genetic program by BL001, and (3)
increased alpha cells subsequent to LRH-1 beta cell-specific
deletion. However, this possibility still needs to be validated by
specific lineage tracing studies. The fact that BL001 and STZ-
treated mice displayed fewer bi-hormonal cells suggest that
such trans-differentiation may be facilitated by the increase in
Tregs and M2 macrophages and/or by IL6 and IL1049,50.
Antecedents for such immune-regenerative mechanism have
been described in salamander and zebrafish51,52. Furthermore,
Tregs and M2 macrophages are key remodeling players in
mouse tissue repair (muscle, bone and vasculature) promoting
cell differentiation and expansion53,54.
In summary, our data define LRH-1 as a novel target for the
treatment of diabetes, which can be modulated by BL001. The
inhibitory effect of the drug on the immune system, its tolero-
genic action and its effects on beta cells survival and regeneration
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models (Fig. 8). The finding that the drug also decreases beta cell
apoptosis in islets from patients with T2DM, and improves their
insulin secretion as well as improves beta cell survival in xeno-
transplantation, opens the exciting perspective that it could be of
value also in the human clinic. In this perspective, the develop-
ment of new LRH-1 agonists, more stable than BL001 and
adapted to oral administration is an urgent need.
Methods
BL001 synthesis and formulation. BL001 [(3aS,6aR)-1,2,3,3a,6,6a-hexahydro-4-
(3-methoxyphenyl)-5-((E)-oct4-en-4-yl)-N-phenylpentalen-3a-amine] was syn-
thesized by Sreeni Labs Private Limited (India), at a HPLC purity >98%. The semi-
solid compound was dissolved in 100% DMSO, at 0.5 mg/ml and 100 μg/ml stock
concentrations for in vitro and in vivo studies, respectively. The optimal for-
mulation for in vivo administration (hereafter referred to as vehicle) was: 1%
DMSO, 40% WellSolve (Celeste Corporation, Japan) and 59% water. In vitro
pharmacology activity assay and ADME-Tox studies were outsourced to Cerep/
Eurofins (http://www.cerep.fr); pharmacokinetic studies were performed by GVK
Biosciences Pvt. Ltd. (http://www.gvkbio.com/).
Mice. RIP-B7.119, LRH-1 Lox/Lox (kindly provided by Dr. K. Schoonjans, EPFL,
Switzerland), RIP-Cre55, C57BL/6 mice (purchased from Janvier Labs, France), and
NOD mice (Charles River, Calco Italy) were housed in ventilated plastic cages
under a 12-h light/dark cycle, and were given food and water ad libitum. Mice
experimentations were approved by the CABIMER Ethics Committee for Animal
Experimentation, and performed in accordance with the Spanish law on animal use
RD 53/2013. NOD mice studies were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of the
German Federal Animal Protection Law. Protocols were approved by the Com-
mittee on the Ethics of Animal Experiments of the University of Ulm (Tier-
forschungszentrum Ulm, Oberberghof) and the Regierungspräsidium Tübingen
(Permit Numbers: 1199 and 1327 to R.S.). Mice were randomly distributed for all
experiments and not subject to blind analysis. Seven- to eight-week-old males and
females RIP-B7.1 mice were injected daily i.p. with 10 mg/kg b.w. BL001, starting
either 5 days prior to or after immunization. Immunization was achieved by
injection of 50 μg preproinsulin (ppINS) expression plasmid (PlasmidFactory
GmbH, Germany) into the two anterior tibialis muscles. Mice were euthanized 4
and 8 weeks after immunization, and pancreases and spleens were extracted for
immunocytochemistry and proliferation assays, respectively. In addition, 8-week-
old male C57BL/6 mice were treated with BL001 for 5 days prior or after an i.p.
injection of 150 mg/kg b.w. streptozotocin (STZ) prepared in 0.01 M sodium citrate
at pH 4.5. Twelve-week-old female NOD mice were injected daily i.p. with 10 mg/
kg b.w. BL001, for up to 25 weeks. Circulating glucose levels were measured from
tail vein blood samples using an Optium Xceed glucometer (Abbott Scientifica SA,
Barcelona, Spain). Non-fasting blood glucose ≥13.8 mmol/l for two consecutive
measurements was considered to indicate overt diabetes. For insulin tolerance tests
(ITT), animals were fasted for 5 h, and then i.p. injected with 0.5 U/kg b.w.
Actrapid Insulin. Glycemia was measured at 0, 30, 60, 90, and 120 min after this
injection. Cytokine levels were assessed in blood and culture media using the
mouse V-PLEX ProInflammatory Panel 1 kit 10-Plex (Meso Scale Discovery,
Rockville, USA). Detection was performed by electrochemiluminescence technol-
ogy, and data acquired on a MSD MESOTM QuickPlex SQ120. Blood triglyceride
and cholesterol levels were measured using an Accutrend Plus apparatus (Roche
Diagnostics, Mannheim, Germany), using the appropriate strips. Temporal MRI
scan of mice were acquired using a Bruker BioSpec 9.4 T/20 animal MRI system,
equipped with 400 mT/m gradients and a 40 mm quadrature resonator. Images
were acquired using a Turbo-RARTE sequence with respiratory gating (TEeff= 24
ms, TR= 1400 ms, Rare Factor= 4, slice thickness= 0.75 mm, in-plane resolution
= 78 × 78 μm).
Mouse islet isolation. Mouse islets were isolated by collagenase dissociation,
handpicked, and maintained in 11.1 mM glucose/RPMI-1640 (ThermoFisher Sci-
entific, Madrid, Spain) supplemented with 10% fetal bovine serum (FBS; Sigma-
Aldrich, Madrid, Spain), 100 U/ml penicillin (Sigma-Aldrich) and 100 mg/ml
streptomycin (Sigma-Aldrich)56.
Human islet isolation, procuration and treatment. Human islets were either
obtained from The Cell Isolation and Transplantation Center (Department of
Surgery, Geneva; Switzerland) or purchased from Tebu-Bio (Barcelona, Spain).
Islets from non-diabetic or T2DM organ donors were obtained in Pisa or pur-
chased from Tebu-Bio (Barcelona, Spain). Signed informed consents were obtained
from the families of organ donors. The ethical and investigation committee of the
University Hospital of Virgen Macarena and Virgen del Rocio approved all pro-
cedures (#2013-04398 to B.R.G.). Human islet preparations were washed, hand-
picked, and subsequently maintained in CMRL-1066 (ThermoFisher Scientific)
containing 5.6 mM glucose, and supplemented with 10% FCS, 100 U/ml penicillin,
100 μg/ml streptomycin, and 100 μg/ml gentamycin (all purchased from Sigma-
Aldrich). Human and mouse islets were either untreated or exposed to various
concentrations of BL001 for 24–48 h prior to (1) addition of 2 ng/ml IL1beta, 28
ng/ml TNFalpha and 833 ng/ml IFNgamma; (2) addition of 1 mM streptozotocin;
(3) assessment of glucose-induced insulin secretion; (4) measurement of apoptosis.
In some experiments, LRH1 was repressed in mouse islets and primary peritoneal
macrophages by RNA interference. To this end, On-target plus NR5A2 siRNA-
smart pool (Dharmacon, cat number L-047044-01) along with either control on-
target plus non-targeting pool (Dharmacon, cat number D00181010) for islets or
siLuciferase (5′-CGUACGCGGAAUACUUCGA-3′) for macrophages were used in
these studies. Fifty nM of siRNAs were pre-mixed with Lipofectamine (Thermo-
Fisher Scientific) and subsequently added to cells for 24 h. Fresh medium was then
added and cells cultured under various treatments. Apoptosis was measured at 24
and 72 h using the Roche Cell Death Detection ELISA kit (Roche Diagnostics,
Mannheim, Germany). This assay is based in the quantitative sandwich-enzyme
immunoassay principle using monoclonal antibodies against DNA and histones,
respectively, that allow specific detection of mono- and oligonucleosomes in
apoptotic cells. Islet viability was assessed using the MTT assay, according to the
manufacturer’s recommendations (Roche, Spain). In some instance, protein
extracts were prepared from T2DM islets and cleaved-caspase-3 activity was
assessed by western blot analysis57.
Human islet transplantation. Human islet transplantations were performed using
a modified protocol from Robertson and Szot58,59. Briefly, 10-week-old immuno-
competent C57BL/6 male mice were anesthetized by an i.p. injection of 100 mg/kg
ketamine and 10 mg/kg xylazine, 150–200 islets were collected without cen-
trifugation in a minimum of medium, and transplanted under the kidney capsule
using flame-polished borosilicate glass capillaries (Harvard Apparatus, GC100T-
10). Upon termination of the experiment, animals were sacrificed and transplanted
kidneys extracted, fixed and embedded for further histology analysis. In order to
accurately assess transplant reject/engraftment the entire kidney was sectioned and
insulin/glucagon co-immunostaining for was performed at every 15th slice, an
interval of ~75–150 µm that corresponds to the median size of the majority of
islets.
Cell culture and assays. The mycoplasma-free alpha TC1–6 cell line was pur-
chased from ATCC (CRL-2934; Barcelona), and maintained in DMEM (Ther-
moFisher Scientific) supplemented with 10% FBS, 15 mM HEPES, 0.1 mM non-
essential amino acids, 0.02% BSA, 2 g/l glucose, 1.5 g/l sodium bicarbonate and 5
Fig. 6 BL001 protects human islets against apoptosis and rescues insulin secretion in islets of type 2 diabetic donors. a A 24 and 72 h exposure to cytokines
(CTK) or b streptozotocin (STZ) increased cell death in human islets. This effect was prevented by 10 μM BL001 (BL). n= 10 independent islet
preparations, performed in either duplicates or triplicates. Double immunostaining for insulin (INS) and cleaved PARP (Cl.PARP) in sections from human
isolated islets exposed to either c cytokine (CTK) or d streptozotocin (STZ) and treated or not with 10 μM BL001 (BL). Scale bars: 25 µM. Right panels of
each time point are enlargements of boxed area in left panel. e After a 24-h exposure to 0 (C) −1 μM BL001, islets from normoglycemic donors (n= 5
independent donors) were similarly stimulated by glucose to release insulin. f In contrast 0.1–1 μM BL001 increased glucose-stimulated insulin secretion in
islets of type 2 diabetic donors (n= 8 independent donors). Data are means+ s.e.m. g Electron micrographs show apoptotic beta cells in islets of type 2
diabetic donors (T2DM), which were unfrequent when these islets were exposed to 1 μM BL001 (T2DM BL). Scale bars: 2 µM. h Quantification shows that
the percentage of apoptotic beta cells decreased after exposure to 1 μM BL001, in three independent donors. i Western blot of cleaved caspase-3 (Cl.C3)
and actin in protein extracts isolated from control (T2DM) and BL001 treated T2DM islets (T2DM BL) along with j densitometric analysis. n= 3
independent donors. k 10-week-old C57BL/6 male mice were transplanted with 150–200 human islets under the kidney capsule. Two days after
transplantation, mice were treated daily with BL001 or vehicle for seven days. Kidneys were harvested and processed for immunofluorescence. Two
independent representative image sets of kidney sections immunostained with sera against insulin (red) and glucagon (green). DAPI nuclear
counterstaining is used. Scale bar: 25 µM. Right panels correspond to the white squares indicated in the left panels. Rc Renal cortex. l Quantification of
insulin-positive cells in islets transplanted under the kidney capsule. n= 5 independent transplantations. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
0.0001, two-way ANOVA (a, b) and Student’s t test (e, f, h, j, l)
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Fig. 7 BL001 potentiates islet genes involved in immunomodulation. Isolated mouse islets were treated with 0.1–10 μM BL001 for 24 h and RNA isolated
for DNA microarray analysis (n= 3 independent islet preparations per BL001 concentrations). a Venn diagram depicting the number of GO terms
significantly enriched after three different BL001 treatment. b Enrichment plot for the seven GO terms common to all three BL001 concentrations. c
Heatmaps displaying logFC values of transcripts modulated by BL001, and their association with common GO processes. Blue cells reflect the membership
of a gene to a given GO BP term. Validation by QT-PCR of d Ccl2, e Ptgs2, f Ccl3, g Il1r1, h Ccl7, and i Il6 transcript levels in mouse islets treated with
BL001. n= 5 independent islet preparations. *p < 0.05 and **p < 0.01, Student’s t test versus control untreated (C)
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µM beta mercaptoethanol (all purchased from Sigma-Aldrich). The proliferation of
splenocytes isolated from mouse spleens was assessed after a 3-day culture in RPMI
1640 medium supplemented with 8% FBS, 20 mM L-glutamine, 1% sodium pyr-
uvate, 1% nonessential amino acids, and 1% penicillin/streptomycin (all from
Invitrogen), in the presence or absence of the insulin peptide SLYQLENYCA. Cells
were pulsed with [3H]-thymidine for the last 24 h of culture, harvested and lysed
onto membranes prior to liquid scintillation counting using a Beckman Coulter LS
6500 counter. Mouse primary macrophages were isolated from the peritoneal
cavity, and cultured in DMEM/F12–10 (ThermoFisher Scientific) supplemented
with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin (all
purchased from Sigma-Aldrich). Cells were stimulated with 1 μg/ml LPS (in
DMSO), in the absence or presence of 0.1, 1, or 10 μM BL001 for 24 h. The
secretion of cytokines was measured in the culture medium by electro-
chemiluminescence technology from MesoScale Discovery (Rockville, USA), and
RNA was extracted from cells.
Flow cytometry. Subpopulations of T helper cells extracted from mouse pancreas,
were characterized by flow cytometry (FACSCalibur, BD Biosciences, Madrid,
Spain), using the following antibodies (Supplementary Table 3): FITC-conjugated
anti-mouse CD4; Alexa fluor 647-conjugated anti-mouse IL17; Alexa fluor 647-
conjugated anti-mouse IL4; PE-Cy7-conjugated anti-mouse IFNgamma. Reg-
ulatory T cells were evaluated using FITC-conjugated anti-mouse CD4, in com-
bination with APC-conjugated anti-mouse CD25, and PE-conjugated anti-mouse
FoxP3 antibodies. Pancreatic macrophage subpopulations were assessed using
Alexa fluor 488 anti-mouse CD45, BV421 anti-mouse CD11b, APC anti-mouse F4/
80 and PE anti-mouse CD206. Dendritic cells were evaluated using Alexa fluor 488
anti-mouse CD45, PE anti-mouse CD103 and Alexa fluor 647 anti-IDO. Data were
analyzed using FlowJo V9 software (Tree Star). Cell sorting was performed using a
FACSAria I (BD).
Immunohistochemistry and electron microscopy. Pancreases and isolated islets
were fixed and embedded as previously detailed56. Primary and secondary anti-
bodies are listed in Supplementary Table 3. Nuclear counterstaining was performed
by DAPI, and sections were mounted using DAKO fluorescent mounting medium.
Islet cell apoptosis was measured using a TUNEL assay (In Situ Cell Death
Detection Kit, Roche, Madrid, Spain). Images were acquired using either a Leica
DM6000B or a Leica TCS SP5 confocal microscope. For the assessment of beta-
and alpha-cell mass, images of pancreatic sections were automatically acquired
using a software (NIS-Elements imaging)-controlled data acquisition Nikon eclipse
Ti-e microscope (Nikon). Morphometric quantification was performed using the
Fiji/ImageJ software. Insulitis was scored in paraffin sections of pancreas, stained
with H&E. Cells with small nuclei were considered of haematopoietic origin.
Insulitis scoring was performed as a grade of 0 to 4 according to percentage of
infiltrated islet area (0, 0%; 1<10%; 10%<2>55%; 55%<3>75%; 4>75%). For elec-
tron microscopy, pancreatic islets were processed using a standard Spurr proto-
col60. Electron microscopy images were acquired with an EMCCD camera (TRS
2kx2k). The number of non-apoptotic and apoptotic (visualized by blebbing and
nuclear condensation) beta cells was counted and the respective percentage of
dying cells was expressed as the number of apoptotic cell type over the total
number of beta cells.
DNA microarray. Labeled cRNA samples were prepared from pools of at least 100
islets isolated from 8-week-old C57BL/6 female mice, treated or not with increasing
concentrations of BL001, and subpopulations of M2-like macrophages (CD45
+/F4/80+/CD11b+/CD206+) purified from the pancreas of either vehicle- or
BL001-treated and immunized C57BL/6 mice. Three independent preparations of
cRNA were prepared per group, and hybridized to the GeneChip Mouse Gene 2.0
ST Array (islets) and to the Clariom S Assay Mouse Array (M2-like macrophages)
(Affymetrix, Santa Clara, CA), using standard protocols of the Genomic Core
Facility of CABIMER. For each microarray experiment, the Robust Multiarray
Analysis (RMA) method was applied on a per-chip basis for background correc-
tion61. Subsequent normalization across arrays, and summarization were per-
formed using a quantile algorithm and median-polish, respectively62, via oligo
package from Bioconductor (http://www.bioconductor.org). A differential gene
expression analysis was then performed using the limma package63. Computed p
values were corrected using the false discovery rate (FDR) method, to harmonize
for the multiple comparisons of all genes64.
For the islet samples, gene set analysis was performed using the logistic
regression model65, while GO annotation for genes in the microarrays were
extracted from Bioconductor GO.db annotation package66. Heatmaps of logFC
values from differential expression analyses (different concentrations of BL001
versus control) were generated for those genes which were expressed in all groups
(raw p-value < 0.05), and associated to the statistically enriched (p-adjusted <0.05)
seven GO terms identified at all drug concentrations.
For the M2-like macrophages, a heatmap of log2 expression values of a subset of
M2 gene signatures21, was generated for the CD45+/F4/80+/CD11b+/CD206+
subpopulation isolated from either untreated (IMN) or BL001-treated immunized
(IMN BL) mice. LogFC values from differential expression analyses (IMN BL
versus IMN) were generated for these genes (raw p-value < 0.05).
RNA isolation and quantitative PCR (QT-PCR). Total RNA was extracted using
the RNeasy Micro Kit (Qiagen). Complementary DNA using 0.5 to 1 µg RNA was
synthesized using the Superscript II (ThermoFisher Scientific). The RT-PCR was
performed on individual cDNAs using SYBR green (Roche)56. Primers can be
obtained upon request.
Statistical analysis. The Ruth Lenth’s power of analysis was applied to the dif-
ferent animal models to ensure that adequate numbers of animals had been studied
to detect significant changes. Results are expressed as mean ± s.e.m. (line plots as a
function of time) or as mean+ s.e.m. (bar graphs). Statistical analysis were per-
formed using the GraphPad Prism software (GraphPad Software, La Jolla, USA).
Statistical differences were estimated by one- or two-way ANOVA, with Bonferroni
post hoc tests, Student’s t test or non-parametric Mann–Whitney test, whichever
was appropriate.





































Fig. 8 Proposed model of BL001/LRH-1 cellular action. Schematic view of the effects of BL001 in changing the pancreas pro-inflammatory immune
environment toward an anti-inflammatory environment, which promotes beta cell regeneration, possibly through alpha-to-beta cell trans-differentiation
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Data availability. The Microarray raw data that support the findings of this study
have been deposited in the Gene Expression Omnibus repository with the super-
series accession number GSE94505 and subseries numbers GSE94505 and
GSE104322.
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